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Cachexia affects up to two thirds of all cancer patients with progressive disease.  It is 
a syndrome characterised by weight-loss, anorexia, fatigue, asthenia, peripheral 
oedema, and is responsible for around 20% of cancer deaths.  Cachectic patients 
suffer loss of both muscle mass and adipose tissue (with comparative sparing of 
visceral protein) and the lean tissue loss appears resistant to nutritional support. 
Progress in the treatment of cancer cachexia has been hampered due to poor 
understanding of the molecular mechanisms of skeletal muscle wasting in humans 
(rather than preclinical models) combined with a lack of accurate phenotyping 
particularly with respect to loss of skeletal muscle mass and function.  The aim of the 
present thesis was to improve the knowledge and tools available for early 
intervention studies.  The thesis focused on skeletal muscle as a key compartment in 
cancer cachexia.  The experimental model was patients with upper gastrointestinal 
(UGI) cancer undergoing potentially curative surgery due to the associated higher 
incidence of cachexia along with the ability to access tissue biopsies.  The thesis 
broadly divides into two sections.  Part I reports a series of cancer cachexia 
biomarker discovery studies based on direct biopsy and analysis of human skeletal 
muscle. Part II focused on assessment and phenotyping of skeletal muscle mass and 
function in cachectic UGI cancer patients. In addition, the feasibility of longitudinal 
clinical studies that utilise such methodology is reported.   
 
Intramuscular  β-dystroglycan protein content (assessed using Western blot) was 
identified as a potential biomarker of cancer cachexia whereas changes in the 
structural elements of muscle (myosin heavy chain or dystrophin) appeared to be 
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survival biomarkers.  Using transcriptomics, an 82-gene signature was demonstrated 
to correlate with weight-loss.  Quantitative real-time polymerase chain reaction 
(qRT-PCR) was carried out to examine the genes from this signature that were most 
upregulated. The exercise activated genes, CAMk2 and TIE1, correlated positively 
with weight-loss across different muscle groups (Rectus abdominis, Vastus lateralis, 
Diaphragma) indicating that cachexia was not simply due to inactivity and 
suggesting that these genes could be used as biomarkers of cachexia. None of the 
biomarkers discovered were consistent with pre-clinical models and therefore require 
further study before progressing to a validation programme.  Electron microscopy of 
muscle biopsies demonstrated that the number and size of intramyocellular lipid 
droplets was increased in the presence of cancer and increases further with weight-
loss/loss of adipose mass in other body compartments. The specific mechanisms and 
drivers of this phenomenon remain to be elucidated, but could relate to enhanced 
lipolysis or mitochondrial dysfunction in skeletal muscle as well as influencing 
muscle mechanical quality.  Physiological assessment of patients with cancer 
cachexia established the negative impact that cachexia can have on muscle mass, 
function, muscle quality and quality of life, but demonstrated that the degree of 
impairment varies with sex and between muscle groups.  Furthermore, the challenge 
of longitudinal studies in this patient group where frailty and clinical deterioration 
limit repeated assessments was highlighted. Such issues emphasise the need for a 
dual approach to the classification of cancer cachexia: if molecular markers prove 
difficult to discover or validate, then more specific and robust physiological indices 
of skeletal muscle mass and function may be the more important route to improve 
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BP, blood pressure 
BSA, bovine serum albumin 
C, Celsius 
CAMk, Ca2+/calmodulin-dependent protein kinase 
CART, cocaine and amphetamine regulated transcript 
CASCO, cachexia score 
cDNA, complementary deoxyribonucleic acid 
CEA, carcinoembryonic antigen 
cFT, calculated free testosterone 
CoA, coenzyme A 
COMP, cartilage oligomeric matrix protein 
COPD, chronic obstructive pulmonary disease 
CRP, C-reactive protein 
CRUK, Cancer Research UK 
CSA, cross-sectional area 
CSF, cerebrospinal fluid 
CT, computerised tomography 
DEPC, diethylpyrocarbonate 
DEXA, dual energy x-ray absorptiometry 
DGC, dystrophin glycoprotein complex  
DNA, deoxyribonucleic acid 
DTT, dithiothreitol 
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E1, ubiquitin activating enzyme 
E2, ubiquitin carrier protein  
E3, ubiquitin protein ligase 
ECL, enhanced chemiluminescence 
EDTA, ethylenediaminetetraacetic acid 
EE, energy expenditure 
EGTA, ethylene glycol tetraacetic acid 
eIF, eukaryotic initiation factor 
ELISA, enzyme-linked immunosorbent assay 
ENST, Ensemble transcript identifier 
EORTC, European Organisation for Research and Treatment of Cancer 
ERCP, endoscopic retrograde cholangiopancreatography 
F, female 
FA, fatigue 
FAACT, Functional Assessment of Anorexia/Cachexia Therapy 
FACIT, Functional Assessment of Chronic Illness Therapy 
FACT-G, Functional Assessment of Cancer Therapy 
FDA, Food and Drug Administration 
FDR, false discovery rate 
FFM, fat-free mass 
FM, fat mass 
FOXO, Forkhead box subgroup O transcription factor 
FSH, follicle-stimulating hormone 
FU, follow-up 
GABRAPL1, gamma aminobutyric acid receptor-associated protein-like 1 
GDF, growth and differentiation factor 
GH, growth hormone 
GLP, glucagon-like peptide 
GO, Gene Ontology 
GOBP, Gene Ontology biological processes 
GPS, Glasgow Prognostic Score 
Grb, growth factor receptor-bound protein 
GSKβ,  glycogen  synthase  kinase  3β 
H&E, haematoxylin and eosin stain 
Hb, haemoglobin 
HC, healthy controls 
HEPES, hydroxyethyl piperazineethanesulfonic acid 
HGD, hand grip dynamometry 
HGS, hepatocyte growth factor-regulated tyrosine kinase substrate 
HINT3, histidine triad nucleotide binding protein 3 
HIV, human immunodeficiency virus 




HSP90AB1, heat shock protein 90kDa alpha (cytosolic), class B member 1 
HU, Hounsfield Unit 
ICD, International Classification of Diseases 
ICU, intensive care unit 
ID, identification 
IFN, interferon 
IGF, insulin-like growth factor 
IGFBP, insulin-like growth factor binding protein 
IKES, isometric knee extensor strength 
IKK,  IκB  kinase 
IL, interleukin 
IM, intermuscular 
IPA, ingenuity pathway analysis 
IRS, insulin receptor substrate 
ISAK, International Society for the Advancement of Kinanthropometry 
IκB,  inhibitor  of  kappa-B 
JAK, janus kinase 
JNK, Jun N-terminal kinase  
kDa, kiloDalton 
KEGG, Kyoto Encyclopedia of Genes and Genomes  
KPS, Karnofsky performance score 
L3, 3rd lumbar vertebra 
LBM, lean body mass 
LC3, light chain 3 
LD, lipid droplet 
LH, luteinising hormone 
LLEP, lower limb explosive power 
LMF, lipid mobilising factor 
LSB, Laemmli sample loading buffer 
M, male 
MAC-16, murine adenocarcinoma 16 mouse model 
MAC, mid-arm circumference 
MAFbx, muscle-specific F-box, also known as atrogin-1 
MAMC, mid-arm muscle circumference 
MAPK, mitogen-activated protein kinase 
MAS, microarray suite software 
MATLAB, matrix laboratory 
MC4R, melanocortin 4 receptor 
MCA, methylcholanthrene 
MDT, multi-disciplinary team 
Met-tRNA, methionyl transfer-RNA 




MIC-1, macrophage inhibitory cytokine-1 
MMP3, matrix metalloproteinase 3 
MR, magnetic resonance 
MRF, myogenic regulatory factors 
MRI, magnetic resonance imaging 
mRNA, messenger ribonucleic acid 
mTOR, mammalian target of rapamycin 
MURF-1, muscle-specific RING finger-1 
MUST, Malnutrition Universal Screening Tool 
MYBP-C, myosin binding protein-C  
Myc, myelocytamotosis 
MyHC, myosin heavy chain 
MyLC, myosin light chain 
MyoD, myoblast determination protein 
N, Newton 
N/A, not applicable 
NF-κB,  nuclear  factor  kappa-B 
NHL, non-Hodgkin's lymphoma 
NIH, National Institutes of Health 
NLL, non-lymphocytic leukaemia 
nNOS, neuronal nitric oxide synthase 
NPY, neuropeptide Y 
NSCLC, non-small cell lung cancer 
NUDC, nuclear distribution C homolog 
OGJ, oesophago-gastric junction 
p70s6k, p70 ribosomal s6 kinase 
PAGE, polyacrylamide gel electrophoresis 
PBMC, peripheral blood mononuclear cell 
PBS, phosphate buffered saline 
PCK1, phosphoenolpyruvate carboxykinase 1 
PDK1, phosphoinositide-dependent kinase-1 
PET, Positron Emission Tomography 
PF, physical function 
PI3K, phosphatidylinositol 3-kinase 
PIF, proteolysis-inducing factor 
PIP3, phosphatidylinositol (3,4,5) trisphosphate 
PKB, protein kinase B 
PKR, double-stranded RNA-dependent protein kinase 
PMSF, phenylmethanesulphonylfluoride 
POLRMT, polymerase (RNA) mitochondrial (DNA directed) 
POMC, pro-opiomelanocortin 




PSA, prostate specific antigen 
Q.CSA, mid-femur quadriceps cross-sectional area 
QLQ-C30, Quality of Life Questionnaire Core 30  
QoL, quality of life 
qRT-PCR, quantitative reverse transcription-polymerase chain reaction 
RCAN1, regulator of calcineurin 1 
RIE, Royal Infimary of Edinburgh 
RMA, Robust Multi-array Average 
RNA, ribonucleic acid 
ROC, Receiver Operating Characteristic 
ROI, region of interest 
rpm, revolutions per minute 
SAM, significance analysis of microarrays 
SARM, selective androgen receptor modulator 
SC, subcutaneous 
SCLC, small cell lung cancer 
SCRINIO, screening the nutrition risk of oncology patients 
SD, standard deviation 
SDS, sodium dodecyl sulphate 
SEM, standard error of the mean 
SF-36, Short Form-36 health survey 
SGK1, serum/glucocorticoid regulated kinase 1 
SHBG, sex hormone binding globulin 
SI, systemic inflammation 
SLC25A37, solute carrier family 25 (mitochondrial iron transporter), member 37 
SNAP23, Synaptosomal-associated protein 23 
SNARE, Soluble NSF Attachment Protein) REceptors 
SOCS, Suppressor of Cytokine Signalling 
SPSS, Statistical Package for Social Services 
STAT, Signal Transducer and Activator of Transcription 
STS, sit-to-stand time 
TAM, tumour-associated macrophage 
TBS, Tris-buffered saline 
TBST, TBS Tween 
TEM, transmission electron microscopy 
TGF, transforming growth factor 
TIE1, tyrosine kinase with immunoglobulin-like and EGF-like domains 1 
TNF, tumour necrosis factor 
TNM, Tumour lymph Nodes and presence of Metastases staging system 
TRAF, TNF receptor-associated factor 
TSC2, tuberous sclerosis 2 
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UICC, Union Internationale Contre le Cancer 
UPP, ubiquitin proteasome pathway 
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VEGF, vascular endothelial growth factor 
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Chapter  1:  Introduction 
1.1 Overview 
Cachexia affects up to two thirds of all cancer patients (Laviano et al., 2005) and is 
also a feature of many other disease states including chronic obstructive pulmonary 
disease (COPD), chronic heart failure, chronic renal failure, rheumatoid arthritis and 
human immunodeficiency virus (HIV).  It is a chronic wasting syndrome due to a 
combination of metabolic change, reduced food intake, reduced levels of physical 
activity, and increasing patient age (Skipworth et al., 2007).  Weight-loss is one of 
the hallmarks of cachexia with depletion of both adipose tissue and lean body mass.  
In particular, there is a disproportionate loss of skeletal muscle.  Patients may present 
with varying degrees of weight/tissue loss and it is important to consider cachexia as 
a journey rather than an event.  A recent international consensus paper on cancer 
cachexia highlighted this continuum with a classification of three stages of cachexia: 
pre-cachexia, cachexia and the terminal state of refractory cachexia (Fearon et al., 
2011).  Cachexia is a significant cause of cancer patient morbidity and around 20% 
of cancer-related deaths are directly caused by malnutrition and cachexia due to 
immobility and cardio-respiratory failure (Tisdale, 2002).  In spite of this, there are 
currently no evidence-based therapeutic agents in clinical use to reverse or even 
attenuate progression of cachexia in cancer patients.  One of the major reasons for 
this is a limited understanding of the specific molecular mechanisms leading to the 
development of cancer cachexia combined with a scarcity of data describing the 
impact on muscle function and physical activity.  A PubMed search (using search 
terms:  ‘cachexia’  and  ‘cancer’)  indicates that over a quarter of publications relating 
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to cancer cachexia are review articles, highlighting the need for more primary 
investigations that shed light on the detailed mechanisms that produce the syndrome 
in patients.  Furthermore, the majority of molecular hypotheses have been generated 
using pre-clinical models or reflect biochemical concepts and there has been little 
progress in relating these potential mechanisms to changes observed in the patient.  
With this background, the key theme of this thesis was to centre on skeletal muscle 
of patients with upper gastrointestinal (UGI) cancer, with or without cachexia, under 
two broad aims.  Firstly, to stage cancer cachexia by investigating potential early 
skeletal muscle biomarkers relating to the presence or development of cachexia and; 
secondly, to assess the muscle phenotype of patients with cancer cachexia.    
 
The introductory section of this thesis gives an overview of cancer cachexia and 
current understanding of the biological processes involved.  The concept and 
potential of biomarkers in general will be described along with an outline of current 
data relating to biomarkers of cancer cachexia.  This provides a background and 
rationale for the subsequent investigations described in the rest of the thesis. 
 
1.2 Cancer cachexia 
1.2.1 What is cachexia? 
The  word  cachexia  is  derived  from  the  Greek  ‘kakos’  meaning  ‘bad’  and  ‘hexis’  
meaning  ‘condition’,  ‘habit’  or  ‘state  of  being’.    It  has  been  recognised  for  many  
years as a complex syndrome with an associated poor outcome.  Indeed, the Greek 
physician Hippocrates described cachexia in the third century Before Christ (BC): 
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 “the  flesh  is  consumed  and  becomes  water,…the  abdomen  fills  with  
water; the feet and the legs swell, the shoulders, clavicles, chest and 
thighs  melt  away…The  illness  is  fatal.”. 
       Hippocrates, 460-370 BC 
 
Cachexia is a clinical syndrome characterised by anorexia, early satiety, severe 
weight-loss, weakness, anaemia and oedema.  It is due to a combination of reduced 
energy intake and metabolic change.  Cachexia can be recognised easily in its 
advanced stage, but is much more difficult to predict for the purposes of early 
intervention.  In the past, cachexia was poorly defined and publications in the field 
used arbitrary degrees of weight-loss over differing time periods to categorise 
cachectic cohorts.  This conundrum was highlighted in an article investigating the 
cachexia-anorexia syndrome in which the authors (Lasheen and Walsh, 2010) 




>10% of pre-illness weight (Feliu et al., 1992) 
>10% in past 6 months (Fietkau et al., 1997) 
>5% of pre-illness weight (Bruera et al., 1999) 
>5% in previous 6 months (Strasser F, 2002) 
>5% in previous 6 weeks (Rowland et al., 1996) 
>5 pounds weight in last 2 months (Loprinzi et al., 1994) 
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Part of the difficulty for researchers has been that understanding of the basic 
characteristics and molecular mechanisms leading to cachexia and its subsequent 
impact on patients is limited.  However, the lack of an agreed definition has 
hampered interpretation and comparison of individual studies, along with limiting 
identification and treatment of cachectic patients and the development of therapeutics. 
 
Patients with 10% or more weight-loss from pre-illness weight are generally 
considered malnourished/wasted and this cut-off is used to classify patients as 
cachectic in many studies.  Furthermore, 10% weight-loss is associated with higher 
surgical risk (Windsor and Hill, 1988) and has more substantial systemic effects on 
lung function, poorer laboratory nutritional measures and worsened survival in 
pancreatic cancer patients compared with using lower weight-loss values (Bachmann 
et al., 2009).  However, in recent years, there has been a concerted effort to come up 
with more meaningful and relevant definitions based on current evidence.  As 
knowledge about cancer cachexia evolves, these definitions will no doubt be refined, 
but at present they represent an effort to provide consistency to allow more 
meaningful collaborative research and interpretation of larger data sets.  A summary 
of each of these definition papers follows: 
 
Definition of cancer cachexia: effect of weight-loss, reduced food intake, and 
systemic inflammation on functional status and prognosis (Fearon et al., 2006). 
This was the first paper to attempt a considered definition of cancer cachexia related 
to the multidimensional nature of the syndrome rather than a crude weight-loss cut-
off.  It utilised a cohort of patients entered into a separate nutritional trial and 
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analysed a definition of weight-loss alone or incorporating additional measures of 
nutritional intake and inflammation.  All patients had a weight-loss >5% and the 
study divided the patients according to weight-loss above or below 10%.  Using 
weight-loss alone, >10% as a definition did not distinguish the groups according to 
subjective measures of quality of life (QoL), but they did have significantly different 
hand grip strength and Karnofsky performance scores (KPS). When patients were 
stratified by combining weight-loss >10%, reduced food intake <1500 kcal/day and 
systemic inflammation with a C-reactive protein (CRP) > 10mg/l then cachectic 
patients had significantly poorer subjective and objective measures of QoL, function, 
performance status and survival. 
 
Cachexia: a new definition (Evans et al., 2008).  
This paper described the consensus from a meeting of cachexia researchers in 2006.  
The definition was: 
 
“cachexia,  is  a  complex  metabolic  syndrome associated with underlying 
illness and characterised by loss of muscle with or without loss of fat 
mass.  The prominent clinical feature of cachexia is weight-loss in adults 
(corrected for fluid retention) or growth failure in children (excluding 
endocrine disorders).  Anorexia, inflammation, insulin resistance and 
increased muscle protein breakdown are frequently associated with 
wasting disease.  Wasting disease is distinct from starvation, age-related 
loss of muscle mass, primary depression, malabsorption and 
hyperthyroidism  and  is  associated  with  increased  morbidity.”     
 
In order to make this definition more meaningful for practical use, the diagnostic 
criteria were refined to: 
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 “weight-loss of at least 5% in 12 months or less in the presence of 
underlying illness, plus three of: decreased muscle strength, fatigue, 
anorexia, low fat-free mass index or abnormal biochemistry (increased 
inflammatory markers: CRP >5.0mg/l or 1L-6 >4.0 pg/ml, anaemia: Hb 
<12  g/dl,  or  low  serum  albumin:  <3.2  g/dl).”     
 
The paper also suggested that cachexia could be described as mild (weight-loss >5%), 
moderate (>10%) or severe (>15%) over the preceding 12 months.  In cases where 
weight-loss was not able to be assessed, a body mass index (BMI) <20 kg/m2 was 
thought to be adequate to represent cachexia.  This definition was broadly related to 
cachexia of any aetiology (i.e. cancer, cardiac failure, COPD, HIV), was not 
evidence-based, and did not take into account potential differences between each of 
these disease aetiologies.  
 
Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document 
elaborated by Special Interest Groups "cachexia-anorexia in chronic wasting 
diseases" and "nutrition in geriatrics" (Muscaritoli et al., 2010).  
This definition was based on answers of experts in the field to a series of questions.  
Cachexia was defined as: 
 
“a  multifactorial syndrome characterised by severe body weight, fat and 
muscle loss and increased protein catabolism due to underlying 
disease/s’.”   
 
The authors suggested that, due to the wide range of clinical manifestations 
associated with cachexia, staging is warranted.  The consensus agreed that 
inflammation has a role in the pathogenesis of cachexia, cachexia is different to 
malnutrition but anorexia can significantly contribute to the nutritional deterioration 
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of cachexia if it is not properly treated.  The authors suggested utilising an adapted 
questionnaire for anorexia.  There was also agreement that cachexia was associated 
with changes in body composition – most importantly loss of skeletal muscle.   The 
importance of staging cachexia was emphasised and a proposal to stratify patients 
into pre-cachectic or cachectic was outlined.  Pre-cachexia was defined as the 
presence of all the following factors: underlying chronic disease, unintentional 
weight-loss >5% over the preceding 6 months, chronic/recurrent systemic 
inflammatory response, anorexia or anorexia-related symptoms.  The authors 
suggested that obese people can have pre-cachexia but it may be difficult to diagnose 
and commented on the concept of sarcopenic obesity. 
 
Definition and classification of cancer cachexia: an international consensus 
(Fearon et al., 2011).  
This paper describes a definition specific to cachexia caused by cancer.  The 
definition was reached after focus group meetings and two Delphi rounds.  It defined 
cancer cachexia as:  
 
“a  multifactorial  syndrome  characterised  by  an  ongoing loss of skeletal 
muscle mass (with or without loss of fat mass) that cannot be fully 
reversed by conventional nutritional support and leads to progressive 
functional impairment.  The pathophysiology is characterised by a 
negative protein and energy balance driven by a variable combination of 
reduced  food  intake  and  abnormal  metabolism.”     
 
Diagnostic criteria for cancer cachexia were defined as:  
 
“weight-loss >5% over the preceding 6 months (in absence of simple 
starvation); or BMI <20 kg/m2 and any degree of weight-loss >2%; or 
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appendicular skeletal muscle index consistent with sarcopenia (males 
<7.26 kg/m2; females <5.45 kg/m2) and any degree of weight-loss >2%.”     
 
The values for appendicular skeletal muscle are based on Computed Tomography 
(CT) cross-sectional imaging of skeletal muscle at the 3rd lumbar vertebra (L3) level.  
Alternative measures that the authors suggested were bioimpedance analysis, or mid-
arm muscle area by anthropometry.  Importantly, this paper also highlighted the need 
to consider the stages of cancer cachexia; pre-cachexia, cachexia and refractory 
cachexia.  These are key points to consider as the treatment type and aggressiveness 
will be determined according to where the patient is on the cachexia journey. 
 
Even though these definitions are in their infancy, there have already been groups 
publishing descriptions of potential scoring systems to categorise the severity of 
cachexia.   
 
The cachexia score (CASCO): a new tool for staging cachectic cancer patients 
(Argiles et al., 2011).  
This descriptive paper outlined proposals for a scoring system based on five domains: 
measures of weight-loss and body composition, inflammation/metabolic 
abnormalities and immunosuppression, physical performance, anorexia and QoL.  
However, the score has not been validated in patients and concrete evidence for a 
relationship between some of the proposed plasma markers and cachexia is lacking 
(Baracos, 2011).  
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Defining and classifying cancer cachexia: a proposal by the SCRINIO 
(Screening the nutrition risk of oncology patients) Working Group (Bozzetti 
and Mariani, 2009). 
The authors of this paper chose a cut-off of 10% weight-loss to distinguish pre-
cachexia and cachexia with the addition of the presence or absence of symptoms 
(anorexia, fatigue or early satiety).  This resulted in a severity staging system with 
four classes of cachexia.  Whilst the authors did examine the scoring system in 1307 
of their cancer outpatients, it has not, to date, been validated in any other independent 
cohorts. 
 
The motivation behind the development of cachexia scoring/staging systems is 
positive.  However, cachexia definitions have only emerged recently and there is 
ongoing development of and discussion about them amongst researchers.  It is 
therefore perhaps premature to propose scoring systems until the appropriate 
evidence base, measurement tools and statistical methodology is available, has been 
agreed upon and validated (Baracos, 2011). 
 
1.2.2 Epidemiology and demographics 
Weight-loss is seen as the hallmark of cachexia and commonly triggers patients to 
consult a physician.  At diagnosis, one third of all cancer patients will have lost >5% 
of their original body weight and the overall incidence of weight-loss in the general 
cancer population is 63% (Laviano et al., 2005).  Taken together with the fact that 
one in three individuals will develop cancer in their lifetime, these figures highlight 
 29 
the importance of cachexia and the necessity to improve our understanding of the 
field. 
 
1.2.2.1 Impact of tumour type 
Although cachexia can occur in patients with cancer affecting any organ, there is a 
considerable degree of variation in the frequency of weight-loss associated with 
different tumour types.  This is evident from the results of a study of cancer patients 
by the Eastern co-operative oncology group in the 1980s (Dewys et al., 1980).  Table 
1.1 shows the results.   
 
Of particular note is the aggressive weight-loss associated with pancreatic cancer 
with the values in the table relating to weight-loss in the preceding 2 months 
(whereas it is over 6 months for the other tumour types).   
 
A more recent study (Fox et al., 2009) investigated variations in the incidence of 
cancer cachexia according to four different definitions.  The study included 8451 
cancer patients (mixed tumour types) who were classified as cachectic according to 
(1) International Classification of Diseases (ICD) definition alone, (2) ICD codes 
with addition of anorexia, abnormal weight-loss and feeding difficulties, (3) 
prescription  of  certain  ‘anti-cachectic’  drugs,  or  (4)  post-cancer diagnosis weight-
loss >5%.  The incidence of cachexia was much lower than reported in the 1980s 
(Table 1.1) study (2.4%, 5.5%, 6.4%, 14.7% according to the different definitions 
respectively).    
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Table  1.1:  Frequency  of  weight-loss  according  to  tumour  type 
 
Tumour type Weight-loss* 
None 0-5 % 5-10 % >10 % 
Favourable NHL 69 14 8 10 
Breast 64 22 8 6 
Acute NLL 61 27 8 4 
Sarcoma  60 21 11 7 
Unfavourable NHL 52 20 13 15 
Colon 46 26 14 14 
Prostate 44 28 18 10 
Lung Small cell 43 23 20 14 
Non-small cell 39 25 21 15 
Pancreas 17 29 28 26 
Gastric Nonmeasurable 17 21 32 30 
Measurable 13 20 29 38 
 
 
Adapted from Dewys et al (Dewys et al., 1980).  *Data refers to % 
weight-loss over the preceding six months apart from pancreatic cancer, 
which is over the preceding two months.  Numbers refer to percentage 
of total patient number for each tumour type.  Abbreviations: NHL, Non-




The authors estimated that 23% of cancer patients might have cachexia at some point 
after their cancer diagnosis as determined by any of the four definitions.  The tumour 
types that were most associated with cachexia by any of the definitions were: breast 
(26.5%), prostate (25.7%), lung (20.3%) and colorectal (11.7%).  Of note, only 3.9% 
of pancreatic cancer patients were cachectic by any of the definitions.  These 
percentages contradict previous reports (Table 1.1) and also the majority of recent 
publications where, for example, pancreatic cancer is associated with cachexia in ~80% 
of patients (Fearon et al., 1999).  These conflicting results may be due to problems 
with data capture using ICD codes, which are dependent on a physician entering the 
details.  There are many papers in a variety of diseases highlighting inaccuracies in 
the ICD classifications due to its subjective nature and what type of information is 
put in (Zeng and Bell, 2011, Hagen et al., 2009, Gibson and Bridgman, 1998, 
Campos-Outcalt, 1990, Lloyd and Rissing, 1985, Hsia, 1990), and it is likely that this 
has impacted to some degree on the results of the study.  Furthermore, one of the 
four definitions (definition 4) relied on post-diagnosis weight-loss (in contrast to 
other studies which generally report pre-diagnosis weight-loss) and there was no 
comment on any different treatment modalities that may have influenced progression 
of cachexia (i.e. did they have chemotherapy or resectional surgery?).  It is therefore 
likely that the methodology of the study has yielded misrepresentative results.   
 
The percentage of weight losing individuals seems to be highest in patients 
diagnosed with pancreatic or gastric cancer (>80%) (Dewys et al., 1980).  In one 
study, 85% of patients with newly diagnosed unresectable pancreatic cancer lost a 
median of 14% of their pre-illness stable weight, increasing to a median of 25% near 
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the time of death (Wigmore et al., 1997b).  Indeed, the prevalence of weight-loss in 
cancer patients has been quoted as high as 86% in the last 1-2 weeks of life 
(Teunissen et al., 2007).   
 
Why pancreatic or gastric cancer should be more strongly associated with cachexia 
than tumours such as breast cancer is still not clear (Tisdale, 2005).  One possibility 
is that certain tumours are more likely to present earlier in the disease process prior 
to the development of weight-loss or any systemic symptoms.  For example, weight-
loss may be the first and only presenting symptom of a patient with pancreatic cancer 
whereas a breast tumour or lymphoma may be noticed by the patient as a lump 
during self-examination when the tumour is at an earlier stage and prior to changes in 
body composition.  Alternatively, precipitation of an acute phase response with 
resultant hypermetabolism and loss of skeletal muscle proteins may be more 
common in certain tumour sites (e.g. pancreatic cancer (Fearon et al., 1999)). 
 
It is also important to consider that along with the differences in prevalence of 
cachexia between different tumour sites, there is also variation within individual 
types of tumour.  For example, although up to 85% of pancreatic cancer patients 
develop cachexia, 15% will not (Tisdale, 2009).  The reasons for this remain unclear, 
but it raises the intriguing possibility of a cachexia resistant phenotype or genotype. 
 
1.2.2.2 Impact of gender 
It is well recognised that men have a different body composition to women and the 
prevalence of each tumour type varies between genders.  For example, Cancer 
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Research United Kingdom (CRUK) data shows that in 2009 the top 5 cancers for 
men were: prostate, lung, bowel, bladder and NHL, whereas for women it was: breast, 
bowel, lung, uterus and ovary (Website, 2009).  Likewise, sex-specific differences in 
survival for similar cancer types have been reported (Skipworth et al., 2011, 
Oberaigner and Siebert, 2011).  It might therefore be supposed that the likelihood 
and impact of cancer cachexia would also vary according to gender.  However, there 
are few studies that have investigated this directly and many others have not taken it 
into consideration in the interpretation of results, but rather have pooled data for men 
and women.   
 
In an animal model of cardiac cachexia using Sprague Dawley rats, body weight was 
seen to decline in male rats following myocardial infarction surgery, but not in 
females (Palus et al., 2009).   Similarly, in a mouse model of cancer cachexia (colon-
26 tumour), males demonstrated a more severe phenotype.  Male mice had greater 
and more rapid loss of overall body weight, skeletal muscle and cardiac muscle along 
with an increased mortality compared with female mice (Cosper and Leinwand, 
2011).  Furthermore, in the same paper, male cachectic mice had poorer survival and 
increased markers of autophagy compared with the females.  The administration of 
an oestrogen antagonist to females led to a cachectic phenotype similar to the males 
suggesting a role of the gonadal hormones in this sexual dimorphism.  Likewise, in a 
study of transgenic mice overexpressed with myostatin (thought to be an inhibitor of 
skeletal muscle mass) in skeletal muscle, male mice demonstrated lower muscle 
mass, reduced muscle fibre size and decreased numbers of myonuclei along with 
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decreased cardiac muscle mass and increased fat mass (Reisz-Porszasz et al., 2003).  
However the same changes were not apparent in female mice.   
 
In humans, there is also evidence of sexual dimorphism in body composition changes 
with weight-loss and cachexia.  In obese ‘healthy’  patients undergoing a weight-loss 
program, although both genders lost similar amounts of weight and body fat, men 
lost more visceral fat than women whereas subcutaneous fat was depleted more in 
women than men (Wirth and Steinmetz, 1998).  In HIV patients, an autopsy study 
demonstrated that women had a lower frequency of cachexia than men, although died 
at a younger age (Morgello et al., 2002).  Observations in lung cancer patients have 
shown that significant muscle wasting is twice as prevalent in males compared with 
females (Baracos et al., 2010).  Indeed, weight-loss (including muscle loss) has been 
suggested to play a role in mediating sex-related differences in lung cancer patients’ 
survival (Palomares et al., 1996, Chlebowski et al., 1996).  Likewise, female gender 
has been shown to be a key determinant of weight stabilisation, with resultant 
improved QoL and survival duration, in a post hoc analysis of data from patients 
with unresectable pancreatic cancer enrolled in a multicentre nutritional intervention 
study (Davidson et al., 2004).   
 
There may also be sex differences in the impact of cachexia on muscle function.  In 
an immobilisation study, relative to the loss of muscle mass, females sustained a 
proportionally greater loss of strength than males (Yasuda et al., 2005).  Similarly in 
a cohort of hospitalised patients with mixed disease aetiologies, handgrip strength 
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was demonstrated to decrease significantly more in men with severe weight-loss than 
in women (Norman et al., 2012). 
 
1.2.2.3 Impact of ageing 
It is generally accepted that increasing age is associated with increased frailty.  This 
is due in part to the age related degenerative loss of skeletal muscle known as 
sarcopenia (Rosenberg, 1997).  However, this loss of muscle may not be obvious 
with conventional clinical assessment tools.  This was illustrated in a study of 
longitudinal body composition changes in healthy men age 20-96 years (Jackson et 
al., 2012).  The authors showed that BMI, fat mass, and percentage of body fat 
increased between 20-80 years before reaching a plateau, whereas fat-free mass 
(including skeletal muscle) peaked at 47 years and then declined with ageing.  
However, although BMI (a conventional anthropometric assessment tool) reflected 
the increase in fat mass that occurred with healthy ageing, it was unable to identify 
the loss of fat-free mass that started at age 47 years (Jackson et al., 2012).  This 
suggests a need for more sophisticated measures of body composition studies in 
sarcopenia or cachexia, rather than only including anthropometric assessments. 
 
Given that the average age of cancer patients is 60-70 years, it is probable that age 
related loss of muscle would be relevant.  Furthermore, the process of sarcopenia is 
exacerbated by chronic illness, inadequate diet and bedrest (Cuthbertson et al., 2005, 
Coker and Wolfe, 2012), and it is likely that the presence of systemic 
inflammation/cachexia will exacerbate this muscle loss.   
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1.2.2.4 Impact of obesity 
There is an increasing level of obesity in the general population (especially in 
Western cultures) and obesity is itself a risk factor for the development of cancer. It 
is important to recognise that underneath the mantle of fat there may be clinically 
occult  muscle  wasting.    This  trend  to  what  has  been  termed  ‘sarcopenic  obesity’  in  
advanced cancer patients has recently been emphasised (Prado et al., 2008).  Indeed, 
in a study of patients with advanced pancreatic cancer, CT defined sarcopenic 
obesity was shown to be an independent determinant of reduced survival (Tan et al., 
2009). 
 
This has added a further layer of complexity in the clinical assessment of such obese 
individuals and there has been a paradigm shift towards the concept of the cachectic, 
but overweight, cancer patient.  There has also been recognition that conventional 
anthropometric measures are probably inadequate in identifying at risk individuals 
and therefore utilising more detailed imaging modalities such as CT or Magnetic 
Resonance (MR) imaging may be necessary. 
 
1.2.3 Symptoms of cancer cachexia 
Whilst weight-loss and muscle loss may be predominant features of cachexia, 
patients present with a spectrum of symptoms.  In a study examining the symptoms 
prevalent in cancer patients with cachexia-anorexia syndrome (defined as weight-
loss >10% and anorexia of any severity), 9 out of the 26 symptoms assessed were 
found to be distinctly related to cachexia: early satiety, constipation, nausea, taste 
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changes, vomiting, dysphagia, fatigue, weak, and lack of energy (Lasheen and Walsh, 
2010).  Likewise, a recent systematic literature review looking at the association of 
involuntary weight-loss with a variety of domains related to cachexia found patients 
with weight-loss to have more depression, abdominal fullness, taste changes, 
vomiting, mouth dryness, dysphagia and loss of appetite (Blum et al., 2011).  These 
symptoms appear quite non-specific and can be present in many other disease 
conditions.  There will also be overlap, of course, between the symptoms related to 
the underlying cancer and those of cachexia.  For example, anorexia may be a 
common symptom of patients with cachexia, but in those who have oesophageal or 
head and neck tumours, the effect will be exacerbated by dysphagia/odynophagia and 
anatomical obstruction to food related to the site of the tumour itself.   Similarly 
patients with colorectal malignancies may have constipation or a feeling of 
abdominal fullness associated with impending obstruction of the colon by tumour 
bulk.  Many of the symptoms related to cachexia are caused or exacerbated by the 
presence of the systemic inflammatory response and this will be discussed further in 
Section 1.2.6.2.  Clinical history and examination remain the fundamental tools in 
diagnosing patients with cachexia and malnutrition.  Advanced cachexia is easily 
recognised, but diagnosing cachexia in its early stages remains challenging.  
Although different symptoms predominate in individual patients and may also 
change with time, weight-loss, anorexia and fatigue/weakness are among the 
commonest symptoms reported and are often the triggers that spur patients to attend 
their physician.  These three symptoms in the context of cachexia will be discussed 




Weight-loss is seen as the hallmark of cachexia and may be the only change that 
triggers a patient to consult their physician.  It is due to the combined loss of both 
lean and adipose tissue and it should be remembered that the magnitude of functional 
tissue loss may be masked by the presence of peripheral oedema/ascites or even 
increased visceral mass due to tumour (Lieffers et al., 2009).  As previously 
discussed, the incidence of weight-loss in the general cancer population is 63% 
(Laviano et al., 2005) and this increases to over 80% for patients diagnosed with 
pancreatic or gastric cancer (Dewys et al., 1980). Weight-loss >5% suggests 
developing cachexia, while patients with >15% weight-loss are well advanced into 
the cachectic state.  The presence of weight-loss has long been recognised as a poor 
prognostic factor in cancer patients. In patients with gastrointestinal cancer, severe 
wasting may account for 30-50% of deaths and up to 80% of deaths in patients with 
advanced pancreatic cancer (Davidson et al., 2004, Nelson, 2000, Palesty and 
Dudrick, 2003, Ripamonti, 1999).  Furthermore, weight-loss may also be associated 
with poor prognosis in cancer patients who are staged initially as having curative 
disease.  A recent study of 227 patients undergoing surgery for pancreatic cancer 
demonstrated that 40.5% of patients were cachectic pre-operatively (as defined by 
weight-loss >10%) (Bachmann et al., 2008).  A total of 150 of these patients 
underwent tumour resection with curative intent and the remaining 77 underwent a 
palliative operation due to the presence of locally advanced disease or metastases. 
The successful tumour resection rate was significantly different between cachectic 
and non-cachectic patients (48.9% vs. 77.8% respectively, p<0.001). In those 
patients who underwent a resection with curative intent, mean survival was 451 days 
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in patients with pre-operative weight-loss compared to 654 days for those who had 
not lost weight (p=0.001).   
 
The individual contributions of muscle versus adipose tissue depletion to the total 
weight-loss in cancer patients is unclear, but has recently gained interest. Many 
studies confirm loss in both body compartments (Lieffers et al., 2009, MacFie and 
Burkinshaw, 1987, Sarhill et al., 2003), but there have been others in human cancer 
cachexia demonstrating predominant fat loss (Fouladiun et al., 2005, Heymsfield and 
McManus, 1985) that has clouded understanding of the process.  Part of the difficulty 
in interpreting and comparing such studies is that methodologies and cachexia 
definitions differ, and some of these results may be more reflective of simple 
starvation than of cachexia (Blum et al., 2011).  However, data exist to suggest that 
there are differences in the magnitude and time course of alterations in muscle and 
fat compartments (Fearon, 2008, Abdiev et al., 2011, Kiyama et al., 2005, Fouladiun 
et al., 2005).  Additionally, a recent study using a murine model of cancer cachexia 
reported that genetic ablation of lipases not only prevented increased lipolysis but, 
unexpectedly preserved skeletal muscle mass in the mice (Das et al., 2011).  This 
indicates that the physiological interplay between fat and muscle in human cancer 
cachexia may be more complex and more significant than previously thought (Johns 
et al., 2012, Fearon, 2011).  Future studies using consistent definitions and more 
sophisticated body composition analyses are likely to shed light on this issue. 
 
1.2.3.2 ANOREXIA 
Anorexia is the loss of the desire to eat associated with a reduced food intake. An 
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inadequate net nutritional intake occurs frequently in cancer patients who fail to 
increase their intake appropriately to cope with increasing resting energy demands.  
The relationship between anorexia and weight-loss is not clear-cut.  Whilst many 
studies have reported a strong correlation between the two, in patients with weight-
loss >10%, 39% of individuals did not have anorexia, 16% of patients had a normal 
food intake and 12% had anorexia without any weight-loss (Blum et al., 2011).  The 
presence of anorexia with or without weight-loss is associated with poor QoL, low 
performance status and poorer survival (Chang et al., 2005) and is an independent 
risk factor for poor prognosis in lung cancer (Hoang et al., 2005), prostate cancer 
(Collette et al., 2004) and terminally ill cancer patients (Maltoni et al., 1995). 
 
Body weight and BMI have been used as traditional indicators of nutritional status, 
but with the increasing tendency towards obesity in the West, and the possible 
presence of compounding factors such as oedema or ascites, these markers may be 
normal even in a patient who is cachectic and malnourished.  Therefore, in the 
clinical assessment of patients at nutritional risk, tools  such  as  the  ‘Malnutrition 
Universal  Screening  Tool’  (MUST)  is  perhaps more useful and has gained favour in 
hospitals throughout the UK. In addition to BMI and percentage weight-loss, the 
effect of disease on food intake is taken into account and scored to categorise the 
patient’s  risk  of  malnutrition  (BAPEN, 2012).  Other tools for assessing anorexia 
include detailed food intake records or questionnaires such as the Functional 
Assessment of Anorexia/Cachexia Therapy scale (FAACT, (Chang et al., 2005)).   
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Anorexia has a neurohormonal origin due to disturbances of the central mechanisms 
controlling food intake along with several secondary mechanisms (Laviano et al., 
2003) (Figure 1.1).  Energy intake is controlled by the hypothalamus where 
peripheral signals convey information on energy and adiposity status. The arcuate 
nucleus within the hypothalamus plays a key role in feeding and metabolism. In 
particular, the pro-opiomelanocortin (POMC) neurons are a target for cytokine 
activation leading to hyperactivation of the melanocortin 4 receptor (MC4R) causing 
anorexia (Deboer and Marks, 2006, Marks et al., 2001). This has led to interest not 
only in developing MC4R antagonists to reverse anorexia, but also MC4R agonists in 
the treatment of obesity (Nahon, 2006). 
 
The role of cytokines in cancer anorexia may well be effected through influencing 
both the neuropeptide Y (NPY) and POMC systems.  In particular interleukin (IL)-1 
has been associated with the induction of anorexia by blocking NPY induced feeding 
by a mechanism which may involve the attenuation of NPY activity by cytokines, 
inhibition of NPY synthesis, inhibition of neuronal firing rates or an attenuation of its 
postsynaptic effects (Plata-Salaman, 2000, King et al., 2000). An Australian study 
has suggested that macrophage inhibitory cytokine-1 (MIC-1), a cytokine known to 
be secreted by human tumours, is a potent modulator of appetite in mice bearing 
human prostate cancer xenografts (Johnen et al., 2007).  This induced hypophagia 
due to reduced NPY expression and increased POMC expression within the arcuate 
nucleus. However, plasma MIC-1 levels only weakly correlated with dietary intake 
in patients with oesophago-gastric cancer.  Furthermore, there was no correlation  
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FIGURE 1.1:  PATHOGENESIS OF ANOREXIA   
 
 
Abbreviations: Co-A – Coenzyme A, IL – interleukin, TNF – Tumour 
necrosis factor, NPY – Neuropeptide Y, AgRP – Agouti-related peptide, 
POMC – pro-opiomelanocortin, CART – cocaine and amphetamine-
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with weight-loss, anthropometry or survival, questioning the relevance of MIC-1 in 
humans (Skipworth et al., 2010a). 
 
Treatments to reverse muscle loss in cancer cachexia will involve addressing 
anorexia and attempting to improve any reduced food intake.  Giving small, frequent 
energy-dense meals that are easy to eat (e.g. dairy products/ice cream) can improve 
food intake and patients should eat in pleasant surroundings and attention should be 
given to the presentation of food with avoidance of extremes of taste/smell and 
avoiding meals with a very high fat content which can delay gastric emptying 
(Stewart et al., 2006).  The addition of nutritional supplements can help.  Appetite 
stimulants such as megesterol acetate and corticosteroids can temporarily improve 
symptoms, but patients gain fat/oedema rather than muscle and there are potentially 
toxic side effects (Maltoni et al., 2001).  At present, such medications are not 
licenced in the UK.  More recently, the finding that cancer cachexia can alter appetite 
hormones such as ghrelin has led to trials looking at their potential in treatment of 
anorexia (Ashitani et al., 2009, Akamizu and Kangawa, 2011).  However, results are 
inconclusive and as such, they have not yet been adopted into clinical practice (Blum 
et al., 2011). 
 
1.2.3.3 FATIGUE   
Fatigue is common in cancer patients (Fearon et al., 2006, Teunissen et al., 2007), 
and whilst the majority of cachectic individuals may suffer from fatigue, the ability 
of fatigue to define cachexia is more limited (Strasser, 2008).  The perception of 
fatigue varies between individuals at markedly different rates making it quite a 
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subjective symptom and difficult to quantify.  Physiologically, there are three types 
of fatigue – psychological  (involving  the  central  nervous  system  and  patients’  
perception), muscular  (resulting from adenosine triphosphate (ATP) depletion) and 
synaptic (occurring at the neuromuscular junction when the action potential 
frequency exceeds the rate of acetylcholine synthesis) (Seeley, 1995).  In cancer 
cachexia, there is limited physiological research assessing fatigue according to these 
categories, with the majority of studies focusing on  patients’  feeling/assessment 
using questionnaires.  Contributing factors can include anaemia, cytokine release, 
side effects of cancer therapies, as well as depression, anxiety and difficulty sleeping 
(Ahlberg et al., 2003).  Assessment tools have been developed to investigate fatigue 
in cancer patients such as the FACIT (Functional Assessment of Chronic Illness 
Therapy; previously known as FACT-G (Functional Assessment of Cancer Therapy)) 
questionnaire.  In pancreatic cancer patients with severe weight-loss, fatigue 
(assessed by FACIT) was found to be a significant symptom and furthermore, was 
predictive of survival (at least equalling predictive ability of KPS and Hb) (Robinson 
et al., 2008).  Increased levels of cancer related fatigue (assessed by FACIT) have 
also been associated with lower handgrip strength, quadriceps strength and reduced 
muscle mass in patients with advanced gastrointestinal or lung cancers (Kilgour et al., 
2010).  Other groups have also associated increased fatigue with poorer measures of 
physical function (Brown et al., 2005, Stone et al., 2000).  A recent review by 
Strasser et al (Strasser, 2008) concluded that fatigue was a global outcome of 
cachexia rather than a diagnostic marker, and other reports highlight the conflicting 
results as to whether there is an association between severe weight-loss and fatigue 
or depression (Blum et al., 2011).  Given these inconclusive results, it remains to be 
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ascertained whether increasing fatigue is a global illness marker, caused by or 
leading to poorer muscle function and exacerbation of muscle loss. 
 
1.2.3.4 OTHER EFFECTS 
Along with the symptoms discussed above, there are a myriad of other symptoms 
that can affect patients with cancer cachexia.  Many studies have demonstrated 
poorer QoL indices with cachexia (Fearon et al., 2006, Argiles et al., 2007, 
Fouladiun et al., 2007).  The loss of weight and appetite in patients can have a 
negative psychological impact on patients and also their friends and family (Dodson 
et al., 2011).  In particular, patients can feel distressed when family members focus 
on trying to increase their calorie/food intake in the context of anorexia and early 
satiety (Reid et al., 2009a, McClement, 2005).  This can put strain on family 
relationships and the home environment along with causing patient anxiety about the 
possible outcomes of the disease (Reid et al., 2009a, Reid et al., 2009b, Strasser et al., 
2006).  Cachexia  also  has  a  detrimental  impact  on  patients’  body  image  (Rhondali et 
al., 2013, Fearon, 2008, Hinsley and Hughes, 2007), emotions, spirituality and 
relationships.  Furthermore, patients often feel socially isolated which can be 
compounded by emotional distancing by carers and healthcare professionals 
(McClement, 2005). 
 
1.2.4 Impact of cachexia on muscle mass and function 
Weight-loss in cachectic individuals has been discussed in Section 1.2.3.1. This 
current section will focus specifically on the loss of skeletal muscle and changes in 
muscle function in cancer cachexia in keeping with the key theme of this thesis.  The 
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molecular mechanisms underlying skeletal muscle depletion will be explored further 
in Section 1.2.6. 
 
1.2.4.1 Impact on muscle mass and methods of assessment 
Animal models of cachexia have been helpful both in gaining knowledge of 
molecular pathways relevant in muscle atrophy and in the assessment of subsequent 
changes in body composition by carcass dissection of cachectic animals at different 
points in the cachexia journey.  Consistent with understanding of cancer cachexia 
and perhaps unsurprisingly, all animal models undergo profound muscle wasting 
(Bennani-Baiti and Walsh, 2011).  However, observations in animal models are not 
necessarily directly reflective of what happens in patients (Bennani-Baiti and Walsh, 
2011, Aulino et al., 2010).  There exists a real challenge in assessing changes in 
muscle mass in human cancer cachexia, which may contribute to discrepant results 
between human and animal models of muscle loss.  Along with the difficulty of 
measuring the true muscle compartment, any investigation of body composition 
when patients are diagnosed with cancer will only give the measure at one time point.  
Of course, muscle loss is a time dependant process, but very few (if any) patients will 
have an accurate measure of body composition when they were healthy pre-cancer 
diagnosis from which to derive true muscle loss.  On top of this, there is great 
heterogeneity in body composition between individuals due to inherited factors and 
also choices influencing health behaviours (e.g. physical activity) that may cause 
difficulty in the interpretation of cross-sectional studies.  For example, there will be 
patients who are motivated and strive to be physically active in spite of illness, whilst 
 47 
at the other end of the spectrum are those who lead sedentary lives, are obese and 
don’t  participate in any physical activities. 
 
In the past, changes in patient’s weight alone, or alterations in anthropometry have 
been the methods employed in body composition studies.  Even now, these measures 
are frequently used partly due to their ease of use in a wider population, lower 
financial outlay, and the difficulties of co-ordinating additional appointments for 
more detailed assessments and/or exposure of patients to radiation-based imaging.  
Indeed, a recent systemic review concluded that in clinical practice, muscle loss in 
patients with cancer cachexia can be assumed to relate to weight-loss provided the 
individual does not have fluid retention, a large tumour mass or obesity (defined as 
BMI ≥30 kg/m2) (Blum et al., 2011). 
 
With increasing availability of imaging modalities in parallel with advancements in 
technology, the opportunity for more detailed and sophisticated body composition 
studies has arisen.  Cross-sectional imaging (using CT or MR imaging) has become 
the gold standard, but cost and sometimes access to scanners can be prohibitive.  
Other technologies to assess body composition such as dual energy X-ray 
absorptiometry (DEXA) and bio-impedance have been widely used by many 
research groups.  Table 1.2 summarises some of the pros and cons of utilising each 
modality in body composition studies.   
 
The loss of muscle mass (with or without loss of body fat) represents a cornerstone in 
each of the cachexia definition proposals (see Section 1.2.1).  The rest of this section  
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Table  1.2:  Pros  and  cons  for  different  methods  available  for  
assessing  body  composition 
 
 Pros Cons 
Anthropometry Portable  
Well tolerated 
Inexpensive 
Can be subjective 
Dependant on accurate land-marking 





Influenced by oedema/recent physical 
activity 
No visualisation of anatomy 
CT scan Accurate anatomic outline of body 
tissues 
Quick 
Requires appropriate facilities 
Dose of radiation (high) 
Expensive 
DEXA Well tolerated 
Relatively quick 
Dose of radiation (low) 
No visualisation of anatomy 
MR scan Accurate anatomic outline of body 
tissues 
Requires appropriate facilities 





This table is based on observations rather than direct comparison 
studies.  The method that an individual investigator chooses will be 
influenced by local hospital/research centre equipment and funding 
available.  Abbreviations: CT – Computed tomography, MR – Magnetic 




will thus focus on recent advancements in understanding of muscle mass in cancer 
cachexia related to the current gold standard of cross-sectional imaging.  
 
CT scans have become a routine part of the clinical assessment and a method of 
monitoring treatment response in oncology patients.  However, the potential for 
assessing body composition in cancer patients only came into popular use thanks to 
the  work  emanating  from  Professor  VE  Baracos’  lab  in  Canada  (Mourtzakis et al., 
2008), which was based on earlier studies in healthy adults (Shen et al., 2004).  
Using image analysis software of a CT cross-sectional image at the 3rd lumbar 
vertebrae (L3) level, they were able to extrapolate whole body free fatty mass and 
appendicular skeletal muscle estimates, which correlated well with other body 
composition methods.  In addition, CT could give information on individual muscles 
and viscera and differentiate between visceral, subcutaneous and intramuscular fat 
(Mourtzakis et al., 2008).  Cut-offs were established to classify sarcopenic (in 
reference to low muscle mass rather than age-related muscle atrophy) and non-
sarcopenic individuals.  Other groups have used CT scans to measure different 
individual muscle/fat compartments (Bachmann et al., 2009), but the applicability to 
whole body measures and the association with survival has  made  Baracos’  
methodology more relevant to cancer cachexia.   
 
Using this CT methodology, it has been shown that patients with oesophago-gastric 
cancer undergoing chemotherapy have a reduction in free fatty mass (FFM) and a 
greater proportion of patients become sarcopenic following completion of the 
treatment course (Awad et al., 2012).  Furthermore, the toxic effect of 
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chemotherapeutic agents in different tumour types appears to be increased in those 
with lower muscle mass measures on CT (Prado et al., 2011, Prado et al., 2009, 
Prado et al., 2007).  Likewise the apparent promotion of muscle gain by selumetinib 
in patients undergoing treatment for cholangiocarcinoma has been reported (Prado et 
al., 2012), opening up discussion about its potential as an anti-cachexia agent.  These 
data would suggest that doses of chemotherapeutic agents should be adjusted in line 
with  an  individual  patient’s  body  composition  and  the  degree  of  muscle  wasting.     
 
Another intriguing observation that has come to light with use of CT imaging, 
highlights the importance of muscle mass per se in cancer cachexia.  The concept of 
sarcopenic obesity (i.e. ‘hidden’  muscle  wasting  - that despite a patients 
obese/overweight body habitus, they are deplete of muscle) was first publicised in 
studies of elderly people (Baumgartner, 2000, Zamboni et al., 2008).  It has 
subsequently been estimated that 4-12% of elderly individuals are affected, using 
muscle mass as an indicator of sarcopenia (Stenholm et al., 2008).  In patients with 
gastrointestinal and respiratory tumours, CT based cut-offs for sarcopenia 
demonstrated that 15% of obese cancer patients were sarcopenic which was 
associated with poorer functional status compared with obese non-sarcopenic 
patients and was also an independent predictor of survival (hazard ratio 4.2) (Prado 
et al., 2008).  Interestingly, the authors also reported that sarcopenic obesity was 
more common in men than women, re-iterating the need for gender to be taken into 
consideration in studies of cancer cachexia.  In another similar study of pancreatic 
cancer patients undergoing palliative treatment, 39.6% of patients were 
overweight/obese (BMI ≥25 kg/m2) and of these, 40.9% were sarcopenic using CT 
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imaging.  This sarcopenic overweight/obese cohort had the worst median survival of 
only 55 days and sarcopenic obesity was found to be an independent prognostic 
variable (Tan et al., 2009).   
 
Whilst CT image analysis has proven useful for whole body muscularity measures, 
cross-sectional imaging of the thigh muscles has also been utilised in elderly and 
cancer patients with both CT (Maughan et al., 1983, Goodpaster et al., 2006, 
Goodpaster et al., 2008, Delmonico et al., 2009) and MR imaging (Weber et al., 
2007b, Weber et al., 2007a, Weber et al., 2009).  Assessing an individual muscle 
group such as the quadriceps carries the advantage of being able to relate these 
measures to muscle function of the same muscle group and thus calculate mechanical 
muscle quality (Maughan et al., 1983, Goodpaster et al., 2006, Weber et al., 2009).  
Additionally, in patients undergoing prolonged bed rest, lower limb musculature (e.g. 
the quadriceps) is prone to wasting (Pisot et al., 2008).  Furthermore, antigravity 
muscle groups appear to respond differently to non-anti-gravity muscles (de Boer et 
al., 2008) and thus assessment of individual muscle groups in cancer cachexia may 
be more informative.  Some groups have also utilised MR spectroscopy that details 
the chemical composition of muscle and gives information about, for example, 
intramyocellular lipid content (Weber et al., 2007b).  Using MR imaging and MR 
spectroscopy, Weber et al were able to demonstrate a reduction in quadriceps cross-
sectional area (CSA) of ~33% along with increased intramyocellular lipid content in 
cachectic gastrointestinal cancer patients compared with healthy controls (Weber et 
al., 2009, Weber et al., 2007a). 
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Advances in body composition analysis have been fundamental in improving our 
understanding of muscle mass and composition changes in cancer cachexia.  Patients 
with low muscle mass have difficulty with activities of daily living, mobility and 
may end up bed bound which can further compound muscle loss.  However, there 
must be additional factors that are relevant other than muscle mass alone.  For 
example, endurance athletes and marathon runners may have relatively low muscle 
mass, but are obviously not unhealthy.  Furthermore in ageing epidemiological 
research, there are reports that muscle strength is a stronger predictor of mortality 
compared with muscle mass (Newman et al., 2006). This raises the likelihood that, 
not only is the muscle mass relevant in cancer cachexia, but how well it functions 
and the relationship between the two (i.e. muscle quality) is important.  
 
1.2.4.2 Impact on muscle function and physical activity 
Given that muscle is one of the predominant tissues influenced by cancer cachexia, it 
is perhaps surprising to find that there are very few primary human studies assessing 
the impact on muscle function.  A recent systemic review of symptoms relating to 
cancer cachexia identified only two studies investigating formally the relationship 
between reduced muscle strength and weight-loss in cancer patients (Blum et al., 
2011). This seems illogical given the prominence that muscle function/strength has 
been given in the various proposals for the definition of cachexia (Section 1.2.1).  
Muscle mass has been correlated with strength in healthy adults (Maughan et al., 
1983) and perhaps the assumption that the two are always highly correlated (Strasser, 
2008) has distracted research groups from investigating this issue any further.  
Another contributing factor may be that extrapolation of elements from QoL scores 
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(e.g. physical function components from Short Form (SF)-36 health survey (SF-36) 
or European Organisation for Research and Treatment of Cancer (EORTC) QoL 
questionnaires) have been used as surrogates for direct physiological assessments of 
muscle function.   
 
Muscle strength and physical activity have been shown to deteriorate in the presence 
of cachexia in animal models (Toledo et al., 2011, Baltgalvis et al., 2010, Baltgalvis 
et al., 2009, Aulino et al., 2010).  However, the relationship between limb strength 
and cancer cachexia in humans is unclear.  Increased fatigue has been related to 
poorer muscle strength in palliative lung/gastrointestinal cancer patients (Kilgour et 
al., 2010) and a study in gastrointestinal cancer patients demonstrated a reduction in 
absolute quadriceps strength of 30-40% (Weber et al., 2009).  Contrary to this, a 
study in lung cancer patients showed similar quadriceps strength compared with 
healthy controls (Wilcock et al., 2008).  One explanation is that there may be 
differences in functional changes according to tumour type.  However, whilst the 
lung cancer study recruited patients with weight-loss <10%, (Wilcock et al., 2008) 
patients in the gastrointestinal cancer study (Weber et al., 2009) all had weight-
loss >10% in 6 months.  It is thus more likely that quadriceps muscle function is 
influenced by the degree of weight-loss.  Interestingly, there are data from both 
animals (Aulino et al., 2010) and patients with gastrointestinal cancer (Weber et al., 
2009) that report normalising strength to muscle size/CSA (muscle mechanical 
quality) abrogates the significant difference from controls i.e. that the available 
strength per unit muscle is not reduced in cachexia.  In contrast, animal models have 
suggested that the process of cachexia involves selective and early loss of key 
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elements of the contractile structures within skeletal muscle which would likely 
impact on muscle mechanical quality (Acharyya et al., 2005). Moreover, 
ultrastructural analysis has demonstrated myofibrillar disarray, irregular muscle 
membranes and dystrophic muscle morphology in the muscles of tumour-bearing 
cachectic animals (Acharyya et al., 2005).  Given these contrasts, there is a pressing 
need to explore these relationships in other human datasets.   
 
Hand grip dynamometry has been shown as a sensitive marker of sarcopenia in 
elderly adults (Lauretani et al., 2003) and is suggested as the preferred measure of 
muscle strength in studies of cancer cachexia (Fearon et al., 2011) mainly due to the 
accessibility and ease of measurement in the clinical setting.  Patients with low hand 
grip strength prior to surgery for oesophageal cancer suffer more morbidity and have 
increased post-operative mortality rates (Chen et al., 2011) and hand grip strength 
has been demonstrated to be significantly lower in cachectic pancreatic cancer 
patients with weight-loss >10% versus 5-10% (Fearon et al., 2006).   
 
The use of physical activity monitoring with portable accelerometers is well tolerated 
by cancer cachexia patients (Maddocks et al., 2010) and is thought to represent a 
useful objective endpoint for trials (Maddocks et al., 2010, Dahele et al., 2007, 
Strasser, 2008).  One study, utilising the ActiGraph physical activity monitor 
(accelerometer), in palliative pancreatic cancer patients demonstrated significantly 
reduced physical activity in weight losing cancer patients versus healthy volunteers.  
In addition, cancer patients had decreasing spontaneous physical activity associated 
with progression of their disease with time (Fouladiun et al., 2007).  Weight-loss 
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(along with plasma CRP and Hb) was a significant predictor of spontaneous activity 
and SF-36 self-reported physical functioning and bodily pain predicted variations in 
overall daily physical activity (Fouladiun et al., 2007).  Similarly in a study of 
patients with UGI malignancies undergoing palliative care, using the ActivPALTM 
accelerometer a reduction in the median total number of steps taken by cancer 
patients of 43% compared with controls was seen along with a fall in the time spent 
in quiet standing of 32% (~2hrs/day less) (Dahele et al., 2007).  This tendency 
towards sedentary behaviour and reduced physical activity will undoubtedly 
exacerbate decline in muscle mass and function in cachectic cancer patients given the 
data from bed-rest and immobility studies (Biolo et al., 2005). 
 
These issues clearly need to be explored further given that the maintenance of 
independence and QoL are desirable by patients and that physical activity relates to 
psychological wellbeing (Maddocks et al., 2010, Netz et al., 2005, Rejeski and 
Mihalko, 2001, McAuley et al., 2000). 
 
1.2.5 Impact of cachexia on survival 
In 1932, Shields Warren from Harvard medical school reported a series of 500 
autopsies on cancer patients (Warren, 1932).  The immediate cause of death in 114 of 
these (22%) was secondary to inanition of the patients and up to two thirds of this 
cadre of patients exhibited some degree of cachexia (Palesty and Dudrick, 2003).   In 
1980, Dewys et al demonstrated the adverse effects of weight-loss on survival and 
introduced the notion that even lower amounts of weight-loss (<5%) may 
significantly worsen prognosis (it had previously been thought that only >10% was a 
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‘significant’  weight-loss) (Dewys et al., 1980). There has already been discussion 
relating to the poorer survival seen in patients with cancer cachexia with relation to 
weight-loss earlier in the introduction to this thesis (Section 1.2.3.1). This section 
will thus discuss various scoring systems that have been proposed in recent years.   
 
1.2.5.1 SCORING SYSTEMS 
In the field of oncology, where survival has traditionally been used as the gold-
standard outcome measure, prognostic scoring systems have received a lot of interest.  
The ability to make informed decisions about treatment options and have frank 
discussions with patients and their relatives about disease trajectory are made much 
easier  if  there  is  some  way  of  reliably  predicting  a  patient’s  clinical  course.    Likewise,  
although individual markers have been associated with morbidity and mortality in 
cachectic patients, there has been growing interest in developing prognostic scoring 
systems combining more than one measure in order to more accurately predict 
survival and outcome.  
 
(i) Glasgow prognostic score (GPS) 
This simple scoring system is based on CRP and albumin levels.  A point is awarded 
for a raised CRP or hypoalbuminaemia to give a maximum score of 2 if both are 
present.  Prognosis has been shown to be significantly poorer in patients with 
metastatic breast or non-small cell lung cancer and a higher GPS score (Forrest et al., 
2004, Al Murri et al., 2006).  GPS has also been associated with changes in several 
biochemical variables associated with systemic inflammation in patients with 
advanced lung and gastrointestinal cancer (Brown et al., 2007), and more recently 
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has been correlated with concentration of proinflammatory cytokines (IL1, IL6, IL8, 
TNF-α, VEGF-a, midkine) and transferrin (Krzystek-Korpacka et al., 2008). 
 
(ii) CRP plus white blood cell (WBC) count 
A group in Montreal used a similar scoring system to the GPS, but replaced albumin 
with WBC count.   In a study of patients with non-small cell lung cancer, median 
survival was only 3 months in those with a score of 2 at presentation, compared with 
7 months if patients scored 1 and 19 months in those who scored 0 (MacDonald, 
2007). 
 
(iii) CRP, weight-loss and food intake  
In a study of 170 weight-losing patients with unresectable pancreatic cancer, weight-
loss alone was not a prognostic variable and did not identify patients with altered 
body composition or reduced subjective function or health status.  However, the 
three-factor  profile  of  systemic  inflammation  (CRP  ≥  10mg/l),  reduced  food  intake  
(≤  1500kcal/day)  and  weight-loss (≥10%)  defined  those  with  both  adverse  function 
and prognosis (Fearon et al., 2006).   
 
(iv) Clinical prognostic scoring system 
This scoring system was developed in an effort to improve prognostic accuracy and 
risk predication of death in patients with gastro-oesophageal cancer.  Variables used 
for scoring are CRP, rate of weight-loss, KPS and clinical stage of disease (primary 
Tumour, lymph Nodes and presence of Metastases (TNM) staging system).  Analysis 
of 220 patients revealed accurate predication of death at 12 and 24 months (Deans et 
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al., 2007b). Weight-loss >2.75% per month was an independent prognostic indicator 
of decreased survival in oesophageal cancer.   
 
1.2.6 Molecular mechanisms of muscle wasting in cachexia 
Although there may be loss of both fat and muscle tissue in cancer cachexia, it is the 
loss  of  skeletal  muscle  that  will  have  the  most  profound  effects  on  patients’  function  
and activities of daily living.  Skeletal muscle is essential to provide movement, 
strength, respiration, balance, posture, and to regulate body temperature (Lenk et al., 
2010). There is some recent evidence of cross-talk between fat and muscle and that 
the former may play a key role in modulating muscle wasting (Section 1.2.3.1).  
However, the main theme of this thesis is focussed on skeletal muscle in cachexia, 
and thus this section will concentrate on molecular mechanisms of atrophy within 
skeletal muscle.  Potential biomarkers of cachexia could be either systemic mediators 
of the cachectic process or relevant end-organ change within skeletal muscle that 
occur as a result of such mediator activity.  This section provides an overview of the 
structure and composition of skeletal muscle and physiology, a summary of known 
systemic mediators of cachexia followed by a focus on the molecular pathways and 
alterations in structural proteins relevant to muscle wasting in cachexia.  Due to the 
lack of data in some of these areas, the discussion includes knowledge derived from 
other models of muscle wasting where relevant. 
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1.2.6.1 Structure and functional physiology of skeletal muscle 
1.2.6.1.1 Gross anatomy of muscle 
Muscle is defined as: 
 “ an animal tissue by contraction of which  bodily  movement  is  effected”  from the 
Latin musculus, the diminutive of mus meaning (a little) mouse.   
(Chambers Etymological English Dictionary, 1960) 
 
There are two major types of muscle in man – smooth and striated.  Smooth muscle 
is an involuntary muscle (meaning it is controlled by the autonomic nervous system) 
and is primarily responsible for contractions in hollow organs such as blood vessels, 
the gastrointestinal tract, the bladder, glands and eyes.  Striated muscle can be either 
cardiac (a highly specialised involuntary muscle) or skeletal (under voluntary control) 
(Seeley, 1995).  Cardiac and smooth muscle do not form part of the investigation of 
this thesis and thus subsequent discussion in this section will relate exclusively to 
skeletal muscle. 
 
Skeletal muscle is the major reservoir of body proteins, consisting of around 640 
separate muscles that account for 40% of total body weight or 50% of fat free mass 
(FFM).  The majority of muscles are classified (according to the structural 
arrangement) as fusiform with muscle fibres arranged longitudinally tethered by 
tendons at each end.  Alternatively, muscles can be pennate with the muscle fibres 
inserting into a tendon at an angle.  Muscles are arranged in bundles of fibres (~85% 
of total tissue) bound by connective tissue mainly comprised of collagen.  The 
myofibril is the base unit of muscle comprising thick (predominantly myosin) and 
thin (predominantly actin) filaments.  Other organelles such as mitochondria are 
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packed between the myofibrils.  Collections of myofibrils are bound by a delicate 
external lamina and the sarcolemma to make up muscle fibres that are surrounded by 
the endomysium.  Muscle nuclei lie underneath the sarcolemma.  A heavier 
connective tissue layer called the perimysium encases bundles of muscle fibres into 
fascicles, which in turn are arranged into groups ensheathed by the epimysium.  Each 




There are three classes of muscle protein as outlined in Table 1.4 (Goll et al., 2008). 
 
The myofibrillar proteins are integral to muscle contraction and function and are 
thought to be key targets in cancer cachexia (Acharyya et al., 2004).  Myofibrils are 
1-3  μm  in  diameter  and  are made up of myofilaments.  There are more than 17 
different proteins present in the myofibrillar structure (Goll et al., 2008).  Actin is the 
primary protein within thin filaments, which measure 8 nm in diameter and 1000 nm 
in length.  Thick filaments are predominantly composed of myosin and are 12 nm in 
diameter and 1800 nm in length.  These filaments are specifically organised into 
repetitive  sarcomere  subunits  that  give  rise  to  the  typical  ‘striated’  appearance  of  
skeletal muscle under the microscope (Figure 1.3A). Two other filament components 
contribute to the sarcomere – one spans half-sarcomeres and is composed of single 
molecules of titin (the largest vertebrate protein) and the other   
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Schematic illustrating the composition and arrangement of individual 
muscles.  Each muscle is made up of highly organised groups of muscle 



















Table  1.3:  Classes  of  skeletal  muscle  protein 
 
 Myofibrillar Sarcoplasmic Stroma 
% Muscle protein by weight 55-60 30-35 10-15 










filament is made from nebulin that spans the length of the actin filaments (Clark et 
al., 2002).  
 
THE SARCOMERE 
The sarcomere is divided into zones, bands and discs according to its appearance 
under a microscope (Figure 1.3B):  
- Z-disc – from the German zwischen meaning between, it is a structure for the 
attachment of actin myofilaments 
- A-band – stands for anisotropic, dark band extends the length of the myosin 
myofilaments within a sarcomere, the actin and myosin myofilaments overlap 
for some distance at both ends of the A band and on cross-section of this 
overlap, each myosin myofilament is surrounded by six actin filaments 
- I-band – stands for isotropic, light band includes a Z-disc and extend from 
either side of the Z-disc to the ends of the myosin myofilaments, the I band 
on either side of the Z-disc consists only of actin myofilaments 
- H-zone – from the German helle meaning bright, within the A band centrally 
where actin and myosin myofilaments do not overlay and only myosin 
myofilaments are present 
- M-band – from the German mittel meaning middle, a dark band in the middle 
of the H zone, consisting of delicate filaments that attach to the centre of 
myosin myofilaments 
- T-tubule – tube-like invagination along the sarcolemma where actin 


















(A.) Electron microscopic image (11000x magnification) illustrating 
the typical striated appearance of skeletal muscle caused by the 
repetitive sarcomere units. The ruler at the bottom left corner of the 
image  represents  0.2  μm. (B.) Diagram outlining the individual zones, 
bands and discs that can be seen in A.  A single sarcomere 










In humans, muscle fibres have been classified into two main types based on whether 
they express the gene for a slow or a fast myosin isoenzyme: slow type I/oxidative 
fibres which have a red appearance owing to the high capillary density, and fast type 
II/glycolytic fibres which are paler/white in appearance. 
 
In cachexia, evidence from animal models suggests that type II fibres are selectively 
targeted (Acharyya et al., 2005) with relative preservation of type I fibres in fasting 
(Li and Goldberg, 1976), exposure to glucocorticoids (Goldberg and Goodman, 1969, 
Dahlmann et al., 1986), sepsis (Tiao et al., 1997), and cancer cachexia (Baracos et al., 
1995, Acharyya et al., 2004).  However, whether this occurs in human cancer 
cachexia is unclear.  Furthermore, not all groups have demonstrated type I and II 
fibre differences even in animals. Indeed in a recent exposition of the colon-26 
cachectic murine model, both glycolytic and oxidative fibres underwent wasting 
(Aulino et al., 2010).   
 
 
The activity patterns of a muscle do seem key in determining its phenotype. If 
muscle cells are infrequently recruited, they develop into fast/glycolytic units 
whereas if they are recruited more often, they form slow/oxidative units.  In the 
colon-26 murine model of cancer cachexia, there have been reports of switching of 
myosin isoforms in the soleus muscle of cachectic mice (Diffee et al., 2002), 
although in pancreatic cancer patients with cachexia, no difference in the ratio of 




1.2.6.1.2 MUSCLE PHYSIOLOGY: 
CONTRACTION AND THE SLIDING FILAMENT THEORY 
Skeletal muscle contraction is a voluntary process, although can be involuntary by 
the stimulation of reflexes.  Despite the macroscopic appearance of the muscle 
reducing in size during contraction, the myofilaments do not actually shorten.  Rather, 
a phenomenon referred to as the sliding-filament theory occurs; where myofilaments 
slide past one another to cause the sarcomere to shorten (Seeley, 1995, Berne, 1996).  
During contraction, cross-bridges form and release between the thin (actin molecules) 
and thick (the heads of the myosin molecules) filaments.  This occurs in a stepwise 
fashion with the result that the thin and thick filaments appear to be sliding over one 
another until at full contraction the I-band and H-zone completely disappear.  This 
cross-bridge  cycling  accounts  for  most  of  the  body’s  ATP  (energy)  consumption.    
The release of cross-bridges results in relaxation of muscle and sarcomeres passively 
(although usually with application of some force) lengthen with the resultant 
reappearance of the I-band and H-zone.  
 
A muscle contraction is initiated following elicitation of an action potential in a 
motor nerve.  Each nerve controls many muscle cells that are functionally grouped 
into  a  ‘motor  unit’  although  each muscle cell will only have one neuromuscular 
junction.  Synchronous contraction of a motor unit occurs due to the generation of 
action potentials in all muscle cells triggered by the release of acetylcholine at 
endplates.   
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The sliding-filament theory is possible due to a process termed excitation-contraction 
coupling (Berne, 1996).  This has four main steps: 
- action potential induced by acetylcholine that leads to; 
 - opening of calcium channels in the sarcoplasmic reticulum 
- subsequent diffusion of calcium which reversibly binds to troponin 
- finally this causes conformational alteration of the thin filament allowing 
cross-bridge cycling to commence 
The binding of calcium to troponin (which has 4 calcium binding sites) is one of the 
key steps in this process.  It is attached to actin filaments and has the unique 
capability of changing its shape when calcium is bound. 
 
This section has given an overview of the anatomy and physiology of healthy 
skeletal muscle.  The next section will discuss the systemic and intracellular 
mechanisms that are thought relevant in muscle wasting related to cachexia.  
 
1.2.6.2 Systemic mediators of cachexia 
Cancer cachexia is considered, at least in part, to result from interactions between the 
host and the tumour.  Components of this interaction are then thought to drive 
molecular pathways resulting in anorexia and muscle atrophy.  This can occur either 
directly (such as with proteolysis-inducing factor (PIF) stimulating the ubiquitin 
proteasome pathway (UPP)), or indirectly via other cascades (such as pro-
inflammatory cytokines leading to induction of the acute phase response (APR)).  
There are also various hormones that have been implicated in muscle wasting.  This 
section gives a brief overview of the potential systemic mediators of cancer cachexia. 
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1.2.6.2.1 Tumour-derived mediators 
PIF 
PIF is a 24 kDa sulphated glycoprotein.  It was originally discovered in the murine 
adenocarcinoma (MAC)-16 cachectic mouse model (Todorov et al., 1996) but has 
also been isolated from the urine of cachectic cancer patients (Cariuk et al., 1997).  
PIF appears to both depress protein synthesis and increase protein degradation (both 
by ~50%) (Lorite et al., 1998).  Its potential actions are: 
- stimulation of the UPP (Lorite et al., 2001) 
- activation of the transcription factor Nuclear Factor Kappa-B (NFκB), with 
resultant specific depletion of myosin (Wyke and Tisdale, 2005) 
- increase tripeptidyl peptidase II which cleaves peptides generated by the 
proteasome into tripeptides (Balow et al., 1986, Chand et al., 2005) 
- induction of cytokine production (IL-6, IL-8 and TNFα  (Watchorn et al., 
2002, Watchorn et al., 2005)).   
 
Whilst all of these mechanisms are relevant to cachexia, other research groups have 
been unable to identify PIF or relate it to cachexia (Jatoi et al., 2006).  As such, the 
exact role and relevance to human cancer cachexia remains under debate (Wieland et 
al., 2007, Blum et al., 2011). 
 
Lipid mobilising factor (LMF)/ Zinc-α2-glycoprotein (ZAG) 
LMF (homologous to ZAG (Hirai et al., 1998)) is produced by cachexia inducing 
tumours and has been shown to stimulate lipolysis in both animal models and in 
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cachectic cancer patients (Mracek et al., 2011).  ZAG expression and secretion by 
adipose tissue is enhanced in cachectic cancer patients. Given its lipid mobilising 
effect, ZAG may contribute to adipose atrophy associated with cancer cachexia in 
human beings (Mracek et al., 2011).  Although interest has generally focussed on its 
effects on lipid mobilisation, substrate utilisation and activation of mitochondrial 
oxidative pathways in brown adipose tissue, there is also some evidence that there 
may be an effect on skeletal muscle.  LMF/ZAG acts through a β-adrenoreceptor and 
since β-agonists (e.g. formoterol) stimulate skeletal muscle hypertrophy in animals, it 
is not surprising that LMF has been shown to stimulate protein synthesis and 
decrease protein degradation (via reduction in UPP) (Islam-Ali and Tisdale, 2001).  
Furthermore, formoterol has been shown to reverse muscle wasting in tumour 
bearing rats by decreasing protein degradation (mainly via inhibition of UPP) and 
increasing protein synthesis (Busquets et al., 2004) suggesting the LMF/ZAG may 
protect skeletal muscle from atrophy and explain why loss of fat precedes loss of 
protein in cachectic cancer patients.  More recently, another lipid mobilising factor, 
distinct from ZAG, has been shown to promote lipolysis in the methylcholanthrene 
(MCA)-induced sarcoma bearing cachexia model (Argiles et al., 2007). 
 
Cytokines and the APR 
(i)  ‘Classical’  cachectic  pro-inflammatory cytokines 
Pro-inflammatory cytokines, in particular IL-6, IL-1, TNF and interferon (IFN)-γ,  are  
central to systemic inflammation and the induction of the APR (Table 1.4).  Cytokine 
interaction between host and tumour cells within the tumour mass results in 
activation of peripheral blood mononuclear cells (PBMC) passing through the local  
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Table  1.4:  Main  pro-inflammatory  cytokines 
   
Cytokine Cellular source Functions 
TNFα Macrophages 
Lymphocytes 
Mediates muscle protein loss 
Stimulates liver lipogenesis 
Insulin resistance 
Anorexia 









Main inducer of acute phase response  
 (in combination with other mediators) 
Suppresses food intake 
IFN-γ Lymphocytes 
Natural killer cells 
Potentiates catabolic effects of other mediators 
 
 
The cellular source of the main pro-inflammatory  ‘classical’  cytokines  
and an outline of some functions relevant in the development of 
cachexia and the acute phase response.  Abbreviations: IFN, interferon; 




tumour vasculature. Increased pro-inflammatory cytokine release by PBMCs has 
been demonstrated previously in patients with evidence of an APR (Wigmore et al., 
2002, O'Riordain et al., 1999). Recent advances in tumour biology have suggested 
that macrophages may be one important cellular sub-type involved in the intra-
tumoural interaction between host and tumour cells (Yuan et al., 2008).  In cancer, 
host mononuclear cells are recruited to tumours by various signals including hypoxia. 
Thus, a major inflammatory component of tumour stroma is made up of so-called 
tumour–associated macrophages (TAMs). The resultant Th-2 type micro-
environment may favour tumour progression via the promotion of angiogenesis, the 
remodelling of the extracellular matrix to allow invasion, and the suppression of 
adaptive immunity (Yuan et al., 2008). How TAMs may be involved in the activation 
of host PBMCs is not yet known but macrophage-associated cytokines have been 
shown to induce an APR in isolated human hepatocytes (Wheelhouse et al., 2006). 
Furthermore, high tumour chronic inflammatory cell content is associated with poor 
patient prognosis (Deans et al., 2006). Once activated, host PBMCs then 
initiate/trigger their own cytokine cascade. Circulation of PBMCs and cytokines to 
target end organs may then induce various distant effects (Figure 1.4).  
 
In the liver, during a positive APR, net export protein synthesis is increased. Near 
complete inhibition of the ability of human hepatocytes co-cultured  with  PBMC’s  to  
produce acute phase protein has been achieved by using anti-IL-6 antibodies 
(O'Riordain et al., 1999).  This implies that IL-6 is one of the key mediators of this 
response.  In mice with a mutation in the adenomatous polyposis coli (APC) tumour 
suppressor gene, elevated circulating IL-6 levels are associated with the presence of   
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cachexia (Baltgalvis et al., 2008).  Knockout of IL-6 prevented loss of muscle weight 
and epididymal fat, and reduced intestinal polyp number by 32%, implying the 
existence of an IL-6 cytokine amplification loop between host and tumour cells. 
Furthermore, recent human studies have suggested that IL-6 overexpression in 
weight losing pancreatic cancer patients is related to the ability of certain IL-6-
producing tumours to sensitise PBMC and induce cytokine expression in PBMCs 
(Martignoni et al., 2005). However, there are reports that other pro-inflammatory 
markers such as IL-1β  may  be  more  closely  associated  with  clinical  features  of 
cancer cachexia (Scheede-Bergdahl et al., 2012).  
 
In the brain, pro-inflammatory cytokines induce central anorexia by exerting actions 
on the orexigenic NPY and the anorexigenic POMC systems within the hypothalamic 
arcuate nucleus, thus resulting in reduced food intake. In particular, IL-1 may block 
feeding induced NPY, possibly via inhibition of NPY synthesis, inhibition of 
neuronal firing or an attenuation of its post-synaptic effects (Plata-Salaman, 2000, 
King et al., 2000).  A recent Australian study has suggested that MIC-1, a cytokine 
know to be secreted by human tumours, is a potent modulator of appetite in mice 
bearing human prostate cancer xenografts (Johnen et al., 2007). The associated 
hypophagia appeared to be caused by reduced NPY expression and increased POMC 
expression within the arcuate nucleus. Furthermore, a MIC-1 antibody could reverse 
weight, fat and lean tissue loss.  
 
In skeletal muscle, in vitro and in vivo studies have confirmed a wide range of 
intracellular effects of cytokines that result in the net degradation of myofibrillar 
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protein and amino acid mobilisation. These include the promotion of insulin 
resistance,  activation  of  NFκB  transcription  factor  pathways,  and  increased  activity  
of the UPP.  Studies in C2C12 myoblasts and murine models have suggested that 
pro-inflammatory cytokines may target depletion of certain myofibrillar proteins in a 
specific fashion: administration of TNF and IFN-γ  reduced  mRNA  and  protein  
expression of myosin heavy chain (MyHC) but not other core proteins (Acharyya et 
al., 2004). Further studies by the same American group, using the colon-26 mouse, a 
model believed largely to be cytokine dependent, have also suggested that pro-
inflammatory cytokines may disturb the membranous morphology of skeletal muscle 
(Acharyya et al., 2005). Such mice demonstrated significant deregulation of the 
dystrophin glycoprotein complex (DGC), a large membrane-bound complex involved 
in the protection of muscle from contraction-induced injuries. Furthermore, 
deregulation of the DGC was associated with enhanced cancer-induced muscle 
atrophy.  
 
(ii) Other pro-inflammatory cytokines 
More recently, there has been growing interest in the role of other pro-inflammatory 
cytokines in cancer cachexia.  IL-8, vascular endothelial growth factor (VEGF)-a, 
and midkine have been implicated in recent years.  These cytokines are involved in 
stimulating the expression of other pro-inflammatory agents, increasing the 
permeability of blood vessels and triggering degranulation of inflammatory cells 
(Kadomatsu and Muramatsu, 2004, Henson and Vandivier, 2006, Dvorak, 2005).  IL-
8 has been shown to modulate acute phase protein production from isolated human 
hepatocytes (Wigmore et al., 1997a).  More recently, a group from Poland studied 
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levels of VEGF-A, VEGF-C, IL-8,  midkine,  TNFα,  IFN-γ,  IL-1 and IL-6 in the 
serum of 96 gastro-oesophageal cancer patients (Krzystek-Korpacka et al., 2008), 49 
of whom were cachectic (as defined by weight-loss >5% in preceding 3 months).  
There was a significant increase in both IL-6 and IL-8 levels in cachectic versus non-
cachectic patients and a trend to raised levels of midkine and VEGF-a.  Using 
multiple logistic regression modelling, both midkine and VEGF-a were independent 
predictors of weight-loss in gastro-oesophageal cancer patients.   
 
(iii) Anti-inflammatory cytokines 
Whilst pro-inflammatory cytokines induce cachexia and the APR, other cytokines 
(such as IL-4, IL-10 and IL-13) may have anti-inflammatory actions and may 
therefore be potential repressors of cachexia.  The development of wasting and the 
APR in the cachectic patient may thus depend on the balance between pro- and anti-
inflammatory cytokines.  Both IL-4 and IL-10 reduce the production of the pro-
inflammatory cytokines IL-1, IL-6, IL-8  and  TNFα (Fiorentino et al., 1991, Bogdan 
et al., 1991, de Waal Malefyt et al., 1991).  This has led to investigation into the 
potential for using anti-inflammatory cytokines in the treatment of cancer cachexia.  
In the colon-26 adenocarcinoma mouse model, IL-10 gene transfer reduces cachexia 
and prolongs survival (Fujiki et al., 1997).  IL-10 gene transfer has also been shown 
to suppress the peritoneal dissemination of gastric cancer cells in nude mice. 
Improved survival and a reduction in weight-loss were also observed in the IL-10 




(iv) Host Cytokine Genotype 
In recent years, host genotype has been proposed as one determinant of the 
development of cachexia. In particular, cytokine genotype may influence the 
aetiology of systemic inflammation and the APR (Tan et al., 2008).  Specific IL-10 
and IL-6 polymorphisms have been related to systemic inflammation and adverse 
prognosis,  and  a  TNFα  polymorphism  was  associated with adverse prognosis in 
patients with gastro-oesophageal cancer (Deans et al., 2007a).  IL-1β  polymorphisms  
were associated with development of cachexia and adverse prognosis in pancreatic 
and gastric cancer (Barber et al., 2000b, Zhang et al., 2007).  Conversely, the  IFNγ  
‘allele  2’  polymorphism  was  related  to  improved  survival  in  patients  with  non-
resectable pancreatic cancer (Halma et al., 2004). 
 
1.2.6.2.2 Host-derived mediators 
The APR in Cancer Cachexia 
An organism responds to the presence of infection, tumour, immunological disorders, 
tissue injury, trauma or surgery by eliciting the APR, a response designed to help 
limit tissue injury. However, in certain circumstances when the APR is prolonged or 
severe, it can be lead to detrimental effects. The APR is a complex physiological 
event involving reprioritization of hepatic protein synthesis, resulting in increased 
synthesis of the positive acute phase proteins (serum amyloid A, CRP, fibrinogen, 
α1-acid glycoprotein,  α1-antichymotrypsin and haptoglobin). Furthermore, the 
plasma concentrations of negative acute phase proteins (albumin, per-albumin and 
transferrin) fall.  However, reduction in negative acute phase reactants is not due to 
decreased hepatic synthesis, but possibly by increased transcapillary escape 
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secondary to an increase in micro-vascular permeability. This was demonstrated by 
the finding that total albumin synthesis rate in both the fasting and fed state is not 
different between patients with advanced cancer and healthy controls, even in the 
face of significant hypoalbuminaemia (Fearon et al., 1998, Barber et al., 2000a). This 
means that, in the cachectic patient, the increased hepatic synthesis of positive acute 
phase reactants is not compensated for by reduced synthesis of negative acute phase 
reactants. Thus, the net result is increased demand for amino acids by the liver.  
 
How the APR is linked to the development of muscle atrophy in cancer cachexia is 
not clear. However, it has been hypothesised that persistent hepatic synthesis of 
positive  acute  phase  reactants  represents  a  nutritional  “sink”  into  which  amino  acids  
mobilised from skeletal muscle are lost. The significant mismatch between the 
amino-acid composition of muscle and acute phase proteins (it has been calculated 
that 2.6g of muscle protein must be catabolised to produce 1g of fibrinogen) (Preston 
et al., 1998, Reeds and Hutchens, 1994) demonstrates how aggressively the APR 
may drive nutritional depletion. To complicate matters further, nutritional support, an 
obvious required treatment for malnourished cancer patients, may accelerate positive 
acute phase protein synthesis and thus exacerbate one of the basic mechanisms that 
contributes to the loss of lean tissue. In weight losing patients with pancreatic cancer, 
synthesis rates of hepatic export proteins (fibrinogen) are elevated in the fasted state, 
but rise even higher during enteral feeding (Barber et al., 2000a). These findings 
emphasise the need for inclusion of anti-inflammatory/anti-APR supplementation 
within any programme of high calorie/high protein nutritional support in the 
treatment of cancer cachexia. After a 3-week course of oral nutritional supplements 
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enriched with eicosapentaenoic acid (an anti-inflammatory n3 fatty acid) in patients 
with pancreatic cancer, the combined synthetic rate of albumin and fibrinogen was 
significantly reduced in the fed state and demonstrated a tendency to fall in the 
fasting state. Furthermore, patient weight had stabilised (Barber et al., 2004). 
 
The Relationship Between APR and Survival 
The positive acute phase reactant CRP is often used as a marker of the APR and can 
be measured easily in the clinical setting.  In cancer patients, CRP correlates with the 
circulating concentration of IL-6 (Barber et al., 1999) and is thus an indirect marker 
of systemic inflammation and pro-inflammatory cytokine activity. CRP has gained a 
great deal of interest in recent years as a prognostic marker in cancer patients.  In 
several tumour types (lung (Forrest et al., 2004, Scott et al., 2002), lymphoma 
(Legouffe et al., 1998), breast (Heys et al., 1998), renal (Bromwich et al., 2004), 
pancreatic (Falconer et al., 1995), gastro-oesophageal (Ikeda et al., 2003, Rashid et 
al., 1982, Crumley et al., 2006) and colorectal (McMillan et al., 2003)), an elevated 
CRP is associated with an adverse outcome and poor prognosis.  Indeed, in gastro-
oesophageal cancer, it has been used to predict the outcome of patients post tumour 
resection.  In 67 patients with resectable gastric or oesophageal cancer, CRP in 
isolation has been shown to be more accurate than the tumour stage in predicting 
early prognosis one year after surgical resection (Deans and Wigmore, 2005).  Pre-
operative elevation of CRP has also been associated with reduced cancer specific 
survival following curative resection of colorectal cancer (McMillan et al., 2003), 
and in a study of 102 patients with pancreatic cancer, the presence of a high CRP 
reduced median survival from 222 days to just 66 days (Falconer et al., 1995).  
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Fibrinogen, another positive acute phase reactant, has been studied to a lesser extent 
than CRP.  Investigations in melanoma and lung cancer patients have shown an 
association between elevated fibrinogen levels and a poor outcome (Guida et al., 
2003, Pavey et al., 2001).  Another study of 212 lung cancer patients at the Royal 
Marsden Hospital who were taking part in phase I trials and also a retrospective 
study of 172 non-small cell lung cancer (NSCLC) patients revealed low levels of 
albumin as a prognostic factor for reduced survival (Arkenau et al., 2008, Paralkar et 
al., 2008). 
 
1.2.6.2.3 Other circulating mediators 
Calcium and Vitamin D 
A potential role for calcium and vitamin D in muscle wasting relates to evidence 
from the myopathy (predominantly Type II fibre atrophy) seen in osteomalacia, 
which can be exacerbated in ageing (Solomon and Bouloux, 2006, Janssen et al., 
2002).  Calcium, phosphate and vitamin D levels all impact on muscle function.  
Smaller muscle fibres are seen in vitamin D null mice and supplementation can 
reverse these changes (Endo et al., 2003).  In sarcopenia, patients with low vitamin D 
have been shown to have ~2x risk of reduced muscle mass and strength (Visser et al., 
2003).  Vitamin D deficiency has been reported in excess of 80% of cancer patients 
(Stone et al., 2011) along with being particularly prominent in patients receiving 
chemotherapy (Fakih et al., 2009).  Likewise, a retrospective study of advanced 
cancer patients reported 70% vitamin D insufficiency and an association with 
anorexia and fatigue (Dev et al., 2011).  The observation in this study of a higher 
proportion of men with hypogonadism and females being deplete of vitamin D 
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suggests a possible link with androgen pathways.  In cachectic cancer patients, 
vitamin D gene receptor polymorphisms have been linked as predictors of a more 
aggressive form of cachexia (Punzi et al., 2012).  
 
Glucocorticoids 
Glucocorticoid atrophy is specific to type II fibres. Its mechanism of action is 
through upregulation of protein degradation pathways, upregulation of myostatin and 
enhanced glutamine synthetase activity (Solomon and Bouloux, 2006, Carballo-Jane 
et al., 2004).  Glucocorticoids inhibit physiological secretion of growth hormone and 
appear to reduce insulin-like growth factor (IGF)-1 activity in target organs.  There 
are several types of cachexia associated with increased cortisol levels and muscle 
atrophy is a dose limiting side effect of treatment with synthetic glucocorticoids 
(Clarke et al., 2007). In cachectic pancreatic cancer patients, elevated serum 
cortisol/insulin ratios have been demonstrated compared with controls (Fearon et al., 
1998).   
 
Insulin 
Insulin can stimulate protein synthesis via the phosphatidylinositol  3’-kinase 
(PI3K)/protein kinase B (PKB or Akt) pathway (Section 1.2.6.3.2).  Insulin 
resistance has been demonstrated in cancer cachexia (Johns et al., 2012).  Likewise, 
patients with uncontrolled diabetes can have marked muscle atrophy (Workeneh and 
Bajaj, 2013).   
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In human cancer patients, treatment with low dose insulin therapy as part of a 
combination therapy regime (with the addition of indomethacin and recombinant 
erythropoietin) resulted in a rise in carbohydrate intake, an increase in body fat, and a 
fall in serum free fatty acids.  However, there was no change in lean body mass 
(LBM), maximum exercise capacity or spontaneous physical activity (Lundholm et 
al., 2007). 
 
Growth hormone (GH) 
GH has several anabolic effects and can increase LBM in patients with GH 
deficiency (Carroll et al., 2004). This loss of muscle mass can be reversed by GH 
supplementation in adult GH deficiency although without noticeable impact on 
strength (Hoffman et al., 2004).  The mechanisms are not completely understood, but 
in myoblasts, insulin-like growth factor (IGF)-1, phosphorylation of Janus kinase 
(JAK)-2, Signal Transducer and Activator of Transcription (Stat)-5 and increased 
Suppressor of Cytokine Signalling-2 (SOCS-2) have all been implicated (Sadowski 
et al., 2001, Frost et al., 2002).  It has a particularly profound action on stimulating 
IGF-1 in the liver, but GH can also have IGF-1 independent effects.  
 
Insulin-like growth factors 
Two insulin-like growth factors have been discovered.  IGF-1 is a major anabolic 
factor in skeletal muscle.  In mice overexpressing IGF-1, muscle mass is 
significantly increased compared with controls (Hayashi et al., 2004, Shavlakadze et 
al., 2005).  IGF-2 has a developmental role and involvement with muscle 
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differentiation (Florini et al., 1996).  It has not been investigated in cachexia and thus 
the rest of this paragraph will focus on IGF-1.   
 
The main effects of IGF-1 are mediated through the PI3K/Akt pathway resulting in 
increased muscle protein synthesis and accelerated satellite cell proliferation and 
differentiation.  Along with muscle, many other organs produce IGF-1 in autocrine 
or paracrine forms, but GH causes increased circulating IGF-1 by increased synthesis 
in the liver (Delafontaine et al., 2004).  The effects of IGF-1 are influenced by IGF-1 
binding proteins (IGFBPs).  There are 6 different IGFBPs which all inhibit binding 
of IGF-1 to its receptor, but in addition, IGFBP-1, -3 and -5 can also enhance the 
action of IGF-1 (Delafontaine et al., 2004).  A possible role for IGF-1 in the 
pathogenesis of cancer cachexia has been suggested.  IGF-1 signalling was impaired 
in the Yoshida ascites hepatoma (AH)-130 rat model of cancer cachexia (Costelli et 
al., 2006).  However, there was no prevention of cachexia by the administration of 
exogenous IGF-1 and there is a lack of conclusive evidence for a role in human 
cancer cachexia.  
 
Androgens 
Androgens can act on satellite cells (Sinha-Hikim et al., 2003) and IGF-1 (Lewis et 
al., 2002).  They may also cause a state  of  ‘anti-catabolism’  via anti-glucocorticoid 
effects (Danhaive and Rousseau, 1988, Zhao et al., 2004).  Increased androgen levels 
are associated with increased muscle size and strength (Bhasin et al., 1996).  Recent 
evidence also suggests a potential role for selective androgen receptor modulators 
(SARMs) as therapeutic agents in cachexia (Negro-Vilar, 1999, Dobs et al., 2013).  
Testosterone inhibits release of TNF, IL-1, IL-6 from macrophages and stimulates 
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production of IL-10 (D'Agostino et al., 1999, Li et al., 1993, Malkin et al., 2004).  
Low testosterone levels (hypogonadism) may thus lead to an increase in pro-
inflammatory cytokine production.  A recent study looking at hypogonadism in male 
cancer patients demonstrated low levels of testosterone in the presence of high 
plasma IL-6 (Garcia et al., 2006).  Similarly, in males with pancreatic cancer, 
systemic inflammation and opioid use were associated with hypogonadism 
(Skipworth et al., 2011).  In this same study, male hypogonadism and female 
hyperoestrogenism were associated with shortened survival. 
 
1.2.6.3 End-organ changes: protein degradation and synthesis in 
cancer cachexia 
In healthy adults, skeletal muscle mass is maintained by physical activity and 
nutritional status, reflecting a balance between protein synthesis (anabolism) and 
degradation (catabolism).  A predominance of either will result in muscle 
hypertrophy or atrophy.  Muscle is a dynamic organ with an average daily turnover 
rate in human adults of 1-2% (Fearon et al., 1988).  The IGF-1/PI3K/Akt/mammalian 
target of rapamycin (mTOR) pathway is the key regulator of anabolism in skeletal 
muscle.   Protein synthesis begins with the association of met-tRNA and the 40S 
ribosome, a process regulated by eukaryotic initiation factor 2 (eIF2), which in turn 
is influenced by external signals integrated through mTOR.  Intracellular protein 
catabolism/breakdown involves four major systems: the UPP, the autophagy 
(lysosomal) pathway, caspases, and the calcium-dependent calpain pathways. The 
individual prominence of each of these anabolic and catabolic pathways in muscle 
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wasting conditions is still unclear. In cancer cachexia, there is a general body of 
opinion that muscle degradation is more important than a reduction in protein 
synthesis (Argiles et al., 1999).  However, the evidence for a predominance of a 
reduction in protein synthesis, an increase in protein degradation or a combination of 
both is less conclusive.  
 
This section will discuss the key signalling pathways that are thought to be relevant 
in muscle wasting of cancer cachexia.  It should also be noted that most molecular 
hypotheses relating to cancer cachexia have been generated using pre-clinical models 
or reflect biochemical concepts (Tisdale, 2009) and there has been little progress in 
relating these potential mechanisms to changes observed in patients.  Due to this lack 
of data, much of pathway detail is derived from animal and cell experiments or other 
models.  The first part will outline the key mechanisms of muscle protein 
degradation and synthesis followed by a discussion about key components of and 
relationships between these pathways in the context of cancer cachexia. 
 
1.2.6.3.1 PROTEIN DEGRADATION 
UBIQUITIN PROTEASOME PATHWAY 
The discovery, in the 1980s, of ubiquitin and proteasomal degradation of substrate 
proteins culminated in the Nobel Prize in Chemistry being awarded in 2004 to 
Avram Hershko, Aaron Ciechanover, and Irwin Rose (Nobelprize.org, 2004).  Since 
this discovery, there has been a wealth of data confirming UPP to be a key path for 
degradation of proteins in mammalian cells responsible for the bulk of proteolysis in 
the cytosol (Rock et al., 1994) (Figure 1.5).    
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Schematic of the ubiquitin proteasome pathway adapted from Jagoe et 
al (Jagoe and Goldberg, 2001).  Proteins are tagged by ubiquitin via the 
E3 ligases before being delivered to the core proteasome machinery for 
degradation.  This results in rapid release of peptides that are 
hydrolysed into amino acids in the cytosol.  Abbreviations: Ub, Ubiquitin; 
E1, ubiquitin activating enzyme; E2, ubiquitin carrier protein; E3, 
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The proteasome may comprise as much as 1% of the total cell protein (Jagoe and 
Goldberg, 2001), is a very large complex (2000kDa) made up of at least 50 subunits, 
and is unlike typical proteases in that it requires ATP for protein degradation.  The 
26S  core  is  comprised  of  a  19s  ‘lid’  and  a cylindrical 20S central proteasome.  
Within this central 20S core, there are three different proteolytic mechanisms that 
digest proteins.   
 
Once a protein has been identified for degradation, there are three enzyme systems 
that are involved in covalent linkage from an internal lysine on the substrate to a 
chain of ubiquitin molecules: 
- E1 is the ubiquitin activating enzyme 
- E2 is a ubiquitin carrier protein  
- E3 is a ubiquitin protein ligase 
The E3 binds both the protein substrate and the E2 (carrying the activated ubiquitin), 
with the resultant transfer of the activated ubiquitin from the E2 to the substrate.  
Once there is a chain containing four or more ubiquitin molecules, the complex is 
degraded rapidly into small peptides (3-25 residues in length) (Jagoe and Goldberg, 
2001), which are released by the proteasome and rapidly hydrolysed to amino acids 
in the cytosol.  The poly-ubiquitin chain is also broken down to release free 
ubiquitin, which can then be re-used in degrading other substrates.   
 
The E3 ligases play a pivotal role in determining which proteins pass into the 
proteasome.  This is because each E3 ligase (functioning with a specific E2) 
exclusively binds individual proteins or types of proteins.  Numerous E3s from 
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several distinct families have been discovered, and there are likely to be several 




Autophagy is a strictly regulated lysosomal pathway responsible for the degradation 
of cytoplasmic material and organelles.  Proteases in this system are located inside 
lysosomal structures and are known as cathepsins (Goll et al., 2008).  It is activated 
during stress conditions such as amino acid starvation, unfolded protein response or 
viral infection.  There are three different autophagic routes known that are dependent 
on the delivery route of the cytoplasmic material to the lysosomal lumen: 
- 1) macro-autophagy (or simply, autophagy); a portion of cytoplasm to be 
degraded is wrapped inside a specialised organelle, the autophagosome, 
which then fuses with lysosomal vesicles and delivers the engulfed cytoplasm 
for degradation 
- 2) micro-autophagy; lysosomal membrane itself sequesters a portion of 
cytoplasm by a process that resembles pinching off of phagosomes or 
pinosomes from the plasma membrane 
- 3) chaperone-mediated autophagy; proteins possessing a specific sequence 
signal are transported from the cytoplasm, through the lysosomal membrane 
to the lysosomal lumen (Bonaldo and Sandri, 2013).   
 
Autophagins, a class of cysteine proteases putatively involved in the formation of 
autophagosomes, are particularly abundant in the skeletal muscle (Marino et al., 
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2003).  Within muscle, it has not been established whether micro- and chaperone 
mediated autophagy play a role, and most of the data from muscle relates to the role 
of macro-autophagy in the autophagic process (Bonaldo and Sandri, 2013).  Given 
this, the other two types will not be discussed any further and macro-autophagy will 
be referred to as autophagy from now on in the text.   
 
The steps involved in autophagy are as follows (Klionsky et al., 2008): 
1. Induction by a stress signal such as starvation,  
2. The formation of an autophagosome (double membrane bound),  
3. Autophagosomes receive lysosomal constituents such as lysosomal 
membrane proteins and proton pumps, by the fusion with endosomes or 
multi-vesicular bodies,  
4. Finally autophagosomes fuse with lysosomes – after fusion with endosomes 
or lysosomes, autophagosomes are called amphisomes or autolysosomes 
respectively 
 
Within these the material is then degraded and either the degradation products are 
transported back to the cytoplasm where they can be reused for biosynthesis or 
energy production, they become lysosomes that are able to undergo fusion with 
endosomes or autophagosomes or if the degradation of the cargo is not complete, the 
autolysosome becomes a residual body containing indigestible material and 




Calcium dependent proteolysis relies on the activity of cysteine proteases, which are 
known as calpains (calcium-activated neutral protease) – first reported by Guroff in 
1964 (Guroff, 1964).  There are at least 15 different calpain family members, and 
although they are thought to be important in tissue injury, necrosis and autolysis, the 
role of all members has not yet been established fully.  Their activity is regulated by 
the relative concentration of intracellular calcium, enzyme phosphorylation and by 
calpastatin levels (a physiological calpain-specific inhibitor). The physiological 
significance (i.e. whether they function in normal turnover of any cell proteins) is 
unclear because they only have limited proteolytic ability.  One theory is that this 
results in irreversible modifications of their substrates that lead to activity changes or 
to degradation by other proteolytic systems (Saido et al., 1994, Costelli et al., 2005, 
Williams et al., 1999b) – i.e. they exert a regulatory rather than a digestive function.  
Evidence would suggest that in skeletal muscle, they are not involved at all in the 
bulk degradation of sarcoplasmic or sarcolemmal proteins (Goll et al., 2003), but 
rather in myofibrillar degradation by disrupting thick and thin filaments from 
myofibrils permitting subsequent steps in which suitable protein substrates are 
allowed to gain access to the degradative (e.g. UPP) machinery (Goll et al., 2003, 
Hasselgren et al., 2002, Costelli et al., 2005).  In atrophying muscle, calpains can 
only play a major role if cytosolic calcium homeostasis is perturbed by cell injury 




The caspases are a family of cysteine-dependent aspartate-directed proteases, which 
are involved in apoptosis (Goll et al., 2008, Costelli et al., 2005).  Apoptosis is a 
mechanism for ordered disruption and disposal of proteins in a damaged cell in order 
to maintain homeostasis and tissue integrity (MacKenzie and Clark, 2012, Dupont-
Versteegden, 2006).  Events such as viral infections, hormones and toxic stimuli can 
induce apoptosis (MacKenzie and Clark, 2012) which at the molecular level is 
dependent on the balance between pro- and anti-apoptotic proteins (e.g. Bcl-2 family, 
heat shock proteins and inhibitors of apoptosis proteins (Dupont-Versteegden, 2006).  
Caspases can be inflammatory cytokine activators (caspases 1 and 5) or apoptotic.  
This latter group is further divided into the initiators of apoptosis (caspases 2, 8, 9, 
10 and 12) and the apoptotic effectors (caspases 3, 6 and 7) (Dupont-Versteegden, 
2006, MacKenzie and Clark, 2012).  The apoptotic pathway is well characterised and 
progresses through the following sequence in the dying cell: 
- nuclear and cytoplasmic condensation 
- plasma membrane blebbing 
- release of apoptotic bodies (small membrane-enclosed particles containing 
cellular components) 
- disposal by phagocytes or neighbouring cells which recognise the presence of 





1.2.6.3.2 PROTEIN SYNTHESIS 
Muscle hypertrophy is the result of a greater rate of protein synthesis (anabolism) 
than protein degradation (catabolism).  Exercise, amino acids and various hormones 
are all thought to influence the rate of protein synthesis.  At the cellular level, there 
are two main determinants: translational efficiency (protein synthesis per unit 
amount of RNA) and translational capacity (total ribosomal content per unit tissue) 
(Millward et al., 1973).  The majority of research has focussed on the Akt/mTOR 
pathway, which is thought to be the main driver of translational efficiency, and also 
has a role in ribosomal biogenesis (Rennie et al., 2004).  However, more recently, the 
β-catenin/myelocytamotosis (Myc) signalling pathway, which operates 
independently of the mTOR pathway, has also been implicated in the regulation of 
ribosomal biogenesis (translational capacity) (McCarthy and Esser, 2010). 
 
The Akt/mTOR pathway (Figure 1.6) has been strongly implicated in skeletal muscle 
hypertrophy both in vitro (Rommel et al., 2001) and in vivo (Bodine et al., 2001b).  
Not only is there evidence that activation of the pathway and its downstream targets 
p70 ribosomal S6 kinase (p70S6K) and 4E binding protein (4E-BP1, also known as 
PHAS-1) is involved in regulating skeletal muscle fibre size, but also that pathway 
activation can oppose muscle atrophy induced by disease.  
 
The Akt pathway can be activated by insulin or IGF-1 (Sandri, 2008).  IGF-1 is well 
documented as a muscle growth-promoter and is synthesised by the liver under GH 
control.  This produces IGF-1 both in the circulation and locally by skeletal muscle   
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Schematic illustrating the main components of the IGF-
1/PI3K/Akt/mTOR protein synthesis pathway.  Solid arrows represent 
activation and dashed arrows represent inhibition.  Abbreviations: IGF-1, 
insulin-like growth factor 1; IRS-1, insulin receptor substrate-1; PI3K, 
phosphoinositide 3-kinase; PIP3, phosphatidylinositol (3,4,5) 
trisphosphate; PDK1, phosphoinositide-dependent kinase-1; Akt, Ak 
strain thymoma/protein kinase B; FOXO, forkhead box sub-group O; 
mTOR, mammalian target of rapamycin; p70S6K, p70 ribosomal S6 
kinase; 4EBP1, 4E binding protein 1; eIF, elongation initiation factor; 
















Insulin/IGF-1/other growth factors 
Protein 
 93 
(IGF-1 splicing products).  This in turn activates Akt.  Of the three Akt genes 
(Akt1/PKB-α,  Akt2/PKB-β  and  Akt3/PKB-γ),  Akt1  and  2 are expressed at higher 
levels in muscle, with Akt3 being predominant in the brain.  Each has distinct 
functions evidenced by the phenotype of knockout mice: Akt1 null mice have growth 
retardation and muscle atrophy, Akt2 null mice suffer from Type II diabetes like 
syndrome and Akt3 null mice have impaired brain development (Yang et al., 2004). 
 
When Akt activates mTOR protein synthesis is promoted through the action of its 
downstream targets.  These are 4E-BP1, which stimulates protein translation when 
phosphorylated and p70S6K, which leads to the formation of the translation initiation 
complex (Weigl, 2012).  
 
1.2.6.3.3 CATABOLIC/ANABOLIC PATHWAY ACTIVATION AND INTERACTION IN 
CANCER CACHEXIA 
Given the complexity of human biology in both health and disease, it would seem 
inconceivable that a single pathway is responsible for the profound tissue changes 
and muscle wasting evident in cancer cachexia.  The body may respond to the 
activation or depression of a degradation pathway with a compensatory change in 
synthetic pathways or vice versa.  Several recent studies in cachexia have made a 
concerted effort to link pathways or search for additional novel factors implicated in 
muscle atrophy.  This section will discuss these findings. 
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UBIQUITIN PROTEASOME PATHWAY/E3 UBIQUITIN LIGASES 
In many models of cachexia, including cancer, the UPP is thought to be fundamental 
in the process of muscle atrophy (Jagoe and Goldberg, 2001).  In 2001, two research 
groups, led by Alfred Goldberg and David Glass, independently identified two 
muscle-specific E3 ubiquitin ligases.  Muscle RING-Finger protein-1 (MuRF1) and 
Muscle Atrophy F-box (MAFBx)/atrogin-1 (named differently by the two labs) were 
shown to be upregulated in many animal models of muscle wasting, including cancer 
cachexia (Bodine et al., 2001a, Gomes et al., 2001). This has been used to provide an 
argument for a major contribution of the UPP in muscle wasting, such that these 
genes are now measured as surrogate indicators of UPP activation.  Similarly, 
microarray profiling of four models of muscle atrophy (cancer cachexia, diabetes 
mellitus, uraemia, fasting) demonstrated a common signature of genes termed 
‘atrogenes’  which included MuRF1, MAFBx/atrogin-1 and components of the 
ubiquitin proteasome (Lecker et al., 2004).  More recently, the identification of a 
third  ubiquitin  ligase,  termed  E3α-II, in pre-clinical models of cancer cachexia adds 
further evidence of the key role of the UPP in muscle atrophy (Kwak et al., 2004). 
 
However, human investigations have failed to be as conclusive.  Studies including 
patients in intensive care units with sepsis, following bed rest, amputation for 
vascular disease, limb immobilisation, COPD, amyotrophic lateral sclerosis and 
ageing have demonstrated both increased and decreased expression of MuRF1 and 
MAFBx/atrogin-1 (Fredriksson et al., 2008, Doucet et al., 2007, Salanova et al., 2008, 
Leger et al., 2006, de Palma et al., 2008, Edstrom et al., 2006).  Likewise, 
investigations of UPP activity have shown similar levels to healthy controls in 
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patients with lung cancer and weight-loss <10% (termed pre-cachexia by the authors) 
(Op den Kamp et al., 2012).  Another study in lung cancer patients with low weight-
loss (mean 2.9%) demonstrated no change in components of the UPP using Northern 
blotting, but suggested that the lysosomal pathway was increased (Jagoe et al., 2002).  
In contrast, in gastric cancer patients with average weight-loss of 5.2%, increased 
UPP activity (determined by measurement of RNA and cleavage of specific 
fluorogenic substrates) was observed compared with controls, with a further effect 
with increasing tumour stage, weight-loss and lower albumin (Bossola et al., 2003).  
The same group also measured higher levels of ubiquitin mRNA in gastric cancer 
patients compared with controls, but there was no relationship with increasing 
weight-loss.  This led the authors to conclude that the UPP was activated early in 
disease before there was overt clinical evidence of cachexia (Bossola et al., 2001).  In 
another investigation using dot blot for components of the UPP in patients with 
various cancers and minimal weight change, mRNA levels were increased by 2-4x in 
cancer patients (Williams et al., 1999a).  The authors similarly concluded that the 
UPP was upregulated before protein breakdown is increased given that patients had 
minimal weight-loss.  The concept of changes in activation of the UPP according to 
where a patient is on the cancer cachexia journey is supported by the observations by 
Khal et al in both humans with cancer cachexia (Khal et al., 2005a) and the MAC16 
murine cachexia model (Khal et al., 2005b).  However, in these studies, UPP activity 
seemed to increase after a threshold of ~10% weight-loss with a peak between 12-19% 
weight-loss.  Furthermore, UPP activity seemed to decrease after 20% weight-loss 
suggesting that other mechanisms such as a reduction in protein synthesis may be 
more relevant after this point. 
 96 
AUTOPHAGY/LYSOSOMAL PATHWAY 
The autophagy pathway is necessary to drive substrates to lysosomes, and lysosomal 
proteolysis is dependent on the activity of cathepsins (Attaix and Bechet, 2007).  
Previous muscle incubation research in muscles from cachectic animals suggested 
that autophagy played an insignificant role in overall protein degradation (Baracos et 
al., 1995, Llovera et al., 1995, Temparis et al., 1994, Costelli et al., 2005).  Contrary 
to this, an elevation of total lysosomal protease activities has been seen in muscles 
and liver of tumour bearing rats (Greenbaum and Sutherland, 1983, Lundholm et al., 
1980, Tessitore et al., 1994) along with increased muscle levels of cathepsin L 
mRNA in septic rats (Deval et al., 2001).  Likewise, activation of autophagy has 
been demonstrated in C2C12 myotubes (Zhao et al., 2007, Mordier et al., 2000).  
Furthermore, in animal models of denervation and starvation induced atrophy, 
induction of several autophagy related genes has been demonstrated (Mammucari et 
al., 2007).  These included light chain (LC) 3, Gamma-Aminobutyric Acid Receptor-
Associated Protein-like (GABARAP)-1, Bcl-2/adenovirus E1B 19kDa interacting 
protein 3 (BNIP3) and BNIP3l,  all  of  which  had  been  on  the  ‘atrogene’  list  
previously reported by Lecker et al (Lecker et al., 2004).  
 
Autophagy has also been demonstrated to play a role in cardiac atrophy associated 
with cancer cachexia (Cosper and Leinwand, 2011).  In the colon-26 tumour mouse 
model, autophagy (without UPP activation) in cardiac muscle was demonstrated to 
be responsible for loss of both myofibrillar and sarcomeric proteins, which is in 
contrast to skeletal muscle where myosin appears to be a selective target.  
Furthermore, male mice lost more body, muscle and cardiac mass than females and 
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at a faster rate.  This intriguing observation requires further study, but raises 
questions about a potential role of sexual dimorphism in cancer cachexia. 
 
Human studies have reported increased cathepsin D enzyme activity in cancer 
patients (Schersten and Lundholm, 1972) and cathepsin B mRNA in lung cancer 
patients (Jagoe et al., 2002).  In the latter study, cathepsins B levels were higher in 
early versus late stage tumours.  Components of the UPP were unchanged in cancer 
patients, and thus the authors concluded that lysosomal proteolysis may be relevant 
early and the UPP may be activated later in the disease process (Jagoe et al., 2002).  
This perhaps has some appeal because, although one study detected radio-labelled 
myofibrillar proteins in lysosomes (Gerard and Schneider, 1979), there is other 
evidence suggests that lysosomal proteolysis in isolation is not sufficient to degrade 
myofibrillar proteins (Lowell et al., 1986, Furuno et al., 1990, Cohen et al., 2009).   
 
Forkhead box O (FOXO) TRANSCRIPTION FACTORS 
FOXO transcription factors are a Forkhead family of proteins, which are now 
thought to be an important link between proteasomal and lysosomal proteolysis.  In 
humans there are 39 distinct members and 19 subgroups (A-S).  The O group is 
regulated by the insulin/IGF-1/PI3K/Akt signalling pathway and there are 3 members 
in mammalian cells: FOXO 1 (also known as FKHR), FOXO3 (FKHRL1) and 
FOXO4 (AFX) (Sandri et al., 2004, Carter and Brunet, 2007).  FOXO is inactive in 
its phosphorylated state induced by Akt, where it is exported to the cytoplasm 
(Brunet et al., 1999).  Conversely, FOXO is activated by dephosphorylation and 
translocation to the nucleus (Ramaswamy et al., 2002, Sandri et al., 2004).  In the 
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context of cachexia, FOXO1 was  found  amongst  the  list  of  ‘atrogenes’  (Lecker et al., 
2004), and all have been implicated in pre-clinical models of muscle atrophy. 
 
FOXO3 activation leads to atrophy of muscle fibres (Sandri et al., 2006), and in 
starvation and glucocorticoid induced atrophy of myotubes and mice, FOXO 
transcription factors were shown to activate the E3 ligases atrogin-1 and MuRF and 
other  ‘atrogenes’  (Sandri et al., 2004, Stitt et al., 2004).  Overexpression of Akt could 
inhibit this response confirming relevance of this pathway in cachexia (Sandri et al., 
2004).   Subsequently, the key role of FOXO3 in induction of autophagy in skeletal 
muscle in vivo was also demonstrated.   Mammucari et al reported upregulation of 
several autophagy genes by FOXO3 (Mammucari et al., 2007) including LC3, 
GABARAPL1, BNIP3 and BNIP3l, which comprised part of the ‘atrogene’  list  
(Lecker et al., 2004).  BNIP3 was shown to be a major effector of FOXO3 mediated 
autophagy with its protein expression being induced by FOXO (Mammucari et al., 
2007, Mammucari et al., 2008).  The co-ordinate activation by FOXO transcription 
factors of both the proteasome and especially the autophagy pathway was illustrated 
in myotubes and mice.  FOXO3 overexpression led to stimulation of both pathways, 
but with a 3 fold greater increase in lysosomal proteolysis (Zhao et al., 2007, Zhao et 
al., 2008).  The authors suggested that under FOXO control, the UPP was responsible 
for degradation of myofibrillar proteins whereas activation of autophagy accounted 
for loss of mitochondria and endurance. 
 
In humans, reduced levels of Akt and phosphorylated (inactive) FOXO3 have been 
observed in the skeletal muscle of cachectic compared with non-cachectic pancreatic 
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cancer patients.  However, an unexplained twofold reduction in the levels of FOXO1 
and FOXO3 protein was also observed making the data challenging to interpret 
(Schmitt et al., 2007). 
 
CALPAINS 
Calpains have also been implicated in the degradation of sarcomeric and cytoskeletal 
proteins in cultured myotubes (Purintrapiban et al., 2003).  In this particular study, 
the addition of a calpain inhibitor resulted in a 20% reduction in overall protein 
degradation.  Similarly, this was reported in a murine hindlimb suspension model 
where inhibition of calpain activity preserved sarcomere structure and furthermore 
prevented a fall in the isometric force generating capability (Salazar et al., 2010).  
Gastric cancer patients with minimal weight-loss (average 1.24%) had an increase in 
Rectus abdominis muscle calpain activity by 70% compared with controls, 
suggesting a role for the calpains early in the cachexia journey before significant 
clinical changes are apparent (Smith et al., 2011). 
 
CASPASES 
A role for caspases in muscle protein degradation was suggested due to the 
observations of reduced myonuclei numbers in muscle atrophy of heart failure or 
Duchenne muscular dystrophy (Adams et al., 2001, Sandri, 2002).  Caspase-3 has 
been shown to cleave actomyosin complexes and caspase-3 inhibitors can prevent 
accumulation of actin fragments in skeletal muscle of diabetic or uremic rats 
suggesting that activation of caspase-3 may be an initial step in enhanced muscle 
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protein degradation (Du et al., 2005).  However, other authors disagree with these 
findings suggesting that non-apoptotic cells would be unlikely to activate sufficient 
caspase-3 to contribute to the turnover of myofibrillar proteins (Goll et al., 2008). 
 
There is evidence of apoptosis in skeletal muscle in the Lewis lung carcinoma mouse 
and AH-130 hepatoma animal models of cachexia (van Royen et al., 2000), but a role 
in human cancer cachexia has not been proven. In gastric cancer patients with mild-
moderate weight-loss (mean 6%) there were similar numbers of apoptotic myonuclei 
compared with controls and no increase in caspase-1 or caspase-3 on 
immunohistochemistry (Bossola et al., 2006).   
 
NFκB  PATHWAY 
The  NFκB  family  are  pivotal for the modulation of several cellular processes – 
apoptosis, differentiation, inflammation and stress responses (Hayden and Ghosh, 
2004, Oeckinghaus et al., 2011, Acharyya and Guttridge, 2007).  There are 5 known 
NFκB  transcription  factors,  all  of  which  are  expressed in skeletal muscle with 
p65/p50 being the prototypical heterodimer.  In the inactive state, they are bound to 
the inhibitor of kappa B (IκB) in the cytoplasm and translocate to the nucleus on 
activation.  TNFα, IL-1β and PIF can  all  activate  the  NFκB  pathway,  and  the  
PI3K/Akt pathway also has some regulatory activity by phosphorylation of IκB 
kinase (IKK),  which  activates  NFκB.  There may also be interplay between the 
NFκB  pathway  and  the FOXO transcription factors with IKK negatively regulating 
FOXO3a independent of Akt (Hu et al., 2004).  In myotubes and mice, TNF and 
IFN-γ  induced  activation  of  NFκB  with  downregulation  of myoblast determination 
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protein (MyoD) (essential for repair of damaged tissue and regulates skeletal muscle 
differentiation) and dysfunction of skeletal myofibres was demonstrated (Guttridge et 
al., 2000).  Likewise, chronic muscle specific NFκB activation in transgenic mice led 
to profound muscle wasting due to accelerated ubiquitin proteasome dependent 
proteolysis (Cai et al., 2004).  
 
In newly diagnosed lung cancer patients with pre-cachexia (defined as weight-loss 
<10%), although plasma markers of systemic inflammation were increased,  NFκB  
dependent signalling was similar to the healthy controls (Op den Kamp et al., 2012).  
However, in gastric cancer patients with mean weight-loss of 10.9%, there was a 25% 
increase in phospho-p65, and a 25% decrease in IκBα protein expression in cancer 
patients compared with controls (Rhoads et al., 2010).  These differences did not 
relate to  either  tumour  stage  or  cachexia  suggesting  that  change  in  NFκB  activity  
occurred early and was sustained with increasing weight-loss.  These contradictory 
results could indicate differences in signalling mechanisms according to tumour site, 
but require further investigation. 
 
PROTEIN SYNTHESIS 
A primary role for suppressed protein synthesis in muscle atrophy in cancer cachexia 
has been proposed (Emery et al., 1984a, Rennie et al., 1983).  In insulin receptor 
knockout mice, there is evidence that reductions in muscle mass and function are due 
to depression of synthesis and not an increase in degradation (O'Neill et al., 2010).  
With such a large body of evidence for increased protein degradation in cancer 
cachexia, it seems hard to completely dismiss some role of the proteolytic pathways.  
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However, some authors have argued that the changes in catabolic pathways are 
purely a secondary adaptive response (Rennie et al., 1983, Emery et al., 1984a). 
 
A reduction of protein synthesis in cachexia may occur through either inhibition of 
amino acid uptake, or the suppression of RNA translational efficiency/capacity 
(Acharyya et al., 2004).  Indeed, some tumour models show as much as a 40% 
decrease in total muscle RNA compared with control animals (Emery et al., 1984b, 
Baracos et al., 1995, Acharyya et al., 2004).  The concept that skeletal muscle protein 
synthesis in cachexia is reduced simply due to anorexia (Tisdale, 2009) seems 
unlikely.  In animal models where anorexia is absent, depression of protein synthesis 
has also been demonstrated suggesting that the protein synthetic machinery is 
defective (Smith and Tisdale, 1993).   In the MAC-16 cancer cachexia model, 
catabolism and anabolism appear to occur in tandem with up to a 60% fall in protein 
synthesis (Beck et al., 1991).  In another animal model, the APC(Min/+) mouse, a 
reduction in protein synthesis seemed to precede a rise in proteolysis, suggesting 
time dependant activation of pathways (White et al., 2011).   
 
Branched chain amino acids are substrates for protein synthesis in skeletal muscle, 
but can also enhance protein synthesis by initiating signal transduction pathways that 
modulate translation initiation (Yoshikawa et al., 2001).  Leucine seems to be most 
potent (Eley et al., 2007) and some authors have used this observation as a rationale 
to supplement leucine in the diet of cachectic patients (Tisdale, 2009). 
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dsRNA-dependent protein kinase 
The opposing views on protein synthesis and degradation in cancer cachexia may be 
resolved by the discovery of the role of double stranded RNA-dependent protein 
kinase (PKR) in muscle atrophy (Eley and Tisdale, 2007).  PKR is one of four 
mammalian cell eIF2α kinases that responds to distinct stress conditions that affect 
transcription and protein synthesis.  Both PIF and angiotensin II have been 
implicated in activation of PKR, which subsequently can activate IKK with 
stimulation of NFκB activity (Eley et al., 2008).  The finding of increased 
phosphorylation of PKR and eIF2α in myotubes and MAC-16 tumour bearing mice 
thus provided a potential link between a depression of protein synthesis and 
increased degradation in cancer cachexia (Eley and Tisdale, 2007).    
 
Likewise, the finding that levels of phospho-PKR and phosphor-eIF2α were 
increased in gastro-oesophageal cancer patients compared with controls supports a 
role for PKR as an initiator of human cancer cachexia (Eley et al., 2008). 
 
MYOSTATIN/ACTIIB  
Myostatin was first discovered in 1997 (McPherron et al., 1997) in knockout animals 
with muscle hypertrophy. The potential for profound effects on muscle phenotype 
are evident in the mutations leading to myostatin deficient cattle (Grobet et al., 
1997), whippet dogs (Mosher et al., 2007) and even a human spontaneous mutation 
(Schuelke et al., 2004).  This has led to a growing body of research investigating the 
potential role in muscle wasting disorders.   
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Physiologically myostatin appears to be a gatekeeper maintaining satellite cells in 
reversible quiescence (Amthor et al., 2006).  Myostatin (or growth and 
differentiation factor 8 (GDF-8)) is a member of the TGF-β superfamily of secreted 
growth factors that play an important role as a negative regulator of growth  and 
differentiation and can also promote adipogenesis (Artaza et al., 2005, Whittemore et 
al., 2003).  It is predominantly expressed in muscle, but is also present in the 
circulation (Wagner et al., 2002).  Follistatin appears to be a complementary 
antagonist to myostatin (Amthor et al., 2004).  Myostatin signalling involves 
interaction with the myogenic regulatory factors (MRF), inhibiting the synthesis and 
activity of MyoD (Amthor et al., 2004, Guttridge, 2004). Myostatin is inhibited by 
the anabolic actions of GH (Liu et al., 2003) and in contrast dexamethasone can 
increase myostatin expression (Ma et al., 2001).  Exercise may decrease myostatin 
levels, but there are conflicting results.  
 
Myostatin acts by binding to its receptors (activin receptor (ActR) type I, ActRIIA 
and ActRIIB) in muscle, which initiates  a signaling cascade leading to increased 
expression  of atrogin-1 and MuRF1 and subsequent degradation of myofibrillar 
proteins (Glass, 2010). Direct evidence linking muscle wasting in cancer cachexia 
with survival has been lacking until recently.   One study in colon-26 carcinoma-
bearing mice demonstrated that ActRIIB antagonism prolonged survival, prevented 
muscle wasting and reversed muscle loss during cancer cachexia.  In addition, it was 
shown that ActRIIB pathway activation induced the ubiquitin ligases and enhanced 
ubiquitination of muscle proteins.  Furthermore, ActRIIB antagonism abolished 
 105 
activation of the UPP and dramatically stimulated satellite cell proliferation, which 
presumably contributed to the rapid reversal of muscle loss seen in the treated 
animals (Zhou et al., 2010).  
 
In a recent study of myostatin expression in muscle biopsies from weight stable lung 
and gastric cancer patients, there was evidence of an increase only amongst the 
gastric cancer patients (Aversa et al., 2012).  This suggests that in human cancer 
cachexia, myostatin alterations vary by tumour site but may play a role early in the 
cachexia journey.   
 
TNF receptor-associated factor (TRAF) 6 
TRAFs are proteins involved in activation of various aspects of intracellular 
signalling(Paul et al., 2010, Paul and Kumar, 2011). TRAF6 is an important E3 
ubiquitin ligase, which targets proteins for degradation (Pickart, 2001, 
Mukhopadhyay and Riezman, 2007). Several studies have shown TRAF6 to be 
related to activation of NFκB, mitogen-activated protein kinase (MAPK) and 
PI3K/Akt pathways (Yang et al., 2009, Yamashita et al., 2008). TRAF6 expression 
level and auto-ubiquitination were enhanced in skeletal muscle during atrophy in 
mice (Paul et al., 2010). This study also demonstrated that through the activation of 
Jun N-terminal kinase (JNK)1/ 2, p38 MAPK, adenosine monophosphate-activated 
protein kinase (AMPK), and NFκB, skeletal muscle-restricted depletion of TRAF6 
rescues myofibril degradation and preserves muscle fibre size and strength upon 
denervation (Paul et al., 2010). Inhibition of TRAF6 also preserves the orderly 
pattern of intermyofibrillar and subsarcolemmal mitochondria in denervated muscle. 
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These results suggest that depletion of TRAF6 prevents cancer cachexia in an 
experimental mouse model and provides a novel therapeutic target for prevention of 
skeletal muscle wasting in cancer cachexia. 
 
Signal transducer and activation of transcription (STAT)3 
Recent work has focused on STAT3 activation in skeletal muscle and has linked it 
with muscle wasting and the acute phase response in cancer cachexia (Bonetto et al., 
2011). This contemporary study characterized serum cytokines and the muscle 
transcriptome in the colon-26 adenocarcinoma model of cancer cachexia.  There was 
evidence of STAT3 activation, target gene expression and the acute phase response 
in both the liver and skeletal muscle of the mice.  In addition, it was shown that 
transcription of suppressor of cytokine signalling (SOCS)3, a classical feedback 
inhibitor of STAT3 activation was induced. SOCS3 binds to activated Janus kinase 
(JAK) and inhibits STAT3 activation (Glass, 2005). However, in contrast to the high 
SOCS3 mRNA levels in muscle, little or no increase in SOCS3 protein either in 
muscle or in liver was observed. This lack of SOCS3 protein explains, in part, how 
high pSTAT3 levels could persist regardless of high SOCS3 RNA levels and how 
sustained STAT3 activation might continue to drive muscle wasting while activating 
its inhibitor. 
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DOWNSTERAM TARGETS: ALTERATIONS IN MUSCLE STRUCTURE 
Myofibrillar proteins 
It is presumed that the main downstream targets of cachexia are the myofibrillar 
proteins because of their overall abundance and functional relevance in skeletal 
muscle architecture (Clark et al., 2002).  Normally proteins comprising the myofibril 
are amongst the most stable in the body, but during atrophy induced by unweighting, 
the myofibrillar apparatus decreases in mass to a greater extent than soluble 
sarcoplasmic components (Munoz et al., 1993) and results in decreased strength.  As 
discussed earlier in the introduction, (Section 1.2.6.1) the myofibril is a precisely 
aligned filament system arranged in repeating units of sarcomeres with myosin being 
the main component of thick filaments and actin the main component of thin 
filaments (Seeley, 1995).  The E3 ligase MuRF1 has been demonstrated to play a key 
role in myofibrillar degradation.  It has two substrates; cardiac troponin-I (Kedar et 
al., 2004), and MyHC (Clarke et al., 2007).  In the latter study, whilst there was 
selective depletion of MyHC, actin levels remained unperturbed.  This selective 
targeting of MyHC had previously been demonstrated in both myotubes and colon-
26 cachectic mice (Acharyya et al., 2004) with no alteration in levels of other 
myofibrillar proteins (tropomyosin, troponin, sarcomeric actin, actinin, myosin light 
chain (MyLC)).   
 
However, more recent studies suggest that different mechanisms are responsible for 
degradation of the thick and thin filaments, and there also seems to be time 
dependent activation.  In denervation murine models of atrophy, MuRF1 was 
induced after 3 days but did not cause a reduction in MyHC till 14 days after 
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induction (Cohen et al., 2009).  There was loss of other components of the myofibril 
(MyLCs and myosin binding protein-C (MyBP-C), which are proteins that stabilise 
the thick filament) due to MuRF1 but only after 10 days.  This suggested that other 
mechanisms were responsible for the fall in muscle mass during the first week.  
Similarly, given that MuRF1 did not degrade the thin filaments, the authors 
concluded that a MuRF1 independent mechanism must be responsible (Cohen et al., 
2009).  Interestingly, a study published in 2012 suggested that MyHC was not 
selectively targeted in cancer cachexia but rather decreased in parallel with other 
myofibrillar proteins (Cosper and Leinwand, 2012).  Furthermore, the authors 
suggested previous studies had flawed muscle lysis methodology leading to the 
misinterpretation of selective MyHC loss.  However, other research groups do not 
seem to have commented on experiencing similar methodological difficulties. 
 
In humans, loss of MyHC has also been reported in patients with gastro-oesophageal 
cancer cachexia (Eley et al., 2008, Acharyya et al., 2005).  Another study in 
pancreatic cancer patients with cachexia showed a 45% decrease in MyHC protein 
levels compared with controls (Schmitt et al., 2007).   
 
Dystrophin glycoprotein complex (DGC) 
During contraction of muscle, the contractile machinery inside the myofibres must 
remain intimately connected with the membrane and extracellular matrix.  If this 
does not occur, movement would be improperly transmitted and myocytes would risk 
damage to their membranes (Lapidos et al., 2004).  One function of the DGC is just 
that; to provide a strong mechanical link from intracellular cytoskeleton (namely 
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subsarcolemmal actin) to the extracellular matrix (Figure 1.7). The DGC is a large, 
multimeric complex comprising a group of transmembrane, peripheral membrane, 
and extracellular and cytosolic proteins – mutations of which may give rise to 
distinct muscular dystrophies (Batchelor and Winder, 2006).  It holds not just 
structural but also signal transduction/reception properties and is comprised of 
transmembrane, cytoplasmic and extracellular proteins (Batchelor and Winder, 2006, 
Lapidos et al., 2004).  An active signal transduction pathway is maintained by 
interaction of the DGC with Growth factor receptor-bound protein (Grb)2 and 
neuronal Nitric Oxide Synthase (nNOS) (Rando, 2001, Acharyya et al., 2005). 
 
The integral function that the DGC plays in maintaining muscle structure led to an 
investigation of the link between muscular dystrophy and cancer cachexia (Acharyya 
et al., 2005).  Using the colon-26 mouse model, it was evident that the membranes of 
cachectic muscles were wrinkled indicating that the sarcolemma and associated basal 
lamina was abnormal.  Confirmation of membrane damage was seen by an increase 
of Evans blue dye uptake in cachectic muscle.  Assessment of the different 
components of the DGC revealed what the authors referred to as deregulated DGC 
(reduction of dystrophin, hyperglycosylation  of  β-dystroglycan  and  β-sarcoglycan in 
cachectic mouse muscle. Furthermore, deregulated DGC was also seen in 59% 
(16/27) of patients with gastro-oesophageal cancer but not any of the controls, and 























Adapted from Acharyya (Acharyya and Guttridge, 2007).  Schematic 
illustrating the components of the dystrophin glycoprotein complex, 
which provides a strong mechanical link between intracellular actin and 
extracellular laminin.  Dystroglycan and sarcoglycan components are 


















This part of the introduction has discussed current knowledge relating to the 
phenotype of cancer cachexia, along with the potential molecular mechanisms 
involved.  The next section will provide a background on biomarkers and their 
relevance to disease and cachexia. 
 
1.3 Biomarkers – an overview 
“He  replied,  when evening comes you say, it will be fair weather, for the sky is red, 
and in the morning, today  it  will  be  stormy,  for  the  sky  is  red  and  overcast”   
(Matthew 16v2-3a, Holy Bible, Hodder & Stoughton) 
 
Since biblical times, red sky has been used as a predictive biomarker of weather 
conditions.  However, although ‘biomarkers’ have been in everyday use for many 
years, the explicit terminology only became more widely used in the scientific 
literature during the 1960s.  Table 1.5 outlines some of the historical landmarks in 
biomarker discovery with some examples. 
 
Traditionally, biomarkers tended to be physiological variables (e.g. pyrexia as a 
biomarker of infection, a heart murmur can be seen as a biomarker of cardiac valve 
disease, or blood pressure as a biomarker of hypertension).  Over the past century, 
the increasing use of biochemistry in healthcare has led to markers such as blood 
glucose in diabetes and creatinine in renal disease.  In recent decades, the field of 
biomarkers has expanded exponentially with the advent of more sophisticated and 
complex techniques and technologies (such as microarrays or deep nucleotide 
sequencing) and the mapping of the Human Genome leading to discovery of many   
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Table  1.5:  Historical  landmarks  in  the  discovery  and  
development  of  biomarkers 
 
Year Landmark 
1847 Urinary Bence Jones protein was used as a cancer biomarker 
1954 Test developed for measuring transaminases in myocardial infarction 
1967 Serum creatine phosphokinase used as an improved biomarker test for myocardial infarction 
1971 Carcinoembryonic antigen reported as a biomarker of cancer 
1987 Troponin I reported as a sensitive biomarker for myocardial infarction 
2000 Potential to discover gene biomarkers with the completion of sequencing the human genome 
 




molecular biomarkers of disease (Kurian et al., 2007).  In parallel with this, the 
pharmaceutical industries have become increasingly interested in the potential for 
biomarkers to be used as measures of drug response, potential drug targets and 
surrogate markers of endpoints allowing more rapid assessment of treatment effects 
during trials.  
 
The increasing availability of molecular biomarkers has revolutionised everyday 
clinical medical practice.  There has been increasing interest and dependency 
amongst physicians on biomarkers used to diagnose conditions (e.g. troponin in 
myocardial ischaemia/infarction, imaging modalities – Positron Emission 
Tomography (PET)-CT), monitor response to treatments (e.g. carcinoembryonic 
antigen (CEA), antibiotic levels) along with screening to predict development of 
disease or at risk populations (e.g. cervical smears, prostate specific antigen (PSA), 
genetic mutations).  The drive towards personalised medicine is closely linked to 
biomarker discovery and has generated a wealth of data allowing prediction of an 
individual  patient’s  likely  response  to  treatment or development of side effects.  
Furthermore, it is now possible to fill online tools with levels of markers (cholesterol, 
height/weight) and risk factors (lack of exercise, diet) to give a prediction of your 
personal risk of developing a number of diseases (cardiovascular/stroke/cancer) 
(Siteman Cancer Center).  
 
It has been estimated that the global biomarker market will increase to £12.7 billion 
by 2014 (Henry, 2011).  In late 2006 the biomarkers consortium was established as a 
unique partnership between the Food and Drug Administration (FDA), National 
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Institutes of Health (NIH) and industry in an effort to co-ordinate and facilitate 
biomarker research.  Indeed, this consortium now funds a range of projects ranging 
from plasma biomarkers of Alzheimer’s disease through to diagnostic markers of 
ageing (Consortium).  It is thus apparent that the field of biomarker research and 
application to everyday practice is going to continue to expand. 
 
1.3.1 Definition of a biomarker 
Many different definitions of biomarkers have been proposed, mainly associated with 
the specific context of their use.  In the broadest sense, a biomarker is a measurable 
entity that indicates the presence or absence of a condition.  There is a temptation to 
used  the  terms  ‘biomarker’  and  ‘surrogate’  interchangeably.    However,  there  is  a  
clear hierarchical distinction between biomarkers and surrogate endpoints (Jain, 
2010).  This was highlighted in 1998, when the Biomarker Definitions Working 
Group (part of the NIH) presented (and subsequently published in 2001) their 
preferred definitions for biomarkers and surrogate endpoints:  
 
Biomarker - A characteristic that is objectively measured and evaluated as an 
indicator of normal biologic processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention.  
Clinical Endpoint - A characteristic or variable that reflects how a patient feels, 




Surrogate Endpoint - a biomarker intended to substitute for a clinical endpoint.   A 
surrogate endpoint is expected to predict clinical benefit (or harm, or lack of benefit 
or harm) based on epidemiologic, therapeutic, pathophysiologic or other scientific 
evidence.  
Biomarker Definitions Working Group - 1998 
     (Biomarkers Definitions Working, 2001) 
 
1.3.2 Categories and uses of biomarkers 
Biomarkers can be categorised in many ways such as by method (e.g. imaging vs. 
molecular) or tissue compartment (e.g. blood versus muscle versus urine).  However, 
more helpful is the proposal by Ransohoff in 2003 of two major categories of 
approaches presently available for the discovery of new biomarkers (Ransohoff, 
2003): 
- hypothesis-driven research: investigation of molecules believed to be 
involved in cancer biology, putative candidate genes or proteins are 
considered one by one as possible biomarkers 
- discovery-based research: gene-expression patterns or mass-spectromic peaks 
which may be used to select and identify new candidate genes or proteins by 
conventional methods or be used themselves as patterns or signatures of 
disease (Gion and Daidone, 2004) 
 
There are almost an infinite number of varied potential uses for biomarkers both as 
research tools and in the clinical care of patients.  This ranges from red hair and fair 
skin as a biomarker of susceptibility to skin cancer (Mitra et al., 2012), single-
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nucleotide polymorphisms as biomarkers of oesophageal/pancreatic/hepatocellular 
cancer risk (He et al., 2013) through to monitoring of drug levels in patients (Wong 
et al., 2013).    
 
Molecular and genetic based biomarkers are divided into three types with the 
suggestion that there should be a stepwise progression of biomarkers from 0-2 
(Mildvan et al., 1997). 
Type 0: NATURAL HISTORY MARKER  
These can be used to identify a population predisposed to a disease, to identify 
patients with a disease, for staging, to predict prognosis/disease progression or to 
identify recurrent disease (Jain, 2010).  
Type 1: BIOLOGICAL ACTIVITY MARKER 
These can be used for target discovery valuation of drug activity, understanding 
mechanisms of action, toxicity and safety evaluation and investigation of 
pharmacodynamics/kinetics (Sahu, 2011). 
Type 2: SURROGATE MARKER OF THERAPEUTIC EFFICACY  
This is the use of biomarkers as surrogate endpoints. 
 
1.3.3 Biomarker validation – from discovery to clinical use 
Discovering a potential biomarker does not necessarily translate into it being a useful 
biomarker.  Table 1.6 outlines the phases of biomarker development.  The literature   
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Table  1.6:  Phases  of  biomarker  development 
 
Phase  Description Number of analytes Number of samples 
Discovery Identify candidate biomarkers 1000s 10s 
Qualification Confirm differential abundance of 
candidates 
30-100 10s 






and optimise assay 
4-10 Many 1000s 
 
 
Adapted from Rifai et al (Rifai et al., 2006).  Number of analytes = 
proteins expected to be evaluated as candidate biomarkers in each 





is packed with descriptions of 1000s of potential biomarkers and yet relatively few 
have been adopted in routine clinical practice.  The focus of this section is on the 
processes that a biomarker passes through from first discovery to the point of use. 
 
The steps of biomarker validation have been emphasised by Pepe et al (Pepe et al., 
2001), who describes five phases: 
- pre-clinical exploratory phase that identifies promising directions 
- clinical validation in which an assay can detect and characterise a disease 
- retrospective longitudinal validation (i.e. a biomarker can detect disease at an 
early stage before it becomes clinically detectable or has other predictive 
value) 
- prospective validation of the biomarker accuracy 
- testing its usefulness in clinical applications to predict clinically relevant 
parameters (Tahara et al., 2009, Rifai et al., 2006). 
 
Even after validation, there will be various FDA/regulatory testing and approvals and 
marketing hurdles to overcome (Jain, 2010).  There are many reasons why a 
biomarker (even a valid one) may not make it into routine use.  This will be 
discussed further in Section 1.3.6.   
 
1.3.4 Potential sources of biomarkers in humans 
Ideally, a biomarker should be assessed with the minimum of discomfort or 
complexity to the patient.  At the level of biomarker discovery and biomarkers which 
can inform pathophysiology or drug targets, more invasive methods (e.g. biopsies) 
 119 
may be required until a less invasive correlate can be identified.  Biomarkers are 
present in all parts of the human body.  Figure 1.8 illustrates potential sources of 
biomarkers in humans ordered by degree of invasiveness. 
 
1.3.5 The  ‘ideal’  biomarker 
To be clinically acceptable, the ideal biomarker should have a sensitivity and 
specificity close to 100%.  Sensitivity refers to the percentage of positive samples 
identified as true positive and specificity is the percentage of negative samples that 
are true negative.  These are important factors to consider in performing biomarker 
studies because higher numbers of false positives will increase the amount of work 
generated whereas false positives will increase the amount of cost of a study 
(Mayeux, 2004).  In clinical practice, it is perhaps surprising to find that several of 
the commonly used biomarkers have relatively low values.  For example PSA, used 
as a biomarker of prostate cancer, has a sensitivity of 86% and a specificity of 33% 
(positive predictive value of 41%).  Despite this, the FDA has approved its use in 
combination with a digital rectal examination (Issaq et al., 2011, NCI, 2009).  
Equally other biomarkers for breast, bladder and ovarian cancer have relatively low 
sensitivity or specificity results (Issaq et al., 2011).  These results are indicative of 
the complexity and heterogeneity of human beings, and it is unlikely that a test with 
100% sensitivity and specificity will ever be developed.  In bladder cancer, it has 
been shown that using multiple biomarkers gives better sensitivity and specificity 
(Horstmann et al., 2009) and thus using biomarker patterns, combinations or 
signatures may prove to be more relevant. 
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FIGURE 1.8: POTENTIAL SOURCES OF BIOMARKERS IN PATIENTS 
 
 
Abbreviations: BP, Blood pressure; CSF, cerebrospinal fluid. 
 
  
least invasive to 
most invasive 
•Phenotype (eg weight) 
•Questionnaire (eg diet) 
•Clinical test (eg BP, imaging) 
•Urine 
•Blood (whole/plasma/serum) 
•Other fluid compartment (eg CSF) 
•Tissue biopsy/resection 
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Jain has suggested that a biomarker is valid if: 
“1.  It  can  be  measured  in  a  test  system  with well-established performance 
characteristics. 
2. Evidence for its clinical significance has been established” (Jain, 2010).   
 
It is also important that a biomarker is able to pick up something that is not evident 
with a careful clinical assessment and that the method of obtaining the biomarker is 
the least invasive possible, without prohibitive cost and tolerated well by patients.   
 
1.3.6 Problems and limitations of biomarkers 
Despite the diversity and wealth of literature describing potential biomarkers and 
their applications, relatively few have progressed to the point of clinical use.  This 
can be due to inadequate sensitivity and specificity as discussed above, or financial 
constraints in the widespread use of the biomarker.  However, there are particular 
idiosyncrasies to biomarker research that confound initially exciting results.  Some of 
the potential sources of errors and problems in biomarker research are outlined below. 
 
RECRUITMENT 
In designing a biomarker study, it is important to ensure that a population is not too 
niche where limitations of age, gender or ethnicity can mean that the results do not 
apply to other populations.  This is particularly relevant in genetic studies where 
there can be geographical variation (Beaumont, 2004).  Other variables known to 
have an impact on the proposed biomarker should also be taken into consideration at 
the beginning of any investigation.  For example, will tumour stage or type impact on 
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a proposed biomarker (Issaq et al., 2011, Horstmann et al., 2009)?  Likewise, the 
control population should be carefully screened for any confounding co-morbidities. 
 
METHODS 
There are reported differences in the presence of certain proteins in serum versus 
plasma (Issaq et al., 2011) and thus explicit methods need to be defined and adhered 
to in order to avoid introducing error.  There can also be limitations of the modality 
used to assess the biomarker.  For example, cross-sectional imaging can be 
misinterpreted depending on the expertise of the radiologist, and every laboratory 
technique carries an error margin. Storage of tissue samples needs to be consistent 
and any freeze thaw cycle taken into consideration given the potential for 
protein/RNA changes giving false results or resulting in degradation of potential 
biomarkers.  The statistical analysis can also lead to errors.  Although many 
biological phenomena occur in a continuous fashion, many biomarker studies 
oversimplify results into positive/negative cut-offs (Gion and Daidone, 2004).  
Whilst this can be informative and is appealing for practical reasons, some 
statisticians have warned about pitfalls in using this method without first exploring 
correlative relationships (Altman et al., 1994, Gion and Daidone, 2004). 
 
APPLICABILITY 
Another limiting step in biomarker research is the potential for wider use.  The 
source of the biomarker is important – carrying out a brain biopsy may be possible in 
a central tertiary care facility with availability of specialists, but may not be available 
outside this sphere.  Likewise, if the method in which a proposed biomarker is 
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obtained is too invasive, carries significant risk, or is too costly then clinicians and 
patients are unlikely to embrace its use.  Variations within and between equipment 
and the settings used will also need to be accounted for – i.e. comparison of images 
from an older MR scanner with lower resolution values in a district hospital with the 
latest specification MR scanner at the regional centre.   
 
1.4 Current biomarker research in cancer cachexia 
There are relatively few papers relating to biomarkers in cancer cachexia in the 
literature.    A  search  of  PubMed  using  the  terms  ‘biomarkers’,  ‘cancer’  and  ‘cachexia’  
identified 143 papers.  Of these, 12 were foreign language and around 26 were 
review articles.  The remaining 105 were a mixture of original investigations, case 
reports, treatment trials, and papers looking at biomarkers in cancer per se rather than 
relating to cachexia.  Indeed, less than half of the papers mentioned cachexia, 
malnutrition, muscle wasting, or weight-loss in the title and there were few human 
studies.  The lack of a standard definition of cachexia in the past has also introduced 
a unique challenge in biomarker research.  If, for example, weight-loss cut-offs are 
used, there is an assumption that weight-loss is a robust biomarker of cachexia. The 
investigator is thus left with the intriguing problem of relating a biomarker to another 
biomarker that may or may not relate accurately to the presence of the original 
condition (cachexia) being examined.  With the recent strive towards a unified and 




The majority of human cancer cachexia biomarker research is still very much 
focussed on the identification of potential biomarkers.  Most of these have been 
hypothesis-driven (i.e. analysing selected candidates) and have been discussed 
previously in the molecular mechanisms of cachexia, Section 1.2.6. However, a 
couple of the more recent discovery-based research studies of biomarkers in human 
cancer cachexia deserve particular mention. 
 
Blood biomarkers 
Identification of serum proteins involved in pancreatic cancer cachexia (Felix et 
al., 2011) 
This study examined serum from patients with pancreatic cancer (stage II) 
undergoing resectional surgery.  Serum samples were analysed by mass spectrometry 
(CM-10 and Cu-IMAC platforms) and results of controls (n=20) and patients with 
(n=23) or without cachexia (n=10) were compared.  47 significant peak differences 
were identified of which 15 were examined by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE).  Four potential biomarkers (1.4-
2.3x fold change) of cancer cachexia were isolated: glucagon-like peptide 1 (GLP-1), 
apolipoprotein (Apo)-CII and -CIII and ZAG.  The novel findings of this study need 
to be placed into context.  Cachectic patients were defined as those with a weight-
loss >12% in 6 months compared with 0% in the non-cachectic group.  The rationale 
for this is not clear from the paper and whilst the authors conclude that identified 
proteins  could  be  used  “for  early  diagnosis  of  cachectic  pancreatic  cancer  patients”,  
this has to be questioned given the severity of weight-loss where patients can hardly 
be  classified  as  ‘early’  in  the  cachexia  journey.  Furthermore, in validating ZAG 
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protein levels using enzyme-linked immunosorbent assay (ELISA), there was no 
difference between cachectic patients and a separate group of cancer patients with 
weight-loss 4.5% in 6 months.  This lack of additive effect with increasing weight-
loss suggests that the markers may relate more closely to cancer per se or represent 
general illness markers.  Another confounding factor was that the mean age of 
controls was some 20 years younger than the cachectic patients and yet there did not 
appear to be any attempt to control for this, nor for gender in the data analysis.  In 
spite of this, the results confirm the potential for investigating blood in the search for 
biologically relevant biomarkers of cancer cachexia.  
 
Urinary biomarkers 
Mass spectromic detection of candidate protein biomarkers of cancer cachexia in 
human urine (Skipworth et al., 2010b) 
Mass spectrometry was utilised to examine urine from control, cachectic (weight-
loss >10%) and weight stable gastro-oesophageal cancer patients (n=8 each group).  
Higher numbers of protein species were evident in cachectic patient urine.  Proteins 
that were prevalent in cachectic patients were associated with muscle (myosin 
species), cytoskeleton (α-spectrin, nischarin) and microtubules (microtubule-actin 
crosslinking factor/microtubule-associate protein 1B/bullous pemphigoid antigen 1).  
Of particular note was the presence of MyHC7/cardiac muscle/β variant and 
unconventional myosin species 5c, 7a, 9a and 10 in almost 40% (n=3/8) of cachectic 
patients whilst it was absent in all weight-stable and control patients.  Although the 
number of patients in this study is fairly modest, the results appear to suggest a role 
for myosin loss in human cancer cachexia; similar to the evidence from animal 
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models of muscle wasting where the myofibrillar proteins are selectively targeted 
and membrane permeability is increased (Acharyya et al., 2005).  The authors 
indicate  that  the  study  was  “a  preliminary  attempt  to  identify  urinary  proteins  that  
might  be  used  in  future  biomarker  studies”  and  indeed,  the  data  pave  the  way  for  
larger validation studies to be done.  
 
Summary of Introduction 
This introductory section of the thesis has provided an overview of current 
knowledge relating to the cachexia phenotype, the molecular mechanisms relevant in 
muscle wasting and the potential of biomarkers. Data from animal models of muscle 
wasting have been fundamental in improving our knowledge of pathways relevant in 
muscle anabolism and catabolism along with identification of potential therapeutic 
targets, but these mechanisms may not relate to changes observed in the human 
patient.  For example, glucocorticoids cause profound proteolysis in pre-clinical 
models of cachexia (Schakman et al., 2009).  In stark contrast in patients with 
Cushing’s syndrome (characterised by elevated glucocorticoids), there was no 
evidence of upregulation of calpains, cathepsin D nor components of the UPP 
(Ralliere et al., 1997).  This indicates that the UPP may not be fundamental in the 
more chronic wasting seen in patients with Cushing’s syndrome (Williams et al., 
1999a).  Whether the same is true in cancer cachexia patients remains unclear.  The 
limited number of primary human cancer cachexia biomarker investigations 
highlights a recurrent problem – there is limited understanding of the molecular 
processes that lead to cancer cachexia in humans.  Human research remains at the 
stage of searching for biomarkers that can inform pathophysiology and/or drug 
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targets.  Therefore, with muscle being a fundamental target in cancer cachexia, it 
would seem there is a pressing need for more primary investigations using muscle 
biopsies for biomarker discovery research before looking for correlates in blood or 
urine.   
 
With this background in mind, the next section will describe the objectives of this 
thesis. 
 
1.5  Thesis  objectives 
1.5.1 Definition and classification of cancer cachexia 
The definitions of cachexia were discussed at the beginning of the introduction in 
Section 1.2.1.  Despite this recent development, studies that have attempted to 
validate these definitions are only just coming into publication.  It is thus difficult to 
know what would be the best definition to use in this thesis.  A percentage weight-
loss cut-off definition is not ideal as there will be overlap between cachectic patients 
and those who are pre-cachectic.  Some patients in the weight stable group will go on 
to develop cachexia and yet results will be analysed in  the  ‘non-cachexia’  group,  and  
thus may dampen any significant differences (Figure 1.9). 
 
However, within everyday clinical practice, a simple above or below cut off would 
be more easily applicable.  Likewise, more complex definitions which rely on 
sophisticated body composition measures using CT/MR imaging/DEXA, 
biochemical variables or functional parameters may limit their applicability outside  
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FIGURE 1.9: PHASES OF CACHEXIA 
 
 
    The spectrum of cachexia 
 
Cachexia is a journey rather than an event.  Categorising patients by 
strict weight-loss cut-offs will inevitably include patients at the verge of 












of research studies due to access to the appropriate equipment or availability of 
finance.   
 
The applicability of a cross-sectional based diagnostic criteria in the context of a 
process which progresses with time could also be questioned.  Without the 
availability of pre-morbid body compositional analysis, CT can only be based on 
population-based cut-offs that may not be so easily applicable on a patient-by-patient 
basis.  Patients are generally able to give an estimate of pre-morbid body weight.  
Whilst this does rely on patient recollection and is thus open to a degree of error, 
there is evidence that self-reported weight is reliable (Stunkard and Albaum, 1981, 
Perry et al., 1995). 
 
Therefore, this thesis is based around the definition and classification of cancer 
cachexia as proposed by Fearon et al in 2011 (Fearon et al., 2011).  This is because it 
is specific to cancer cachexia, is based on an international consensus rather than from 
a  single  centre’s  experience,  encompasses  the  notion  that  loss  of  skeletal  muscle will 
have more profound impact on a patient than loss of other tissue compartments and 
highlights the importance of cachexia as a journey.  The model that is used are 
patients with UGI cancer undergoing resectional surgery due to the higher percentage 
of patients that are cachectic according to previously reported data (Dewys et al., 
1980) and the access to tissue biopsies whilst the patient is anaesthetised. 
 
Given the profound impact skeletal muscle loss may have  on  patients’  muscle  
function and QoL, the framework for this thesis is centred on loss of muscle.  The 
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first part of the thesis will focus on staging of cancer cachexia by investigating 
potential biomarkers relating to early cachexia.  In the second part of the thesis, the 
phenotype of the patient with cancer cachexia is explored by assessing muscle mass, 




1.5.2 Overall hypotheses of thesis 
 
1. That there are potential biomarkers of cancer cachexia in human skeletal muscle.  
 
2. That more specific physiological phenotyping of cancer cachexia from the 
evaluation of skeletal muscle mass, function and ultrastructure may prove feasible, 






1.5.3 Aims of thesis 
A) Cachexia biomarker discovery in human skeletal muscle 
1.  To determine if, within skeletal muscle, changes in specific proteins or mRNA 
species (identified from preclinical models reported in the literature) correlate with 
conventional markers of cachexia in humans and might be candidate biomarkers for 
cancer cachexia (Chapter 3). 
2.  To determine from within human skeletal muscle obtained at cancer diagnosis if a 
systems biology approach (transcriptomics) can provide early cachexia candidate 
biomarkers (Chapter 4). 
3.  To determine if candidate biomarkers within the human skeletal muscle 
transcriptome can be identified by a longitudinal analysis of patients recovering from 
cachexia (Chapter 5). 
 
B) Assessment of skeletal muscle mass, function and ultrastructure 
1.  To determine changes in skeletal muscle mass and non-contractile elements 
content in vivo using cross-sectional imaging and k-means statistical analysis in 
patients with cancer cachexia (Chapter 6). 
2.  To characterise the relationship between skeletal muscle mass/function (gross 
mechanical quality) and QoL in patients with cancer cachexia (Chapter 7). 
3.  To determine the nature of change in skeletal muscle at the ultrastructural level 
associated with cancer cachexia with a specific focus on lipid droplets (Chapter 8) 
4.  To determine the feasibility of a longitudinal study in patients with cancer 
cachexia and to assess the influence of cachexia on recovery from resectional surgery 
(Chapter 9). 
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Chapter  2:  Methods  and  materials 
2.1 Patient recruitment 
2.1.1 Patient identification, consent and ethics 
Patients were identified via the UGI cancer multi-disciplinary team (MDT) meetings.  
These meetings comprised surgeons, physicians, oncologists, nurse specialists, 
dieticians, pathologists and radiologists and were held weekly to discuss all cancer 
referrals mainly from the Lothian, Borders and Fife regions along with tertiary 
referrals from other hospitals in the central belt of Scotland.  The meetings were held 
weekly (one for gastro-oesophageal cancers and another for hepatobiliary cancers) in 
the Royal Infirmary of Edinburgh.  Figure 2.1 illustrates  the  ‘normal’  pathway  that  a  
patient would progress along once diagnosed with cancer. It is from the surgical 
cohort that potential patients to be included in the studies outlined in this thesis were 
identified.  Cancer patients discussed at these MDT meetings who were thought to 
have surgically resectable tumours were subsequently approached at their outpatient 
clinic appointment.  The study was discussed with them and a patient information 
sheet supplied (see Appendix 1). 
 
Control patients for the muscle biopsy studies (Part I) were recruited from elective 
theatre lists.  Those who were undergoing surgery for benign, non-inflammatory 
conditions were approached at outpatient clinics or pre-operative assessment clinic.  
The study was discussed with them and a patient information sheet supplied (see   
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FIGURE 2.1: THE DIAGNOSIS TO TREATMENT PATHWAY FOR PATIENTS 




Patients with a suspected or confirmed diagnosis of UGI cancer were 
referred to the central MDT meeting (comprising surgeons, radiologists, 
pathologists, nurse specialists, physicians, oncologists, and dieticians). 
A consensus decision on treatment was then made.  Patients included in 
this thesis were recruited from the Curative Surgery cohort.  
Abbreviations: MDT, multi-disciplinary team; UGI, upper gastrointestinal; 
ERCP, endoscopic retrograde cholangiopancreatography.  
Diagnosis 
(from the community, endoscopy, 
radiology, pathology) 





(e.g. chemotherapy, radiotherapy) 
Symptomatic control 
(e.g. stent, ERCP, laser, analgesia) 
Curative Surgery  
(Research Cohort) 
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Appendix 1).  Control patients for the physiological assessment studies (Part II) were 
recruited from the community.  Adverts were placed in buses and bowling clubs and 
interested participants were asked a screening questionnaire (see Appendix 1). 
 
All patients were then approached again in person, if they had a further clinic visit, or 
were phoned to confirm their willingness to participate in the study and to answer 
any questions.  The Clinical Research Facility (housing the muscle function 
equipment) and an MR scan were then booked to coincide with the patient attending 
for operation (if arriving the day before surgery) or their pre-assessment visit, which 
was  usually  carried  out  in  the  week  preceding  their  operation.    Patients’  were  asked  
about clinical details and these were recorded and confirmed/supplemented with 
information from the patients hospital records.  Written consent was taken prior to 
entry into the study (see Appendix 1).  All procedures were approved by the local 
research ethics committee (Reference 06/S1103/75). The studies conformed to the 
standards set by the Declaration of Helsinki. 
 
2.1.2 Proposed pathway/protocol of investigation 
Following consent, patients underwent a series of anthropometric and muscle 
function assessments and MR imaging as detailed below.  For patients in the muscle 
biopsy studies, tissue samples were collected at the time of operation.  A diagram of 
the planned patient pathway is shown below (Figure 2.2).  Repeat assessments for 
cancer patients were carried out at around 6, 12 and 18 months following surgery and 
aimed to tie in with routine post-operative surgical outpatient appointments.   
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In cancer patients a repeat quadriceps muscle biopsy was planned at 
one of the follow up assessments if there was significant progressive 
weight-loss. Abbreviations: MRI; Magnetic resonance imaging, QoL; 




2.2 Anthropometric assessments 
2.2.1 Height, weight and weight change 
Body weight was measured with participants in light clothing using a beam scale 
(Seca, UK).  Height was measured using a standard wall mounted measure.  Weight 
change was calculated as the percentage difference between stable pre-morbid 
weight and the weight at assessment.  The pre-morbid weight was taken from the 
clinical notes if available or from patient recalled weight.  Whilst this could be 
subject to recall bias, there is evidence that self-reported weight is reliable (Perry et 
al., 1995, Stunkard and Albaum, 1981). 
 
2.2.2 Body mass index (BMI) 
BMI was calculated according to the formula: 
BMI (kg/m2) = weight (kg)/ height (m)2. 
 
2.2.3 Triceps skin fold (TSF) thickness 
Callipers (Holtain Ltd Crymych UK) were used to measure the TSF thickness (mm) 
at the mid-arm point of the non-dominant arm (land-marked according to 
international standards ((ISAK) guidelines 2001) (Kinanthropometry, 2001).  
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2.2.4 Mid-arm muscle circumference (MAMC) and cross-sectional 
area (CSA) 
Mid-arm circumference (MAC) was measured (at the same site as for TSF above) to 
calculate MAMC using the formula: 
MAMC (cm) = MAC (cm) – [π  x  TSF (mm)]  
Arm muscle CSA was calculated according to the equation: 
(MAC - π  x  TSF2/4π)  – 10 (male) or (MAC - π  x  TSF2/4π)  – 6.5 (female) 
(Heymsfield et al., 1982). 
 
2.3 Measures of muscle function 
2.3.1 Hand grip dynamometry 
Patients were seated with the shoulder relaxed, the elbow flexed at 90° and the 
forearm unsupported. Hand grip strength (kg) was measured using a hydraulic 
dynamometer (Fabrication enterprises Inc., USA). Three measurements were 
obtained for each side and the highest value used in further analysis 
 
2.3.2 Isometric knee extensor strength (IKES) 
Maximum voluntary IKES (Newtons (N)) was measured using an established 
method (Moulds et al., 1977).  The participant was seated in an adjustable straight-
backed chair with the pelvis secured and the knee flexed at 90o.  A cuff was placed 
around the ankle and attached via an inextensible chain to a strain gauge and data 
acquisition system (Powerlab, AD instruments, UK) (Figure 2.3A).  Following 
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instruction, the participant made a maximum voluntary contraction, which was held 
for 5 seconds.  Three separate measurements were obtained for each limb and the 
highest value used in subsequent analysis.  Data were normalised to body weight 
(N.kg-1).   
 
2.3.3 Lower limb explosive power (LLEP) 
LLEP (Watts (W)) was measured using the Nottingham Power Rig (Medical 
Engineering Unit, University of Nottingham, UK) (Bassey and Short, 1990) (Figure 
2.3B).  The participant was seated on the rig with the seat position adjusted so that in 
full extension the footplate was fully depressed.  The participant pushed as hard and 
as fast as possible against the footplate to accelerate the flywheel. The final velocity 
of the flywheel was used to calculate the average power output (W) during a single 
maximal thrust of the lower limb.  The process was repeated five times with each 
limb and the highest value used in subsequent analysis.  Data were normalised to 
body weight (W/kg).  
 
2.3.4 Sit-to-stand time (STS) 
As a measure of functional ability, STS was measured.  Patients were seated and the 
time taken to rise from a seated to standing position without the aid of their arms was 











(A.) Chair, frame and strain gauge used to measure isometric knee 
extensor strength.  (B.) Nottingham Power Rig used to measure lower 
limb explosive power. 
 
  
Ankle bracelet attached to strain 
gauge at back of frame. 
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2.3.5 Three metre timed up-and-go (TUG) 
As an additional measure of functional ability, TUG was measured.  Two points were 
marked on the floor 3m apart.  Chairs were placed on each of these marks.  Patients 
were seated on one of the chairs and asked to walk around the other chair and back to 
the original seat; a 6m journey in total.  Patients were observed for the entire journey 
to ensure they walked and did not run (if this did occur, the measure was cancelled 
and a further measurement taken).  The total time was recorded and the best of three 
measurements was used for analysis. 
  
2.4 Quality of life assessment (QoL) 
2.4.1 Karnofsky Performance Score (KPS) 
 
KPS was assessed in each patient by one observer.  Appendix 1 outlines the scoring 
system (Karnofsky DA, 1949). 
 
2.4.2 European Organisation for Research and Treatment of 
Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) 
EORTC QLQ C-30 (Aaronson et al., 1993) was assessed in cancer patients and 
results analysed using linearised scores (scoring manual, version 3). The 
questionnaire is outlined in Appendix 1. 
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2.5 Direct measurement of physical activity  
2.5.1 Use of the ActivPAL™ monitor 
Physical activity and sedentary behaviour were recorded continuously over a three-
seven day period using an ActivPAL™ activity monitor (Figure 2.4) (PAL 
technologies Ltd., Glasgow, UK).  ActivPAL™ is about half a credit card size 
accelerometer-based activity monitor worn on the anterior aspect of the thigh. This 
instrument gives time stamped information every 0.1s on posture (sitting/lying, 
standing or walking/running) and walking cadence. It has been shown to be valid, 
accurate and sensitive in older adults (Grant et al., 2008) and in cancer patients 
(Dahele et al., 2007, Maddocks et al., 2010). Patients were instructed regarding use 
of the monitor and the protocol for bathing/showering. 
 
2.5.2 Analysis of ActivPAL™  results 
As soon as the study time period was over, the monitor was removed from the patient 
and data downloaded through the Universal Serial Bus (USB) portal using the 
ActivPALTM software provided.  The results were entered into an Excel® (Microsoft 
Corporation) spreadsheet for further analysis.  The range was a minimum of 3 and up 
to 7 days of data.  The output gives details of number of steps, up/down transitions, 
time spent sitting/lying, time spent standing, time spent stepping along with an 
estimate of energy expenditure (Metabolic Equivalent of Task (MET)) for each 24 
hour period.  An example of this output summary is shown in Figure 2.5. 
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FIGURE 2.4: THE ACTIVPALTM MONITOR 
 
 
   
 








ActivPALTM data output summary sheet.  Colour key is in the top left 
corner.  Abbreviations: EE, energy expenditure; MET, metabolic 
expenditure of task; u/d, up/down. 
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2.6 Radiological imaging 
2.6.1 MR imaging 
2.6.1.1 MR scan protocol 
Participants lay supine within the 1.5 Tesla MR Imaging system (Phillips Gyroscan 
Intera, The Netherlands) using a Q-body receiving coil with the system isocentre 
located at the mid-femur point where an oil-capsule was placed on the skin for 
reference (land-marked prior to the scan according to international standards ((ISAK) 
guidelines 2001) (Kinanthropometry, 2001).  Longitudinal relaxation time (T1)-
weighted spin echo axial images were prescribed from the proximal border of the 
patella to the superior anterior iliac spine. Imaging parameters were: slice thickness 
10 mm (no gaps); acquisition matrix 512 × 512; field of view 500 mm; echo time 15
ms; repetition time 425ms; and flip angle 90°. Three acquisitions were obtained to 
improve the signal to noise ratio. The number of slices acquired ranged from 38 to 45 
depending on thigh length. The legs were immobilised and supported using strapping 
during data acquisition to minimize motion artefact. Based on visual inspection of 
the images, no motion artefact was apparent. The total scan time was 6 minutes. 
 
2.6.1.2 Analysis of MR images 
The CSA of the thigh muscle was quantified on each image by drawing a region of 
interest (ROI) around the quadriceps muscle using the biomedical imaging software 
package ANALYZE 8.0 (Mayo Clinic, Rochester, USA) (Figure 2.6). This  
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(a, inset) Single MR slice (cropped display) taken at mid-thigh level. The 
manually drawn region of interest (ROI) comprising the quadriceps 
muscle group (left leg) is outlined in red. The posterior boundary of the 
ROI excluded closely located muscles (i.e., Sartorius, Adductor longus 
and the short head of Biceps femoris). (a) Histogram representing the 
intensity distribution for pixels lying within the ROI for the whole volume. 
Resulting cut-off values between contractile and non-contractile values 
are also shown for each application of the k-means clustering algorithm. 
(b) K-means processed image for the ROI shown in (a). Voxels tagged 
as the high intensity non-contractile component after the 1st clustering 
application are highlighted in green, those tagged as the low intensity 
non-contractile component found after the 2nd clustering application are 
highlighted in red. The ROI boundary shown in red in (a) has been 
removed for clarity. (c) Resulting optimized contractile tissue component 
segmented  from  ROI.  The  ROI’s  shown in (b) and (c) have been 
cropped and magnified for illustration purposes. 
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initial quantification of the muscle cross-sectional area is dependent upon the 
anatomical knowledge and manual segmentation skills of the operator. Intra- and 
inter-investigator reliability (using 6 whole leg scans i.e. ~270 images) for 
segmentation was measured using Bland Altman analysis with plots of individual 
slice volumes demonstrating maximum differences within and between (n = 2) raters 
of no greater than 0.4% (3.8 cm3) when expressed as a percentage of a total gross 
muscle volume of 1 litre. For studies utilising an individual cross-sectional slice, the 
mid-femur point was chosen (identified on scan with the oil-capsule).  Volume 
measurements were obtained by multiplying area measurements by slice thickness 
for all cross-sectional slices comprising quadriceps muscle.  Values were adjusted for 
height (CSA divided by height squared) (VanItallie et al., 1990).   
 
2.6.1.3 MR image analysis and muscle optimization using k-means 
statistical clustering  
The manually outlined ROI for each slice of the quadriceps group were converted to 
binary mask images. Software developed in matrix laboratory (MATLAB) version 
7.6 (R2008a, The Mathworks Inc., USA) combined all the MR images into a single 
array and similarly the ROI binary mask images were also combined into a single 
image array. The two arrays were then multiplied so that all areas outwith the 
quadriceps muscle region were masked during cluster analysis. This single masked 
MR image array was created for processing with the k-means algorithm so that a 
global range for voxel intensity values could be determined (i.e., intensity-based 
clustering was performed across the whole MR scan rather than on a slice-by-slice 
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basis to reduce the impact of localised image heterogeneity). 
 
Cluster analysis using the k-means algorithm was performed on the masked MR 
image array in a two step procedure. The number of clusters is decided by the 
operator, subsequent steps are operator independent therefore reducing bias. The first 
application of the k-means algorithm separates the entire quadriceps muscle region 
into 2 clusters by minimizing the cluster variance for the high and low signal 
intensity peaks: i.e. partitioning high signal component (light pixels representing fat) 
and low signal (dark pixels representing muscle, bone, tendon). The grouping is done 
by minimizing the intra-cluster variance (sum of squared distances) between data 
points and the corresponding cluster centroid according to the following equation: 
 
where there are k clusters Si (i = 1,  2,…,  k), (k = 2 in the present implementation), xj 
is the intensity value of an incoming jth pixel, and μi is the centroid (mean intensity 
value) of the ith cluster. The second application of the k-means algorithm is applied 
to the low signal cluster containing the optimized muscle. This is a refinement 
operation that separates the dark pixels (muscle tissue) from the very dark pixels 
(bone, tendon). During the manual outlining of the quadriceps muscle region, the 
operator may include inadvertently pixels representing the femur bone due to the 
discrete nature of the image, therefore a second application of the k-means algorithm 
further aids optimization of the muscle region by excluding obvious non-muscle 
components. The output cluster map was used to reconstruct a k-means optimized 
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muscle MR image array, which was segmented using a 512 × 512 image matrix to 
reform individual images (Figure 2.6). The pixels representing optimized muscle 
within each MR slice were summed to provide a measurement of CSA and total 
quadriceps volume. This process was repeated for each of the remaining cluster maps 
created during the two applications of the k-means algorithm, giving a measurement 
of high and low signal non-muscle components. The gross quadriceps volume was 
calculated from the sum total of the cluster volumes. 
 
2.6.2 Computed tomography (CT) scans 
2.6.2.1 Obtaining CT scans 
CT  scans  were  performed  as  part  of  the  cancer  patients’  routine  management  but  
were not available for the benign controls.  Initially the CTs were manually 
downloaded onto compact discs for subsequent analysis.  During the study period, 
the hospital introduced an online radiology system, which allowed direct access to 
the scans online and the ability to save the image directly. 
 
2.6.2.2 Analysis of CT scans 
The CSA of skeletal muscle and adipose tissue (comprising subcutaneous, visceral 
and intermuscular) was measured at the level of the 3rd lumbar vertebrae (L3).  
Adipose and muscle CSA measured at L3 are linearly related to whole body values 
(Mourtzakis et al., 2008).  All images were analysed by a single trained observer 
with SliceOmatic V4.3 software (Tomovision, Montreal, Canada), which enables 
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specific tissue demarcation using Hounsfield unit (HU) thresholds.  The HU ranges 
used were -29 to +150 for skeletal muscle (Mitsiopoulos et al., 1998), -190 to -30 for 
subcutaneous and intramuscular adipose tissue (Kvist et al., 1986) and -150 to -50 for 
visceral adipose tissue (Vehmas et al., 1996).  Tissue boundaries were corrected 
manually if required.  CSAs (cm2) were computed automatically by summing tissue 
pixels, multiplying by pixel surface area and subsequently normalised for stature 
(cm2/m2).  
 
Routine diagnostic CT scans usually only evaluate the chest, abdomen and pelvis and 
therefore only partial images are available to determine skeletal muscle mass. 
Estimates of whole body stores were generated from the raw data (cm2) using the 
following regression equations (Mourtzakis et al., 2008) which show a close 
correlation between muscle and fat areas in CT images at L3 and whole body 
compartments of FFM and fat mass (FM) respectively. 
- Total body FFM (kg) = 0.3 x [skeletal muscle at L3 (cm2)] + 6.06, (r = 0.94) 
- Total body FM (kg) = 0.042 x [total adipose tissue at L3 (cm2)] + 11.2, (r = 
0.88) 
 
2.7 Mechanical muscle quality 
MR imaging derived mid-femur muscle CSA was combined with the functional 
measurements to give a measure of muscle mechanical quality according to the 
formula:  Muscle Quality (N/mm2) = Strength (IKES)/ CSA. 
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2.8 Tissue sampling and storage (establishing the biobank) 
2.8.1 Blood 
2.8.1.1 Collection of blood sample 
A fasting blood sample was taken on the morning of surgery.  This was either venous 
(peripherally or through a central line if present), or arterial (through arterial blood 
pressure monitoring line) depending on availability according to the magnitude of 
operation that the patient was going to have.  
 
At follow-up appointments, patients were asked to fast overnight prior to their 
assessment.  A venous blood sample (~12ml divided into 3 tubes) was then taken 
from the anticubital fossa.  Pressure was applied till haemostasis was achieved and 
then a plaster was put over the wound.   
 
2.8.1.2 Blood sample preparation and storage 
Samples were collected in lithium heparin tubes.  One tube was delivered to the 
hospital (RIE) biochemistry lab for further analysis.  Normal reference ranges are 
outlined in Table A10, Appendix 1.  The other two each had 1.5ml whole blood 
withdrawn and stored in tubes and then put in a centrifuge cooled to 4°C and spun at 
15000 revolutions per minute (rpm) for 15 minutes.  The supernatant (plasma) was 
pipetted into tubes and stored at -80°C.  The fluid beneath the ‘bead  line’  were red 
cells and these were also pipetted into tubes and stored at -80°C. 
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2.8.2 Rectus abdominis muscle 
2.8.2.1 Collection of Rectus abdominis muscle biopsy 
All biopsies were taken at the start of open abdominal surgery. The edge of the 
Rectus abdominis was exposed and a ~1cm3 specimen removed using sharp 
dissection. The specimen was cleaned of any gross blood contamination and any 
visible fat/fibrous tissue removed.  The specimen was divided for four purposes: 
- Raw muscle: A section of muscle was placed in a tube (NUNC® Cryotubes®, 
Sigma-Aldrich Co. LLC) and snap frozen in liquid nitrogen before storing at -
80°C. 
- Cryo-section: 5ml of isopentane (Sigma-Aldrich Co. LLC) was cooled in a 
tube bathed in liquid nitrogen.  Once the solvent became viscous and the 
edges started to solidify white (temperature approaching -190°C), the muscle 
was introduced to allow freezing.  This was achieved by stitching a section of 
muscle to a cork disc using Vicryl™ (Ethicon Endo-Surgery Inc.) and Optical 
Cutting Temperature (OCT™) medium (Tissue-Tek®, Sakura Finetek, Europe) 
was placed at the base of the muscle.  The specimen was lowered with the 
cork uppermost (i.e. muscle first) into cooled solvent and held for 
approximately 5 minutes (until frozen).  This was then stored in a separate 
tube at -80°C.  
- Paraffin block: A section of muscle was cut and placed in formaldehyde (10% 
formalin solution).  This was left for 24 hours before removal and placing in a 
series of ethanol dilutions and delivering to the University of Edinburgh 
pathology lab for mounting into paraffin blocks.  
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- Electron microscopy: A thin segment of muscle was dissected/teased out.  
This was mounted on a wax strip and pinned with a sterile needle.  This was 
then placed in fixative (3% glutaraldehyde in 0.1M Sodium Cacodylate buffer, 
pH 7.3) for 2 hours before further processing (Section 2.11). 
 
2.8.3 Quadriceps muscle 
2.8.3.1 Collection of quadriceps muscle biopsy 
Baseline 
At the time of resectional surgery, after induction of anaesthesia, iodine solution was 
used to clean the skin.  A 0.5cm skin incision was made with a number 15 scalpel 
blade and deepened to the muscle fascia over Vastus lateralis muscle bulk at the 
level of the mid-femur point.  A Conchotome forceps (Figure 2.7A) was used to 
obtain a muscle biopsy from this site.  Three bites were taken and 5 minutes of direct 
pressure was subsequently applied to achieve haemostasis.  The skin wound was 
closed with Steri-Strips™ and Tegaderm™ dressing (both 3M Nexcare™). 
 
Follow-up 
Patients were fasted overnight prior to the follow-up biopsy, which was carried out in 
the morning.  The procedure was as for the baseline biopsy except for the following 
points: 5ml 1% lignocaine local anaesthesia was infiltrated at the site of biopsy prior 
to skin incision and a Bergstrom needle (Figure 2.7B) was used for the biopsy which 
was taken under suction to improve tissue yield.  The Bergstrom was used because 
on initial attempts at biopsy with the Conchotome under local anaesthesia, patients 
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reported increased pain and bruising after the biopsy.  This was not an issue with use 
of the Conchotome whilst under general anaesthesia.  
 
2.8.3.2 Quadriceps muscle biopsy preparation and storage 
Gross blood and any fat/fibrous tissue were removed. The biopsy was divided into 
two pieces (one for protein, one for RNA extraction) and placed in a tube (NUNC® 
Cryotubes®, Sigma-Aldrich Co. LLC), snap frozen in liquid nitrogen and then stored 
at -80°C. 
 
2.9 Blood measures 
2.9.1 Clinical Chemistry Laboratory, RIE 
All samples were processed in the Department of Clinical Chemistry, RIE (fully 
accredited by Clinical Pathology Accreditation Ltd, UK): Haemoglobin was 
measured using an automated analyser (Sysmex XE-2100), CRP by ELISA (Ely, 
UK), sex-hormone binding globulin (SHBG) (DPC Immulite) and albumin (Olympus 
640). Total testosterone (TT), oestradiol, luteinising hormone (LH), follicle 
stimulating hormone (FSH), insulin and cortisol were measured using standard 
automated methods (Bayer Immuno-I)   following   the   manufacturer’s   instructions.   
Calculated free testosterone (cFT) was calculated according to the Vermeulen 
formula (Ho et al., 2006). 
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FIGURE 2.7: THE CONCHOTOME AND BERGSTROM BIOPSY NEEDLES 
  
A.      B. 
 
                1   2         3 
 
 
Percutaneous Vastus lateralis muscle biopsies were taken using either 
the Conchotome forceps (A.) or the Bergstrom needle (B.). The 
Conchotome biopsy was performed by opening and closing the forceps 
handles. For the Bergstrom needle, part 2 was inserted through the 
rubber bung (1) and into part 3.  Suction was applied using a syringe 
and plastic tubing inserted into the top of the needle.  The component at 
the top of the picture was used after the biopsy to retrieve the muscle 
tissue from within the needle. 
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2.10 Skeletal muscle measures 
2.10.1 Cutting of raw muscle sample 
Raw muscle was placed on a piece of aluminium foil previously cooled over dry ice.  
This was placed on a slate covered in foil and resting in a container of dry ice.  A 
razor blade and forceps were cooled on dry ice.  The forceps and razor blades were 
cleansed in pure ethanol and wiped clean until no macroscopically visible tissue was 
evident.  Instruments were discarded after three uses and a new sterile autoclaved 
forceps and a new razor blade used.  Samples that had been cut were placed back in 
their storage tube and into the -80°C freezer as soon as was feasible thereafter. 
 
2.10.2 Whole protein isolation 
Approximately 20mg of frozen tissue was homogenised in 0.5ml of lysis buffer 
(Triton X-100 (1%), NaCl (150mM), Tris-HCl (50mM), EDTA (1mM), PMSF 
(1mM), protease inhibitors (Roche Diagnostics Ltd.) (1 tablet per 10ml), water to 
10ml) using a Powergen 125 (Thermo Fisher Scientific Inc.) electric homogeniser.  
Samples were left on ice for 15 minutes prior to centrifuging at 13000 rpm for 15 
minutes. The supernatant was removed, and samples were then stored at -80°C.  
 
2.10.3 Nuclear/cytoplasmic protein extraction 
Approximately 20 mg of muscle was re-suspended in 180 μl  of  low  salt  lysis  buffer  
(10mM HEPES, 10mM KCl, 1.5mM MgCl2, 0.1mM EDTA, 0.1mM EGTA, 1mM 
DTT, 0.5mM PMSF, protease inhibitors (Roche Diagnostics Ltd.) (1 tablet per 10 
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ml)) and ground using a handheld glass homogeniser.  Samples were incubated on 
ice for 5 minutes before two cycles of freeze-thaw lysis.  After a brief vortex, 
samples were centrifuged at 4000 rpm for 3 minutes.  The supernatant was removed 
(representing the cytoplasmic portion which was divided into aliquots and stored at -
80) and the pellet (containing the nuclei) re-suspended in 40 μl  high  salt  extraction  
buffer (20mM HEPES, 420mM NaCl, 1mM EDTA, 1mM EGTA, 25% Glycerol, 
1mM DTT, protease inhibitors (Roche Diagnostics Ltd.) (1 tablet per 10ml).  
Samples were incubated on ice for 30 minutes with gentle mixing of the tubes every 
5-10 minutes.  Samples were centrifuged at 4000 rpm for 5 minutes at 4°C.  The 
supernatant (containing the nuclear proteins) was divided into aliquots and stored at -
80°C.  
 
2.10.4 Determination of protein concentration 
 
The tissue homogenisation buffer used for extraction of protein from muscle was 
used to prepare a set of dilutions from a control protein (bovine) as follows: 
A – neat standard 
B – 1 in 2 
C – 1 in 4 
D – 1 in 8 
E – 1 in 16 
F – blank  
 
Each set of standards and samples was done in triplicate using an immunoassay plate.  
Protein solutions from the patients were diluted to 1 in 5, 1 in 10 and 1 in 20 using 
tissue homogenisation buffer.  Reagent was added to each well and the plate shaken 
for at least 15 minutes to allow colour to develop.  The plate was placed in a plate-
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reader to determine protein concentration.  Results from the control protein were 
inspected to ensure a good correlation value and then the volume for the given 
amount of protein calculated for each of the patient samples.  If the calculations for 
the final concentration for each sample dilution (i.e. 1 in 5, 1 in 10, 1 in 20) was not 
similar the plate was discarded and repeated. 
 
2.10.4 RNA isolation 
Total RNA was extracted from approximately 20mg of muscle using TRIzol 
(Invitrogen, UK)  reagent  according  to  the  manufacturer’s  directions.    The  RNA  
pellet was re-suspended in DEPC treated water and RNA concentration was 
determined using a Nanodrop spectrophotometer (LabTech International, UK).  RNA 
quality was assessed using 260/280, 230/260 ratios and the RIN score from the 
BioAnalyzer 2100 instrument (Agilent Technologies). 
 
2.10.5 Western blotting (immunoblotting) 
2.10.5.1 Gel preparation 
Gels were hand poured to the required percentage: separating gel (0.375M Tris, ph 
8.8) and stacking gel (0.125M Tris, pH 6.8).  Alternatively, pre-poured fixed gradient 
percentage gels (4-12%) were used (NuPAGE Novex 4-12% Bis-Tris gradient gels, 
Invitrogen, Paisley, UK). 
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2.10.5.2 Western blotting protocol 
20μg  of  protein  from  each  sample  was  added  to  3μl  of  4  x  LSB (0.5M Tris-HCl pH 
6.8, 20% glycerol, 4% SDS, 0.05%  β-mercaptoethanol, 0.004% bromophenol blue) 
and boiled for 3 minutes.  Proteins were resolved using SDS-polyacrylamide gel 
electrophoresis at 160V for 45 minutes.  Proteins were transferred to a nitrocellulose 
membrane (Amersham Biosciences Ltd, Bucks, UK) using semi-dry transfer (80mA 
for 1 hour).  Membranes were blocked with either 3% BSA/TBST (TBS, 0.05% 
Tween) overnight at 4°C or with 5% milk/TBST for 1hr at room temp. Incubation 
with primary antibody (1:1000) was carried out in either 3% BSA/TBST or 0.5% 
milk/TBST solution at room temperature for 2 hours or overnight at 4°C.  
Membranes were washed with TBST and primary antibody binding detected using 
horseradish-peroxidase conjugated secondary antibodies (1:2000 to 1:5000).  
Specific signal was detected using Amersham ECL reagent (GE Healthcare Life 
Sciences) and exposure on photographic film (Kodak Ltd., UK). 
 
2.10.5.3 Antibodies used 
The primary antibodies used in the study were Akt, pAkt (Ser473), FOXO1, 
FOXO3a, phos-CAMk2(Thr286) (Cell Signaling), Lamin A/C (Santa Cruz 
Biotechnology Inc), alpha-skeletal actin (Novocaestra), CAMk2 (BD Biosciences); 
dystrophin (MANDYS102  (7D2)),  β-dystroglycan (MANDAG2 (7D11)), 
(Developmental Studies Hybridoma Bank,  University  of  Iowa);;  β-sarcoglycan 
(Abcam); myosin heavy chain (fast) (Sigma-Aldrich Co. LLC).  
 
 160 
Secondary antibodies were horseradish-peroxidase conjugated secondary antibodies 
(1:2000 to 1:5000) (anti-mouse, anti-rabbit: Upstate).   
 
2.10.5.3 Western blot image analysis/densitometry 
Photographic films (Kodak Ltd) were scanned onto a computer.  Densitometry 
values were estimated using ImageJ (NIH) software.    
 
2.10.6 Quantitative real time polymerase chain reaction (qRT-PCR) 
2.10.6.1 Primer design and sequences used 
Primers were designed to span introns using Primer Express 3.0 software (Applied 








Gene Forward Primer Reverse Primer 
APCDD1 GCA CCG AGT TCG TGT TCA A TCC CGT TGA AGA CGT TGA G 
BNIP3 GTC AAG TCG GCC GGA AAA TA GCG CTT CGG GTG TTT AAA GA 
CAMK2β GAC GGC AAG TGG CAG AAC CAA CTC TGT CCG GCG AAA 
EIF3I GAA GCC ATG GAT GTA ACC ACA AGG TCC AAA GTG ACC CTT GA 
GABARAPL1 CCA CCG CAA GGA GAC AGA AG GAA AAT GTG ATG ACG GTG TGT GT 
HGS ACA GAC TCT CAG CCC ATT CC AGA CTC GCC ATT GTG GAA CT 
MAFBX CCG GCT GTT GGA GCT GAT A TTG GGC GAT GCC ACT CA 
MURF1 GCT AGG CGT GGC TCT CAT TC TCC TGG ATC AGG CTC GAC TT 
NUDC AAG AAC GGC AGC CTT GAC T GTC CTT CTC ATC TTC CTC CTC A 
POLRMT AGA CCA AGA CCG CAG GAA G CTC CGA CAC GCT CTC AGC 
SGK1 TTT CCA AAG AGG GGT TCT CC TGG CAT GAT TAC ATG GCT CT 
TIE1 GCC CAG ATT GCG CTA CAG ATC AAT GCC CGC GTA AGT 








Gene Forward Primer Reverse Primer 
COMP GAT CAC GTT CCT GAA AAA CAC G  GCT CTC CGT CTG GAT GCA G  
ADIPOQ TAT CCC CAA CAT GCC CAT TCG  TAG GCA AAG TAG TAC AGC CCA  
MMP3 ATG GAC AAA GGA TAC AAC AGG GA TGT GAG TGA GTG ATA GAG TGG G  
PCK1 CAA GAC GGT TAT CGT CAC CCA  GAA CCT GGC ATT GAA CGC TT  
ANGPTL7 CCA GAG ACG AAA AAG TGG CCT  GAG AGC CGG TGG ATG TGT T  
HSP90AB1 GAC TTG TGT CTT CAC CTT GCT  GGT GGA GTT GTC CCG AAG TG  
SLC25A37 AAG ACC CTT CTG AAC ACT CAG G  GTT GAG CTG GTA CAC CGT CC  
PROX1 TTG ACA TTG GAG TGA AAA GGA CG  TGC TCA GAA CCT TGG GGA TTC  
RCAN1 GGC GAC TGG AGC TTC ATT GA  CAT ACG TCC TAA AGA GGG ACT CA  
HINT3 AGA GCC CAA GGA CTA CGA CAG  GCT TCT TTG GCA CCA CAA GAT A  
BNIP3 AAC ACG AGC GTC ATG AAG AAA GGG ATC CGA TGG CCA GCA AAT GAG AGA 
GABARAPL1 CCA CCG CAA GGA GAC AGA AG GAA AAT GTG ATG ACG GTG TGT 
MuRF1 CTT CCA GGC TGC AAA TCC CTA ACA CTC CGT GAC GAT CCA TGA 
MAFBx TCC AGA CCC TCT ACA CAT CCT AGA ATC GTC TCC ATC CGA TAC A 
 
 
Primers were designed using Primer Express 3.0 software (Applied 
Biosystems).  (A.) Primers used in the cross-sectional Rectus abdominis 
muscle transcriptomic study (Chapter 4).  (B.) Primers used in the 
longitudinal Vastus lateralis muscle transcriptomic study (Chapter 5).    
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2.10.6.2 qRT-PCR protocol 
Total RNA was extracted as described in Section 2.10.4.  cDNA was prepared using 
1μg  RNA,  TaqMan  reverse  transcription  reagents  (Applied  Biosystems)  and  random  
hexamer primers (Applied Biosystems). Primers were designed and used as above.  
Samples were run on an ABI 7900HT Fast Real-Time PCR system (Applied 
Biosystems) in triplicates of 20 μl per well using SYBR Green PCR Master Mix 
(Applied  Biosystems)  as  per  manufacturer’s  instructions.  Expression  levels  were  
normalised to ribosomal 18S RNA.  Results were analysed  using  the  ΔCt  method  
(Livak and Schmittgen, 2001). 
 
2.10.7 Microarray target preparation and hybridisation  
3.5μg  of  total  RNA  was reverse transcribed and processed according to the protocol 
provided by Affymetrix for the GeneChip Expression 3' Amplification One-Cycle 
Target Labelling and Control Reagents kit (Affymetrix Inc.). Reverse transcription 
and second strand cDNA synthesis were followed by in vitro transcription and 
biotinylation. Biotinylated cRNA products were cleaned up using columns 
(Affymetrix). The quality of the biotinylated cRNA was assessed by Nanodrop 
(LabTech International, UK) and BioAnalyzer (Agilent Technologies) instruments 
and the cRNA was then fragmented according to Affymetrix protocols. Samples 
were hybridised to the HGU-133plus2 GeneChip array (covering ~54,000 sequences). 
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2.11 Transmission electron microscopy (TEM) 
2.11.1 Sample preparation 
After fixation for 2 hours (3% glutaraldehyde in 0.1M Sodium Cacodylate buffer, pH 
7.3), specimens were washed in three 10-minute changes of 0.1M Sodium 
Cacodylate.  Specimens were then post-fixed in 1% Osmium Tetroxide in 0.1M 
Sodium Cacodylate for 45 minutes and washed in three 10-minute changes of 0.1M 
Sodium Cacodylate buffer.  These sections were then dehydrated in 50%, 70%, 90% 
and 100% normal grade acetones for 10 minutes each, then for a further two 10-
minute changes in analar acetone. Samples were then embedded in Araldite resin.  
Sections,  1μm  thick  were  cut  on  a  Reichert  OMU4  ultramicrotome  (Leica  
Microsystems (UK) Ltd, Milton Keynes), stained with Toluidine Blue and viewed in 
a light microscope to select suitable areas for investigation.  Ultrathin sections, 60nm 
thick were cut from selected areas, stained in Uranyl Acetate and Lead Citrate.   
 
2.11.2 TEM image capture and analysis 
Sections were viewed in a Phillips CM120 Transmission electron microscope (FEI 
UK Ltd, Cambridge, England).  A Gatan Orius CCD camera (Gatan UK, Oxon, 
England) set at 2650x magnification was used to capture images. Photographs were 
taken at random and lipid droplets were counted manually (by one observer blinded 
to the patient diagnosis) in at least two fields per patient and the average count 
recorded.    The  diameter  of  each  visible  lipid  droplet  was  measured  in  μm  using  
ImageJ (NIH) and the mean lipid droplet diameter calculated for each patient.  
Identified lipid droplets were examined at high magnification (11000x) to ensure the 
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absence of a double membrane, thus distinguishing them from vacuolated giant 
mitochondria (Gdynia et al., 2010). 
 
2.12 Statistical analysis 
2.12.1 General analysis 
Statistical Programme for Social Sciences (SPSS) v15.0 (IBM) or GraphPad InStat 
(Graphpad Software Inc.) was used  for  data  analysis.    Student’s  two-tailed t test or 
one-way ANOVA were used to compare means between groups.  Tukey’s  honest  
significance test was used for post-hoc analysis.  The Mann-Whitney test was used 
for non-parametric analysis.  Data were log transformed when appropriate. 
Associations  between  variables  were  evaluated  using  Pearson’s  correlation  (bivariate)  
analysis. Contingency tables were constructed where relevant and analysed by 
Fishers exact test or Chi-squared test. Univariate ANOVA was used to investigate 
the effects of covariates on dependent variables and to establish effect size using 
partial eta-squared. Statistical significance was set at a two-tailed  p  value  of  ≤0.05. 
 
2.12.2 Microarray statistical analysis 
Microarray data was analysed using the Microarray Suite software (MAS) 5.0 
(Affymetrix). To improve the accuracy of the gene to probe relationship, a custom 
chip definition file (Sandberg and Larsson, 2007) was used defining the Affymetrix 
probes by Ensembl transcript ID.  Data were normalised using MAS and robust 
multi-array average (Irizarry et al., 2003).  Genes called absent on every array by the 
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MAS5 software were filtered from the data and remaining genes analysed using 
quantitative function in significance analysis of microarrays (SAM) (Tusher et al., 
2001) implemented in the bioconductor suite (Gentleman et al., 2004). Percentage 
weight-loss or systemic inflammation (CRP level) were the quantitative variables. To 
test the robustness of the approach, the limma package (GK, 2005) in the 
Bioconductor suite was used to identify genes co-varying with weight-loss or 
systemic inflammation. Both SAM and limma generate a false discovery rate (FDR) 
(Benjamini Y, 1995).  All genes identified by both procedures with a FDR<10% 
which covaried with weight-loss were further examined. Functional annotation of 
these genes was carried out using Gene Ontology (GO) (Ashburner et al., 2000) 
utilising the topGO tool (Alexa et al., 2006) in the bioconductor suite along with web 
based Ingenuity Pathway Analysis (Anaylsis).  For analysis of microarray data the 
bioconductor suite (Gentleman et al., 2004) and the R language for statistics (R 













Part  I:  Cancer  cachexia  classification:  molecular  
biomarker  discovery 
 
 “…in  the  beginning  of  the  malady  it  is  easy  to  cure  but  difficult  to  detect,  
but in the course of time, not having been either detected or treated in the 
beginning,  it  becomes  easy  to  detect  but  difficult  to  cure.”  
      Niccolo Machiavelli ‘The  Prince’ 
 
 
“The  journey  to  discover  useful  biomarkers  will  require  imaginative  
exploration,  fastidious  validation  and  some  good  luck” 
       Ransohoff, Science 2003 
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Chapter  3:  Evaluation  of  potential  biomarkers  in  
human  skeletal  muscle  cancer  cachexia;;  a  
comparison  with  pre-clinical  models 
 
3.1 Abstract 
Several potential candidate biomarkers were evaluated in skeletal muscle biopsies 
from a cohort of UGI cancer patients.  A total of 107 patients (15 weight-stable 
healthy controls (HC), 92 UGI cancer patients) were recruited. Cachexia was 
defined as weight-loss  ≥5%.  Rectus abdominis muscle was obtained at surgery and 
analysed by Western blotting or qRT-PCR for Akt/phosphorylated-Akt, FOXO1/3a, 
MAFbx, MuRF1, BNIP3, GABARAPL1, myosin heavy-chain  (MyHC),  dystrophin,  β-
dystroglycan  and  β-sarcoglycan. Patients were followed up for an average of 3 years 
or until death.    β-dystroglycan levels were higher in skeletal muscle from cachectic 
compared with non-cachectic cancer patients (p=0.007). The skeletal muscle from 
cancer patients compared with HC had reduced total Akt protein (p=0.001), 
increased ratio of phosphorylated to total Akt (p=0.002) and increased expression of 
GABARAPL1 (p=0.024). Survival was shortened in patients with low MyHC levels 
or low dystrophin levels (p=0.023 and p=0.008 respectively) in their skeletal muscle.  
The study identified intramuscular protein  level  of  β-dystroglycan as a potential 
biomarker of cancer cachexia.  Changes in the structural elements of muscle (MyHC 
or dystrophin) appear to be survival biomarkers.    
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3.2 Introduction 
In the main introduction to the thesis (Chapter 1), the concept of loss of skeletal 
muscle being the central characteristic of cancer cachexia was discussed.  Cachexia 
in its advanced phase (where patients may have lost 20-30% of their body weight) is 
easily identified, but by this stage, it is often impossible to undertake any realistic 
form of multimodal rehabilitation.  Thus, it might be useful to identify patients who 
are at risk or in the early phase of cancer cachexia so that targeted intervention can 
be instituted.  An early intervention approach has been hampered by a limited 
understanding of the molecular pathways implicated in human cancer cachexia along 
with a lack of validated biomarkers.  
 
Muscle wasting occurs as a result of an imbalance between protein synthesis and 
degradation.  As discussed in Chapter 1, the majority of known signalling pathways 
that contribute to muscle atrophy in pre-clinical models mediate their effects through 
activation of the catabolic UPP (Acharyya and Guttridge, 2007, Glass, 2005). 
Identification of two muscle-specific E3 ubiquitin ligases, MuRF-1 and 
MAFbx/atrogin-1, in several distinct animal models of atrophy (Bodine et al., 2001a, 
Gomes et al., 2001) provides a compelling argument for a major contribution of the 
UPP in muscle wasting, and these are now measured commonly as surrogate 
indicators of UPP activation. Furthermore, insulin regulated FOXO1 and FOXO3a 
have been shown to increase expression of the E3 ligases MuRF1 and MAFbx in at 
different animal models of muscle wasting (Sandri et al., 2004, Zhao et al., 2007, 
Glass, 2010) highlighting these transcription factors as potential mediators of 
cachexia.  
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In humans, reduced levels of phosphorylated (inactive) FOXO3a have been observed 
in the skeletal muscle of cachectic compared with non-cachectic cancer patients, but 
a surprising twofold reduction in the amount of non-phosphorylated (active) FOXO1 
and FOXO3a was also observed (Schmitt et al., 2007). In both myotube and mouse 
models of muscle atrophy, several autophagy genes are upregulated and FOXO3 
appears to be important in inducing expression of these autophagy-related genes 
(Mammucari et al., 2007, Mammucari et al., 2008, Zhao et al., 2007, Zhao et al., 
2008), linking the lysosomal and proteasomal systems. However, there is recent data 
that indicates dissociation between protein dynamics in vivo and activation or 
expression of the UPP-related signalling molecules in human skeletal muscle 
(Greenhaff et al., 2008). Thus the regulation of the UPP and the autophagy process in 
human cancer cachexia and their relationship to clinical status remains to be 
investigated fully.  There is also evidence, in both pre-clinical models and some 
limited human data, of alterations in the dystrophin glycoprotein complex and 
selective degradation of myosin heavy chain (Acharyya et al., 2005, Acharyya et al., 
2004, Clarke et al., 2007). Despite this knowledge, additional data relating to human 
cancer cachexia has been slow to appear.  As discussed in Chapter 1 (Section 1.4), 
there are a few studies investigating potential biomarkers of cachexia in various 
tissue compartments using different methodological approaches. However, a 
comprehensive assessment in human skeletal muscle of markers known to be 
relevant in animal models of muscle atrophy is lacking.   
 
Given this background and in line with the key themes of this thesis, the study 
described in this chapter aimed to identify potential clinically relevant biomarkers of 
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cachexia in skeletal muscle biopsies from UGI cancer patients in relation to weight-
loss and post-operative survival.  The approach taken was hypothesis-driven (Section 
1.3.2) where putative candidate genes and proteins from components of pathways 
known to be relevant in pre-clinical models of cachexia were analysed in human 
skeletal muscle.  Candidate markers were selected according to previous literature 
and included Akt and phosphorylated Akt (pAkt), FOXO transcription factors, 
ubiquitin E3 ligases (control of muscle anabolism/catabolism) (Acharyya et al., 2004, 
Lecker et al., 2004, Bodine et al., 2001a, Sandri et al., 2004, Bodine et al., 2001b), 
BNIP3 and GABARAPL1 (as markers of autophagy) (Lecker et al., 2004, Zhao et al., 
2008, Mammucari et al., 2007, Mammucari et al., 2008), MyHC,  dystrophin,  β-
dystroglycan  and  β-sarcoglycan (as markers of structural alteration in muscle) 






- Molecular changes in skeletal muscle of human cancer cachexia would mirror 
alterations reported in pre-clinical models of muscle atrophy 
- Alterations in pathways of muscle atrophy or in the components of muscle 







Participants: see Section 2.1 
Anthropometric assessments: see Section 2.2 
Muscle biopsy (Rectus abdominis) and blood collection: see Section 2.8 
Blood measures (CRP): see Section 2.9 
Muscle measures (Whole and nuclear protein isolation, Western blotting, antibodies, 
RNA isolation, qRT-PCR): see Section 2.10 
Statistics: see Section 2.12.1 
 
Additional methods  
In 2009, the All Party Parliamentary Group on Cancer published a report of their 
inquiry into inequalities in cancer.  From the evidence that the group assimilated, one 
of the key priority action points was to move towards reporting one-year survival 
rates for all types of cancer 
 “to  speed  up  early  diagnosis  and  help  sharpen  the  focus  on  measuring  outcome…the 
advantage that such an indicator has over five-year survival rates and mortality rates 
is that it is concerned with events in the immediate past. It also starts to shift 
attention away from inputs and onto outcomes”  (All Party Parliamentary Group on 
Cancer, 2009).   
The government subsequently adopted this policy by including it as an improvement 
area for the NHS in the proposed outcomes framework.  Thus one-year survival was 




107 patients were recruited in total (15 HC and 92 UGI cancer patients).  
Demographics for the entire cohort are illustrated in Table 3.1.  Patients were 
classified as cachectic if they had weight-loss  ≥5%.  Compared with HC, cancer 
patients were older (mean (SD) age 65 (10) vs. 56 (17) years, p=0.003), had higher 
average weight-loss (8.1 (9.3) vs. 0 (0) %, p=0.001), lower BMI (25.7 (4.0) vs. 28.0 
(4.5) kg/m2, p=0.046) and a significantly lower KPS (89 (13) vs. 100 (0), p=0.001) 
(Table 3.1).   
 
Within the cancer patient cohort, cachectic patients compared with non-cachectic 
patients had a larger proportion of females than males (19/51 vs. 7/41, Chi squared 
p=0.033), were younger (63 (9) vs. 68 (9) years, p=0.022), had shortened median 
survival (562 vs. 846 days, p=0.030), and a lower BMI (24.6 (3.7) vs. 27.0 (4.0) 
kg/m2, p=0.004.  KPS was also significantly lower in cachectic compared with non-
cachectic patients (86 (14) vs. 92 (10), p=0.020) (Table 3.1).   
 
Analyses were performed according to availability of muscle tissue for different 
biomarkers.  This resulted in four separate groups of patients and the demographics 
for these are illustrated in Table 3.2.  Figure 3.1 shows the overlap between groups.  
No significant differences were evident between these groups and the entire cohort.  
Individual biomarkers were also grouped to allow optimal use of the muscle sample.  
For example, MyHC (molecular weight ~200 kDa) and dystrophin (~400 kDa) were 
analysed separately due to the requirement for 4-12% gels for Western blot and 
prolonged electrophoresis and transfer due to their large molecular weight.  
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Table  3.1:  Patient  demographics  for  the  entire  cohort 
 
 Control All Cancer Cancer Cancer 
   No cachexia Cachexia   
 (n=15) (n=92) (n=41) (n=51) 
M/F 8/7 66/26 34/7 32/19† 
Age (years) 56±17 65±10* 68±9 63±9† 
Weight-loss (%) 0.0±0.0 8.1±9.3* 0.8±3.0 13.9±8.6† 
Survival (days) - 675 846 562† 
BMI (kg/m2) 28.0±4.5 25.7±4.0* 27.0±4.0 24.6±3.7† 
CRP (mg/l) 3.5±2.7 15.5±31.3 12.0±29.6 18.3±32.6 
CRP≥5mg/l  (Y/N) 4/11 41/51 15/26 26/25 




Results for controls and cancer patients (with or without cachexia) are 
presented as mean ± SD or categorically except for median survival.  
* = p<0.05 cancer versus  control  patients,  †  =  p<0.05  cachectic versus 
non-cachectic cancer patients.  Abbreviations: M, male; F, female; BMI, 
body mass index; CRP, C-reactive protein; KPS, Karnofsky performance 




Table  3.2:  Individual  cancer  patient  groups  according  to  
which  biomarkers  were  evaluated.   
 
 GROUP    
 1 2 3 4 
 (n=42) (n=52) (n=47) (n=29) 
M/F 28/14 34/18 28/19 15/14 
Age (years) 65±10 66±9 64±9 63±10 
BMI (kg/m2) 25.7±4.5 25.5±3.6 25.3±3.9 25.5±4.9 
Weight-loss (%) 7.5±9.5 8.9±8.0 9.7±11.0 9.6±10.3 
Cachexia (Y/N) 22/20 32/20 29/18 18/11 
CRP (mg/l) 20.7±38.7 17.4±32.1 14.2±30.3 21.2±35.8 
CRP≥5mg/l  (Y/N) 20/22 26/26 21/26 23/16 




Results are presented as mean ± SD.  Each group was used to assess 
different candidate biomarkers as follows: 
1= Akt, pAkt, β-dystroglycan, β-sarcoglycan 
2= FOXO1, FOXO3a, BNIP3, GABARAPL1, MuRF1, MAFBx  
3= MyHC 
4= Dystrophin 
Abbreviations: M, male; F, female; BMI, body mass index; CRP, C-
reactive protein; KPS, Karnofsky performance score; mg, milligrams; l, 




FIGURE 3.1: VISUAL REPRESENTATION OF THE OVERLAP IN PATIENT 
GROUPS 
 
  1 2 3 4   1 2 3 4   1 2 3 4 
Control         Cancer       Cancer      
Control         Cancer       Cancer      
Control         Cancer       Cancer      
Control         Cancer       Cancer      
Control       Cancer       Cancer      
Control       Cancer       Cancer      
Control       Cancer       Cancer      
Control       Cancer       Cancer      
Control       Cancer       Cancer      
Control       Cancer       Cancer      
Control       Cancer       Cancer      
Control      Cancer       Cancer      
Control      Cancer       Cancer      
Control      Cancer       Cancer      
Control      Cancer       Cancer      
Cancer         Cancer       Cancer      
Cancer         Cancer       Cancer      
Cancer         Cancer       Cancer      
Cancer         Cancer       Cancer      
Cancer         Cancer       Cancer      
Cancer         Cancer       Cancer      
Cancer         Cancer       Cancer      
Cancer         Cancer       Cancer      
Cancer         Cancer       Cancer      
Cancer         Cancer       Cancer      
Cancer         Cancer       Cancer      
Cancer        Cancer       Cancer      
Cancer        Cancer       Cancer      
Cancer        Cancer       Cancer      
Cancer       Cancer       Cancer      
Cancer       Cancer       Cancer      
Cancer       Cancer       Cancer      
Cancer       Cancer      Cancer      
Cancer       Cancer      Cancer      
Cancer       Cancer      Cancer      
Cancer       Cancer           
 
 
All of the 107 patients recruited for this study are illustrated.  Control 
patients are represented in grey and cancer patients in black.  Only the 
first four controls and first eleven cancer patients had all candidate 
biomarkers assessed.  Other patients were group specific.  The groups 
are as per Table 3.2: 
1= Akt, pAkt, β-dystroglycan, β-sarcoglycan 




Skeletal muscle protein potential biomarkers of cancer cachexia 
Results of the skeletal muscle protein biomarkers of cachexia are illustrated in Figure 
3.2. Level of total Akt protein was reduced in cancer patients compared with HC 
(0.49 (0.31) vs. 0.89 (0.17), p=0.001), but there was no significant difference in pAkt 
protein level (0.47 (0.34) vs. 0.29 (0.2), p=0.104).  However, the ratio of pAkt to 
total Akt was increased in cancer patients compared with HC (1.33 (1.04) vs. 0.32 
(0.21), p=0.002).   
 
Cachectic  cancer  patients  had  significantly  higher  levels  of  β-dystroglycan than non-
cachectic cancer patients (1.01 (0.16) vs. 0.87 (0.20), p=0.007).  There was also a 
trend  towards  increased  levels  of  β-sarcoglycan (0.63 (0.28) vs. 0.55 (0.55), p=0.052).   
 
Other protein biomarkers were not significantly different in either HC vs. cancer 
(FOXO1, FOXO3a, MyHC, β-dystroglycan, β-sarcoglycan, dystrophin) or in 
cachectic compared with non-cachectic cancer patients (Akt, pAkt, pAkt/Akt ratio, 
FOXO1, FOXO3a, MyHC, dystrophin) (Figure 3.2). 
 
 
Skeletal muscle mRNA potential biomarkers of cancer cachexia 
Results of the skeletal muscle mRNA biomarkers of cachexia are illustrated in Figure 
3.3. There was a significantly increased expression of GABARAPL1 (1.60 (0.76) vs. 
1.10 (0.57), p=0.024) and a trend towards an increase in expression of BNIP3 in 
cancer patients compared with HC (1.37 (0.49) vs. 1.07 (0.57), p=0.058).  MuRF1 
and MAFBx expression levels were not significantly different in cancer patients  
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Graphs showing levels (AUD) of protein biomarkers in HC and cancer 
patients (with or without cachexia) normalised to loading control. *p<0.05 
HC vs. all cancer, #p<0.05 no cachexia vs. cachexia.  Abbreviations: 









Graphs  showing  fold  change  (ΔCT)  of  mRNA biomarkers in HC and 
cancer patients (with or without cachexia).  *p<0.05 HC vs. all cancer.  




compared with HC.  None of the mRNA potential biomarkers related to the presence 
of cachexia. 
 
Skeletal muscle potential biomarkers and survival 
Patients  who  survived  ≤1  year  post-operatively compared with those who 
survived >1 year had significantly higher average weight-loss (12.0 (11.1) vs. 6.3 
(8.0) %, p=0.007) and a lower KPS (83 (13) vs. 91 (12), p=0.004) (Table 3.3).   
 
Given  that  there  are  no  ‘normal’  cut-offs for skeletal muscle protein levels or mRNA 
expression of potential markers, Receiver Operating Characteristic (ROC) analysis 
was performed for all of the selected markers.  Although there were no strong 
significant candidates, there was a trend for MyHC, dystrophin and pAkt (area under 
the curves were 0.674 (p=0.069), 0.714 (p=0.070) and 0.669 (p=0.068) respectively).  
Co-ordinates of the ROC curves were inspected and a cut-off  of  ≥0.87 AUD chosen 
for MyHC to give a sensitivity of 84.8% and specificity of 46.2%; a cut-off  of  ≥0.31 
AUD chosen for dystrophin to give a sensitivity of 85.0% and specificity of 55.6%; 
and a cut-off  of  ≥0.19 AUD chosen for pAkt to give a sensitivity of 87.5% and 
specificity of 42.3%.  Kaplan-Meier survival analysis using these cut-offs (Figure 3.4) 
showed a significantly shorter survival for those with lower compared with higher 
MyHC levels (median survival 316 vs. 1326 days, p=0.023) and lower compared 
with higher dystrophin levels (median survival 341 vs. 660 days, p=0.008), but no 
significant difference between high and low pAkt levels (p=0.320).   
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To examine further the difference in survival for MyHC and dystrophin, the 
demographics of the low versus higher levels of MyHC and dystrophin groups were 
inspected (Table 3.4).  None of the variables differed significantly between the 
groups for either MyHC or dystrophin.   
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Table  3.3:  Patient  demographics  for  cancer  patients  surviving  
≤  1  and  >  1  year.     
 
 Survival  ≤1yr Survival>1yr 
 (n=27) (n=64) 
M/F 18/9 48/16 
Age (years) 66±10 65±10 
Weight-loss (%) 12.0±11.1 6.3±8.0* 
Survival (days) 245 1195* 
BMI (kg/m2) 25.3±3.5 26.0±4.2 
CRP (mg/l) 18.0±36.3 14.6±29.4 
CRP≥5mg/l  (Y/N) 16/11 25/39 




Results are presented as mean ± SD or categorically except for median 
survival. * = p<0.05 survival >1yr vs survival ≤1yr.  Abbreviations: M, 
male; F, female; BMI, body mass index; CRP, C-reactive protein; KPS, 
Karnofsky performance score; kg, kilograms; m, metres; mg, milligrams; 











Kaplan-Meier survival analysis was done comparing groups according to 
ROC derived AUD cut-offs curves for (A) low (<0.87 AUD) vs high 
(≥0.87 AUD) MyHC protein levels; Log Rank p=0.023 and (B) low (<0.31 
AUD)  vs  high  (≥0.31 AUD) dystrophin protein levels; Log Rank p=0.008. 
Abbreviations: ROC, receiver operating characteristic; AUD, arbitrary 
units of densitometry. 
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Table 3.4: Patient demographics according to MyHC and 
Dystrophin protein levels 
 
A. MyHC 
 Low High 
 (n=12) (n=35) 
M/F 7/5 21/14 
Age (years) 63±7 64±10 
BMI (kg/m2) 24.9±4.4 25.4±3.8 
Weight-loss (%) 9.8±7.4 9.6±12.1 
Cachexia (Y/N) 9/3 20/15 
CRP (mg/l) 20.3±41.6 12.1±25.8 
CRP≥5mg/l  (Y/N) 7/5 14/21 
KPS 88.2±10.8 92.1±12.1 
 
   
B. Dystrophin  
 Low High 
 (n=8) (n=21) 
M/F 5/3 10/11 
Age (years) 62±13 63±9 
BMI (kg/m2) 26.8±6.3 25.0±4.3 
Weight-loss (%) 9.5±7.5 9.7±11.3 
Cachexia (Y/N) 7/5 14/21 
CRP (mg/l) 45.8±52.3 11.8±22.4 
CRP≥5mg/l  (Y/N) 5/3 8/13 




Results are presented as mean ± SD or categorically.  ROC analysis 
was used to determine AUD cut-offs for (A) MyHC (low<0.87 AUD, high 
≥0.87 AUD) and (B) Dystrophin (low <0.31 AUD, high ≥0.31AUD). No 
significant differences were found between groups. Abbreviations: M, 
male; F, female; BMI, body mass index; CRP, C-reactive protein; KPS, 
Karnofsky performance score; ROC, receiver operating characteristic; kg, 
kilograms; m, metres; mg, milligrams; l, litres; Y, yes; N, no; AUD, 





Contrary to the initial hypothesis, very few of the candidate markers of muscle 
atrophy derived from pre-clinical models mirrored changes in human skeletal muscle.  
Only increased β-dystroglycan appeared to relate to the presence of significant 
weight-loss in cancer patients.  There appeared to be suppression of total Akt protein 
levels in the skeletal muscle of cancer patients but with a relative increase in Akt 
activity (expressed as the ratio of phosphorylated to total Akt).  There was also some 
evidence of increased autophagy (increased GABARAPL1) in cancer patients. Low 
MyHC and low dystrophin protein levels both related to shortened survival.   
 
In one of very few similar studies, Schmitt et al examined protein levels and 
phosphorylation status of muscle atrophy/hypertrophy pathway components in eight 
pancreatic cancer patients with cachexia compared with eight weight-stable cancer or 
pancreatitis patients (Schmitt et al., 2007). Reduced levels of Akt, MyHC and 
FOXO1 were observed in the cachectic group.  In the current study, which looked at 
a much larger cohort of patients with a variety of UGI cancers, along with non-
cancer HC, we did not observe any differences in these markers between cachectic 
and non-cachectic patients.  Although cancer patients (compared with non-cancer HC) 
did have a reduction in Akt levels, there was a relative increase in overall Akt 
activity (expressed as the ratio of pAkt to total Akt).  It should be noted that whilst 
FOXO3 antibody and methodology for determining MyHC levels differed, the 
antibodies for FOXO1, Akt and pAkt were the same between the present study and 
that by Schmitt and coworkers and would thus not explain these contrasting results.  
An alternative explanation is that the observations of Schmitt et al may be tumour 
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specific or reflect markers of more moderate cachexia whereas our observations 
relate to the presence of cancer alone or to cachexia earlier in the disease process.  
Schmitt et al defined cachexia as >10% weight-loss in 6 months whereas for the 
current  study,  cachexia  was  defined  as  ≥5% weight-loss in line with recent 
definitions (Fearon et al., 2011).  However, when analysed according to a 10% 
weight-loss cut-off, the results for individual variables from the current study did not 
differ from using a 5% weight-loss cut-off.  Another explanation for the Akt results 
in the present study would be that total protein turnover might be suppressed in 
cancer patients with a reduction in the available pool of Akt and that increased 
phosphorylation represents a compensatory mechanism.  In support of this, in COPD 
patients with cachexia, an increased ratio of pAkt to total Akt has also been observed 
with the suggestion that this represents an attempt to restore muscle mass (Doucet et 
al., 2007, Vogiatzis et al., 2010). 
 
After the discovery that they were upregulated in several distinct models of atrophy 
(Lecker et al., 2004), the muscle-specific E3 ubiquitin ligases, MuRF-1 and atrogin-
1/MAFbx have been used commonly to indicate activation of the UPP.  Likewise, 
markers of autophagy have been shown to be increased in cachectic mice and under 
the control of FOXO3 (Mammucari et al., 2007).  However, in the current study, 
FOXO transcription factors and the ubiquitin E3 ligases were similar between HC 
and cancer patients and were not influenced by the presence of cachexia.  Cancer 
patients did have increased expression of GABARAPL1 and a trend towards 
increased expression of BNIP3, both of which play a key role in autophagy.  
However, neither of these autophagy markers related significantly to survival or 
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weight-loss.    There  was  evidence  of  increased  β-dystroglycan protein levels in 
cachectic patients  and  a  trend  towards  increased  protein  levels  of  β-sarcoglycan.  
Dysregulation of the dystrophin glycoprotein complex (DGC) is a feature of 
muscular dystrophies and has been associated with cachexia (Acharyya et al., 2005).  
In the context of muscular dystrophy there would be downregulation of all 
components of the DGC, but this finding has not been replicated in cancer cachexia 
(Acharyya et al., 2005).  However, neither has an increase in protein levels been 
demonstrated making it difficult to interpret the findings of the current study.  In a 
mouse model of muscular dystrophy treated with an AMPK activator, increased 
utrophin  coincided  with  an  increase  in  β-dystroglycan and resultant strengthening of 
the sarcolemma (Ljubicic et al., 2011). It is therefore conceivable that the 
relationship  between  β-dystroglycan and cachexia seen in the current study 
represents an attempt at muscle membrane repair as it enters a more dysregulated 
state with progressive weight-loss.  Given that the current study is not mechanistic 
and utrophin was not investigated as a potential marker, this suggestion is speculative.  
Nevertheless, β-dystroglycan remains a candidate biomarker for cancer cachexia and 
is worthy of further evaluation. 
 
It is striking that there was an association between low levels of structural muscle 
proteins and shortened survival.  The lack of significant demographic differences 
between the low and higher level MyHC/dystrophin groups suggests that they are 
bona fide independent biomarkers of post-operative survival.  Perhaps lower levels 
of these structural proteins identify a susceptible population where muscle 
structure/membrane integrity has already started to become compromised.  In an 
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ideal world it would have been highly interesting to see if these patients had gone on 
to develop an accelerated form of cachexia.  However, the difficulties of such 
longitudinal analyses are explored further in Chapters 5 and 9.  Alterations in 
membrane structure and integrity have been demonstrated in colon-26 tumour 
bearing mice which is thought to be due, at least in part, to disruption of the DGC 
(Acharyya et al., 2005).  This normally provides a strong mechanical link between 
the intracellular cytoskeleton and extracellular matrix (Lapidos et al., 2004).  
Mutations in the DGC cause muscular dystrophies/ cardiomyopathy, and a link with 
human cancer cachexia has been made.  DGC deregulation was demonstrated in 
gastro-oesophageal cancer patients and related to the presence of significant weight-
loss (>10%) and systemic inflammation, and to a shortened survival (Acharyya et al., 
2005). 
 
It has been proposed that there is selective targeting of myofibrillar proteins, in 
particular MyHC, in cancer cachexia (Acharyya et al., 2004, Clarke et al., 2007).  In 
addition, myofibrillar degradation appears to occur in a time dependent manner.  One 
animal study of muscle atrophy after denervation or fasting, demonstrated early 
targeting of thin filament components with subsequent loss of MyHC (Cohen et al., 
2009).  Adding to the concept that membrane damage is important in the 
pathogenesis of cancer cachexia, Skipworth and co-workers have recently shown that 
the presence of various myosin species in the urine of patients with oesophago-
gastric cancer relates to significant (>10%) weight-loss) (Skipworth et al., 2010b).  
The observations in the current study that patients with lower skeletal muscle 
dystrophin or MyHC protein levels are associated with a shortened survival are 
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entirely consistent with this concept.  Therefore, measurements of these structural 
elements in skeletal muscle may be suitable biomarkers relating to survival in UGI 
cancer patients.  Further study is required to determine whether the mechanism of 
such an association relates, in part, to the subsequent development of cachexia. 
 
By comparing cachectic, non-cachectic and HC groups, this study evaluates the 
potential of certain variables to act as biomarkers of cachexia.  However, it is not 
possible to determine the precise role of these variables in cachexia by comparing the 
cachectic with non-cachectic groups.  The patients without cachexia at diagnosis 
represent a mixed group some of whom will remain weight stable, but a significant 
other group will progress to cachexia and are therefore in a pre-cachectic state 
(Figure 1.12).  This heterogeneity within the weight-stable group potentially masks 
changes in some variables that may play a role in development of cachexia/pre-
cachexia.  In order to further explore this area, longitudinal assessments of patients 
would be required to determine which individuals progress to losing weight after the 
initial biopsy (see Chapter 9). 
 
It is important to appreciate that this study is capturing a snapshot in time of what is 
really a journey comprising early, cachectic and refractory phases (Fearon et al., 
2011) in a heterogeneous population at various points on this spectrum.  There is 
evidence that different proteolytic/synthetic pathways may be activated or repressed 
according to degree of weight-loss.  For example, in a study of lung cancer patients 
with mean weight-loss of 2.9%, the lysosomal but not the UPP was activated (Jagoe 
et al., 2002), whereas in patients with gastric cancer and mean weight-losses of 5.2% 
 191 
and 5.6% have shown increases in components of the UPP (Bossola et al., 2001, 
Bossola et al., 2003).  There is also evidence in cancer patients (Khal et al., 2005a) 
that UPP activity increases with weight-loss up to 12-19% and then declines as 
disease severity progresses. Likewise, a recent study of gastric cancer patients 
showed evidence of increase in calpains in patients with minimal or no weight-loss, 
but did not show any difference in expression of the ubiquitin E3 ligases in cancer 
compared with control patients (Smith et al., 2011).  Longitudinal studies in human 
cancer cachexia may be informative in this regard, and indeed this is one of the aims 
of this thesis explored in subsequent chapters (Chapters 5 and 9)  
 
In the present study, non-cachectic patients were 5 years older than cachectic patients.  
Sarcopenia of ageing has been well characterised and the non-cachectic group would 
thus have had 5 extra years of age-related muscle wasting.  It is possible that this age 
gap may have influenced differences in levels of biomarkers between groups.  
Conversely, a younger age at diagnosis of cancer is a risk factor for poorer outcome 
in certain tumour types (e.g. breast (Fowble et al., 1994)).  Whether younger patients 
are more likely to suffer from cachexia or more aggressive weight-loss is not known, 
but represents an area for future exploration. 
 
The potential biomarkers of cachexia in the current study were selected from 
evidence relating predominantly to muscle wasting in animal models.  The lack of 
association of biomarkers with cachexia may therefore simply reflect differences 
between animal and human cancer cachexia.  Whereas the majority of animal models 
of cachexia undergo rapid and profound weight-loss, human cancer cachexia is a 
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chronic disease process.  Furthermore, in humans, there will be added confounding 
factors such as level of baseline physical activity, bed rest, the presence of co-
morbidities, dietary preferences, personal motivation and sickness behaviour.   
 
The majority of potential biomarkers that were evaluated relate to protein 
degradation rather than synthetic pathways.  There is reasonable evidence to suggest 
that in muscle atrophy associated with ageing/ bed-rest, suppression of protein 
synthesis is of greater importance than increased protein degradation (Rennie et al., 
2010).  Therefore, it may be that studies investigating biomarkers selected from 
anabolic pathways may identify candidates that relate more strongly to cachexia.   
Alternatively, changes in muscle at the molecular level may not have a strong 
influence on muscle phenotype.  Evidence of such dissociation has been 
demonstrated (Greenhaff et al., 2008) in the skeletal muscle of healthy men.  
Increased amino acid and insulin availability was shown to lead to changes in 
anabolic signalling molecules and components of the UPP, which did not result in 
the expected corresponding alterations in muscle protein synthesis or breakdown 
(Greenhaff et al., 2008).  Whether this also occurs in the context of human cancer 
cachexia remains to be elucidated. 
 
This Chapter has demonstrated that many of the key components of known muscle 
wasting pathways from preclinical models do not transpose directly to being robust 
biomarkers of human cachexia.  β-dystroglycan is a biomarker of weight-loss in 
cancer patients. Skeletal muscle Akt protein levels/phosphorylation status and 
GABARAPL1 expression are biomarkers relating to cancer and possibly early 
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cachexia. MyHC and dystrophin are biomarkers associated with survival.  In the next 
chapter, a different approach is taken to investigate potential biomarkers of cancer 
cachexia using a biomarker-discovery study (see Section 1.3.2).  
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Chapter  4:  Using  transcriptomics  to  identify  novel  




The results from Chapter 3 did not parallel reported molecular pathways from pre-
clinical cachexia studies.  In the current Chapter, a different approach was taken 
using transcriptomics to investigate global gene changes. RNA profiling was 
performed on Rectus abdominis muscle biopsies from 21 patients (3 controls and 18 
with UGI cancer) using the Affymetrix U133+2 platform. Quantitative significance 
analysis of microarrays (SAM) identified an 82-gene signature that correlated with 
weight-loss. Selected genes correlating with weight-loss were validated using qRT-
PCR and studied as cachexia biomarkers in Diaphragma and Vastus lateralis muscle 
biopsies from a second independent cohort. CAMk2 correlated positively with 
weight-loss in all muscle groups while CAMk2 protein levels were elevated in Rectus 
abdominis muscle. TIE1 was positively associated with weight-loss in both Rectus 
abdominis and Vastus lateralis muscle groups while others (APCDD1, EIF3I, HGS, 
NUDC, SKG, POLRMT, and TSC2) demonstrated tissue specific expression patterns. 
Promoter analysis identified binding sites for SP1, ARNT.AHR and TFAP2A over-
represented in the proximal promoters of the weight-loss associated genes while 
FOXO binding sites were under-represented, further supporting the idea that the 82-
gene signature is distinct.  Thus, quantitative SAM analysis was able to discover new 
potential molecular intramuscular biomarkers of human cancer cachexia. The 
exercise activated genes, CAMk2 and TIE1, correlated positively with weight-loss 
across muscle groups indicating that cachexia was not simply due to inactivity. This 
analysis supports the findings from Chapter 3 that preclinical models do not reflect 
accurately the molecular characteristics of human muscle wasting.  
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4.2 Introduction 
Whilst potential biomarkers relating to early cachexia, weight-loss and survival were 
identified in Chapter 3, the results showed an overwhelming lack of similarity 
between reported markers of muscle wasting in pre-clinical models and those that 
were tested in human muscle.  The reasons for this are unclear, but possible 
explanations include: human and animal cancer cachexia are two different processes, 
the study population is too heterogeneous to discriminate with a single biomarker, 
the weight-loss cut-off is too crude, sample size is small resulting in a Type II error, 
or that the method of biomarker assessment (Western blotting/qRT-PCR) is not 
sensitive enough to allow stratification of patients. 
 
Regardless of which is correct, the question of which pathways are relevant in human 
cancer cachexia remains unanswered.  The majority of biomarkers explored in 
Chapter 3 related to proteolytic pathways and it might be that markers of anabolism 
may be more relevant.  Taking a hypothesis-driven approach in biomarker discovery 
has been criticised due to the following potential confounders: 
- the response to any disease usually involves multiple networks and pathways 
rather than a single molecule 
- there is variability in how cells and tissues interact with their environment 
with potential responses in distant cells outwith a single molecule or network 
- the efficacy of a single biomarker can be negated due to population 
heterogeneity (Kurian et al., 2007). 
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Although there was a good evidence base for investigating the gene and protein 
biomarkers in Chapter 3, some of these pitfalls may have influenced the results.  As 
such, rather than continuing with further hypothesis-driven targeted assessment of 
individual markers from these pathways, a global biomarker discovery-based 
approach (see Section 1.3.2) was taken to identify candidate biomarkers or patterns/ 
signatures which may be relevant in human cancer cachexia.  Transcriptomics was 
chosen as the method for this study.   
 
Transcriptomics is a method employed for the global study of gene expression at the 
RNA level using microarray platforms.  It is one of the growing number of high 
throughput, multi-dimensional  ‘-omic’  technologies  (e.g. genomics, metabolomics, 
cellomics, proteomics, physiomics and pharmacogenomics), and has gained 
increasing popularity as a powerful research tool because microarrays are able to 
survey the entire human genome on a single chip.  Indeed, the original description of 
the  ‘atrogenes’  in  animal  models  of  cachexia  utilised  transcriptomics  (Lecker et al., 
2004).  The debate over which molecular pathways are important in cancer cachexia 
was discussed in Section 1.2.6.3.  Overall, it remains unclear what regulates muscle 
mass in vivo nor is it clear to what extent protein degradation contributes over 
inhibition of protein synthesis (Emery et al., 1984a, Greenhaff et al., 2008). Given 
the paucity of data derived from cancer cachexia patients, and the results from the 
preceding Chapter, this Chapter describes the profiling of global molecular changes 
in the skeletal muscle of cancer patients and relates these to weight-loss and systemic 
inflammation.   
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4.3 Hypotheses 
- Skeletal muscle of weight losing cancer patients would have a unique 
transcriptomic gene signature 
- The use of transcriptomics would identify novel biomarkers of human cancer 





Participants: see Section 2.1 
Anthropometric assessments: see Section 2.2 
Muscle biopsy (Rectus abdominis) and blood collection: see Section 2.8 
Blood measures (CRP): see Section 2.9 
Muscle measures (Whole protein isolation, Western blotting, antibodies, RNA 
isolation, qRT-PCR, microarray target preparation/hybridisation): see Section 2.10 
Statistics (general and microarray): see Section 2.12 
 
Additional methods 
A second cohort of patients was recruited for validation from an independent clinical 
centre (Karolinska Institutet, Stockholm, Sweden).  This part of the study was 
conducted by Dr. Olav Rooyackers, Karolinska Institutet, Stockholm, Sweden. These 
patients were undergoing surgery for oesophageal cancer and Vastus lateralis muscle 
biopsies were taken with a Bergstrom needle and Diaphragma biopsies were 
obtained by sharp dissection when possible. Weight and self-reported change in 
weight over time were recorded for this cohort and thus rate of weight-loss was used 






Thirty-four subjects were included in the study from two centres (Edinburgh and 
Stockholm). Twenty-one patients were recruited (3 controls and 18 patients with 
UGI cancer) from centre 1 (Edinburgh). Thirteen patients with oesophageal cancer 
were also recruited from centre 2 (Stockholm) as a validation cohort.  
 
Patient demographics and anthropometric characteristics are shown in Table 4.1.  
Average weight-loss for centre 1 cancer patients was 8.9% (range -0.5 - 22.4%).  
Compared with the control group, patients in centre 1 with cancer were older, had 
significant weight-loss and had a lower BMI.  Similarly, patients in centre 2 were 
older and had significant weight-loss compared with centre 1 controls. Demographics 
were similar between centre 1 and 2 cancer patients (Table 4.1). 
 
Microarray analysis: novel genes associated with weight-loss in cancer (centre 1) 
The initial microarray study was undertaken on Rectus abdominis muscle samples 
from centre 1 patients. Using both RMA and MAS normalized data hierarchical and 
k-means clustering were undertaken with data where genes with a low standard 
deviation were removed.  No obvious pattern emerged from this analysis.  
 
Genes varying with percentage weight-loss were then determined. In the correlation 
analysis, the weight stable group contained both cancer patients and healthy controls   
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Table  4.1:  Clinical  data  for  control  subjects  and  cancer  
patients  from  centres  1  and  2 
 
 Centre 1 Centre 1 Centre 2 
 Control Cancer Patients Cancer Patients 
 (n=3) (n=18) (n=13) 
M/F 2/1 12/6 12/1 
Age (years) 45(2) 67(2)* 65(1.5)* 
Weight-loss (%) 0 8.9(1.6)* 7.7(2.0)* 
BMI (kg/m2) 28.5(1.7) 24.4(0.8)* 25.5(1.2) 
CRP (mg/l) 2.7(0.9) 19.7(8.1) - 
MAMC (cm) 23.8((1.7) 23.7(0.5) - 
 
 
Results are present as mean (SEM). Centre 1 – Edinburgh, UK, Centre 
2 – Stockholm, Sweden. * p<0.05 compared with centre 1 control.  
Abbreviations: BMI, body mass index; CRP, C reactive protein; MAMC, 
mid arm muscle circumference; M, male; F, female; kg, kilograms; m, 





in order to identify bona fide cachexia associating genes. All genes identified by the 
limma analysis were also present in the SAM generated list.  This latter list was used 
for further analysis. SAM identified 73 genes with false discovery rate (FDR)<10% 
which co-varied positively with weight-loss and 9 genes with a FDR<10% which co-
varied negatively with weight-loss (Table 4.2). 
 
For these 82 genes identified by SAM analysis, correlation coefficients (R) were 
generated  using  Pearson’s  product  moment  correlation.  Positive  coefficients  ranged  
from R= 0.82 to 0.57, p<0.01 and negatively correlating genes ranged from R= -0.74 
to -0.65, p<0.01. Each relationship was visually examined by plotting the data. 
Cluster analysis of the 82 genes revealed visual distinction of patients with <5% 
reported weight-loss from those with >5% reported weight-loss (Figure 4.1).  
 
The majority of the genes correlating with weight-loss had not been associated 
previously with cachexia in humans or animal models. Notably the FOXO 
transcription factors and E3 ligases MURF1 and MAFbx were not on the list. This 
Affymetrix derived weight-loss gene-signature was validated by qRT-PCR of the 9 
genes with the highest correlations (APCDD1, CAMk2, EIF3I, HGS, NUDC, 
POLRMT, SGK, TIE1 and TSC2) and 8 validated the microarray data (Figure 4.2 A 
and B).  
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TABLE  4.2:  Genes  correlating  with  weight-loss.     
Gene FDR 
(%) 
R Gene description ENST 
(00000…) 
CAMk2β 0 0.82 Calcium/calmodulin-dependent protein kinase type II beta 
chain 
346990 
ZER1 0 0.77 Zyg-11 related protein homolog  291900 
TAF12 0 0.74 Transcription initiation factor TFIID subunit 12  263974 
GCDH 0 0.71 Glutaryl-CoA dehydrogenase 222214 
HGS 0 0.70 Hepatocyte growth factor-regulated tyrosine kinase 
substrate 
329138 
GPS1 0 0.70 G protein pathway suppressor 1 320548 
DCTN3 0 0.69 Dynactin complex subunit 3 259632 
TSC2 3.01 0.69 Tuberous sclerosis 2 protein 382538 
RFC2 3.01 0.69 Replication factor C subunit 2  055077 
NUP160 5.03 0.68 Nuclear pore complex protein 160 378460 
APEH 3.01 0.68 Acylamino-acid-releasing enzyme 296456 
VWF 3.01 0.68 von Willebrand factor precursor  261405 
LY6G5B 0 0.68 Lymphocyte antigen 6 complex, locus G5B 375865 
KBTBD5 0 0.67 Kelch repeat and BTB domain-containing protein 5  287777 
TIE1 3.01 0.67 Tyrosine kinase with immunoglobulin-like and EGF-like 
domains 1  
372475 
27341 3.01 0.66 Gastric cancer antigen Zg14 323013 
TTC18 5.03 0.66 Tetratricopeptide repeat protein 18  372928 
PRODH 6.05 0.66 Proline oxidase 334029 
WARS 3.01 0.66 Tryptophanyl-tRNA synthetase 355338 
DCXR 3.01 0.65 Dicarbonyl/L-xylulose reductase 306869 
CSNK2B 5.03 0.65 Casein kinase II subunit beta (CK II beta) (Phosvitin) 
(G5a).  
383433 
FLYWCH1 5.03 0.65 FLYWCH-type zinc finger 1 isoform a 344592 
NUDC 3.47 0.65 Nuclear migration protein nudC (Nuclear distribution 
protein C homolog) 
321265 
TRMT1 5.03 0.65 N(2) 357720 
PRPF31 6.05 0.65 U4/U6 small nuclear ribonucleoprotein Prp31 (Pre-
mRNA-processing factor 31)  
263436 
INTS4 5.03 0.65 Integrator complex subunit 4 (Int4).  354849 
FAM39E 5.03 0.65 FAM39B protein (Fragment) 359512 
25851 5.03 0.64 0 379795 
DNPEP 6.05 0.64 Aspartyl aminopeptidase (EC 3.4.11.21).  322176 
RPUSD3 5.03 0.64 RNA pseudouridylate synthase domain containing 3 287624 
RPA2 3.01 0.64 Replication protein A 32 kDa subunit 373909 
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EIF3I 5.03 0.64 Eukaryotic translation initiation factor 3 subunit 2 (eIF-3 
beta) (eIF3 p36) (eIF3i) 
373586 
C11orf59 5.03 0.64 UPF0404 protein C11orf59 278671 
CORO6 3.01 0.64 Coronin-6.  337761 
EIF4EBP3 5.03 0.64 Eukaryotic translation initiation factor 4E-binding protein 
3 (4E-BP3) (eIF4E-binding protein 3). 
297183 
P4HB 5.03 0.63 Protein disulfide-isomerase precursor (EC 5.3.4.1) (PDI) 
(Prolyl 4- hydroxylase subunit beta)  
331483 
MCAT 5.03 0.63 Malonyl CoA-acyl carrier protein transacylase 290429 
Hs.461200 5.03 0.63 Protein FAM39A.  378819 
YIF1A 5.03 0.63 Protein YIF1A (YIP1-interacting factor homolog A)  376901 
PYCR2 5.03 0.63 Pyrroline-5-carboxylate reductase 2 (EC 1.5.1.2) (P5CR 2) 
(P5C reductase 2). 
316940 
ABCF2 5.03 0.63 ATP-binding cassette sub-family F member 2 (Iron-
inhibited ABC transporter 2).  
222388 
C11orf68 6.05 0.63 Uncharacterized protein C11orf68 (Basophilic leukemia-
expressed protein Bles03) (Protein p5326).  
312536 
NDUFS5 5.03 0.63 NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 372969 
TRAPPC2L 6.05 0.62 trafficking protein particle complex 2-like 301021 
PCYT2 5.03 0.62 Ethanolamine-phosphate cytidylyltransferase (EC 
2.7.7.14) (Phosphorylethanolamine transferase) 
(CTP:phosphoethanolamine cytidylyltransferase). 
331285 
CTSA 5.03 0.62 Lysosomal protective protein precursor (EC 3.4.16.5) 
(Cathepsin A) (Carboxypeptidase C) (Protective protein 
for beta-galactosidase) 
191018 
PRMT5 5.03 0.62 Protein arginine N-methyltransferase 5  324366 
HHATL 5.03 0.62 Glycerol uptake/transporter homolog.  310417 
DAP3 5.03 0.62 Mitochondrial 28S ribosomal protein S29 (S29mt) (MRP-
S29) (Death- associated protein 3) (DAP-3)  
343043 
DHTKD1 5.03 0.62 dehydrogenase E1 and transketolase domain containing 
protein 1 
263035 
RAPGEF1 5.03 0.61 Rap guanine nucleotide exchange factor 1 (Guanine 
nucleotide-releasing factor 2)  
372195 
TTC17 5.03 0.61 Tetratricopeptide repeat protein 17 039989 
DCPS 5.03 0.61 Scavenger mRNA-decapping enzyme DcpS 263579 
IMP4 5.03 0.61 U3 small nucleolar ribonucleoprotein protein IMP4 (U3 
snoRNP protein IMP4) 
259239 
MT1E 5.03 0.60 Metallothionein-1E (MT-1E) (Metallothionein-IE) 306061 
Hs.349096 5.03 0.60 Small VCP/p97-interacting protein. 354193 
POLRMT 5.03 0.60 DNA-directed RNA polymerase 215591 
MCM7 5.03 0.60 DNA replication licensing factor MCM7 (CDC47 
homolog) 
362082 





Using U133+2 Affymetrix chips and MAS5/RMA normalisation, a 
quantitative SAM analysis was carried out.  Genes that correlated 
positively and negatively with weight-loss were identified (FDR<10%) 
and correlation coefficients generated separately using regression 
analysis.  All data shown have a correlation p-value <0.05.  Genes that 
are highlighted in grey were selected for qRT-PCR validation. 
Abbreviations:  FDR,  false  discover  rate;;  R,  Pearson’s  correlation  
coefficient; ENST, Ensemble transcript identifier. 
 
  
NM_182905 5.03 0.60 family with sequence similarity 39 330546 
FAM39B 5.03 0.60 Protein FAM39B 285718 
PGS1 5.03 0.60 phosphatidylglycerophosphate synthase 1 262764 
EDF1 5.03 0.60 Endothelial differentiation-related factor 1 (EDF-1) 371648 
AKAP8L 5.03 0.59 A-kinase anchor protein 8-like (AKAP8-like protein)  263378 
GSTP1 5.03 0.59 Glutathione S-transferase P  196968 
PSPC1 5.03 0.59 paraspeckle protein 1 335781 
EMD 5.03 0.58 Emerin.  369842 
POP5 5.03 0.58 Ribonuclease P/MRP protein subunit POP5 357500 
TRAPPC3 5.03 0.58 Trafficking protein particle complex subunit 3  373159 
RBM28 5.03 0.58 RNA-binding protein 28 (RNA-binding motif protein 28) 223073 
DNTTIP1 5.03 0.58 Terminal deoxynucleotidyltransferase-interacting factor 1 
(TdT- interacting factor 1) (TdIF1) 
372622 
CLPTM1 5.03 0.57 Cleft lip and palate transmembrane protein 1 337392 
DAPK3 5.03 0.57 Death-associated protein kinase 3 301264 
ZSCAN18 5.03 0.57 Zinc finger and SCAN domain-containing protein 18  240727 
     
CXCR7 9.95 -0.65 C-X-C chemokine receptor type 7 272928 
SGK_85 3.01 -0.65 Uncharacterized serine/threonine-protein kinase SgK085 
(EC 2.7.11.1) (Sugen kinase 85) 
274643 
ALAS1 9.95 -0.65 5-aminolevulinate synthase 310271 
CTSZ 9.95 -0.66 Cathepsin Z precursor (EC 3.4.22.-) (Cathepsin X) 
(Cathepsin P) 
217131 
SGK 3.47 -0.68 Serine/threonine-protein kinase Sgk1 (EC 2.7.11.1) 
(Serum/glucocorticoid-regulated kinase 1 
367858 
C18orf1 3.01 -0.69 Uncharacterized protein C18orf1 ENST0000
0361303 
HYLS1 9.95 .71 Hydrolethalus syndrome protein 1 356438 
TFRC 0 -0.72 Transferrin receptor protein 1 360110 
APCDD1 0 -0.74 Protein APCDD1 precursor (Adenomatosis polyposis coli 
down-regulated 1 protein) 
355285 
 205 




Transcriptomics identified an 82 gene-signature correlating with weight-
loss.  These genes are listed down the right-hand side. Individual 
patients’  weight-loss is plotted along the bottom. Expression data from 
these genes were used to drive cluster analysis and produce a heatmap. 
Red represents decreased expression and blue, increased expression. 
Two clusters of subjects were revealed; high weight-loss (≥5%) and low 
weight loss (<5%). 
  
<  5%   >  5%   
- + 
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FIGURE 4.2A: HEATMAP REPRESENTING MICROARRAY VERSUS QRT-











From the 82 gene-signature correlating with weight-loss, 9 were selected 
for validation by qRT-PCR.  A  heatmap  of  Pearson’s  correlation 
coefficients (A.) and correlation plots (B.) for array data and qRT-PCR 
data with weight-loss are shown.  The qRT-PCR and array data were 
scaled to make them comparable and each dataset is plotted against % 
weight-loss.  For each dataset, the least square line is also shown.  P-
values for the correlations ranged from 0.03 to below 0.01.  All genes 




Microarray analysis: novel genes associated with systemic inflammation in 
cancer (Centre 1) 
Some of the key systemic mediators of cancer cachexia are cytokines and the acute 
phase response (see Section 1.2.6.2).  In order to explore the relationship between 
systemic inflammation and gene changes in cancer cachexia, a provisional analysis 
of the microarray data was performed as described above for weight-loss but using 
CRP in its place. This analysis was not corrected for further multiple testing beyond 
that afforded by the FDR calculation in SAM. Patients without systemic 
inflammation (CRP <5mg/l) were also included to identify inflammation related 
genes rather than genes associated with cancer alone. 76 genes (FDR<10%) 
correlated positively with systemic inflammation and 25 genes (FDR<10%) had a 
significant negative correlation (Table 4.3).   
 
Correlation coefficients ranged from R = 0.82 to 0.44 for positively correlating genes 
and R = -0.44 to -0.72 for negatively correlating genes (p<0.05). Positively 
correlating genes included the transcription factor FOXO1 and the autophagy related 
gene GABARAPL1 but not the E3 ligases MuRF1 and MAFBx. In contrast to the 
weight-loss gene signature (Figure 4.1), clustering with this gene-list did not easily 
differentiate high from low systemic inflammation subjects and no divisive gene 
signature could be distinguished.  Given these findings, subsequent work was 
focused exclusively on weight-loss associated genes. 
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Table  4.3:  Genes  correlating  with  systemic  inflammation 
 
Gene FDR  
(%) 
R Gene description ENST 
(00000…) 
ZNF547 8.42 0.44 Zinc finger protein 547  282282 
C18orf21 5.91 0.45 Uncharacterized protein C18orf21 (HBV X-
transactivated gene 13 protein)  
333234 
C20orf111 8.42 0.45 Uncharacterized protein C20orf111  255174 
RPP21 8.42 0.45 Ribonuclease P protein subunit p21  376644 
FOXO1 7.06 0.45 Forkhead box protein O1  379561 
WDR74 7.06 0.45 WD repeat-containing protein 74 278856 
BTAF1 8.42 0.46 TATA-binding protein-associated factor 172  265990 
UBE2E1 8.42 0.47 Ubiquitin-conjugating enzyme E2 E1  346855 
FAM107A 8.42 0.47 Protein FAM107A  360997 
MSH3 8.42 0.47 DNA mismatch repair protein Msh3 (Divergent 
upstream protein) (DUP) 
265081 
XPC 7.45 0.47 DNA-repair protein complementing XP-C cells 
(Xeroderma pigmentosum group C-complementing 
protein) (p125)  
285021 
CTNS 2.96 0.47 Cystinosin  046640 
EIF3M 8.42 0.48 Eukaryotic translation initiation factor 3 subunit M  323213 
GCLM 4.21 0.48 Glutamate--cysteine ligase regulatory subunit  370238 
SLC25A27 8.42 0.48 Mitochondrial uncoupling protein 4 (UCP 4) 
(Solute carrier family 25 member 27)  
355073 
ASB8 5.91 0.48 Ankyrin repeat and SOCS box protein 8 (ASB-8)  317697 
RAB3GAP2 8.42 0.48 Rab3 GTPase-activating protein non-catalytic 
subunit  
358951 
DAP3 5.91 0.48 28S ribosomal protein S29, mitochondrial (S29mt) 
(MRP-S29) (Death-associated protein 3)  
368336 
PTPN3 0.00 0.49 Tyrosine-protein phosphatase non-receptor type 3 
(EC 3.1.3.48) (Protein-tyrosine phosphatase H1)  
374541 
PDSS2 7.45 0.49 Decaprenyl-diphosphate synthase subunit 2 (EC 
2.5.1.-) (Decaprenyl pyrophosphate synthetase 
subunit 2) 
369031 
SPSB1 8.42 0.49 SPRY domain-containing SOCS box protein 1 
(SSB-1)  
357898 
ADFP 8.42 0.49 Adipophilin (Adipose differentiation-related 
protein) (ADRP)  
276914 
FAM134B 5.91 0.50 Protein FAM134B  306320 
RAD50 8.42 0.50 DNA repair protein RAD50 (EC 3.6.-.-) (hRAD50) 265335 
PSMG4 8.42 0.50 Proteasome assembly chaperone 4 (PAC-4) 
(hPAC4)  
380303 
CCDC86 8.42 0.50 Coiled-coil domain-containing protein 86  227520 
GTF2A2 8.42 0.50 Transcription initiation factor IIA subunit 2 
(General transcription factor IIA subunit 2)  
267869 
DDX21 7.45 0.50 Nucleolar RNA helicase 2 (EC 3.6.1.-) (Nucleolar 
RNA helicase II) (DEAD box protein 21)  
354185 
FAM120B 8.42 0.51 Constitutive coactivator of peroxisome proliferator-
activated receptor gamma  
366751 
CREM 8.42 0.51 cAMP-responsive element modulator (Inducible 
cAMP early repressor) (ICER)  
374734 
CENPQ 8.42 0.51 Centromere protein Q (CENP-Q)  371200 
HMGB2 7.45 0.52 High mobility group protein B2 (High mobility 
group protein 2) (HMG-2)  
296503 
TXNL1 8.42 0.52 Thioredoxin-like protein 1  217515 
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REPS1 8.42 0.52 RalBP1-associated Eps domain-containing protein 1  258062 
PRMT5 7.06 0.53 Protein arginine N-methyltransferase 5  324366 
GNPAT 8.42 0.53 Dihydroxyacetone phosphate acyltransferase (EC 
2.3.1.42) (DHAP-AT) (DAP-AT) (Glycerone-
phosphate O-acyltransferase) 
366646 
CNOT10 8.42 0.53 CCR4-NOT transcription complex subunit 10  328834 
TIMM9 8.42 0.54 Mitochondrial import inner membrane translocase 
subunit Tim9 
216463 
RASL10B 8.42 0.54 Ras-like protein family member 10B Precursor   268864 
MAP3K2 7.45 0.54 Mitogen-activated protein kinase kinase kinase 2  344908 
TMEM111 5.42 0.54 Transmembrane protein 111  245046 
DCP1A 7.45 0.54 mRNA-decapping enzyme 1A (EC 3.-.-.-) 
(Transcription factor SMIF) (Smad4-interacting 
transcriptional co-activator) 
294241 
ATAD2 8.42 0.54 ATPase family AAA domain-containing protein 2  287394 
ZNF197 7.45 0.54 Zinc finger protein 197 (ZnF20) (Zinc finger protein 
with KRAB and SCAN domains 9)  
344387 
CIRH1A 8.42 0.55 Cirhin  352319 
EIF2A 7.45 0.55 Eukaryotic translation initiation factor 2A  383043 
MNAT1 7.45 0.55 CDK-activating kinase assembly factor MAT1 
(RING finger protein MAT1) (Menage a trois)  
261245 
JMJD2C 0.00 0.55 JmjC domain-containing histone demethylation 
protein 3C (EC 1.14.11.-) (Jumonji domain-
containing protein 2C) 
381306 
NFIL3 5.91 0.56 Nuclear factor interleukin-3-regulated protein (E4 
promoter binding-protein 4)  
297689 
EIF3E 8.42 0.56 Eukaryotic translation initiation factor 3 subunit E  220849 
ITSN2 5.91 0.56 Intersectin-2 (SH3 domain-containing protein 1B)  355123 
DPY30 5.42 0.56 Protein dpy-30 homolog (Dpy-30-like protein)  342166 
EIF2B2 8.42 0.57 Translation initiation factor eIF-2B subunit beta  266126 
PTCH1 8.42 0.57 Protein patched homolog 1 (PTC1) (PTC)  375284 
C13orf27 8.42 0.57 Uncharacterized protein C13orf27  376019 
SLBP 8.42 0.58 Histone RNA hairpin-binding protein (Histone 
stem-loop-binding protein)  
318386 
MINA 7.45 0.58 MYC-induced nuclear antigen (Mineral dust-
induced gene protein)  
333396 
ZNF302 8.42 0.58 Zinc finger protein 302 (ZNF135-like) (ZNF140-
like)  
221282 
HEBP1 5.91 0.59 Heme-binding protein 1 (p22HBP)  014930 
LPIN1 8.42 0.59 Lipin-1  256720 
DYNC2LI1 7.45 0.60 Cytoplasmic dynein 2 light intermediate chain 1 
(Dynein 2 light intermediate chain)  
260605 
MPHOSPH10 8.42 0.61 U3 small nucleolar ribonucleoprotein protein 
MPP10 (M phase phosphoprotein 10)  
244230 
UNC50 8.42 0.62 Protein unc-50 homolog (Uncoordinated-like 
protein)  
357765 
CYP4B1 8.42 0.62 Cytochrome P450 4B1  271153 
MCM7 7.45 0.62 DNA replication licensing factor MCM7 (CDC47 
homolog) 
343023 
GABARAPL1 8.42 0.63 Gamma-aminobutyric acid receptor-associated 
protein-like 1  
266458 
UHRF1BP1 7.45 0.64 UHRF1-binding protein 1 (Ubiquitin-like 
containing PHD and RING finger domains 1-
binding protein 1)  
192788 
OSBPL3 0.00 0.65 Oxysterol-binding protein-related protein 3  313367 
EPB41L5 8.42 0.65 Band 4.1-like protein 5  263713 
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GPR125 8.42 0.67 Probable G-protein coupled receptor 125 Precursor  282943 
PSMG1 7.06 0.68 Proteasome assembly chaperone 1 (PAC-1) 331573 
HSPA14 8.42 0.68 Heat shock 70 kDa protein 14  378348 
TMTC1 8.42 0.71 Transmembrane and TPR repeat-containing protein 
1  
256062 
MTMR10 8.42 0.71 Myotubularin-related protein 10  340566 
PHIP 8.42 0.75 PH-interacting protein (PHIP)  275034 
HMOX1 0.00 0.75 Heme oxygenase 1  216117 
USP13 8.42 0.82 Ubiquitin carboxyl-terminal hydrolase 13 
(Ubiquitin-specific-processing protease 13)  
263966 
     
CXCL12 5.91 -0.72 Stromal cell-derived factor 1 (SDF-1) (C-X-C motif 
chemokine 12)  
343575 
C5orf13 4.85 -0.63 Neuronal protein 3.1 (Protein p311)  257435 
CASQ1 5.42 -0.62 Calsequestrin-1 Precursor   368078 
EEF1A2 4.85 -0.62 Elongation factor 1-alpha 2 (EF-1-alpha-2)  217182 
TCEAL8 7.06 -0.61 Transcription elongation factor A protein-like 8  360000 
ANK1 0.00 -0.61 Ankyrin-1 (Erythrocyte ankyrin)  265709 
TPM1 4.85 -0.61 Tropomyosin alpha-1 chain  288398 
SGCD 5.91 -0.59 Delta-sarcoglycan (SG-delta) 337851 
ANK2 7.45 -0.58 Ankyrin-2 (Brain ankyrin) (Ankyrin-B)  264366 
PPP1R3C 0.00 -0.58 Protein phosphatase 1 regulatory subunit 3C  238994 
ICA1 4.85 -0.57 Islet cell autoantigen 1 317367 
SESTD1 7.45 -0.56 SEC14 domain and spectrin repeat-containing 
protein 1  
335289 
ALAS1 4.85 -0.54 5-aminolevulinate synthase, nonspecific, 
mitochondrial Precursor   
310271 
PLCD3 5.42 -0.53 1-phosphatidylinositol-4,5-bisphosphate 
phosphodiesterase delta-3   
322765 
EHD4 5.42 -0.53 EH domain-containing protein 4  220325 
IFIT1 4.85 -0.51 Interferon-induced protein with tetratricopeptide 
repeats 1 (IFIT-1)  
371804 
ADAM19 0.00 -0.50 ADAM 19 Precursor  (EC 3.4.24.-) (A disintegrin 
and metalloproteinase domain 19)  
257527 
MYBPC2 7.45 -0.49 Myosin-binding protein C, fast-type  357701 
MEF2C 0.00 -0.47 Myocyte-specific enhancer factor 2C  340208 
NDRG3 5.42 -0.47 Protein NDRG3  349004 
PRRC1 7.45 -0.46 Protein PPRC1  296666 
PAPSS1 4.85 -0.45 Bifunctional 3'-phosphoadenosine 5'-phosphosulfate 
synthetase 1 
265174 
SYPL2 5.42 -0.45 Synaptophysin-like protein 2  369872 
PKM2 5.42 -0.44 Pyruvate kinase isozymes M1/M2  319622 
LIMCH1 4.85 -0.44 LIM and calponin homology domains-containing 
protein 1  
313875 
ZMYND17 7.06 -0.43 Zinc finger MYND domain-containing protein 17  299432 
 
 
Using U133+2 Affymetrix chips and MAS5/RMA normalisation, a 
quantitative SAM analysis was carried out.  Genes that correlated 
positively and negatively with systemic inflammation were identified 
(FDR<10%) and correlation coefficients generated separately using 
regression analysis.  All data shown have a correlation p-value <0.05.  
Abbreviations:  FDR,  false  discover  rate;;  R,  Pearson’s  correlation  
coefficient; ENST, Ensemble transcript identifier.  
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Confirmation of genes associated with weight-loss in cancer cachexia (centre 2) 
To provide biological validation of the weight-loss gene-signature generated from 
the centre 1 cohort, the 9 technically validated genes (APCDD1, CAMk2, EIF3I, 
HGS, NUDC, POLRMT, SGK, TIE1 and TSC2) were examined using qRT-PCR in 
two additional types of skeletal muscle. This validation was carried out at the 
Karolinska Institutet, Stockholm, Sweden under the supervision of Dr O 
Rooyackers/Prof JA Timmons.  Table 4.4 shows the results.  The significant 
association between CAMk2 and weight-loss observed in the Rectus abdominis 
biopsies from centre 1 (R = 0.82; p = 0.01) (Figure 4.2B) was reflected by a trend in 
both Vastus lateralis biopsies (R = 0.45; p = 0.06) and Diaphragma biopsies (R = 0.5; 
p = 0.07) (Figure 4.3) from centre 2 patients (where statistical significance is partly 
limited by power, due to a lower sample size). TIE1 was also significantly correlated 
with weight-loss in both Rectus abdominis (R = 0.67; p = 0.01) (Figure 4.2B) and 
Vastus lateralis (R = 0.7; p = 0.01) (Figure 4.3). 
 
CAMk2 protein and phosphorylation (Centre 1) 
Given the changes observed in CAMk2 mRNA in centres 1 and 2, the protein and 
phosphorylation level of this kinase in the Rectus abdominis muscle from a larger 
group recruited from centre 1 (n=52) was evaluated. Table 4.5 shows the 
demographics of this cohort.   
 
Western blotting revealed similar protein levels of CAMk2 (Figure 4.4) in weight 
losing and weight stable groups (p=0.302).  However, there was a significant 
increase in phosphorylated (p)CAMk2 (the constitutively active form) in the muscle   
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Table  4.4:  Validation  of  selected  genes  correlating  with  
weight-loss  (centres  1  and  2)   
 
 Centre 1 (n=21) Centre 2 (n=13) 
 Rectus abdominis Vastus lateralis Diaphragma 
Gene R p R  p R p 
Microarray qRT-PCR qRT-PCR qRT-PCR 
APCDD1 -0.7 -0.5 0.03 0.3 0.40 -0.2 0.50 
CAMk2β 0.8 0.5 0.01 0.5 0.06 0.5 0.07 
EIF3I 0.6 0.5 0.02 0.1 0.70 0.2 0.40 
HGS 0.7 0.7 <0.01 0.2 0.60 0.2 0.40 
NUDC 0.7 0.7 <0.01 0.1 0.70 0 0.90 
POLRMT 0.6 0.5 0.02 0.1 0.80 0 0.90 
TIE1 0.7 0.5 0.01 0.7 0.01 0 0.90 
TSC2 0.7 0.5 0.03 0.4 0.20 0 0.80 
 
 
The 8 genes from the transcriptomic gene signature validated by qRT-
PCR (Figure 4.2) were also examined in the cohort from Centre 2 using 
qRT-PCR. For each gene the correlation coefficient from the Affymetrix 
data set is shown followed by the correlation coefficient for qRT-PCR 











In order to validate the findings from the Rectus abdominis, qRT-PCR 
was used to examine mRNA expression of CAMk2β and TIE 1 in 
Diaphragma (red crosses) and Vastus lateralis (closed circles) in centre 
2 patients.  The correlation coefficient for TIE1 in Diaphragma was not 
significant (see Table 4.4) and is thus not illustrated.  Correlation plots 
for mRNA expression level against rate of weight-loss are shown.  




Table  4.5:  Clinical  data  for  cohort  of  cancer  patients  from  
centre  1  undergoing  CAMk2  Western  blotting 
 




Age (years) 66 (1.3) 
Weight-loss (%) 8.9 (1.1) 
BMI (kg/m2) 25.5 (0.5) 
CRP (mg/l) 17.4 (4.4) 




Results are presented as mean (SEM). Centre 1 – Edinburgh, UK.  
* p<0.05 compared with centre 1 control. Abbreviations: M, male; F, 
female; BMI, body mass index; CRP, C-reactive protein; MAMC, mid 
arm muscle circumference; kg, kilograms; m, metres; mg, milligrams; l, 





tissue from weight losing cancer patients compared with the changes noted in weight 
stable cancer patients and controls (p=0.039) (Figure 4.4).   
 
Gene interaction analysis 
The nature of the 82 weight-loss associated gene-signature was characterised in 
greater detail using Bibliometric analysis (Ingenuity database) to establish the 
relationship between the weight-loss correlating genes and the known biological 
interactome. In order to generate valid pathway or ontological enrichment scores it is 
essential to relate the modulated gene list with the genes detectably expressed in the 
tissue of interest and not with the genome as a whole (or the entire gene-chip 
content). This is because the ontological profile of the tissue specific expression will 
already be substantially enriched and bias the enrichment analysis of the regulated 
gene list. The analysis indicated that metabolic pathways relating to 
Aminophosphonate, Tryptophan, Arginine/Proline and Ubiquinone Biosynthesis 
were significantly over-represented in the weight-loss gene list after correction for 
multiple testing (Fishers Exact Test, p<0.002 – p<0.001).  
 
Each of these categories was, however, driven by a small number of overlapping 
genes (PCYT2, PRMT5, EDF1, WARS, GCDH, NDUFS5, P4HB, PRODH and 
PYCR2). For example, WARS catalyzes the aminoacylation of tRNA(trp) with 
tryptophan, an essential function of the cell's protein synthesis machinery while 
GCDH, PRODH and NDUFS5 are mitochondrial located proteins. PRODH (Proline 
dehydrogenase) can enhance reactive oxygen species and degrades Proline while  
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CAMk2 protein and phospho-protein levels are increased in subjects 
with weight loss. Protein levels of CAMk2 (A.) and pCAMk2 (B.) were 
assessed in the Rectus abdominis muscle from centre 1 subjects by 
Western blot. Intensity levels were normalised to loading  control  (α-
skeletal actin) and the mean AUD of CAMk2/actin or pCAMk2/actin are 
shown for subjects with less than (black) or more than (white) 5% weight 
loss. * = p-value <0.05 compared with <5% weight-loss group.  





P4HB (prolyl 4-hydroxylase) is involved with the hydroxylation of prolyl residues in 
preprocollagen and thus an essential extracellular matrix regulating gene. 
 
Network analysis revealed several pathways for the weight-loss associated genes 
including CAMk and IL-6 related gene networks (Figure 4.5).  Identification of a 
Calcium/Calmodulin related gene network supports the wet-lab data and indicates 
that CAMk2 appears to be a universal marker of muscle wasting in cancer cachexia.  
The second pathway features Glut-4 and IL-6, both of which are implicated in 
skeletal muscle metabolism as well as IL-6 being a prominent pro-inflammatory 
mediator.  This network forms numerous connections with the glucocorticoid and 
androgen receptors that are directly involved in regulating skeletal muscle mass. It 
should be noted that despite using a back-ground gene expression file in Ingenuity 
for genes only detected as being expressed in human skeletal muscle (~21,000 probe-
sets, based on MAS present-marginal calls) the Ingenuity network analysis still 
included additional genes and should be used in a qualitative fashion. 
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Using the Ingenuity database, weight-loss correlating genes were 
examined for gene interactions. This analysis revealed networks 
involving IL-6 (A.) and calmodulin (B.). Red symbols represent genes 
upregulated and blue symbols represent those downregulated in the 
weight losing group by Affymetrix analysis. 
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4.6 Discussion 
In this study, the expression of 82 genes correlated with weight-loss in cancer 
cachexia subjects; 73 of these were positively correlated and 9 were negatively 
correlated. Validation of the weight-loss correlating genes by qRT-PCR provided 
excellent technical confirmation of the microarray results.  Biological validation of 
TIE1 and the trend in CAMk2 expression in an independent clinical cohort across 
distinct muscle groups has identified potential novel biomarkers of cancer cachexia 
in humans.   
 
CAMk2 - a biomarker of human cachexia 
The significant correlation of CAMk2 mRNA expression with weight-loss along 
with the small but significant change in phosphorylated protein levels in Rectus 
abdominis suggests that CAMk2 could be a useful biomarker of human cancer 
cachexia.  There was also a positive trend of CAMk2 with weight-loss in Vastus 
lateralis and Diaphragma and although not reaching statistical significance, it is 
possible that the smaller sample size in this group gave rise to a type II error.   
 
The serine/threonine kinase CAMk2 holoenzyme is activated by calcium (Ca2+)/ 
calmodulin leading to autophosphorylation, rendering the kinase constitutively active 
and maintaining CAMk2 activity even after the Ca2+ signal has diminished (Chin, 
2004). Thus oscillatory Ca2+ signals can be converted into a sustained signal to 
activate transcription factors or other processes. CAMk2 is expressed in skeletal 
muscle and levels of the protein as well as phosphorylation status and activity 
increase after exercise training (Rose et al., 2007).  The relationship between 
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CAMk2 expression and cachexia observed in the present study suggests that muscle 
wasting is not simply in response to physical inactivity. The significant positive 
correlation for TIE1 mRNA expression with weight-loss in both the Rectus 
abdominis and the Vastus lateralis muscle groups supports this claim.  In animal 
models TIE1 is required for normal vascular network development (Sato et al., 1995). 
Increased TIE1 mRNA levels in human skeletal muscle in response to physiological 
adaptation to exercise training has been demonstrated (Timmons et al., 2005a) again 
underlining that the present findings are not due to illness related inactivity. Whilst 
the ligands and signalling pathways of TIE1 are poorly understood this receptor can 
interact with PI3K and leads to phosphorylation and activation of Akt, protecting 
cells from apoptosis (Kontos et al., 2002). In functional terms, the up-regulation of 
TIE1 may therefore represent a protective mechanism to oppose apoptosis. 
 
The increased CAMk2 mRNA levels associated with weight-loss across a range of 
muscle tissues implies that these muscle groups have either developed dysregulation 
of calcium sensing or are burdened by greater loading in the face of failing muscle 
function.  CAMk2 has also been implicated in muscle growth through 
phosphorylation of HDAC5 leading to MyoD/MEF2 driven differentiation of muscle 
cells (McKinsey et al., 2000). It is therefore plausible that CAMk2 activation is a 
compensatory strategy in the face of failing protein synthesis.  
 
Alternatively, the CAMk2 response may indicate activation of calcium driven 
proteolytic activities such as calpains and caspases (Jones et al., 2004, Menconi et al., 
2004).  The UPP is considered to be the major pathway for myofibrillar protein 
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breakdown, but it is thought that the calpains are necessary for release of 
myofilaments prior to entry into the proteasome (Goll et al., 2008).  A link between 
these pathways has been demonstrated in myotubes.  Treatment with calcium 
ionophores led to increased proteosome activity whilst treatment with inhibitors of 
CAMk2, caspases and calpains all reduced this proteolytic activity (Menconi et al., 
2004).  It is thus possible that CAMk2 activation occurs at an early stage of 
cachexia in humans reflecting initiation of the calpain pathway prior to UPP driven 
proteolysis.   
 
Finally, recent work has clarified two potential calcium independent activation 
pathways for CAMk2. Generation of reactive oxygen intermediates can increase or 
prolong CAMk2 activity, perhaps through inhibition of protein phosphotases which 
normally limit CAMk2 activation (Howe et al., 2004).  Given the proposed role of 
inflammatory stimuli in cachexia, this could represent an important activation 
pathway for CAMk2. In addition, it has recently been demonstrated that Ca2+-CaM-
eIF2K signalling is responsible for exercise induced inhibition of muscle protein 
synthesis (van Hoek et al., 2009). It is conceivable that chronic inappropriate 
activation of so-called  ‘endurance  specific’  related  signalling  processes (Timmons et 
al., 2005b) is limiting maintenance of skeletal muscle mass. This speculation would 
be supported by the significant elevation in TIE1 expression. However, it is notable 
that (other than TIE1, CTSA and PRODH) the weight-loss gene-signature does not 
overlap with the ~500-strong human endurance training gene-expression signature 
(Timmons et al., 2005b) indicating that the genuine reason for elevated CAMk2 
remains to be determined. 
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Proteolytic pathways in human cancer cachexia differ from pre-clinical models 
Given the robust increase in expression of the E3 ligases reported previously in 
various animal models of cachexia (Bodine et al., 2001a, Gomes et al., 2001, Lecker 
et al., 2004), it is surprising that neither the microarray (this Chapter) nor qRT-PCR 
(as discussed in Chapter 3) results detected any significant difference in the 
expression of MuRF1 and MAFbx between controls and cachectic patients.  
Furthermore, the 82 weight-loss gene signature bore no resemblance to the Atrogen 
signatures (Lecker et al., 2004, Fredriksson et al., 2008).  This is not due to gene-chip 
technology being unable to establish parallels, as it has previously been demonstrated 
that skeletal muscle of ICU patients resembles, in part, the process found in animal 
models (Fredriksson et al., 2008, Lecker et al., 2004). Results of E3 ligase expression 
analysis from other human models of cachexia have been contradictory.  Studies 
including patients following bed rest, amputation for vascular disease, limb 
immobilisation, COPD, amyotrophic lateral sclerosis and ageing have demonstrated 
both increased and decreased expression of MuRF1 and MAFBx (Doucet et al., 2007, 
Salanova et al., 2008, Leger et al., 2006, de Palma et al., 2008, Edstrom et al., 2006).  
This would suggest that the ubiquitin E3 ligases do not play the same role in human 
cancer cachexia as that previously demonstrated in animal and cell studies.   
 
However, cancer cachexia encompasses a spectrum progressing from early weight-
loss through to severe muscle wasting with resultant incapacity, increased morbidity 
and mortality (Fearon, 2008).  The prominence of the individual proteolytic 
pathways at different time points along this spectrum is yet to be determined.  
Investigation of the UPP in the MAC16 murine model and pancreatic cancer patients 
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suggests that UPP activity is reduced with low weight-loss and increases as weight-
loss becomes more severe (Khal et al., 2005a, Khal et al., 2005b). Indeed, in lung 
cancer patients with mean weight-loss of 2.9%, there was no evidence of UPP 
activation (Jagoe et al., 2002).  However, other human studies in patients with gastric 
cancer and mean weight-loss of 5.2% and 5.6% have shown increases in components 
of the UPP (Bossola et al., 2001, Bossola et al., 2003).  Thus, the role of the UPP in 
human cancer cachexia could vary according to the degree of muscle wasting or may 
be  tumour  type  specific.    Recently  a  third  E3  ligase  (E3α-II) associated with muscle 
atrophy has been described (Kwak et al., 2004). This protein was identified in two 
animal models of cancer cachexia but has not yet been investigated in human disease 
and may play a role in the human muscle cachexia process. 
 
The autophagy pathway can be activated in muscle atrophy, but its role in human 
cancer cachexia has not been investigated extensively. Increased cathepsin D and 
acid phosphatase activity has been demonstrated in patients with varying tumour 
types and degrees of weight-loss suggesting that increased lysosomal activity may be 
important in the development of cachexia (Schersten and Lundholm, 1972).  More 
recently, lung cancer patients undergoing resection were shown to have increased 
mRNA levels of cathepsin B in skeletal muscle compared with controls (Jagoe et al., 
2002). The current microarray analysis showed increased expression of 
GABARAPL1 associated with SI in cachectic patients and qRT-PCR (Chapter 3) 
demonstrated increased mRNA expression of both GABARAPL1 and BNIP3 in 
cancer patients compared with controls.  GABARAPL1 is an Atg8 homologue 
important in the formation of the autophagosome (Tanida et al., 2004) and BNIP3 
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has been found to play a predominant role in induction of autophagy in rodent 
skeletal muscle (Mammucari et al., 2007). The role of autophagy in the cell is varied 
and includes programmed cell death, organelle turnover and protection against 
metabolic stress and DNA damage.  Autophagy can be induced by starvation of 
amino acids, which may explain the increase in BNIP3 and GABARAPL1 in cancer 
patients where the acute phase response is activated (mobilising amino acid from 
muscle to liver for consumption) and where food intake may be reduced due to 
anorexia or dysphagia.  Human cancer cachexia is a chronic wasting process and 
weight-loss is not as rapid and generally not as severe as it is in the acute muscle 
wasting seen in the animal models.  Thus the physiological regulators may be distinct 
in each scenario.  Whilst this study showed evidence for activation of the autophagy 
pathway, it was unable to replicate the finding of robust E3 ligase expression in the 
human data set. Neither was there increased FOXO transcription activity.  Instead, 
there was increased  expression  of  two  ‘endurance  exercise’  genes,  CAMk2 and 
TIE1, across different muscle groups in human cancer cachexia. Whether this reflects 
activation of proteolysis via calpains prior to UPP activation, a reduction in protein 
synthesis or activation of alternate pathways remains to be ascertained.   
 
The preceding two chapters have described cross-sectional biomarker studies using 
both a hypothesis-driven biomarker approach (Chapter 3), and a biomarker discovery 
approach utilising transcriptomics  (Chapter 4).  With cancer cachexia being a 
journey rather than an event, there are potential limitations that come with cross-
sectional studies.  As such, the next chapter will describe a further transcriptomic 
study, but this time, longitudinal changes will be investigated.    
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Chapter  5:  Investigating  longitudinal  changes  in  




A longitudinal transcriptomic study was carried out using microarrays to examine 
the global transcriptomic response in paired Vastus lateralis biopsies (baseline (pre-
op: weight-loss 7%) and follow-up (8 months after surgical resection and disease-
free /weight-stable for previous 2 months)) from quadriceps muscle of weight losing 
patients (n=12) with UGI cancer. Prior to surgery 1868 genes were regulated 
compared with follow-up.  Ontology analysis demonstrated regulated genes 
belonged to both anabolic and catabolic biological processes with overwhelming 
down-regulation in baseline samples. Again, none of the literature-derived genes 
from pre-clinical cancer cachexia models demonstrated higher expression in 
baseline human muscle.  Comparison with HC muscle revealed that despite 
differences in the transcriptome at baseline (941 genes regulated), the muscle of 
patients at follow-up was similar to control muscle (only 2 genes regulated). 
Physical activity (as measured by ActivPAL™ step count) did not differ between the 
baseline and follow-up periods (p = 0.9) indicating that transcriptome differences 
reflected the removal of the cancer rather than altered physical activity levels. 
Comparative gene-expression analysis using physical activity signatures supported 
this interpretation.  This study showed that metabolic and protein-turnover related 
pathways are suppressed in weight losing UGI cancer patients whilst removal of the 






Chapter 4 identified a novel gene signature relating to weight-loss. In contrast to 
studies in pre-clinical models, there was no evidence for an increase in proteolytic 
gene expression using genome-wide transcript analysis of three types of skeletal 
muscle in a relatively large group of weight losing UGI cancer patients.  This 
transcriptional analysis was also supported by a lack of alteration in FOXO protein 
levels (Chapter 3).  However protein analysis suggested that CAMk2β  activation 
might play a role and be useful as a biomarker of cancer cachexia.  In general, 
observations from cross-sectional studies are impacted by patient heterogeneity, 
including different phases of cachexia.  Nonetheless, Chapters 3 and 4 seemed to 
suggest that human cancer cachexia is not simply 'runaway' proteolysis.  Examining 
longitudinal changes in the skeletal muscle of cachectic patients is likely to provide 
further clarification.  
 
The original intention was to undertake a longitudinal natural history study of the 
development of cancer cachexia in patients following resection.  It was anticipated 
that as patients developed recurrent disease cachexia would become more prevalent 
and a repeat muscle biopsy could be carried out.  As it happened, patients who 
returned for follow-up were still disease free whereas those that developed 
recurrence (and presumably cachexia) died so quickly as not to be picked up during 
follow-up.   
 
In order to make sense of the data, a repeat muscle biopsy was carried out in those 
patients  who  were  ‘cured’  and  clinically  disease  free  at  follow-up assessment.  
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Molecular profiling of the biopsies taken before and after surgery allowed 
examination of the relevance of tumour burden per se which would potentially be 
informative. 
 
Patients undergoing UGI cancer surgery lose 7-15% of body weight on average 
(Liedman et al., 1997).  It is generally accepted that it will take 6 months for this 
impact of surgery to resolve (Blazeby et al., 2000, Blazeby et al., 2005a, Zieren et al., 
1996, Brooks et al., 2002, Niedergethmann et al., 2006, Liedman et al., 1997).  Thus, 
follow-up for patients in this study was at an average of ~8 months post-operatively 
to try and control for the potential confounding influence of the surgery.  Similarly, 
an  individual’s  level  of  exercise  and  physical  activity  will  be  a  key determinant of 
muscle protein turnover.  Therefore, it was felt informative to assess this in the 
current study. Quadriceps strength (isometric knee extensor strength (IKES)) and 
daily step count (ActivPAL™ monitor) were measured in UGI cancer patients at 
baseline and at follow-up assessment. 
 
This chapter outlines a study investigating the global transcriptional profile of human 
quadriceps muscle in patients before and after potentially curative surgery for UGI 
cancer.  Longitudinal changes in expression of the E3 ligases and autophagy genes 
were also examined because, although results from the cross-sectional studies of 
Chapters 3 and 4 have not suggested a major role in human cancer cachexia, there is 
some evidence that components of the UPP may be activated in a time-dependent 
manner (Khal et al., 2005a).  Furthermore, whereas the studies in Chapters 3 and 4 
used Rectus abdominis muscle, the longitudinal study used quadriceps (Vastus 
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lateralis) muscle which allows for repeat muscle biopsy under local anaesthesia.  It is 
possible that different muscles have different responses to pro-cachectic stimuli and 
it was thus felt that a further assessment of these markers in a different muscle group 




- There would be differences in the transcriptomic signature in skeletal muscle 
of cachectic UGI cancer patients before and then after potentially curative 
surgery (i.e. at a time when tumour-driven cachexia should have resolved). 
- There would be a lack of evidence for alterations in the atrogenes in 





Participants: see Section 2.1 
Anthropometric assessments: see Section 2.2 
Muscle biopsy (Vastus lateralis) and blood collection: see Section 2.8 
Blood measures (albumin and CRP): see Section 2.9 
Muscle measures (RNA isolation, qRT-PCR, microarray target preparation/ 
hybridisation): see Section 2.10 
Muscle function (IKES): see Section 2.3 
Physical activity (step count – ActivPAL™): see Section 2.5 





Demographic details for the UGI cancer patients before and 8 months after 
potentially curative surgery and for the healthy controls are shown in Table 5.1.  
 
At baseline, age was not significantly different between UGI cancer patients and 
controls. BMI and weight in the cancer group did not differ significantly from the 
control group at any time-point. The median time between baseline and follow-up 
biopsies was 8 months (range 5-12 months). All UGI cancer patients were clinically 
cancer-free at the time of repeat biopsy. Mean weight-loss from self-reported usual 
weight was 7.4% at baseline and increased to 13.8% at follow-up. However, this did 
not occur in a linear fashion, but rather was more rapid immediately following 
surgery before stabilising in the two months prior to follow-up biopsy (Figure 5.1). 
 
Eight of the twelve UGI cancer patients were included in the activity meter study, 
and age, BMI, and weight did not differ significantly from the overall UGI cancer 
group (data not shown). In UGI cancer patients, there was an increase in quadriceps 
strength between baseline and follow-up of ~20%, but this did not reach statistical 
significance.  Overall physical activity (step count) was unchanged between the 
baseline and follow-up biopsy time-points (Table 5.1, Figure 5.2). 
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Table  5.1:  Demographics,  blood  results,  physical  activity  and  




 Cancer  patients  (paired) Controls 
 Baseline  (n=12) Follow-up  2  (n=12) (n=6) 
M/F 10/2 10/2 4/2 
Age  (years) 65  (3) 65  (3) 58  (6)   
BMI  (kg/m2) 26.4  (1.3) 24.6  (1.3)* 28.2  (1.7) 
Weight  (kg) 78.2  (4.5) 72.8  (4.4) 84.9  (7.2) 
Weight-loss  (%) 7.3  (2.7)† 13.8  (2.7)*† 0 
CRP  (mg/l) 9.8  (3.6) 8.9  (4.3) 1.8  (1.0) 
Albumin  (g/l) 36  (1)† 42  (1)* 42  (1) 
Daily  step  count  (n=8) 5607  (1083) 5675  (600) N/A 




Data (except gender split) are presented as mean (SEM). †  =  p<0.01 
compared with controls, * = p<0.01 compared with baseline (paired t-
test). Abbreviations: CRP, C-reactive protein; BMI, body mass index; N, 
Newtons; M, male; F, female; IKES, isometric knee extensor strength; kg, 





FIGURE 5.1: REPRESENTATIVE WEIGHT CHANGES OF CANCER PATIENTS 
BEFORE AND FOLLOWING SURGERY 
 
 
Weight was significantly decreased from reported usual weight at 
baseline and both follow-up timepoints (* p < 0.05). At both follow-up 
timepoints  weight  was  lower  than  baseline  (†,  p  < 0.05) but did not differ 
between the follow-up timepoints. Muscle biopsies were taken at 




FIGURE 5.2: LONGITUDINAL QUADRICEPS STRENGTH AND DAILY STEP 




(A.) Mean step count over fours days was not different between the 
baseline and follow-up timepoints.  (B.) Quadriceps strength (IKES) did 
increase by ~20% at follow-up compared with baseline, but was not 
statistically significant.  Abbreviations: N, Newtons; kg, kilograms; IKES, 




Albumin and CRP 
At baseline, UGI cancer patients had reduced albumin levels compared with controls 
(36.0 (0.5) g/l vs. 42.4 (1.3), p < 0.001) (Table 5.1). At the time of follow-up biopsy, 
albumin had returned to within the reference range (36-44 g/l) (Table 5.1). CRP did 
not differ between baseline and follow-up (9.75 vs. 6.0 mg/l, p = 0.5) and was not 
significantly different compared with controls at either time point (Table 5.1). 
 
Paired muscle biopsy transcriptome 
Using paired samples from the UGI cancer patients (n=12) obtained immediately 
pre-operatively (baseline: cancer present; weight losing) and at a median of 8 months 
post-operatively (follow-up: cancer resected; weight stable in preceding at least two 
months), global gene expression was examined using microarrays. Paired samples 
analysis within the SAM method (Tusher et al., 2001) identified 1868 regulated 
genes with a FDR of 6% and a fold change of at least 30% - 1747 downregulated and 
121 upregulated in baseline samples compared with follow-up samples (Figure 5.3).  
Expression of selected regulated genes by qRT-PCR was validated with good 
agreement between the microarray and qRT-PCR data (Table 5.2). 
 
In order to examine the biological context of the regulated genes the hypergeometric 
t-test was used to identify enriched Gene Ontology biological processes (GOBP) and 
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. Using a background 
list of genes detectably expressed in muscle tissue (Gallagher et al., 2010), cellular 
metabolic process was the most enriched biological process (p < 0.001).  
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FIGURE 5.3: CLUSTER ANALYSIS ILLUSTRATING DIFFERENTIALLY 
EXPRESSED GENES FOR CANCER PATIENTS (BASELINE AND 




Expression data from the differentially expressed genes between the 
baseline and follow-up timepoints were used to drive cluster analysis 
and produce a heatmap. Gene expression is also shown for the healthy 
control group. Each coloured rectangle represents a different gene in an 
individual patient.  Red represents higher expression and blue lower 
expression.  Abbreviations: B, baseline cancer patients; FU, follow-up 
cancer patients; HC, healthy controls. 
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Table  5.2:  qRT-PCR  validation  of  selected  genes  from  the  
array  data 
 
 Baseline  vs.  Follow-up Healthy  vs.  Baseline   
 Array  (FDR) qRT-PCR  (p-value) Array  (FDR) qRT-PCR  (p-value) 
COMP 3.9  (4.1) 4.3  (<0.01) 0.7  (53) 0.4  (0.02) 
ADIPOQ 3.3  (4.1) 3.2  (<0.01) 0.4  (48) 0.5  (0.06) 
MMP3 3.2  (6.1) 2.7  (0.04) 0.7  (53) 0.6  (0.20) 
PCK1 3.0  (6.1) 2.5  (0.01) 0.6  (50) 0.5  (0.14) 
ANGPTL7 2.8  (6.1) 2.5  (<0.01) 0.6  (51) 0.6  (0.46) 
HSP90AB1 0.5  (6.1) 0.5  (0.04) 2.2  (10) 2.3  (0.10) 
SLC25A37 0.5  (6.1) 0.5  (<0.01) 2.6  (5.1) 2.6  (<  0.01) 
PROX1 0.5  (2.1) 0.5  (<0.01) 2.8  (0.0) 2.6  (<  0.01) 
RCAN1 0.4  (0.0) 0.5  (<0.01) 2.0  (5.5) 2.4  (<  0.01) 




Array data are presented as fold change (FDR) and qRT-PCR data as 
fold change (Bonferroni corrected p-value for difference in means). n=12 
paired samples for follow-up vs. baseline analysis; n=5 healthy control 
(for one sample there was insufficient RNA for qRT-PCR) and 12 
baseline samples for healthy vs. baseline analysis. qRT-PCR data were 
analysed by paired t-tests for follow-up vs. baseline analysis and by 
unpaired t-tests for healthy control vs. baseline analysis. Abbreviations: 






The enriched GOBP categories included several broad metabolic processes (e.g. 
metabolic process, primary metabolic process), muscle growth categories (e.g. 
striated muscle hypertrophy, regulation of muscle hypertrophy), catabolism 
categories (e.g. endoplasmic reticulum-associated protein catabolic process, 
ubiquitin-dependent protein catabolic process) and anabolism categories (e.g. 
response to insulin stimulus, response to protein stimulus). In each of these 
categories the genes involved were overwhelmingly downregulated in the baseline 
samples. Selected categories are presented in Table 5.3.  
 
Enriched KEGG pathways included the Calcium signalling pathway, the Peroxisome 
pathway and Epidermal growth factor receptor signalling (ErbB signalling pathway). 
IPA was used to examine a set of 350 robustly regulated genes that did not overlap 
with endurance or resistance training datasets (Melov et al., 2007, Keller et al., 2011). 
Network  analysis,  relying  on  the  IPA  database  revealed  the  proteasome,  NFκB  and  
caspases as potential network hubs connected to many down-regulated transcripts 
(Figure 5.2).  
 
Downregulation of these network genes demonstrated that activation of the hub-
genes was lower pre-operatively supporting the lack of activation of proteolytic 
genes in the differential expression analysis. Using gene set enrichment analysis the 
gene expression data for genes under the control of specific transcription factors was 
examined.  This analysis yielded no significant results suggesting that no single 
canonical signalling pathway is driving the muscle cachexia profile.  Pre-clinical   
 241 
Table  5.3:  GOBP  categories  regulated  between  baseline  and  




p-value Count Annotated 
genes on array 
Term 
Expected Actual 
GO:0044237  0.00 784 859 5042 cellular metabolic 
process  
GO:0006350  0.01 288 320 1854 transcription  
 
GO:0045449  0.00 277 315 1784 regulation of 
transcription  
      
GO:0009056  0.03 133 153 858 catabolic process  
 
GO:0030163  0.01 45 59 288 protein catabolic 
process  
GO:0006511  0.01 34 48 216 ubiquitin-dependent 
protein catabolic 
process  
      
GO:0032868  0.02 15 24 99 response to insulin 
stimulus  
GO:0051789  0.03 13 20 85 response to protein 
stimulus  
      
GO:0061061  0.04 37 47 236 muscle structure 
development  
GO:0007517  0.01 31 43 197 muscle organ 
development  
GO:0060537  0.04 20 28 131 muscle tissue 
development  








FIGURE 5.4: GENE NETWORK FOR REGULATED GENES BETWEEN 




IPA analysis revealed a network involving the  proteasome,  NFκB  and  
caspases as potential network hubs with overwhelming downregulation 
of the network genes. Blue symbols represent downregulated genes.  






models (Bodine et al., 2001a, Gomes et al., 2001, Lecker et al., 2004) have identified 
a set of genes, commonly termed atrogenes, which are involved in cancer driven 
muscle wasting. In particular the levels of the E3 ligases MAFBx/atrogin-1 and 
MuRF1 are elevated in the muscle of cachectic animals. These genes were not 
differentially expressed in the microarray data nor when further examined by qRT-
PCR (MAFBx/atrogin-1 p=1.00; MuRF1 p=0.68, paired t-test) (Table 5.4). 
Examination of the autophagy genes BNIP3 and GABARAPL1 (Mammucari et al., 
2008, Zhao et al., 2008) also revealed no changes in expression of these genes 
between baseline, follow-up or healthy control groups (Table 5.4).  
 
Physical activity 
To control for potential changes in physical activity in the baseline versus follow-up 
periods, the average step count per 24 hours was measured (n=8/12 UGI cancer 
patients). Mean (SEM) step count/24 hours at baseline were 5607 (1210) and 5675 
(917) at follow-up. This difference was not significant (p = 0.90, paired t-test) (Table 
5.1, Figure 5.1).  
 
As a complementary approach to direct measurement of physical activity, a 
comparison of the list of differentially expressed genes in cancer cachexia was 
compared with those identified recently in the response to two types of exercise 
training (Melov et al., 2007, Keller et al., 2011).  Of the 848 endurance training 
responsive genes only 60 overlapped with those regulated between the baseline and 
follow-up time-points and even fewer overlapped with strength training.   
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Table  5.4:  qRT-PCR  data  for  selected  atrophy-associated  
genes 
 
 Baseline  vs  follow-up  
cancer  patients 
Baseline  cancer  
patients  vs  control   
Follow-up  cancer  
patients  vs  control   
MuRF1 0.94  (1.00) 1.22  (0.68) 1.30  (0.22) 
MAFBx/atrogin-1 1.0  (1.00) 0.96  (1.00) 0.96  (1.00) 
BNIP3 0.87  (0.18) 0.72  (0.22) 0.83  (0.50) 
GABARAPL1 0.79  (0.26) 0.66  (0.14) 0.84  (0.70) 
 
 
Data are presented as fold change (Bonferroni corrected p-value for 
difference between means). Baseline versus follow-up data was 
analysed using paired t-tests. Abbreviations: qRT-PCR, quantitative real 




In order to compare the response in cancer cachexia with that seen in dietary 
restriction, the overlap with the 2839 differentially expressed genes identified in 
response to simple dieting (Larrouy et al., 2008) was also examined. Only 12 genes 
overlapped between the current study and those regulated in skeletal muscle in 
response to simple dieting.  
 
Thus multiple array analysis strategies demonstrated that the major phenotype of 
skeletal muscle 'responding' to removal of a tumour does not appear to relate to 
changes in physical activity or nutritional status. 
 
Comparison with healthy control muscle 
Comparison of the muscle from the UGI cancer patients at both the baseline and 
follow-up timepoints with muscle from weight stable healthy control subjects 
revealed 941 genes with lower expression (FDR <10%) in baseline UGI cancer 
muscle compared with healthy control muscle. At baseline no genes were expressed 
at higher levels in UGI cancer patients compared with control muscle with FDR 
<10%. Of the 941 downregulated genes, 558 were also regulated between the 
baseline and follow-up samples and all except one (TFDP2 - transcription factor Dp-
2) were higher at follow-up. Highly enriched GOBP categories included lipid 
oxidation, catabolic process, protein polyubiquitination, muscle structure 
development and striated muscle hypertrophy. Enriched KEGG pathways included 
fatty acid metabolism, metabolic pathways, peroxisome, oxidative phosphorylation, 
ubiquitin mediated proteolysis and regulation of autophagy.  
 
 246 
Comparison of gene expression between control muscle and the follow-up samples 
revealed only two genes differentially expressed within the FDR cut-off (NR1D2 & 
HDAC9). Thus the follow-up samples had a transcriptomic profile indistinguishable 
from healthy muscle albeit that the total sample size was limited for this unpaired 
analysis.  This was also visually represented by cluster analysis (Figure 5.3).  
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5.6 Discussion 
This study examined the transcriptomic response of skeletal muscle before and after 
potentially curative surgery for UGI cancer. Resection of UGI cancer is routinely 
associated with a weight-loss of 7-15% of body weight (Liedman et al., 1997) and 
patients will generally not regain nor return to their pre-operative weight. Weight-
loss during the post-surgical phase is considered to be largely due to loss of fat mass 
with only limited changes in muscle mass (Liedman et al., 1997) suggesting that 
greater emphasis should be placed on the restoration of muscle phenotype and 
function rather than body weight. The present study investigated patients undergoing 
tumour resection with an average weight-loss of 7% body weight (i.e. fulfilling the 
diagnostic criteria for cancer cachexia (Fearon et al., 2011)). Patients underwent a 
pre-operative baseline quadriceps biopsy with a repeat quadriceps biopsy performed 
approximately 8 months later when all patients were clinically disease-free and had 
been weight stable for at least 2 months. It is thus reasonable to consider that the 
patients in the present study had recovered from the net catabolic effects of both their 
cancer cachexia and surgery. Sequential paired biopsies allowed analysis of changes 
in skeletal muscle phenotype during recovery while comparison with a group of 
weight-stable healthy controls allowed determination of the completeness of 
recovery. In the present study, patients with UGI cancer demonstrated normalisation 
of muscle phenotype post-surgery. Strikingly neither the cancer cachexia signature 
nor the recovery of healthy muscle phenotype related to levels of physical activity. 
 
The present study demonstrated that in human skeletal muscle, of the 1868 regulated 
genes associated with cancer and weight-loss, the vast majority (94%) were 
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downregulated. Category Analysis of the differentially expressed genes demonstrated 
that both anabolic (e.g. muscle organ development, response to insulin stimulus) and 
catabolic (e.g. ubiquitin-dependent protein catabolic process, regulation of 
proteasomal protein catabolic process) processes were suppressed.  Furthermore 
there was almost a complete lack of overlap with transcriptomic signatures from 
endurance training, strength training or simple dieting (Melov et al., 2007, Keller et 
al., 2011, Larrouy et al., 2008, Timmons et al., 2005a). This is perhaps not surprising 
as each of these situations may be considered within the range of normal physiology 
rather than pathologic states. The current study identified the inflammatory 
transcription factor NF-κB  as  a  hub  gene  using IPA, however, this gene is linked to 
many aspects of muscle remodeling including responses to endurance training. Other 
approaches to identify transcription factors (a priori gene set enrichment analysis and 
post hoc analysis with the web-based oPOSSUM software) did not yield any 
significant results, suggesting that no single transcription factor network is involved 
in human cancer cachexia. Limited numbers, variable human data, and transcription 
factor redundancy are factors that might constrain the discovery of such underlying 
control genes.   
 
Comparison of the UGI cancer patients with weight stable non-cancer controls 
showed that following removal of cancer and stabilisation of weight-loss, the 
transcriptome essentially returns to normal. Taken together, these observations 
suggest that net muscle turnover is suppressed in the early stages of cancer cachexia, 
but with successful cancer treatment, these changes are reversible. These 
observations may have implications for the timing of interventions such as physical 
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therapy, as it may be more productive to intervene during this stable period when the 
molecular phenotype is apparently healthy. Alternatively, it is possible that the 
recovery of the molecular phenotype could be accelerated with such interventions at 
an earlier stage. Future studies may be able to address this point. 
 
In a recent study on the response of adipose tissue to human cancer cachexia, 364 
genes were downregulated and 61 genes upregulated in abdominal subcutaneous 
white adipose tissue (Dahlman et al., 2010). Similar to the present study pathway 
analysis indicated that downregulated genes were involved in cytoskeleton and 
extracellular matrix processes. Changes in gene expression were reciprocal to those 
observed in obesity suggesting that the effects of reduced food intake may dominate 
regulation of fat mass in cachexia.  In the present study, the gene changes in muscle 
were dissimilar to those seen in simple dieting (Larrouy et al., 2008), thereby 
confirming the essential phenotype of cachexia in that the response of muscle to 
cancer is distinct from simple starvation (Nixon and Lawson, 1983, Fearon et al., 
2011) and cannot be explained by cancer-induced anorexia alone. This observation 
may also explain the sub-optimal skeletal muscle response to nutritional 
supplementation observed in cancer patients. 
 
The transcriptomic signal that was detected at baseline in UGI cancer patients 
suggests depression of muscle turnover in patients with cancer-associated weight-
loss supporting earlier ideas that both global protein synthesis and breakdown were 
suppressed. Whilst muscle turnover could be a function of changes in physical 
activity there did not appear to be any differences in 24-hour step count between 
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baseline and follow-up assessments. Furthermore, the genes differentially expressed 
after removal of the tumour showed little overlap with genes expressed after exercise 
training suggesting that increased turnover was not simply a re-training response. 
The median time interval between operation and follow-up biopsy was 8 months and 
it is generally considered that muscle function would be recovered by this time 
(Mathur et al., 2008).   
 
The loss of skeletal muscle protein in cancer cachexia has been attributed to both 
alterations in the transcription of specific genes leading to changes in muscle 
turnover and/or a global reduction in cellular RNA reducing overall translational 
capacity. A global reduction in RNA abundance might be due to reduced 
transcriptional capacity as a result of loss of myonuclei secondary to enhanced 
apoptosis or reduced satellite cell recruitment. Evidence of apoptosis has been 
reported in cachectic patients with cancer similar to those involved in the present 
study (Busquets et al., 2007). However, Lundholm and colleagues reported that 
human skeletal muscle RNA content is unaffected by the presence of a tumor, 
whereas in animal models, there was a decrease in RNA content (Lundholm et al., 
1978). While animal models carrying a variety of tumors have shown reduced RNA 
content in muscle (Emery et al., 1984b, Baracos et al., 1995, Bhogal et al., 2006) in 
two of these models, there was also evidence for concurrent increases in mRNA 
expression of proteasomal subunits (Khal et al., 2005b, Baracos et al., 1995). 
Notably, this Chapter has demonstrated a reduction in mRNA expression for 
proteasomal pathway components in human UGI cancer and similarly, Chapter 4 did 
not show any evidence for changes in mRNA for these components. 
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Direct evidence for the involvement of specific proteolytic and synthetic pathways in 
human cancer cachexia is limited. However the balance of evidence, based on stable 
isotope and global transcript analysis appears to favour the conclusion that 
suppression of both processes occurs, with the reduction in synthetic pathways 
exceeding suppression of the proteolytic pathways. In line with this, Lundholm and 
co-workers used net release of 3-methylhistidine across the leg to examine protein 
degradation and found rates lower in cancer patients compared with healthy controls 
or acutely ill patients. Reduced protein breakdown was also accompanied by 
anabolic blunting in response to feeding suggesting a net catabolic status rather than 
increased degradation (Lundholm et al., 1982). Dworzak and co-workers 
subsequently reported depressed skeletal muscle protein synthesis in the face of 
maintenance of protein breakdown, again suggesting relative catabolic advantage 
(Dworzak et al., 1998). Emery and co-workers found evidence of reduced protein 
synthesis (protein breakdown was not measured) using labelled leucine in cancer 
patients and suggested that part of this synthetic depression was related to reduced 
translation (Emery et al., 1984a). Mechanistically this may reflect increased levels of 
phosphorylated, inactivated eIF2 in weight losing cancer patients compared with 
healthy controls (Eley et al., 2008). Together these data suggest that whilst protein 
degradation may play a selective role in human cancer-associated muscle wasting 
(where specific proteins are targeted), the overall role of this pathway is much less 
than that seen in pre-clinical model systems, and depressed protein synthesis 
probably contributes more to a net increase in muscle loss. This paradigm is 
consistent with the findings of the present study that suggest an overall decrease in 
muscle turnover in cancer cachexia in humans. 
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What remains to be determined is the precise nature of the cross-talk between the 
tumour and the process of skeletal muscle cancer cachexia. Certain transcript 
changes in the present study might be explored as biomarkers of cancer cachexia and 
provide insight into the nature of the process.  Increased serum cartilage oligomeric 
matrix protein (COMP) gene expression in cachectic muscle was seen in the current 
study and a similar pattern of expression has been seen in muscle damage in 
marathon runners (Kim et al., 2009). Similarly expression of matrix metallopeptidase 
3 (MMP3), also increased in cachectic muscle, is increased in models of muscle 
injury (Goetsch et al., 2003). These findings are consistent with the suggestion that 
removal of cancer allows skeletal muscle to recover from net catabolism.  There is 
also recently published data detailing a role for ADIPOQ, upregulated at baseline, as 
a network hub in cachexia (Tan et al., 2011) suggesting that this might have a role in 
cancer-associated muscle atrophy or be a sensitive integrator of the net underlying 
processes e.g. metabolic status of the muscle. Increased expression of the 
phosphoenolpyruvate carboxykinase 1 (PCK1) gene has been found in lean rodents 
(Novak et al., 2009) where it has been linked to increased endurance capacity. 
However the finding of increased PCK1 expression in cachectic muscle in the 
current study may suggest that this is representative of a possible compensatory 
response in the face of catabolic advantage. 
 
Of the genes downregulated at baseline, regulator of calcineurin 1 (RCAN1) inhibits 
calcineurin signalling and is upregulated in muscle adapting to eccentric exercise 
(Mahoney et al., 2008) and calcineurin activation may be a key feature of muscle 
adaptation to endurance exercise in humans (Keller et al., 2011). Again these 
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changes suggest that the muscle is attempting to compensate for the influence of the 
tumour, supporting the conclusion that muscle remodelling/turnover is specifically 
suppressed by the presence of cancer. In rodents inactivation of the transcription 
factor prospero homeobox 1 (PROX1) leads to disorganisation of cardiac muscle 
(Risebro et al., 2009). If this function were recapitulated in skeletal muscle then 
reduced PROX1 expression would indicate a failure of proper muscle remodelling.  
 
The previous analysis of gene expression in muscle of cancer patients outlined in 
Chapter 4, demonstrated that expression of the exercise-activated  genes  CAMk2β  
and TIE1 was increased in patients with increasing weight-loss. However, although 
at the follow-up timepoint UGI cancer patients were weight stable from the 
perspective of the post-operative period, their overall weight was still lower than at 
the  point  of  diagnosis.  Therefore,  it  is  possible  that  CAMk2β  and  TIE1  upregulation  
are indicators of muscle mass regulation; an idea consistent with the relatively clear 
ability of these genes to identify even modest cancer cachexia muscle changes. The 
association of CAMk2β  and  TIE1  with weight-loss in the longitudinal study suggests 
they are 'longer term' markers of muscle status and thus potential biomarkers for 
weight-loss in cancer cachexia. Nevertheless, the optimal biomarker would predict 
the potential for induction of cancer cachexia in the individual and to establish and 
validate such a biomarker would require much larger studies. 
 
Current therapeutic approaches to the management of muscle wasting in cancer 
cachexia include such general measures as nutritional support and exercise 
interventions (Fearon, 2008). Difficulties with low compliance and negligible benefit 
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have stimulated much interest in measures to overcome hypo-anabolism or reduced 
increased catabolism. The predominance of an activated UPP driving protein 
breakdown in some acute animal models of muscle atrophy has led many to suggest 
the UPP should be targeted in patients with cancer cachexia. Whilst the UPP might 
be relevant at some point during the development of cancer cachexia (e.g. during a 
the acute phase of a period of prolonged bed-rest), the findings of the present Chapter 
suggest that more emphasis should be given to the stimulation of anabolism and in 
particular blocking of the specific effect that tumour burden has on muscle signalling. 
The finding that changes in the transcriptome are reversible with successful removal 
of the cancer suggests that optimal benefit might be observed if such cachexia 
therapy was provided during or immediately after oncological therapy, rather than 
being left to a stage when both the cancer and cachexia are refractory to intervention 





Summary  of  Part  I 
Part I has focused on classification of cancer cachexia by investigating potential 
molecular biomarkers related to early cachexia.  The first study in Chapter 3 aimed to 
assess selected candidate biomarkers known to be relevant in muscle wasting in pre-
clinical models.  Overall, there was an overwhelming lack of parallel between the 
pre-clinical models and human cancer cachexia.  In particular, the ubiquitin E3 
ligases were not related to human cancer cachexia.  However, β-dystroglycan was 
shown to be a potential biomarker relating to weight-loss, GABARAPL1 and Akt as 
biomarkers of cancer/early cachexia and MyHC and dystrophin as biomarkers 
relating to survival. Building on these findings, the next study in Chapter 4 used 
global transcriptomic profiling to search for biomarkers relevant in human cancer 
cachexia.   A novel 82 gene signature was identified which could classify patients as 
cachectic or not cachectic based on a weight-loss of 5%.  This signature did not 
relate to any of the key pathways relevant in animal models.  Selected genes from 
this list were validated in Rectus abdominis, Diaphragma and quadriceps (Vastus 
lateralis) muscle using qRT-PCR.  In particular, CAMk2β and TIE-1 (endurance 
genes) seemed to closely relate to cachexia and CAMk2β protein levels were 
increased.  The final study in Part 1 described in Chapter 5 used a novel longitudinal 
approach to investigate changes in the transcriptomic signature in patients recovering 
from ongoing weight-loss after curative resectional surgery.  This suggested that 
there was relative hypo-anabolism in human cancer cachexia with blunting of both 
anabolic and catabolic pathways.  The atrogenes did not change with time, 
suggesting a limited role in human cancer cachexia.  Furthermore, there was no 
overlap between exercise/starvation signatures and the cachectic signature suggesting 
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that it is a bona fide signature of cachexia.  Thus, rather than confirm the 
conventional view from pre-clinical models that there is strong upregulation of 
protein degradation in early cachexia, Part I of the current thesis suggests a 
depression of synthetic pathways and that changes in structural components of the 
muscle (β-dystroglycan) or in compensatory mechanisms (CAMk2β) may be better 
potential biomarkers of early cachexia in muscle. Clearly these findings need to be 
confirmed in different patient groups before being proposed for validation 
programmes. 
 
Having described both potentially novel intramuscular biomarkers relating to 
cachexia, along with stark contrasts in the molecular events in skeletal muscle in 
humans compared with the pre-clinical literature, Part II of the thesis will focus on a 
series of physiological assessment studies to phenotype muscle mass and function in 
























Part  II:  Cancer  cachexia:  physiological  assessment  of  
skeletal  muscle 
 
“Although  nature  commences  with  reason  and  ends  in  experience it is 
necessary for us to do the opposite, that is to commence with experience 
and  from  this  to  proceed  to  investigate  the  reason.” 
Leonardo da Vinci 
 
“Women  may  fall  when  there’s  no  strength  in  men.” 





Chapter  6:  Investigating  the  potential  of  a  novel  MR  
imaging  analysis  method  to  assess  muscle  and  fat  
content  in  cancer  cachexia  patients. 
6.1 Abstract 
Previous studies have suggested that cachexia and sarcopenia of ageing are 
characterized by infiltration of non-contractile tissue within muscle (which 
influences area and volume measurements). This Chapter assessed whether a MR 
image analysis technique could provide useful insights into skeletal muscle 
composition and wasting in cachectic patients.  A novel statistical clustering (k-
means statistical clustering) technique was applied to MR images of the quadriceps 
of young and older healthy women and women with UGI cancer in order to separate 
the contractile and non-contractile tissue compartments.  MR scans of the thigh were 
obtained for 34 women (n = 16 young, (median) age 26y; n = 9 older, age 80y; 
n = 9 UGI cancer patients, age 65y). Segmented regions of consecutive axial images 
were used to calculate cross-sectional area and (gross) volume. Women with cancer 
and older women had 48% and 37% less quadriceps muscle respectively than young 
women (p < 0.001). Application of k-means statistical clustering subtracted a 
significant 9%, 14% and 20% non-contractile tissue from the quadriceps of young, 
older and cancer patient groups respectively (p < 0.001). There was a significant 
effect of group (i.e., cancer vs. healthy) when controlling for age as a covariate 
(p = 0.003). The results showed that k-means statistical clustering provides an 
objective separation of contractile and non-contractile tissue components and is 
therefore a useful tool in the assessment of muscle composition in patients with 
cancer cachexia. Women with UGI cancer had significant fatty infiltration 




6.2 Introduction  
In Part I different approaches were applied to biomarker discovery in skeletal muscle 
for early cachexia.  The findings ran somewhat contrary to pre-clinical models and 
thus need further careful exploration before being considered in the context of a 
biomarker validation programme.  Such issues emphasise the need for a dual 
approach to the classification of cancer cachexia: if molecular markers prove difficult 
to discover/validate, then more specific and robust physiological indices of skeletal 
muscle mass and function may be the more important route to improve clinical 
intervention trial design/cachexia assessment.   
 
As discussed in the Section 1.2.4.1, the measurement of muscle mass in humans can 
be challenging.  The increasing availability of cross-sectional imaging (MR or CT) 
has provided a gold standard and these techniques are able to distinguish between 
different tissue types, e.g. muscle and subcutaneous fat. However, these imaging 
modalities are not without limitations.  One potential confounding factor in studies 
specifically investigating muscle wasting is the infiltration of muscle by fat (both 
inter- and intra-muscular) and/or non-lean tissue (Frantzell and Ingelmark, 1951, 
Forsberg et al., 1991, Overend et al., 1992, Tsubahara et al., 1995, Jubrias et al., 
1997, Kent-Braun et al., 2000, Macaluso et al., 2002, Song et al., 2004) (Figure 6.1).  
Attempts to address this problem have been made with varying success by utilisation 
of post-hoc techniques such as manual design based stereology (Jubrias et al., 1997) 
or image analysis (Frantzell and Ingelmark, 1951, Overend et al., 1992, Tsubahara et 
al., 1995, Kent-Braun et al., 2000, Macaluso et al., 2002, Song et al., 2004) to   
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FIGURE 6.1: MR IMAGES ILLUSTRATING FATTY INFILTRATION WITHIN 
THE QUADRICEPS MUSCLE GROUP. 
   
 
 
MR cross-sectional images at mid-thigh level in healthy women aged 
23 years (a) and 80 years (b) and a woman with UGI cancer aged 
75 years (c).  Fat/non-contractile tissue can be visualised as white 
whereas muscle is darker grey.  Abbreviations: MR, magnetic resonance; 




separately quantify the contractile/non-contractile compartments within the  ‘muscle’  
region of interest.  Ageing is associated with loss of muscle mass (sarcopenia) and 
MR image-derived measurements have shown that older healthy human skeletal 
muscle contains a two- to three-fold greater non-contractile tissue area/volume 
compared with younger muscle (15% vs. 6%) (Kent-Braun et al., 2000, Macaluso et 
al., 2002). Loss of muscle may result in poorer function with subsequent decline in 
physical independence and QoL (Young, 1997) and decreased survival rate following 
critical illness (Lee et al., 2007). In cancer cachexia, as previously discussed, skeletal 
muscle is a primary target. Muscle size is an important determinant of functional 
status and as such, accurate quantification is necessary. 
However, there are few reports of the measurement of muscle size in human cancer 
cachexia and no focus on attempting to differentiate lean from fatty tissue. The use of 
CT and image analysis (a modification of a technique first reported in healthy adults) 
(Shen et al., 2004) to estimate whole body skeletal muscle mass and/or adiposity 
from CSA measurements at the level of L3 has been discussed earlier in Section 
1.2.4.1. This technique has been used to identify the prevalence of the sarcopenic 
obesity phenotype in cancer outpatients (Prado et al., 2008, Tan et al., 2009) and 
abnormal body composition was shown to be related to increased toxicity for 
chemotherapy (Prado et al., 2007).  However, cross-sectional CT at L3 level does not 
inform on limb muscle groups which could be used to correlate with measures of 
function of that particular muscle group and thus give a measure of muscle quality.  
In another study quadriceps muscle CSA was measured using MR imaging and 
muscle strength was measured using dynamometry in weight losing gastrointestinal 
cancer patients to infer change in mechanical muscle quality, but no attempt was 
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made to take account of fatty infiltration (Weber et al., 2009). 
 
The aim of the study in this Chapter is to quantify contractile and non-contractile 
compartments within the knee extensor muscle group on MR images obtained from a 
small group of patients with cancer cachexia.  While fatty infiltration may be readily 
visualized on MR images (Figure 6.1), quantification of its extent is challenging. In 
this preliminary study the application of a statistical technique, known as k-means 
clustering (JB, 1967), was used to quantify contractile (skeletal muscle) and non-
contractile (including fat) components of the total quadriceps muscle mass.  
 
The methodology for image analysis was developed by Dr Calum Gray, Dr Carolyn 
Greig and Dr Tom MacGillivray (University of Edinburgh) primarily to investigate 
its use in healthy older adults.  Although it is the investigation of patients with cancer 
cachexia that form part of this thesis, the results from the healthy young and very 
elderly women will also be included in order to give broader context. In order to 









- Application of k-means statistical clustering would result in significant 
differences between MR imaging derived total quadriceps volume and 
quadriceps muscle (i.e. total volume minus non-contractile tissue),  
- Cachectic muscle would contain a greater amount of fat compared with 
healthy young and elderly muscle 
- The impact of k-means statistical clustering on muscle optimisation (i.e. 
separating the contractile from the non-contractile tissue component) would 






Participants: see Section 2.1 
Anthropometric assessments: see Section 2.2 
MR imaging and analysis (scan protocol, image optimisation, k-means statistical 
clustering analysis): see Section 2.6.1 




6.5 Results  
Three groups of women participated in this study: young healthy, elderly healthy and 
newly diagnosed weight-losing UGI (pancreatic, oesophageal, gastric) cancer (Table 
6.1).  
The older healthy group were significantly older than either the cancer patients or the 
young healthy group (p < 0.001). There were no significant differences in body 
weight between the groups (p = 0.086). There was a trend towards a higher BMI in 
the cancer patients despite the patients having already lost an average of 8% of their 
pre-illness stable weight. The MR imaging procedure was well tolerated by all the 
participants. 
 
Muscle volume  
Figure 6.2 shows the data obtained for quadriceps volume both pre- and post- k-
means clustering analysis (one leg). Pre- k-means analysis of a dataset comprising 
predominantly left leg data n = 29/34 and n = 5/34 right leg data gave mean values of 
quadriceps muscle volume for young women of 1.70 (0.27) l (range 1.12–2.11 l) and 
old women 1.12 (0.26) l (range 0.85–1.76 l). The patients with UGI cancer had a 
mean volume of 1.09 (0.18) l (range 0.80–1.30 l). The differences between groups 
were significant (ANOVA f = 28.24; df (2, 31); p < 0.001). Analysis of the right leg 
gave similar results (ANOVA f = 31.26; df (2,31); p < 0.001).   
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Table  6.1:  Patient  demographics   
 
 Young healthy Old healthy UGI cancer 
 (n=16) (n=9) (n=9) 
Age (years) 26 (19–30) 80 (76–82) 62 (44–78) 
Weight (kg) 64.3 (8.7) 55.6 (8.0) 61.1 (10.7) 
BMI (kg/m2) 22.9 (2.5) 23.2 (3.2) 24.4 (4.7) 
Weight-loss (%) N/A N/A 8.3 (15.2) 
 
 
Results are reported as mean (SD) except for age, which is given as 
median (range).  Abbreviations: UGI, upper gastrointestinal; BMI, body 










Quadriceps volume of the left leg was measured in n=29/34 participants.  
Pre-k-means values (i.e. including non-contractile tissue) are 
represented in black, and post-k-means (i.e. only contractile tissue) in 
white. ANOVA showed a significant group effect, (f = 31.69; df (2,31); 
p < 0.001) and a significant effect of k-means analysis (ϑ = p<0.001 vs. 
pre-k-means of corresponding group). Post-hoc tests with Bonferroni 
correction showed significant differences between young/old and 
young/patients (but not old/patients) both pre- (ϕ = p<0.001 vs. young 
pre-k-means) and post- (Ψ = p<0.001 vs young post-k-means) analysis.  




Effect of k-means analysis  
The effect of k-means analysis (Figure 6.2) was to significantly reduce the mean 
muscle volume by 9% (from 1.70 to 1.54 l) in the young women, by 14% (from 1.12 
to 0.97 l) in older women and by 20% in the patient group (from 1.09 to 0.81 l) 
(ANOVA f = 477.67; df (1, 31); p < 0.001). ANOVA also showed a significant 
interaction (f = 3.87; df (2, 31); p = 0.032), which was due to the greater difference 
between pre- and post-optimized volumes in the cancer patient group (ANOVA 
f = 3.88; df (2,31); p = 0.031). (Analysis of the right leg data gave similar results 
ANOVA f = 4.01; df (2,31); p = 0.028). A comparison of optimized volumes showed 
that healthy old women had 37% and women with cancer 48% less muscle than 
healthy young women. Furthermore, there was a significant effect of the k-means 
optimization with respect to group (i.e., cancer vs. healthy) when controlling for age 
as a covariate (p = 0.003). 
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6.6 Discussion  
After initial segmentation and volume measurement, application of the k-means 
technique  resulted  in  a  significant  reduction  in  ‘muscle’  volume  in  each  group,  
showing that even in healthy participants the quadriceps contains a significant 
amount of non-lean tissue. The percentage of non-contractile tissue in young (9%) 
and older (14%) healthy women respectively is similar to results from previous 
studies using the pixel histogram technique (Kent-Braun et al., 2000, Macaluso et al., 
2002).  However fatty infiltration was significantly greater in the women with cancer 
(20%). Furthermore the influence of cancer on fatty infiltration was still significant 
when age is taken into account. This finding suggests that even at this relatively early 
stage of the disease the muscles of patients with UGI cancer are not only smaller 
(due to disuse as well as age and disease) but also less homogeneous. 
 
The k-means clustering technique used in this study allows a non-invasive estimate 
of non-contractile tissue (i.e. fatty infiltration) from the MR images obtained, but it is 
unable to differentiate the relative proportions of intermuscular to intramuscular 
(including intramyocellular and extramyocellular) fatty tissue.  Such an approach 
would require the use of MR Spectroscopy or histological/ultrastructural analysis of 
tissue biopsies, but there are few studies to date reporting the influence of cancer 
(Weber et al., 2009) or even ageing (Schick et al., 2002, Cree et al., 2004, Machann 




Advances in body composition analysis techniques have enabled the identification 
and characterization of clinically important phenotypes. This is essential because it 
allows more efficient stratification of patients within the cachexia spectrum. For 
example, using estimates of whole body muscle mass derived from muscle CSA 
measurements at L3 level it has been possible to assess the prevalence of sarcopenic 
obesity in cancer outpatients (Prado et al., 2008, Tan et al., 2009). This phenotype is 
a predictor of poor prognosis in both malignant and non-malignant disease (Tan et al., 
2009, Prado et al., 2008, Honda et al., 2007).  Measuring the proportion of contractile 
tissue in a muscle group also potentially enables characterization of different 
phenotypes, as well as conferring the ability to measure small but functionally 
important changes in muscle mass consequent to interventions to improve muscle 
mass. An additional advantage is  that  an  accurate  measure  of  ‘true’  muscle  could  be  
combined with measures of strength and power of the same muscle group, thus 
providing insight into not only the metabolic but also the mechanical consequences 
of cachexia. Measurements of strength or power per unit CSA or volume of the same 
muscle or muscle group could thus not only serve as an additional functional marker 
of frailty but also inform current debate on the influence of cachexia on muscle 
mechanical quality.  Subsequent chapters will explore muscle quality in cancer 
patients. 
 
This chapter has presented a small exploratory study in which a non-invasive 
optimization technique to objectively separate the contractile and non-contractile 
volume components from MR images has been shown to be useful in the assessment 
and phenotyping of cancer cachexia patients and very elderly people. When 
 271 
controlling for age, fatty infiltration appears to be greater in the muscles of weight-
losing patients with UGI cancer. The potential mechanisms underlying the 
differences in muscle composition and the functional consequences require further 
investigation and will be addressed in subsequent chapters.  
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Chapter  7:  Muscle  mass,  function  and  mechanical  
quality  phenotype  in  human  cancer  cachexia 
 
7.1 Abstract 
Using MR scans in combination with direct measures of muscle function, this 
Chapter examines the relationship between cachexia, QoL and the 
mass/function/mechanical quality of lower limb skeletal muscle in gastrointestinal 
cancer patients.  Patients with weight-loss  ≥10%  were  classified  as  cachectic.    
Quadriceps strength and lower limb power were measured in 54 patients with 
gastrointestinal cancer (n=24 cachectic) and 18 controls. Quadriceps CSA was 
measured in 33/54 patients and in all controls using MR imaging.  Muscle 
mechanical quality was defined as quadriceps strength/unit quadriceps CSA.  QoL 
was assessed using the EORTC QLQ-C30. In male cachectic patients, quadriceps 
strength (p=0.003), lower limb power (p=0.026), quadriceps CSA (p=0.019), and 
muscle quality (p=0.008) were reduced compared with controls.  In female cachectic 
patients, quadriceps strength (p=0.001) and muscle quality (p=0.001) were reduced 
compared with controls. Hand grip dynamometry (HGD) did not differ significantly 
across the groups in either males or females.  Physical function (p=0.013) and 
fatigue (p=0.004) as reported from QoL scores were reduced in male cachectic 
compared with non-cachectic patients, but not in females. The results of this Chapter 
showed that muscle quality is reduced in both male and female cancer patients. The 
degree of impairment of lower limb muscle mass, quality and function and the impact 





Chapter 6 described the application of a novel assessment technique in the analysis 
of MR images.  This chapter describes utilisation of this technique to investigate 
muscle mass phenotype along with an assessment of muscle function, mechanical 
quality and QoL in a larger cohort of patients (men and women) with gastrointestinal 
cancer and weight-loss.   
 
Although muscle wasting is a hallmark of cancer cachexia, there are relatively few 
data describing regional loss of muscle mass or function in either male or female 
patients. Muscle loss  may  have  a  direct  influence  on  patients’  QoL as well as a 
significant impact on treatment tolerance (Prado et al., 2007) and is therefore an 
important potential therapeutic target. 
 
Lower limb musculature (e.g. the quadriceps) is prone to wasting in patients 
undergoing prolonged bed rest (Pisot et al., 2008) and muscle mass correlates with 
strength in healthy adults (Maughan et al., 1983). Therefore, it might be anticipated 
that cancer patients with loss of muscle mass would have at least a proportionate loss 
of muscle strength/power.  Moreover, if the mechanical quality, defined as 
quadriceps strength/unit quadriceps CSA, also known as relative strength of muscle 
were reduced, the reduction in function would be proportionately greater.  
Quadriceps strength was shown to be reduced in cachectic pancreatic cancer patients 
(Weber et al., 2009). However, when lower limb extensor strength was normalised to 
quadriceps CSA, there was no apparent reduction in muscle mechanical quality 
(Weber et al., 2009). In contrast, animal models have suggested that the process of 
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cachexia involves selective and early loss of key elements of the contractile 
structures within skeletal muscle which would likely impact on muscle mechanical 
quality (Acharyya et al., 2005). Moreover, ultrastructural analysis has demonstrated 
myofibrillar disarray, irregular muscle membranes and dystrophic muscle 
morphology in the muscles of tumour-bearing cachectic animals (Acharyya et al., 
2005).  
 
Knowledge of the relationship between muscle mass and function and their potential 
influence on QoL in cancer cachexia is limited.  The aim of the present study was to 
characterise regional changes in muscle function in gastrointestinal cancer patients 






- Cancer patients (male and female) with cachexia would have poorer muscle 
strength/function than non-cachectic/low weight-loss cancer patients or 
healthy controls 
- Poorer muscle function would impact on QoL in cancer patients with 
cachexia 
- The response of upper and lower limb muscle compartments would differ to 






Participants: see Section 2.1 
Anthropometric assessments: see Section 2.2 
Blood collection: see Section 2.8.1 
Blood measures (CRP, albumin, haemoglobin, TT, cFT, oestradiol, LH, FSH, 
SHBG): see Section 2.9 
Muscle function (IKES, LLEP, HGD): see Section 2.3 
MR imaging and analysis: see Section 2.6.1 
Muscle mechanical quality: see Section 2.7 
QoL (EORTC QLQ-C30, KPS): see Section 2.4 




Demographics: The healthy controls were older than the cancer patients (78 vs. 65 
years, p<0.001), although the average age of non-cachectic and cachectic patients 
was similar in both males (mean (range): 68(43-88) years vs. 63(39-76) years, 
respectively, p=0.130) and females (65(44-76) years vs. 63(44-83) years, 
respectively, p=0.791). The average weight-loss of cancer patients was 8.4% and all 
healthy controls were weight stable.  The distribution in site of primary tumour was 
similar between non-cachectic and cachectic patients (Chi-squared p=0.438), and in 
males and females (Chi-squared p=0.195) (Table 7.1).  Likewise, there were no 
significant differences in distribution of tumour stage between groups (Table 7.2). 
 
Blood measures/gonadal status: In males, albumin (p<0.001) and haemoglobin 
(p=0.001) differed significantly across the three groups (Table 7.2A).  Post-hoc 
comparisons indicated that controls had significantly higher albumin levels than both 
the non-cachectic (p<0.001) and the cachectic patients (p<0.001). However, there 
was no significant difference in albumin levels between cancer patient groups 
(p=0.519).  Control haemoglobin levels were significantly higher than those of both 
the non-cachectic (p=0.002) and the cachectic patients (p=0.001), but again there was 
no significant difference between cancer patient groups (p=0.904).  While total 
testosterone levels (Table 7.3A) did not differ significantly in males (p=0.801), cFT 
levels were significantly different (p=0.030).  Post-hoc comparisons showed a 
significantly higher cFT in controls compared with both the non-cachectic (p=0.048) 
and cachectic patients (p=0.040), but there was no significant difference in cFT level 
between male non-cachectic and cachectic patients (p=0.931).     
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Table  7.1:  Distribution  of  patient  numbers  according  to  
tumour  site.   
 
 Male cancer patients Female cancer patients 
Site Non-cachectic Cachectic Non-cachectic Cachectic 
Oesophageal 9 5 2 1 
OGJ 3 1 1 0 
Gastric 2 2 2 3 
Pancreatic 6 6 5 4 
Bile duct 0 1 0 0 
Rectal 0 0 0 1 
 
 
Values refer to number of patients in each group.  Chi-squared: male vs. 
female, p=0.195; non-cachectic vs. cachectic cancer patients, p=0.438.  





Table  7.2:  Demographics,  blood  profile,  QoL  scores  and  
quadriceps  strength,  lower  limb  power  and  upper  limb  




 Control Cancer patients p value (dof) F  
 Non-cachectic Cachectic     
(n=9) (n=20) (n=15)   
Age (years) 78 (3) 68(11)A 63(10)A 0.002 (2,41) 7.5 
Height (cm) 171(4) 173(6) 175(7) 0.313 (2,41) 1.2 
Weight (kg) 79.6 (9.9) 80.2(16.3) 73.8(11.3) 0.363 (2,41) 1.0 
BMI (kg/m2) 27.1(3.9) 26.8(5.1) 24.2(3.6) 0.158 (2,41) 1.9 
Weight-loss (%) 0 (0) 1.5(3.0) 14.2(4.2)A, B <0.001 (2,41) 83.7 
MAMC (cm) 26.7(2.3) 25.7(2.7) 25.3(1.8) 0.397 (2,38) 0.9 
Tumour Stage 1 - 1 0 0.846 - 
2 - 3 2   
3 - 11 9   
4 - 5 4   
Albumin (g/l) 43.6(2.7) 36.4(4.0)A 34.9(4.3)A <0.001 (2,41) 14.9 
CRP (mg/l) 4.3(2.8) 19.2(42.2) 19.6(28.8)A 0.723 (2,41) 0.3 
Haemoglobin (g/l) 147.9(11.5) 125.2(17.4)A 122.9(13.7)A 0.001 (2,41) 8.8 
KPS 100(0) 84(11)A 79(14)A <0.001 (2,41) 10.3 
QoL (global) - 138(40) 86(58)  0.006 - 
PF score - 83(21) 60(29)  0.013 - 
FA score - 27(23) 56(32)  0.004 - 
IKES (N) 391(61) 288(90)A 243(90)A 0.001 (2,38) 8.2 
IKES (N/kg) 5.0(0.9) 3.7(1.3)A 3.2(1.0)A 0.003 (2,38) 6.6 
LLEP (W) 157(30) 123(58) 98(45)A 0.027 (2,40) 3.9 
LLEP (W/kg) 2.0(0.5) 1.5(0.5) 1.3(0.7)A 0.033 (2,40) 3.7 




B. FEMALES  
 Control Cancer patients p value (dof) F  
 Non-cachectic Cachectic     
(n=9) (n=10) (n=9)   
Age (years) 79(3) 65(10)A 63(11)A 0.001 (2,25) 9.6 
Height (cm) 159(6) 161(6) 160(8) 0.838 (2,25) 0.2 
Weight (kg) 61.5(8.2) 66.4(11.8) 58.9(9.6) 0.276 (2,25) 1.4 
BMI (kg/m2) 24.4(3.8) 25.7(4.1) 22.9(2.4) 0.237 (2,25) 1.5 
Weight-loss (%) 0 (0) 2.8(5.8) 20.5(10.4)A, B <0.001 (2,25) 24.3 
MAMC (cm) 21.1(2.1) 22.1(1.6) 21.9(1.4) 0.457 (2,22) 0.8 
Tumour Stage 1 - 2 2 0.541 - 
2 - 2 0   
3 - 4 4   
4 - 2 3   
Albumin (g/l) 43.4(2.5) 35.4(5.3)A 31.2(4.6)A <0.001 (2,25) 18.4 
CRP (mg/l) 2.9(3.1) 9.7(24.4) 40.4(49.8)A, B 0.008 (2,25) 5.9 
Haemoglobin (g/l) 132.0(7.8) 121.2(13.7) 109.6(19.5)A 0.011 (2,25) 5.4 
KPS 100(0) 90(12) 77(16)A, B 0.001 (2,25) 9.1 
QoL (global) - 152(41) 100(55) 0.057 - 
PF score - 86(24) 73(24) 0.314 - 
FA score - 26(34) 44(39) 0.356 - 
IKES (N) 296(75) 252(70) 159(68)A, B 0.002 (2,24) 8.6 
IKES (N/kg) 4.8(1.1) 3.9(0.9) 2.7(1.1)A 0.001 (2,24) 9.2 
LLEP (W) 67(28) 63(14) 59(20) 0.718 (2,24) 0.3 
LLEP (W/kg) 1.1(0.4) 1.0(0.2) 1.0(0.3) 0.795 (2,24) 0.2 
HGD (kg) 23(6) 27(10) 22(5) 0.314 (2,23) 1.2 
 
 
Values are presented as mean (SD). F statistic is presented for one-way 
ANOVA comparisons.  A p≤0.05  (Tukey’s  post-hoc) vs. control, B p≤0.05  
(Tukey’s  post-hoc) non-cachectic vs. cachectic cancer patients. 
Abbreviations: dof, degrees of freedom; BMI, body mass index; MAMC, 
mid arm muscle circumference; CRP, C reactive protein; KPS, 
Karnofsky performance score; QoL, quality of life; PF, physical function; 
FA, fatigue; HGD, Hand grip dynamometry; IKES, Isometric knee 
extensor strength; LLEP, Lower limb explosive power; cm, centimetres; 
kg, kilograms; m, metres; g, grams; l, litres; mg, milligrams; N, newtons; 





Table  7.3:  Gonadal  status  of  controls  and  cancer  patients  
(with  and  without  cachexia).   
 
A. MALES 
 Control Cancer patients p value (dof) F 
  Non-cachectic Cachectic     
 (n=9) (n=20) (n=12)   
TT(nmol/l) 15.2(4.3) 13.4(7.6) 13.9(5.5) 0.801 (2,38) 0.2 
cFT(nmol/l) 0.262(0.063) 0.193(0.073)A 0.184(0.067)A 0.030 (2,34) 3.8 
Oestradiol(pmol/l) 113.4(17.8) 85.0(35.6) 87.9(23.2) 0.074 (2,35) 2.8 
LH(U/l) 4.2(2.2) 10.7(8.3) 10.4(5.9) 0.073 (2,37) 2.8 
FSH(U/l) 5.8(3.3) 11.8(9.6) 13.3(10.8) 0.166 (2,38) 1.9 




 Control Cancer patients p value (dof) F 
  Non-cachectic Cachectic     
 (n=8) (n=8) (n=7)   
TT(nmol/l) 1.4(0.5) 1.4(0.6) 0.9(0.3) 0.084 (2,20) 2.8 
Oestradiol(pmol/l) 61.0(21.4) 50.6(25.2) 51.6(28.2) 0.692 (2,19) 0.4 
LH(U/l) 25.1(8.3) 31.5(18.2) 20.4(12.5) 0.304 (2,20) 1.3 
FSH(U/l) 66.3(23.3) 68.8(40.4) 32.4(20.9) 0.054 (2,20) 3.4 
SHBG(nmol/l) 63.7(25.6) 64.8(18.4) 60.2(33.3) 0.949 (2,17) 0.1 
 
 
Values are presented as mean (SD). F statistic is presented for one-way 
ANOVA comparisons.  Ap≤0.05  (Tukey’s  post  hoc)  vs. control.  
Abbreviations: dof, degrees of freedom; cFT, calculated free 
testosterone; TT, total testosterone; LH, luteinising hormone; FSH, 
follicle stimulating hormone; SHBG, sex hormone binding globulin; nmol, 





In females, albumin (p<0.001), haemoglobin (p=0.011) and CRP (p=0.008) differed 
significantly across the three groups (Table 7.2B).  Post-hoc comparisons indicated 
that controls had significantly higher albumin levels than both the non-cachectic 
(p=0.001) and the cachectic patients (p<0.001), but that there was no significant 
difference between cancer patient groups (p=0.112).  The haemoglobin levels of the 
control group were significantly higher than the cachectic patients (p=0.008), but not 
the non-cachectic patients (p=0.253). There was no significant difference in 
haemoglobin levels between female cancer patient groups (p=0.205).  CRP levels in 
cachectic patients were significantly higher than in the controls (p=0.018) and non-
cachectic patient groups (p=0.018).  CRP was similar in controls and non-cachectic 
patients (p=0.987).  Measures of hormonal status in females did not differ 
significantly across the groups (Table 7.3B), although female cachectic patients did 
show a trend towards lower FSH levels (p=0.054).  
 
Upper and lower limb muscle strength/power: Table 7.2 shows the HGD, IKES and 
LLEP data.  HGD did not differ significantly across the groups for either males 
(p=0.593) or females (p=0.314).  However, in males, there were significant 
differences across the groups for IKES (p=0.003) and LLEP (p=0.033).  Post-hoc 
comparisons showed control males to have higher IKES than both non-cachectic 
(p=0.022) and cachectic patients (p=0.003).  Comparison of IKES between non-
cachectic and cachectic patients was not significant (p=0.480).  Cachectic patients 
had significantly lower LLEP than controls (p=0.026).  There were no significant 
differences in LLEP between control and non-cachectic patients (p=0.123), nor 
between non-cachectic and cachectic patients (p=0.576).   
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There was a significant difference across the female groups for IKES (p=0.001), but 
not for LLEP (p=0.795).  Post-hoc comparisons showed IKES to be significantly 
lower in cachectic patients compared with controls (p=0.001), and a trend towards 
being reduced compared with non-cachectic patients (p=0.069).  IKES in controls 
was not significantly different from non-cachectic patients (p=0.151). 
 
Quadriceps muscle CSA and degree of fat infiltration: Quadriceps CSA was 
measured in a subgroup of cancer patients (33/54; 61%).  The remaining 21 patients 
were not assessed due either to patient preference or for logistical reasons.  The 
demographics of the sub-group did not differ from the overall cancer patient cohort 
(Table 7.4).   
 
In males, there was a significant difference in quadriceps CSA across the groups 
(p=0.012) (Table 7.5).  Post-hoc comparisons showed cachectic patients to have 
significantly smaller quadriceps CSA than both control (p=0.049) and non-cachectic 
patients (p=0.019).  Controls and non-cachectic patients had similar quadriceps CSA 
(p=0.996).  In females, there was no significant difference in quadriceps CSA across 
the groups (p=0.159) (Table 7.5).  Although mean percentage fatty infiltration was 
higher in the cancer patients (particularly the non-cachectic patients) than controls, 
the results did not differ significantly across the groups for either sex (p=0.412 males 




Table  7.4:  Demographics  of  cancer  patient  MR  imaging  
subgroup  versus  all  cancer  patients. 
 
 Male cancer patients Female cancer patients 
All MR cohort All MR cohort  
(n=35) (n=17) (n=19) (n=16) 
Age (years) 66 (11) 64 (12) 64 (10) 65 (10) 
Height (cm) 174 (7) 175 (7) 160 (7) 159 (7) 
Weight (kg) 77.5 (14.6) 77.5 (16.6) 62.9 (11.2) 60.4 (9.2) 
BMI (kg/m2) 25.7 (4.6) 25.6 (5.5) 24.4 (3.6) 23.9 (3.4) 
Weight-loss (%) 7.0 (7.3) 10.7 (7.6) 11.2 (12.1) 11.6 (13.0) 
MAMC (cm) 25.5 (2.4) 25.8 (2.4) 22.0 (1.5) 21.8 (1.4) 
Tumour Stage 1 1 0 4 4 
2 5 1 2 2 
3 20 10 8 5 




Values are presented as mean (SD). Comparison of means between all 
cancer patients and the MR imaging cohort for both males and females 
(Student’s  t-test) revealed no statistically significant differences.  MR, 
magnetic resonance; BMI, body mass index; MAMC, mid arm muscle 
circumference; cm, centimetres; kg, kilograms; m, metres. 
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Table  7.5:  Quadriceps  muscle  mass,  mechanical  quality  and  
fatty  infiltration  status  of  controls  and  cancer  patients  (with  
and  without  cachexia).   
 
A. MALES 
 Control Cancer patients p value (dof) F 
Non-cachectic Cachectic   
(n=9) (n=6) (n=11) 
Q. CSA (mm2) 6553(663) 6617(1652) 5666(805) 0.098 (2,23) 2.6 
Q. CSA/height2(mm2/m2) 2236(263) 2222(466) 1823(247)A, B 0.012 (2,23) 5.4 
Fat free Q. CSA (mm2) 5665(644) 5246(1983) 4842(1080) 0.339 (2,21) 1.1 
Fat infiltration (%) 13.4(6.6) 20.3(12.2) 15.1(9.6) 0.412 (2,21) 0.9 




 Control Cancer patients p value (dof) F 
Non-cachectic Cachectic   
(n=9) (n=8) (n=8) 
Q. CSA (mm2) 4613(680) 4152(471) 4152(725) 0.244 (2,22) 1.5 
Q. CSA/height2(mm2/m2) 1831(252) 1660(226) 1622(208) 0.159 (2,22) 2.0 
Fat free Q. CSA (mm2) 4105(655) 3491(542) 3560(790) 0.137 (2,22) 2.2 
Fat infiltration (%) 11.1(3.1) 16.1(7.2) 14.9(5.1) 0.149 (2,22) 2.1 
Muscle Quality (N/mm2) 6.4(1.0) 5.7(1.7) 3.6(1.4)A, B 0.002 (2,21) 9.0 
 
 
Values are presented as mean (SD). F statistic is presented for one-way 
ANOVA comparisons.  A p≤0.05  (Tukey’s  post-hoc) vs. control, B p≤0.05  
(Tukey’s  post-hoc) non-cachectic vs. cachectic cancer patients.  
Abbreviations: dof, degrees of freedom; Q. CSA, Mid-femur quadriceps 





Quadriceps muscle mechanical quality: Quadriceps muscle mechanical quality 
(N/mm2) correlated negatively with % weight-loss in both males (R= -0.48, p=0.018) 
and females (R= -0.63, p=0.001).  There was a significant difference in muscle 
mechanical quality across the three groups in both males (p=0.008) and females 
(p=0.002) (Table 7.5).  Post-hoc comparisons demonstrated that male cachectic 
patients had lower muscle quality than controls (p=0.008).  There was also a trend 
towards muscle quality being lower in male non-cachectic patients compared with 
controls (p=0.079).  There were no significant differences in muscle mechanical 
quality between male cancer patient groups (p=0.870).   
 
In females, muscle mechanical quality was significantly lower in cachectic patients 
compared with both controls (p=0.023) and non-cachectic patients (p=0.001), but no 
significant difference was detected between control and non-cachectic patients 
(p=0.578) (Table 7.5). 
 
Influence of systemic inflammation on muscle strength/power and mechanical 
quality: In males, CRP correlated negatively with IKES (R= -0.42, p=0.006) and 
LLEP (R= -0.38, p=0.012), but not with muscle quality (R= -0.33, p=0.120).  A 
univariate ANOVA model of IKES was constructed incorporating age, tumour stage 
and CRP (R squared, 0.25).  Only CRP was a significant determinant (p=0.019, 
effect size 18.2%).   
 
In females, CRP correlated negatively with IKES (R= -0.60, p=0.001) but not with 
LLEP (R= -0.19, p=0.341).  However, there was a significant negative correlation 
with muscle quality (R= -0.59, p=0.003).  Again, univariate ANOVA modelling (R 
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squared, 0.41) demonstrated CRP as the only significant determinant of IKES 
(p=0.010, effect size 38.8%). 
 
QoL and performance scores: KPS scores were significantly different across the 
groups for both males (p<0.001) and females (p=0.001) (Table 7.1).  Post-hoc 
comparisons revealed that, in males, controls had higher KPS than both non-
cachectic (p=0.003) and cachectic patients (p<0.001).  There were no significant 
differences in KPS between cancer patient groups (p=0.361).  In females, cachectic 
patients had lower KPS than controls (p=0.001) and non-cachectic patients (p=0.050).  
No significant difference in KPS was shown between control and non-cachectic 
patients (p=0.169).   
 
Global QoL scores (EORTC QLQ C-30) correlated negatively with % weight-loss in 
male cancer patients (R= -0.52, p=0.003), but this association was absent in female 
cancer patients (R= -0.29, p=0.292).  In males, physical function score (PF2 
component) was significantly lowered in cachectic compared with non-cachectic 
patients (p=0.013).  The fatigue score (FA component) was significantly higher in 
cachectic compared with non-cachectic male patients (p=0.004).  Conversely, in 
cachectic female patients, neither the physical function score (p=0.314) nor the 
fatigue score (p=0.356) were significantly different compared with non-cachectic 
patients.  In male cancer patients, IKES and mechanical quality correlated 
significantly with global QoL (R= 0.38, p=0.043 and R= 0.58, p=0.031 respectively) 
and physical function score (R= 0.41, p=0.028 and R= 0.64, p=0.014 respectively).  
Quadriceps CSA did not correlate significantly with any subjective QoL variables.  
 288 
In females, there were no significant correlations between subjective QoL variables 
and IKES, CSA and mechanical quality.  There was a trend towards a positive 
correlation between global QoL and mechanical quality (R= 0.52, p=0.068) and 
between physical function score and quadriceps CSA (R= 0.52, p=0.066). 
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7.6 Discussion  
 
This study demonstrates that in gastrointestinal cancer patients there is variability in 
lower limb muscle function, mechanical quality and mass according to the degree of 
weight-loss and sex.  While lower limb muscle mass, strength and power declined in 
male cancer patients, females appeared to experience attenuated loss of muscle mass 
and power. Mechanical quality was reduced in both male and female cancer patients, 
but only in females did it decline progressively with cachexia.  Such sexual 
dimorphism extended to the impact of cachexia on QoL:  a significant association 
was shown between decreased quadriceps mechanical quality and a decline in 
subjective QoL measures in males, but not in females. These findings are consistent 
with recent literature suggesting sexual dimorphism may impact on the effects of 
systemic disease such as cirrhosis (Peng et al., 2007) and cancer (Palomares et al., 
1996, Baracos et al., 2010).  In a recent analysis of body composition based on CT, 
61% of males presenting with non-small cell lung cancer were classified as 
sarcopenic compared with only 31% of females (Baracos et al., 2010).  Another 
study of lung cancer patients demonstrated an eightfold faster rate of weight-loss in 
males and a reduced survival compared with females matched for disease stage 
(Palomares et al., 1996).  
 
The healthy control group in the present study were approximately a decade older 
than the cancer patients. It is known that even healthy ageing results in gradual 
muscle atrophy and decline in muscle function (Thomas, 2007). That a significant 
impairment of muscle function and quality was demonstrated despite the HC 
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experiencing a further 10-year duration of age-associated muscle loss highlights the 
major impact of cancer.  However, the age difference may have impacted on the 
results for the CSA and fatty infiltration.  In Chapter 6, it was shown that female 
cancer patients had smaller and fattier quadriceps muscles than healthy young and 
older women.  The healthy older women also had smaller and fattier muscles than the 
younger women indicating these are features of sarcopenia of ageing.  If the controls 
in the current study had been exactly age matched, it is likely that there would have 
been a significant effect of cancer cachexia on the CSA for women as well as men, 
and also likely that percentage differences in fatty infiltration would have been more 
pronounced.  It is interesting to see that for both men and women, the non-cachectic 
cancer patients had higher % fatty infiltration than the cachectic patients.  Although 
this observation was not significantly different, it might suggest that fatty infiltration 
is an early phenomenon in the cachexia journey before there is an increase in adipose 
tissue loss with more advanced cachexia.  Whether inter or intramuscular fat 
contributes to poorer muscle quality is plausible, but requires further investigation.  
This will be addressed in Chapter 8. 
 
Consistent with the majority of cancer studies, cancer patients showed evidence of 
nutritional deficit (low albumin), anaemia (low haemoglobin) and systemic 
inflammation (raised CRP).  However, other than for CRP in female patients, there 
did not appear to be a further significant deterioration in the presence of cachexia.  
This could indicate that changes in these blood parameters occur early in the cancer 
cachexia journey, or simply reflect a wide heterogeneity of response amongst the 
cancer patients.  
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Quadriceps CSA was similar in female non-cachectic and cachectic patients.  One 
potential explanation would be that loss of adipose tissue alone (rather than in 
combination with lean tissue) accounted for the weight-loss in this group. A more 
likely explanation is that there was a small reduction in muscle mass that could not 
be detected due to the relatively small sample size. In contrast to the females, 
quadriceps CSA was reduced by 15% in males with cachexia compared with male 
non-cachectic patients. These findings are consistent with observations in lung 
cancer patients, where significant muscle wasting is twice as prevalent in males 
compared with females (Baracos et al., 2010). Indeed, weight-loss (including muscle 
loss) has been suggested to play a role in mediating sex-related differences in lung 
cancer patient survival (Palomares et al., 1996). Due to the relatively small cohorts of 
patients with oesophageal, gastric and pancreatic cancer in the present study, survival 
analysis was not possible. However it is interesting to note that other investigators 
have reported sex-specific differences in survival for similar cancer types (Skipworth 
et al., 2011, Oberaigner and Siebert, 2011).  
 
It has been suggested by Weber et al that muscle mechanical quality (i.e. quadriceps 
strength/ CSA) may be preserved in cancer cachexia (Weber et al., 2009).  However, 
this previous study examined a relatively small number of patients with a single 
tumour type (pancreatic cancer), combined males and females within cohorts, and 
compared controls with cachectic patients at one extreme of the weight-loss spectrum.  
In contrast, the present study is larger, includes different tumour types and analyses 
males and females separately. Furthermore, the inclusion of controls and cancer 
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patients with varying degrees of weight-loss allowed differentiation between the 
impact of cancer alone on muscle function/quality and any additional effect of 
cachexia.  Our findings parallel the reduced muscle quality observed in other human 
models of muscle atrophy such as old age (Goodpaster et al., 2006) and are 
consistent with the concept that reduced muscle quality may represent a general 
response of human muscle to chronic wasting. 
 
The mechanism underlying a reduction in quadriceps MQ in patients with cancer 
cachexia may differ between the sexes. In the present study, in non-cachectic male 
patients, quadriceps CSA and strength were both reduced and MQ declined. 
Although quadriceps CSA declined further in the presence of cachexia, there was no 
corresponding further deterioration in quadriceps strength, and thus MQ did not fall 
further. In female cancer patients, quadriceps CSA was unaffected by the presence or 
absence of cachexia and therefore the observed reduction in MQ in the cachectic 
patients was entirely due to a significant decline in strength. Such sexual dimorphism 
has previously been observed in an immobilisation study in which, relative to the 
loss of muscle mass, females sustained a proportionally greater loss of strength than 
males (Yasuda et al., 2005).  
 
Although quadriceps muscle strength was reduced in both males and females with 
cancer, there was an apparent preservation of lower limb power in females. In 
contrast with quadriceps muscle strength, lower limb power is a more complex 
measurement dependent not only upon the force generating capacity but also the 
contractile speed of several muscle groups (not just the quadriceps).  The 
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heterogeneity of response of these different muscles or, conceivably, variation in the 
ratio of Type I/II fibres between men and women may account for the differences 
observed.  There is also evidence in healthy males and females, that there are gender 
differences in muscle fatigability and recovery, along with neuromuscular activation 
(Hakkinen, 1993).  The present study did not extend to investigation of these factors, 
and whether they are important in the context of cancer cachexia has yet to be 
investigated.   
 
The preservation of upper limb (hand grip) strength but not lower limb strength in 
the present study suggests that different muscle groups may respond to systemic pro-
cachectic signals differently.  It is also possible that mechanical factors may play a 
role as cancer patients with weight-loss have reduced physical activity levels (Moses 
et al., 2004). In healthy males undergoing 35 days of bed-rest, postural muscles were 
more susceptible to atrophy than non-antigravity muscles (Pisot et al., 2008).  Thus 
increased sitting or bed rest may account for some of the differential regional wasting 
in the cancer patients.  In older adults, hand grip strength has previously been 
identified as a sensitive marker of sarcopenia, being significantly associated with 
poor mobility (Lauretani et al., 2003).  However, the results of the present study in 
cancer patients appear to indicate that measurement of HGD alone will not inform a 
decline in load-bearing muscle function.  This is a significant observation in relation 
to the concept that HGD is a suitable outcome measure for therapeutic intervention 
trials in cancer cachexia. 
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Diminished muscle strength and mechanical quality could be the result of several 
influences, including systemic factors such as anorexia (limiting energy/protein 
intake) as well as behaviour (poor motivation resulting in physical under-
performance).  In addition, factors intrinsic to muscle such as mechanical 
inefficiency (for example, disturbed muscle architecture or fatty infiltration) may 
play a role. Systemic circulating factors that could influence muscle mass and 
function include pro-inflammatory cytokines and sex hormones. Markers of systemic 
inflammation (e.g. CRP) in patients with cancer cachexia have been associated with 
a poorer prognosis, reduced function, poor nutrition and a shortened survival (Fearon 
et al., 2006).  In the present study, circulating levels of CRP correlated negatively 
with strength in both male and female cancer patients.  In addition, increased plasma 
CRP was associated with reduced lower limb power in male and poorer muscle 
quality in female cancer patients.  Univariate analysis suggested that the impact of 
systemic inflammation on quadriceps muscle strength was greater in female (effect 
size 38.8%) than in male cancer patients (effect size 18.2%).   
 
In the current study, assessment of gonadal status demonstrated a reduction in cFT in 
male cancer patients compared with male controls.  Testosterone stimulates 
production of anti-inflammatory cytokines such as IL-10 and inhibits release of 
TNFα,  IL-1 and IL-6 (Stephens et al., 2008). Lower testosterone levels could 
therefore lead to an increase in pro-inflammatory cytokines that could activate 
muscle proteolysis.  Skipworth and co-workers (Skipworth et al., 2011) have 
demonstrated that hypogonadism (low total and/or free testosterone levels) is 
associated with poorer survival in male cancer patients. It is well established that low 
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testosterone levels impact on muscle mass and function and possibly QoL. 
Furthermore, testosterone replacement has been shown to prevent loss of muscle in 
ageing males (Allan et al., 2008).  In females, oestrogen withdrawal at menopause is 
associated with an accelerated loss of muscle tissue with the greatest rate of loss 
occurring in the earliest postmenopausal years (Aloia et al., 1991).  The females in 
the present study were post-menopausal and thus the influence of cancer on gonadal 
status and muscle mass may be weaker due to already low oestradiol levels.  
 
In the present study, males with cancer cachexia reported poorer global QoL and 
physical function and increased fatigue.  Poorer QoL measures were also associated 
with reduced muscle mechanical quality.  However, the observed differences in 
females did not achieve statistical significance.  This could be due to the preservation 
of LLEP and CSA in the female patients. Indeed, a recent study has shown a 
significant association between LLEP and SF-36 vitality score in patients after stroke 
(Lewis et al., 2011). However, given that the female cohort was smaller, it is also 
possible that the impact on QoL in females was masked by a Type II error.   
 
In summary, the present study suggests that lower limb muscle mechanical quality is 
impaired in cancer patients.  Furthermore, there appear to be sex differences in the 
impact of cachexia at the level of both muscle function and global functional status.  
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Chapter  8:  Muscle  quality  phenotype  in  human  cancer  
cachexia:  investigating  intramyocellular  lipid  droplets   
8.1 Abstract 
The reason for the deterioration in muscle quality seen in Chapter 7 is not clear.  
There may be systemic factors or local muscle factors responsible.  Chapter 6 
showed that female cancer patients had increased fatty infiltration of quadriceps 
muscle.  However, the contribution of inter versus intramuscular fat could not be 
determined.  Such fat accumulation might be both a marker and mediator of 
metabolic change (e.g. insulin resistance) and muscle wasting.  This Chapter 
describes a novel electron microscopy study to assess lipid droplets in cachectic 
cancer patients.  Intramyocellular lipids are an important source of fuel for 
mitochondrial fat oxidation and play an important role in intramuscular lipid 
homeostasis. 19 UGI cancer patients and 6 healthy controls undergoing surgery 
were recruited.  A Rectus abdominis biopsy was performed and processed for 
transmission electron microscopy (TEM).  The number of intramyocellular lipid 
droplets and lipid droplet diameter were calculated from the TEM images.  CT scans, 
performed  as  part  of  patients’  routine  care,  were  analysed  to  determine  amount  of  
adipose (intermuscular, visceral and subcutaneous) and muscle tissue.  Compared 
with controls, UGI cancer patients had increased numbers of lipid droplets (mean 
(SD) 1.8 (1.9) vs. 6.4 (9.1) per 2650x field respectively, p=0.036). Mean lipid droplet 
diameter was also higher in UGI cancer patients compared with controls (0.42 (0.13) 
vs.  0.24  (0.21)  μm,  p=0.015).    Mean  lipid  droplet  count  correlated  positively  with  the  
severity of weight-loss (R= 0.51, p=0.025) and negatively with CT-derived measures 
of intermuscular fat (R= -0.53, p=0.022) and visceral fat (R= -0.51, p=0.029). This 
study suggests that the number and size of intramyocellular lipid droplets is 
increased in the presence of cancer and increases further with weight-loss/loss of 
adipose mass in other body compartments. The specific mechanisms and drivers of 
this phenomenon remain to be elucidated, but could relate to enhanced lipolysis or 
mitochondrial dysfunction in skeletal muscle.    
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8.2 Introduction 
Chapter 7 demonstrated that weight-loss and gender impact on muscle function and 
mass in cancer cachexia patients.  Furthermore, there was a reduction in muscle 
mechanical quality in male and female cancer patients compared with controls.  The 
reasons for these changes are not clear.  Systemic factors may contribute such as 
anorexia with resultant reduced protein/energy intake, impact of the systemic 
inflammatory response along with behavioural factors such as poor motivation and 
physical inactivity.  Local factors could also play a role within muscle itself due to 
mechanical or biochemical inefficiency.  In Chapter 6 and 7, there was evidence of 
increased fatty infiltration on MR imaging of the quadriceps.  However, as 
highlighted in Chapter 6, the proportion of intra versus intermuscular fat could not be 
determined using the k-means clustering technique, and thus the relevance of 
intramyocellular fat in determining muscle quality in cancer cachexia is unknown. 
One study using MR spectroscopy showed increased intramyocellular lipid levels in 
cachectic patients (Weber et al., 2009) and it may be that this influences muscle 
quality/function.  Thus, in order to explore this further, this chapter investigates the 
relationship between intramyocellular fat (lipid droplets) and cancer cachexia in a 
small series of muscle biopsies using transmission electron microscopy (TEM). 
 
 
Whilst both lean and adipose tissue become depleted in cancer cachexia, there is 
evidence that body fat is lost more rapidly than lean tissue (Fouladiun et al., 2005). 
The drivers of lipolysis, or possibly reduced lipogenesis (Tisdale, 2009), in cancer 
cachexia  are  still  to  be  elucidated  fully.  However  TNFα  (Plomgaard et al., 2008), 
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ZAG (Bing et al., 2004, Mracek et al., 2011) and MIC-1 (Ding et al., 2009) have 
been suggested as potential mediators.  Adipose tissue is composed predominately of 
stored lipid droplets (Finn and Dice, 2006) and is intimately involved with energy 
homeostasis and metabolism through secreted adipokines (Wang et al., 2008).  
Additionally, it influences insulin sensitivity, affects immune and inflammatory 
pathways and interacts with catecholamines (Balisteri CR, 2010, Lafontan, 2008).  
The catabolism of lipids generates fatty acids that can either be utilised by skeletal 
muscle or further metabolised to take part in the Krebs cycle (Finn and Dice, 2006).  
Triglyceride-containing lipid droplets are dynamic organelles stored on demand in all 
cells and grow through a fusion process mediated by SNARE proteins, including 
SNAP23 (Jagerstrom et al., 2009). Within skeletal muscle, it is thought that 
intramyocellular lipid/lipid droplets act as fuel stores for mitochondrial fat oxidation 
(Schrauwen-Hinderling VB, 2006).  Lipid droplets are usually in direct contact with 
mitochondria presumably to allow rapid transport when required in situations such as 
exercise (Schrauwen-Hinderling VB, 2006).  Indeed, intramyocellular lipid decreases 
upon acute exercise (Krssak et al., 2000, Decombaz et al., 2001, Rico-Sanz et al., 
2000, Shaw et al., 2010) and almost completely disappears after marathon running 
(Staron et al., 1989, Kayar et al., 1986).  Conversely, physical inactivity and a diet 
excessive in fat can lead to an increase in intramyocellular lipid (Shaw et al., 2010). 
Thus,  it  would  appear  that  a  ‘static’  rather  than  ‘dynamic’  pool  of  intramyocellular  
lipid is pathophysiological.  Endurance training causes a rise in intramyocellular lipid 
content supporting the role of lipid droplets as an energy source during physical 
activity (Schrauwen-Hinderling VB, 2006).  Although the presence of lipid droplets 
in skeletal muscle is part of the normal physiology of healthy individuals with or 
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without physical training, associations have been shown between increased droplet 
number and pathological states such as the presence of type 2 diabetes/insulin 
resistance (Schrauwen-Hinderling VB, 2006, Bostrom et al., 2009) and aging (Crane 
et al., 2010). With aging, not only are numbers of lipid droplets increased, but their 
association with mitochondria appears to be disrupted (Crane et al., 2010) and 
mitochondrial function is altered (Conley et al., 2000, Trounce et al., 1989).   In the 
morbidly obese, raised intramyocellular lipid content has been reported to be 
associated with insulin resistance and to decrease after weight-loss/bariatric surgery 
(Gray et al., 2003, Greco et al., 2002).  In patients with gastrointestinal cancer, 
increased levels of intramyocellular lipid have also been reported. Using MR 
spectroscopy, a 35% higher level of intramyocellular lipids was observed in patients 
with cachexia (defined by >10% weight-loss in previous 6 months) compared with 
weight stable cancer patients (Weber et al., 2009).   
 
The phenotype associated with cancer cachexia (lipid mobilisation, insulin resistance 
(Tisdale, 2009), systemic inflammation (Stephens et al., 2008), sarcopenia (Tan et al., 
2009) and reduced physical activity (Moses et al., 2004)) suggest that there could be 
a relationship between increasing weight-loss and the number/size of 
intramyocellular lipid droplets. The study in this chapter sought to carry out a 
quantitative morphological examination of intramyocellular lipid droplets in human 





- Due to the phenotype associated with cancer cachexia there would be an 
association between increasing weight-loss and the number/size of 
intramyocellular lipid droplets.  
- There would be a relationship between increased intramyocellular lipid 






Participants: see Section 2.1 
Anthropometric assessments: see Section 2.2 
Muscle biopsy (Rectus abdominis) and blood collection: see Section 2.8.1 
Blood measures (CRP, albumin, insulin, cortisol, glucose, HOMA-IR): see Section 
2.9 
TEM (sample preparation and image analysis): see Section 2.11 
CT imaging and analysis: see Section 2.6.2 
QoL (KPS): see Section 2.4 
Statistics: see Section 2.12.1 
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8.5 Results 
Nineteen cancer patients (11 men, 8 women) and 6 controls (2 men, 4 women) were 
recruited.  Demographics are shown in Table 8.1.  There were 8 patients with 
pancreatic cancer, 4 gastric, 3 oesophageal, 3 oesophago-gastric junction and 1 
patient with small bowel cancer. The mean BMI of both the cancer patient and 
control groups was >25 kg/m2. Cancer patients were older than controls (mean (SD) 
age 67 (10) vs. 53 (8) years respectively, p=0.005) and had a significantly higher 
percentage weight-loss (6.0 (7.1) vs. -0.3 (1.4) % respectively, p=0.002). MAMC 
and arm muscle CSA were not significantly different between controls and cancer 
patients.  There was a trend towards higher KPS in controls compared with cancer 
patients (98.3 (3.1) vs. 91.7 (8.6), p=0.083). Significantly more cancer patients 
exhibited systemic inflammation (CRP ≥5mg/l)  than  controls  (n=  11/19  vs.  0/6  
respectively,  p=0.020  Fisher’s  exact  test).  Both  the  average  lipid  droplet  number  (6.4  
(9.1) vs. 1.8 (1.9), p=0.036, see Figure 8.1) and the average lipid droplet diameter 
(0.42 (0.13)  vs.  0.24  (0.21)  μm,  p=0.015)  were  higher  in  the  cancer  cohort  compared  
with controls. 
 
Changes associated with increasing weight-loss/altered body composition in the 
cancer patients 
In the cancer patients, % weight-loss (range -10.4% to 17.1%) correlated negatively 
with MAC (R= -0.51, p=0.024) and MAMC (R= -0.46, p=0.047) and there was a 
trend towards a reduction in arm muscle CSA (R= -0.44, p=0.058). There were, 
however, no significant correlations between % weight-loss and CT-derived values 
of muscle mass. CT-derived measures of intermuscular and visceral fat were not   
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Table  8.1:  Demographics,  anthropometry,  CT-derived  body  
composition  (cancer  patients  only),  performance  status,  
blood  measurements,  and  intramyocellular  lipid  droplet  count  
and  size  for  cancer  patients  and  controls.   
 
 Control Cancer p value 
(n=6) (n=19)  
M/F 2/4 11/8 0.378 
Age (years) 53(8) 67(10) 0.005 
Weight (kg) 68.3(12.3) 70.7(12.8) 0.684 
BMI (kg/m2) 26.0(4.5) 25.1(4.4) 0.671 
Weight-loss (%) -0.3(1.4) 6.0(7.1) 0.002 
MAC (cm) 28.5(3.1) 28.8(3.0) 0.793 
TSF (mm) 18.0(6.1) 14.6(7.4) 0.333 
MAMC (cm) 22.8(3.0) 24.2(2.5) 0.259 
Arm muscle CSA (cm2) 34.3(9.4) 38.7(9.5) 0.339 
KPS 98.3(4.1) 91.7(8.6) 0.083 
Tumour stage 1 - 0 - 
2 - 6 - 
3 - 8 - 
4 - 4 - 
CRP (mg/l) 2.1(1.4) 20.8(42.1) 0.295 
SI/no SI 0/6 11/19 0.020 
Albumin (g/l)* 36.6(6.0) 33.7(4.6) 0.248 
Insulin (mU/l)* - 5.8(3.2) - 
Glucose (mmol/l)* - 6.2(1.6)  
Cortisol (nmol/l)* - 454(109) - 
HOMA-IR* - 1.8(0.9) - 
Cortisol:Insulin ratio* - 96.6(48.1) - 
IM fat (cm2/m2) - 11.0(5.9) - 
Vi fat (cm2/m2) - 115.2(95.3) - 
SC fat (cm2/m2) - 161.1(66.4) - 
Skeletal muscle (cm2/m2) - 43.1(7.6) - 
 
LD count 1.8(1.9) 6.4(9.1) 0.036 
LD diameter (μm) 0.24(0.21) 0.42(0.13) 0.015 
 
 
Results are presented as mean (SD).  Comparison between groups was 
made  using  Student’s  t-test/Fisher’s  exact  test.    SI was defined as CRP 
≥5mg/l.  *Due  to  sample  limitations,  not  all  patients  had  these  variables  
measured: Albumin n=18, Insulin n=13, Glucose n=14, Cortisol n=17, 
HOMA-IR n=10, Cortisol:Insulin ratio n=17.  Abbreviations: BMI, body 
mass index; CRP, C-reactive protein; CSA, cross-sectional area; HOMA-
IR, homeostatic model assessment of insulin resistance; IM, 
intermuscular; KPS, Karnofsky performance score; LD, lipid droplet; 
MAC, mid arm circumference; MAMC, mid arm muscle circumference; 
SI, systemic inflammation; SC, subcutaneous; TSF, triceps skin fold 
thickness; Vi, Visceral; kg, kilograms; m, metres; cm, centimetres; mm, 
millimetres; mg, milligrams; g, grams; U, units; mU, milliUnits; mmol, 
millimoles;;  nmol,  nanomoles;;  μm,  micrometres;;  CT,  computed  
tomography; M, male; F, female.  
 304 
FIGURE 8.1: REPRESENTATIVE ELECTRON MICROGRAPHS FOR 





A. Images are all at 2650x magnification. Greater numbers of lipid 
droplets (white vacuoles) were evident with increasing weight-loss.  % 
values for cancer patients refer to weight change from pre-illness stable 
weight.    Bars  represent  2μm. 
B. 11000x magnification image of a single lipid droplet demonstrating 
the absence of a double membrane, thus distinguishing it from 





significantly associated with weight-loss but there was a trend towards a (negative) 
association between weight-loss and subcutaneous fat (R= -0.42, p=0.082).  Weight-
loss correlated negatively with albumin (R= -0.56, p=0.015), but there were no 
significant associations with CRP (R= 0.15, p=0.549), insulin (R= -0.32, p=0.280), 
glucose (R= 0.19, p=0.509), cortisol (R= -0.27, p=0.295), HOMA-IR (R= -0.18, 
p=0.614) or cortisol:insulin ratio (R= 0.44, p=0.137).   
 
The average lipid droplet number correlated positively with % weight-loss (R= 0.51, 
p=0.025, Figure 8.2), but there was no relationship between weight-loss and lipid 
droplet diameter (R= 0.15, p=0.535).  MAMC, arm muscle CSA and CT-derived 
muscle mass did not correlate significantly with either lipid droplet count or lipid 
droplet diameter.  Both weight (R= -0.61, p=0.007) and BMI (R= -0.46, p=0.050) 
correlated negatively with the number of lipid droplets.  There were significantly 
greater numbers of lipid droplets in patients with lower CT-derived measures of 
intermuscular fat (R= -0.53, p=0.022) and visceral fat (R= -0.51, p=0.029) and there 
was also a trend towards an association between droplet number and subcutaneous 
fat (R= -0.46,  p=0.055).    No  relationship  was  demonstrated  between  patients’  age  
and number of lipid droplets (R= -0.30, p=0.209) or between the number of lipid 
droplets and the lipid droplet diameter (R= 0.34, p=0.152). There were no significant 
associations between the number of lipid droplets and plasma levels of albumin (R= -
0.28, p=0.256), CRP (R= -0.10, p=0.695), insulin (R= -0.26, p=0.391), glucose (R= -
0.03, p=0.926), cortisol (R= -0.13, p=0.633), HOMA-IR (R= -0.38, p=0.280) or 








There was a significant positive correlation between weight-loss (%) and 
LD number (R= 0.51, p=0.025;;  Pearson’s  correlation,  two-tailed).  There 
was no significant difference in LD number according to tumour site 







The current study demonstrates a progressive rise in the number of intramyocellular 
lipid droplets in relation to both increasing weight-loss and depletion of adipose 
tissue mass in patients with cancer. In addition, the presence of cancer was associated 
with increased lipid droplet numbers compared with controls. Thus, the presence of 
increased intramyocellular lipid droplets does not seem to be related exclusively to 
weight-loss but rather is probably linked to the mediators of the processes underlying 
such weight-loss (which is variably expressed depending on the individual patient). 
Increasing weight-loss, however, does seem to exacerbate the observed changes in 
ultrastructure. 
 
Patients with obesity have increased intramyocellular lipid droplets (van Loon et al., 
2004), whereas the current study observed a paradoxical negative association 
between BMI and number of lipid droplets: that is, the lower the BMI, the higher the 
number of lipid droplets.  These findings suggest that increased intramyocellular 
lipid droplets are not specific to either a net positive or negative energy balance but 
may relate to the underlying causes of shifts in energy balance.  
 
Consistent with the above hypothesis, we observed significant negative associations 
between CT-derived measures of fat mass (intermuscular, visceral and subcutaneous) 
and the number of intramyocellular lipid droplets.  This would suggest that the 
changes within the myocytes were not related exclusively to local (skeletal muscle) 
events but rather to the overall state of net lipid mobilisation and negative energy 
balance or perhaps endocrine disruption.  
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The size of lipid droplets as well as their number may be physiologically significant. 
However, in the present study, although the average number of lipid droplets 
increased with progressive weight-loss, there was no association between weight-loss 
and lipid droplet diameter.  This could represent the lipid droplets reaching a plateau 
of growth or may simply be due to there being a wide variability in lipid droplet 
diameter. 
 
The cancer patients in the present study were overweight (mean BMI >25kg/m2) and 
this probably reflects not only the increasing level of obesity in the general 
population, but that obesity is a risk factor for the development of cancer. It is 
important to recognise that underneath this mantle of fat there may be clinically 
occult muscle wasting. Indeed, in the present study there was an association between 
increasing weight-loss and reduced MAMC (an anthropometric index of whole body 
muscle mass). The trend towards sarcopenic obesity in advanced cancer patients has 
recently been emphasised (Prado et al., 2008). Indeed, a recent study of patients with 
advanced pancreatic cancer demonstrated sarcopenic obesity to be an independent 
determinant of reduced survival (Tan et al., 2009). The present study did not relate 
either anthropometric or CT-derived measures of muscle mass to the number of 
intramyocellular lipid droplets, but this probably reflects the relatively small sample 
size and the absence of pre-illness measures of muscle mass from which to estimate 
net loss. In future studies it would be important to characterise further the likely 
parallel between metabolic syndrome, the cancer patient with sarcopenic obesity and 
the mechanisms that underlie the present observed changes in skeletal muscle 
ultrastructure.   
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The controls in the current study were younger than the cancer patients.  It has been 
suggested that ageing results in an increase in intramyocellular lipid content (Crane 
et al., 2010).  Whilst this may be a contributing factor to the lower numbers of lipid 
droplets in the control group, the observed association between weight-loss and lipid 
droplets in the cancer cohort was independent of age.  Likewise, there were no 
observed differences in lipid droplet numbers between men and women (p=0.630) or 
tumour site (one-way ANOVA, p=0.559; see Figure 8.2).  However, given that the 
numbers in each group were small, the influence of these factors would be better 
explored in a larger dataset. 
 
The likely mechanism for the increased deposition of lipid within the skeletal muscle 
of weight losing cancer patients probably reflects an imbalance between fatty acid 
supply and utilisation. The enhanced lipolysis in cancer cachexia has been long 
established. However, recent research has focused more closely on mitochondrial 
dysfunction and, as observed in sepsis (Fredriksson et al., 2008), impaired 
mitochondrial fatty acid oxidation/oxidative capacity may contribute to lipid 
accumulation. Of interest, mitochondrial derangement has been demonstrated in 
COPD muscle wasting (Gosker et al., 2007). The present study did not extend to a 
detailed evaluation of myocellular mitochondrial ultrastructure or function but 
clearly this could be the focus of further research.  
 
In summary, this study suggests that the presence of lipid droplets is related to the 
presence of cancer and increases with weight-loss.  The specific mechanisms/drivers 
of this phenomenon remain to be elucidated.  
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Chapter  9:  Impact  of  cachexia  on  longitudinal  changes  
in  muscle  function  and  mass  in  upper  gastrointestinal  
cancer  patients  undergoing  surgery 
 
9.1 Abstract 
The original intention was to undertake a longitudinal natural history study of the 
development of cancer cachexia in patients following resection.  It was anticipated 
that as patients developed recurrent disease cachexia would become more prevalent.  
As it happened, patients who returned for follow up were still disease free whereas 
those that developed recurrence (and presumably cachexia) died so quickly as not to 
be picked up during follow up.  In order to make sense of the data that had been 
collected, this Chapter describes a longitudinal study (mirroring the approach taken 
in the biomarker discovery studies of Part I) carried out to assess the impact of pre-
operative cachexia on short-term post-operative outcome.  
 
At baseline, 42 UGI cancer patients were recruited: 10 had palliative surgery and 32 
a  “curative”  resection.    Palliative  patients  had  poorer  performance  status  and  an  
increased sit-to-stand  time  compared  with  patients  having  “curative”  resection.    
However, other anthropometric and functional measures did not differ significantly 
between  the  two  groups.  Only  the  patients  in  the  “curative”  group  underwent  
repeated assessment at ~8 months post operatively (median 231 days). The palliative 
group did not survive sufficiently long to allow such follow up.  In  the  “curative”  
group, 3 patients declined and 5 patients died before the second appointment.  
 
Cachectic  patients  who  underwent  “curative”  surgery  had  less  post-operative 
weight-loss compared with non-cachectic patients (-0.7 vs. -4.5 % per 100 days 
respectively, p=0.034).  By eight months post-operatively there were no significant 
alterations in quadriceps strength, lower limb power and HGD in either cachectic or 
non-cachectic patients.  Cachectic patients demonstrated improved global QoL 
(p=0.039) following resection, whereas non-cachectic patients had significant 
deterioration in TSF thickness (p=0.049), MAMC (p<0.001), weight (p=0.001) and 
sit-to-stand (STS) time (p=0.024). In summary, this chapter showed that in patients 
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with UGI cancer undergoing potentially curative resection, those who were 
nutritionally replete pre-operatively had ground to lose post-operatively.  In contrast, 
those who were cachectic pre-operatively benefitted from removal of the tumour and 
suffered attenuated loss from a low baseline.  This study shows the difficulties of 
longitudinal data collection and how some of the baseline variables and clinical 






Chapters 7 and 8 have established that muscle function, mass and quality are 
influenced by cachexia and gender, and that there is an increase in intramyocellular 
lipid droplets with cachexia that may impact on muscle quality. What is not clear is 
whether these changes at the time of surgery are reversible after tumour resection and 
also what impact progressive cachexia may have on subsequent recovery. As 
discussed previously, the initial protocol for the intended longitudinal study was not 
achieved. The original experimental model was to recruit patients at baseline, whilst 
undergoing surgery, and then follow them up every 6 months to identify a sub-
population who developed recurrent cancer cachexia. This latter group would 
comprise  those  who  had  a  ‘curative’  procedure  but  had  developed  recurrent  tumour  
and weight-loss,  and  a  group  from  those  who  had  a  ‘palliative’  procedure  with  
tumour still present who continued to lose weight.  However, as explained in Chapter 
5 and as will be discussed further in Chapter 10, this was not possible.  Thus, an 
alternative model was developed for the longitudinal follow up of muscle function 
and mass.  Similar to the molecular studies, patients undergoing potentially curative 
resection of tumour, with or without cachexia, were followed up and functional 
measurements compared at these time points.  Patients who were disease free at 
follow up were included in the analysis, and in order to try and achieve adequate 
numbers, the first follow up assessment (i.e. ~8 months) was used. 
 
In 2007 there were 23000 new cases of UGI cancer (UK) and surgery remains the 
mainstay of treatment providing potential cure.  However, major surgery is 
associated with semi-starvation, stress response, abnormal post-operative immune 
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function and increased protein catabolism with resultant sequelae (Fearon et al., 2013, 
Gustafsson and Ljungqvist, 2011). Furthermore, even in cancer patients who undergo 
curative surgery 5 year survival is poor – for example, ~20% following oesophageal 
resection (Hulscher et al., 2001) and ~10% following Whipples 
pancreaticoduodenectomy (Conlon et al., 1996).  Although many cancer patients are 
weight losing at diagnosis, there are few studies examining the impact of cachexia on 
post-operative progress.  In pancreatic cancer, cachectic patients (weight-loss >10%) 
were more likely to have unresectable tumours and have poorer survival than those 
who were not cachectic pre-operatively (Bachmann et al., 2008, Bachmann et al., 
2009). 
 
With this in mind, the first part of this chapter is a comparison of the baseline 
phenotype of patients undergoing curative resection versus palliative surgery. The 
second section investigates the impact of pre-operative cachexia on short-term post-
operative recovery of muscle function/mass and QoL in patients who had a curative 
resection.  For the reasons outlined previously it was not possible to use the present 
longitudinal data to examine the predictive value of the molecular biomarkers 





- Patients undergoing palliative surgery would have poorer muscle function 
and survival compared to patients undergoing potentially curative resectional 
surgery. 
- Patients with pre-operative cachexia would have poorer muscle function, 






Participants: see Section 2.1 
Anthropometric assessments: see Section 2.2 
Blood collection: see Section 2.8.1 
Blood measures (CRP, albumin): see Section 2.9 
Muscle function and functional ability (IKES, LLEP, HGD, STS, TUG): see Section 
2.3 
MR imaging and analysis: see Section 2.6.1 
Muscle mechanical quality: see Section 2.7 
QoL (EORTC QLQ-C30, KPS): see Section 2.4 





UGI cancer patients identified to undergo potentially curative resection were 
included in the study.  At the time of surgery, if patients had tumour that was 
unresectable, underwent a palliative procedure (e.g. bypass) or had evidence of 
metastases they were  classified  as  ‘palliative’.  If patients underwent a successful 
tumour  resection,  they  were  classified  as  ‘curative’.    A weight-loss above 10% of 
pre-illness weight was used to define cachexia.  Patients were followed up at 
approximately 8 months post-operatively. The results of the cross-sectional study in 
Chapter 7 suggested sexual dimorphism in the response of muscle to cachexia.  
However, due to the limited numbers of patients, further sub-dividing by gender 
prohibited meaningful analysis.  For example there was only one female cachectic 
patient who had an MR scan. There were also some measures that were not 
performed in all patients either due to patient preference (e.g. blood sample), or lack 
of availability (e.g. limited time slots for MR imaging).   
 
Of the 42 patients recruited in total, 32 had a ‘curative’ operation and 10 had a 
‘palliative’  operation.  Patients  had  assessments  immediately  pre-operatively, and 
repeated measures were carried out at a median of ~8 months (231 days; range 134-
425 days) post-operatively. Those in the palliative group were only analysed at 
baseline (due to n=1 at follow up). Figure 9.1 illustrates the outcome at follow up 




FIGURE 9.1– OUTCOME AT TIME OF FIRST FOLLOW UP (~8 MONTHS) FOR 




Patients were classified as curative or palliative dependant upon 
whether the primary tumour was resected at time of surgery and whether 
there was evidence of metastases.  An attempt to follow-up all patients 
was made.  16% of patients who underwent curative resection and 90% 
of patients who had palliative surgery had died before the 2nd 
assessment.  Of the patients who underwent MR scans, only 11 in the 
curative group had a scan at both baseline and follow-up assessment.  
Abbreviations: MR, magnetic resonance. 
 
  
42 patients had surgery 
32 curative resection 
14 had MR scan 
24 had 2nd assessment 
19 had MR scan (11 overlapped 
with baseline assessment) 
5 died 
3 declined 
10 palliative surgery 
7 had MR scan 
1 had 2nd assessment 
1 had MR scan 
9 died 
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Baseline phenotype of patients undergoing curative resection or palliative 
surgery 
Demographics are illustrated in Table 9.1.  In the curative cohort, 6 patients had 
gastric cancer, 13 oesophageal, 4 OGJ, and 9 had pancreatic cancer.  The majority 
(n=29) of patients had adenocarcinoma and 3 patients had squamous cell carcinoma 
(oesophageal).  5 patients had stage 1 cancer, 7 stage 2, 19 stage 3 and 1 stage 4 
cancer.  15 patients had undergone neoadjuvant chemotherapy and 17 had not.   
 
In the palliative cohort, 2 patients had gastric cancer and 8 had pancreatic cancer.  
All 10 had adenocarcinoma.  5 patients had stage 3 and 5 had stage 4 cancer.  1 
patient had undergone neoadjuvant chemotherapy and 9 had not.  
 
Patients undergoing palliative surgery had significantly lower KPS and increased 
STS time compared with those undergoing curative resection.  There was also a trend 
towards lower TSF in palliative compared with curative cohort.  However, 
quadriceps CSA (derived from mid-femur MR scans) were similar and the proportion 
of patients who were cachectic did not significantly differ between the two groups. 
Patients who had a curative resection had significantly greater median survival 
compared with the palliative group (985 vs. 245 days respectively, Log-Rank 
p<0.001).  Figure 9.2 illustrates the Kaplan-Meier survival curves for each group. 
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Table  9.1:  Demographics,  anthropometry,  muscle  function,  
functional  ability  and  muscle  mass  for  patients  undergoing  
‘curative’  vs.  ‘palliative’  surgery 
 
A. Total cohort 
 ‘Curative’  surgery ‘Palliative’  surgery p value 
 (n=32) (n=10)  
Age (years) 65.1 (9.2) 62.9 (11.8) 0.541 
M/F 21/11 6/4 0.746 
KPS 85.6 (11.9) 75.0 (16.5) 0.031 
Height (cm) 169.8 (8.4) 167.8 (10.5) 0.539 
Weight-loss (%) -6.6 (7.8) -10.3 (13.5) 0.429 
Cachexia Y/N 13/19 3/7 0.817 
Weight (kg) 76.2 (16.0) 67.3 (13.8) 0.122 
BMI (kg/m2) 26.3 (4.7) 23.7 (3.3) 0.113 
MAC (cm) 30.0 (3.5)* 27.2 (2.3) 0.023 
TSF (mm) 16.4 (7.4)* 11.8 (5.1) 0.076 
MAMC (cm) 24.8 (2.7)* 23.5 (2.3) 0.179 
Arm CSA (cm2) 40.7 (10.0)* 35.7 (7.2) 0.153 
Strength (N/Kg) 3.6 (1.2)** 3.3 (1.1) ** 0.527 
Power (W/Kg) 1.3 (0.5)* 1.3 (0.3)* 0.999 
HGD (kg) 35.3 (10.5)* 28.7 (9.4) 0.098 
STS (s) 0.6 (0.2)*** 0.8 (0.1)** 0.010 
TUG (s) 6.8 (1.3)*** 7.5 (1.4)** 0.195 
 
B. MR imaging cohort 
 ‘Curative’  surgery ‘Palliative’  surgery p value 
 (n=14) (n=7)  
Q. CSA (mm2) 5278.7 (1268.6) 5332.1 (1524.1) 0.933 
Q. CSA/height2 (mm2/m2) 1902.1 (325.2) 1873.7 (322.4) 0.975 
Fat free Q. CSA (mm2) 4390.1 (1182.8)** 4585.5 (1454.4) 0.753 
Fat free Q. CSA/height2 (mm2/m2) 1604.3 (321.4)** 1606.4 (329.7) 0.989 
Fat infiltration (%) 13.7 (6.0)** 14.7 (4.4) 0.718 
 
 
Results  are  presented  as  mean  (SD)  or  categorically.    Student’s  t-test or 
Fisher’s  exact  test  were  used  to  compare  values.    Not all variables could 
be measured in all patients: *=n-1, **=n-2, ***=n-4.  Abbreviations: M, 
male; F, female; KPS, Karnofsky performance score; BMI, body mass 
index; MAC, mid arm circumference; TSF, triceps skin fold; MAMC, mid 
arm muscle circumference; CSA, cross-sectional area; Q. CSA, mid-
femur quadriceps cross-sectional area; HGD, hand grip dynamometry; 
STS, sit-to-stand; TUG, 3m timed up-and-go; MR, magnetic resonance; 
cm, centimetres; mm, millimetres; kg, kilograms; N, newtons; W, watts; s, 





FIGURE 9.2: POST-OPERATIVE SURVIVAL CURVES FOR PATIENTS WHO 




Kaplan-Meier  survival  analysis  was  done  comparing  ‘curative’  and  
‘palliative’  surgery  groups;;  median survival 985 vs. 245 days respectively, 




The impact of cachexia on post-operative recovery in patients undergoing 
curative surgery 
Patients  in  the  ‘curative’  group  were  further  divided for analysis into those who were 
cachectic (weight-loss >10% - given that this weight-loss relates to surgical risk 
(Windsor and Hill, 1988) pre-operatively and those who were not cachectic (weight-
loss <10%).  Repeated measures at the first follow-up appointment were compared 
with baseline values. 
 
The demographics of patients undergoing curative resection divided into cachectic 
and non-cachectic groups are illustrated in Table 9.2. Cachectic patients had 
significantly increased weight-loss compared with non-cachectic patients, but other 
demographic variables were similar.  75% of patients re-attended at a median of 231 
days (~ 8 months) post-operatively and underwent repeat measures.  
 
Blood measures 
Results for albumin and CRP are illustrated in Table 9.3.  Serum albumin 
concentration increased significantly at the follow up assessment compared with 
baseline in both cachectic (41.2 vs. 34.0 g/l, p=0.002) and non-cachectic patients 
(42.4 vs. 36.7 g/l, p=0.001).  Mean CRP levels were higher in cachectic than non-
cachectic patients at baseline, but this was not significant (36.7 vs. 5.3 mg/l, 
p=0.450).  Likewise, follow up CRP levels did not significantly differ from baseline 
values in either group. 
  
 322 
Table  9.2:  Patient  demographics  for  those  undergoing  
‘curative’  surgery  according  to  the  presence  or  absence  of  
cachexia 
 
 Cachexia No cachexia p-value 
(n=13) (n=19) 
Age (years) 63 (7) 66 (10) 0.323 
M/F 8:5 13:6 0.981 
Tumour stage 1 2 3 0.748 
2 2 5 
3 9 11 
4 0 0 
Tumour site Oesophagus 3 9 0.244 
Stomach 3 4 
OGJ 1 3 
Pancreas 6 3 
Height (cm) 170 (7) 168 (8) 0.541 
Weight (kg) 71.8 (12.4) 78.1 (17.9) 0.276 
BMI (kg/m2) 24.8 (3.5) 27.5 (5.1) 0.107 
Weight-loss (%) 14.5 (4.9) 1.7 (4.4) <0.001 




Results are presented as mean (SD) or categorically.  Comparison 
between groups was  made  using  Student’s  t-test/Fisher’s  exact test.  
Abbreviations: M, male; F, female; OGJ, oesophago-gastric junction; 





Anthropometric variables (Table 9.3) were similar in cachectic patients at follow up 
compared with baseline assessments (weight 72.9 vs. 71.5 kg, p=0.465; BMI 24.8 vs. 
24.2 kg/m2, p=0.401; TSF 13.4 vs. 13.8 mm, p=0.699; MAMC 23.7 vs. 24.5 cm, 
p=0.123 respectively).  In non-cachectic patients, all measures significantly fell at 
follow up assessment compared with baseline (weight 69.0 vs. 79.7 kg, p=0.001; 
BMI 24.0 vs. 27.6 kg/m2, p=0.001; TSF 14.1 vs. 18.1 mm, p=0.049; MAMC 23.3 vs. 
25.6 cm, p<0.001 respectively).  In order to control for potential influence of 
variation in time from baseline to follow up, % change per 100 days was calculated 
for each measure (Figure 9.3).  Using this, weight decreased at a significantly higher 
rate in non-cachectic than in cachectic patients (-4.5% vs. -0.7%, p=0.034).  
However, for the other variables, there were no significant differences between the 
groups in % change per 100 days. 
 
Muscle mass 
Mid-femur quadriceps CSA was measured using MR scan and mid-arm muscle CSA 
was calculated from anthropometric values using previously validated formulae 
(Heymsfield et al., 1982).  Table 9.4 illustrates the results.  In cachectic patients, 
quadriceps CSA and arm muscle CSA did not differ significantly between follow up 
and baseline (quads CSA 1823 vs. 1832 cm2/m2, p=0.904; arm CSA 36.7 vs. 39.5 
cm2, p=0.122 respectively).  When expressed as change over time, mean quads CSA 
change was 0.4 %/100 days and mean arm muscle CSA change was -3.8 %/100days 
(Figure 9.4).  
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Table  9.3:  Baseline  and  follow-up  blood  measures  and  
anthropometry  for  UGI  cancer  patients  (with  and  without  
cachexia)  undergoing  ‘curative’  surgery. 
 
 Cachexia  p-value Not cachexia  p-value 
 Baseline Follow-up  Baseline Follow-up  
       
 (n=7) (n=7)  (n=11) (n=11)  
Albumin 34.0 (3.4)* 41.2 (2.9)* 0.002 36.7 (3.7) 42.4 (3.4) 0.001 
CRP 36.7 (56.5) 13.0 (16.5) 0.346 5.3 (8.5) 9.2 (12.2) 0.450 
       
 (n=9) (n=9)  (n=15) (n=15)  
Weight (kg) 71.5 (14.8) 72.9 (12.3) 0.465 79.7 (19.8) 69.0 (14.1) 0.001 
BMI (kg/m2) 24.2 (4.1) 24.8 (3.9) 0.401 27.6 (5.4) 24.0 (3.6) 0.001 
TSF (mm) 13.8 (3.9)* 13.4 (5.0)* 0.699 18.1 (8.7) 14.1 (6.1) 0.049 
MAMC (cm) 24.5 (2.6)* 23.7 (3.1)* 0.123 25.6 (3.0) 23.3 (2.7) <0.001 
* = n-1       
 
 
Results are presented as mean (SD).  Comparison between baseline 
and follow-up measurements was made using paired t-test.  
Abbreviations: UGI, upper gastrointestinal; CRP, C-reactive protein; BMI, 
body mass index; TSF, triceps skin fold thickness; MAMC, mid-arm 





FIGURE 9.3: PERCENTAGE CHANGE IN ANTHROPOMETRY PER 100 DAYS 





The % change per 100 days between baseline and follow-up 
assessments was calculated. Comparison of cachectic with not 
cachectic  patients  was  done  using  Student’s  t-test.  * p<0.05 compared 
with cachectic.  Abbreviations: UGI, upper gastrointestinal; TSF, triceps 
skinfold thickness; MAMC, mid-arm muscle circumference. 
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In non-cachectic patients, follow up compared with baseline assessments 
demonstrated a trend towards a fall in quads CSA (1836 vs. 2081 cm2/m2, p=0.063) 
and a significant fall in arm muscle CSA (34.9 vs. 43.6 cm2, p<0.001).  Change over 
time in non-cachectic patients was -4.3 %/100 days for quads CSA and -8.2 %/100 
days for arm CSA.  These values were not significantly different from the cachectic 
cohort (p=0.120 and p=0.123 respectively, Figure 9.4). 
 
Muscle function and functional ability 
Quadriceps strength, lower limb power and HGD did not differ between baseline and 
follow up for either cachectic or non-cachectic patients (Table 9.4). When values 
were expressed as change over time (Figure 9.4), although lower limb muscle 
function increased in cachectic more than non-cachectic patients, this was not 
significant (strength, 17.5 vs. 2.6 %/100 days respectively, p=0.127; power, 8.6 vs. 
3.9 %/100 days respectively, p=0.436).  Only HGD significantly improved in 
cachectic compared with non-cachectic patients (4.0% vs. -1.9%, p=0.043).  STS 
time and 3m timed up-and-go (TUG) were similar in cachectic patients at baseline 
and follow up (Table 9.4).  In non-cachectic patients, there was a significant rise in 




Muscle quality (quadriceps strength/unit CSA) was not significantly different 
between cachectic and non-cachectic groups or time points (Table 9.4).  The % 
change in muscle quality per 100 days was higher in cachectic compared with 
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Table  9.4:  Baseline  and  follow-up  muscle  mass,  function,  
functional  ability  and  quality  for  UGI  cancer  patients  (with  and  
without  cachexia)  undergoing  ‘curative’  surgery. 
 
 Cachexia  p-value Not cachexia  p-value 
 Baseline Follow-up  Baseline Follow-up  
       
 (n=8) (n=8)  (n=15) (n=15)  
A. CSA 39.5 (9.0) 36.7 (10.2) 0.122 43.6 (11.5) 34.9 (9.3) <0.001 
       
 (n=6) (n=6)  (n=5) (n=5)  
Q. CSA 1832 (169) 1823 (301) 0.904 2061 (496) 1836 (367) 0.063 
       
 (n=9) (n=9)  (n=15) (n=15)  
HGD 35.1 (7.8) 37.0 (8.3) 0.173 37.7 (12.9)* 35.2 (10.3)* 0.103 
Quads strength 3.1 (1.0) 3.7 (0.6) 0.118 3.8 (1.4) 3.9 (1.2) 0.924 
Lower limb power 1.2 (0.5) 1.4 (0.4) 0.308 1.4 (0.5) 1.5 (0.6) 0.379 
       
 (n=8) (n=8)  (n=12) (n=12)  
STS 0.67 (0.25) 0.65 (0.18) 0.628 0.55 (0.16) 0.63 (0.13) 0.024 
TUG 6.9 (1.1) 6.6 (1.0) 0.455 6.6 (1.2) 6.9 (1.6) 0.179 
       
 (n=6) (n=6)  (n=5) (n=5)  
Muscle quality 0.04 (0.02) 0.05 (0.01) 0.384 0.05 (0.01) 0.05 (0.01) 0.486 
* = n-1 
 
      
 
 
Results are presented as mean (SD).  Comparison between baseline 
and follow-up measurements was made using paired t-test.  
Abbreviations: UGI, upper gastrointestinal; STS, sit-to-stand time; TUG, 
3m timed up-and-go; Q. CSA, mid-femur quadriceps muscle cross-




FIGURE 9.4: PERCENTAGE CHANGE IN MUSCLE MASS, FUNCTION AND 















The % change per 100 days between baseline and follow-up 
assessments was calculated for muscle function (A.), muscle mass (B.), 
and muscle quality (C.).  Comparison of cachectic with not cachectic 
patients  was  done  using  Student’s  t-test. * p<0.05 compared with 
cachectic.  Abbreviations: UGI, upper gastrointestinal; Q. CSA, mid-
femur quadriceps muscle cross-sectional area; A. CSA, mid-arm muscle 





non-cachectic patients, but the difference was not significant (20.4 vs. -3.8 %/100 
days, p=0.200 respectively, Figure 9.4). 
 
QoL 
The EORTC-QLQ C-30 was used to assess QoL (Table 9.5).  In cachectic compared 
with non-cachectic patients, baseline global QoL was significantly lower (86.1 vs. 
143.6, p=0.011) and there was a trend toward the fatigue score being higher (44.5 vs. 
29.9, p=0.078).  In cachectic patients, global QoL significantly improved at the 
follow up assessment (138.9 vs. 86.1, p=0.039).  KPS and physical function scores 





Table  9.5:  Baseline  and  follow-up  QoL  for  UGI  cancer  patients  
(with  and  without  cachexia)  undergoing  ‘curative’  surgery. 
 
 Cachexia  p-value Not cachexia  p-value 
 Baseline Follow-up  Baseline Follow-up  
 (n=6) (n=6)  (n=13) (n=13)  
Global QoL 86.1 (71.0) 138.9 (39.0) 0.039 143.6 (40.6) 141.0 (37.6) 0.790 
Fatigue 44.5 (42.8) 29.6 (26.0) 0.158 29.9 (26.2) 32.5 (19.5) 0.487 
Physical function 77.8 (30.6) 82.2 (27.2) 0.602 84.5 (23.7) 80.0 (15.6) 0.187 
KPS 87.1 (12.5)* 88.6 (9.0)* 0.736 85.7 (10.9)* 85.0 (10.2)* 0.807 
* = n+1 
 
      
 
 
Results are presented as mean (SD).  Comparison between baseline 
and follow-up measurements was made using paired t-test.  
Abbreviations: QoL, quality of life; KPS, Karnofsky performance score; 





Comparison of ‘palliative’ versus ‘curative’ patients at baseline 
The patients  in  the  ‘palliative’  group had a higher proportion of advanced disease 
(i.e. 50% stage 4 cancer vs. 3% in curative group).  Likewise, the median survival for 
palliative vs curative cohorts was significantly reduced.  Due to this, it was not 
possible to carry out any follow up analysis of the palliative cohort as 90% of this 
cohort had died before a follow up assessment could be carried out.  Even in those 
patients who had undergone  ‘curative’  resection, 16% had died prior to follow up.  
These figures emphasise the devastating impact that UGI cancer can have on patients 
and highlights that even in those who are deemed suitable for potentially curative 
surgery, outcome is still very guarded.  The results are in keeping with other studies 
where, for example, ~10-22% of patients with oesophageal cancer undergoing 
surgery failed to return to a 6 month follow up appointment (Blazeby et al., 2005a, 
Barbour et al., 2008, Djarv et al., 2008).  Reasons for the poor post-operative 
survival in this group will include progression of disease, co-morbidities and 
complications of major surgery, and it is also likely that a reasonable proportion of 
these patients would deteriorate with progressive cachexia.  The poor outcome in the 
palliative group suggests a pressing need for research into methods that allow better 
pre-operative staging and patient selection in order to avoid exposing patients to the 
potential risks of major surgery when symptomatic treatment may be more 
appropriate.  Previously, it has been reported that pre-operative cachexia (weight-loss 
>10%) reduced the likelihood of a curative resection in patients with pancreatic 
cancer and was associated with more advanced disease and poorer survival 
(Bachmann et al., 2008, Bachmann et al., 2009).  The results of the current study 
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contrast with this as only 30% of the palliative group were cachectic pre-operatively 
compared with 41% in the curative surgery group.  This may reflect the inclusion of 
oesophageal and gastric in addition to pancreatic cancer patients in the current study, 
or perhaps some aspect of tumour biology which resulted in a more aggressive 
disease in the palliative cohort.  Alternatively, the palliative patients may have been 
late on in the cachexia journey and had some degree of progressive fluid retention 
which contributed to their apparent lack of weight-loss. It is interesting that the only 
significant differences between the curative and palliative groups were a reduced 
performance score and an increased STS time.  This latter test is a measure of 
functional ability and the fact that this deteriorated in preference to any of the other 
functional measures suggests that it may be useful as a marker of early frailty.  




Longitudinal phenotypic changes in the presence or absence of cachexia for 
patients undergoing potentially curative resection 
The fact that, in the curative group, both cachectic and non-cachectic patients had 
significantly increased albumin levels following surgery suggests that by ~8 months 
there has been recovery from the negative nutritional consequences of cancer. With 
albumin being a negative acute phase protein, improved levels of albumin may also 
reflect abrogation of an acute phase response to the presence of a tumour.  However, 
although the mean CRP levels were higher in cachectic patients at baseline, there 
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were no significant differences following surgery, nor were levels significantly 
different from non-cachectic patients. 
 
There are relatively few longitudinal studies assessing muscle function in human 
cancer cachexia, and those that are published tend to use QoL derived physical 
function scores.  In the current study, patients who were disease free at follow up and 
had undergone a curative resection demonstrated differences in recovery post 
operatively according to the degree of cachexia at the time of surgery (Table 9.4).  
 
Contrary to the initial hypothesis, cachectic patients did not fare worse in the short 
term following curative resectional surgery.  Indeed, they appeared to maintain many 
of the muscle functional, mass and other variables.  Furthermore, QoL improved at 
follow up compared with baseline.  In contrast, there appeared to be some 
deterioration post-operatively for some of the measured variables in the non-
cachectic patient group (i.e. weight, TSF, MAMC, quads and arm muscle CSA).  The 
reasons for this intriguing observation are not clear.  One might anticipate that 
patients who are weight losing pre-operatively would be frailer and would experience 
increased morbidity and mortality in the post-operative period.  Indeed, previous 
studies in pancreatic cancer patients undergoing surgery have shown poorer 
outcomes in cachectic (weight-loss >10%) individuals (Bachmann et al., 2008, 
Bachmann et al., 2009, Pausch et al., 2012).  In contrast, other authors have failed to 
demonstrate a clear relationship between pre-operative body composition and 
subsequent survival in patients undergoing pancreatic resection (Aslani et al., 2010).   
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Table  9.6  Summary  of  differences  in  longitudinal  phenotypic  
changes  in  cancer  patients  (with  and  without  cachexia)  
undergoing  ‘curative’  surgery. 
 
 Cachexia No cachexia 
Weight   
TSF thickness   
MAMC   
Quadriceps strength   
Lower limb power   
HGD /  
Global QoL   
Physical function score   
Fatigue score   
KPS   
Quadriceps CSA   
Arm muscle CSA   
 
 
Overall post-operative change in anthropometry, muscle function, mass 
and  QoL  in  patients  undergoing  ‘curative’  resectional surgery.  Time 
period between measurements was ~8 months.  = no change in 
variable,  = decline in variable,  = improvement in variable.  This 
summary does not inform on what might have happened between 
assessments (i.e. if there was initial decline followed by improvement 
resulting in overall no change in variable).  Abbreviations: TSF, triceps 
skin fold; MAMC, mid arm muscle circumference; HGD, hand grip 
dynamometry; QoL, quality of life; KPS, Karnofsky performance score; 




In this latter study, whilst patients had a reduction in total body fat pre-operatively, 
protein stores were preserved with only ~14% of patients being protein deficient at 
the time of surgery.  This might suggest that the relative contribution of each tissue 
compartment to overall weight-loss may relate more strongly to post-operative 
progress and survival rather than gross weight-loss per se.  The results of CT based 
body composition analyses demonstrating an adverse prognosis in patients with 
sarcopenic obesity in cancer cachexia would be supportive of this concept (Tan et al., 
2009).  Clearly, in the design of future cancer cachexia studies, it would be 
informative to utilise body composition measures to stratify patients at the outset 
rather than using them solely as outcome measures. 
 
Although non-cachectic patients showed evidence of decline in anthropometric and 
muscle CSA measures, in the cachectic cohort all anthropometric and functional 
variables were relatively well preserved post-operatively.  Given that all patients 
underwent similar major surgical resections, it would seem unlikely that there was no 
response to this surgical insult in the cachectic cohort.  There are several studies 
examining the impact of major surgery on cancer patients although very few have 
been stratified by presence of cachexia.  In patients undergoing open colorectal 
surgery, at 1 month post-operatively, weight, lean body mass, fat mass and physical 
performance (HGD/knee extension strength) had all reduced and there had been a 
rise in fatigue levels (Jensen et al., 2011).  Likewise in patients undergoing 
oesophagectomy, physical function (6 minute walk and knee extensor strength) 
declined (Tatematsu et al., 2013) post-operatively.  In gastric  ‘curative’  surgery  
patients undergoing assessments pre-operatively and at 6 and 12 months, weight was 
 337 
lost during the first 6 months post-operatively before stabilising primarily due to a 
decline in body fat of up to 40%.  Body cell mass was unchanged post op and 
furthermore, there was no obvious deterioration in HGD (Liedman et al., 1997).  
Assessment of pancreatic cancer patients who underwent pancreatic resection 
(Whipples) at 4.6 years post surgery showed similar functional performance 
(respiratory muscle strength and hand grip strength) to patients undergoing 
cholecystectomy other than a lower body weight (Royall et al., 1996) although 
values  were  still  above  patients’  ‘ideal’  weight.    Conversely,  in  oesophageal cancer 
patients undergoing resection, those with the lowest hand grip strength compared to 
those with higher values had increased complications, hospital stay and mortality 
even compared with other risk factors (anaemia, hypoalbuminaemia, renal 
impairment, diabetes, increased MCV>100 and weight-loss) (Chen et al., 2011).  
These differences in functional outcome may reflect variation in follow-up time or 
assessment of different muscle groups (i.e. hand grip vs. quadriceps strength).  The 
finding in Chapter 7 that HGD at baseline does not inform on load-bearing muscle 
function would reflect a similar concept that upper and lower limbs do not respond to 
the same degree to the insults of cachexia or major surgery. 
 
In the current study, although a one-off follow up assessment at around 8 months 
allowed insight into post-operative changes, it does not inform on where patients 
may be on their recovery trajectory.  There is general acceptance that the acute post-
operative phase will have subsided within 6 months (Blazeby et al., 2005b, Blazeby 
et al., 2000, Zieren et al., 1996, Brooks et al., 2002, Viklund et al., 2006, Reynolds et 
al., 2006) after which a stabilisation and recovery phase occurs.  However, this latter 
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phase can be variable and is dependent on what outcome is being measured.  
Furthermore, different research groups have reported contrasting results making it 
difficult to grasp the exact nutritional and physiological consequences of major 
surgery.  For example, stabilisation of weight-loss and nutritional decline following 
pancreatic, oesophageal or gastric surgery after 4-6 months has been reported 
(Niedergethmann et al., 2006, Liedman et al., 1997, Ludwig et al., 2001, Melvin et 
al., 1998, McLeod et al., 1995) whereas other groups demonstrate persistent 
deterioration in these variables after the same operations (Martin and Lagergren, 
2009, Ong et al., 2000, Carey et al., 2011).  Some of these contrasting results may be 
explained by variation in follow up period, patient heterogeneity and perhaps 
differences in standards of post-operative care, but it highlights the need for further 
investigations.  In the current study, it would seem likely that, rather than there being 
no impact of surgery in cachectic patients, the results reflect the timing of the follow 
up assessment whilst patients are in a recovery phase (Figure 9.5). 
 
However, this would not account for significant deterioration in anthropometry and 
quads/arm muscle CSA seen in the non-cachectic patients over a similar follow up 
period post-operatively.  One hypothesis is that the tissue loss experienced by 
cachectic patients pre-operatively resulted in a blunted response to the stress of 
surgery.  That is, changes in anabolic and catabolic pathways brought about by host- 
tumour interaction had produced such a profound effect that the benefit of removing 
the pro-cachectic stimulus of the tumour outweighed the negative impact of major 
surgery, giving the appearance of greater recovery.  
  
 339 
FIGURE 9.5: SCHEMATIC ILLUSTRATING POST-OPERATIVE RECOVERY OF, 




Assessment of patients at two time points (in the current Chapter, at pre-
operative and late post-operative recovery stages) will not inform on 




















The non-cachectic group did not have this same pre-operative change and thus they 
suffer the sequelae of major resection, although will still benefit from the potential 
for cure.   
 
Muscle loss probably does not occur in a linear fashion or at a constant rate.  It is 
conceivable that if muscle has already been lost, it becomes more difficult to 
continue tissue loss at the same rate.  This concept may explain the deterioration in 
variables in non-cachectic patients where undergoing major surgery is the first 
stimulus to muscle loss whereas cachectic patients have already lost muscle and thus 
may have an abrogated response. 
 
There will be many behavioural and social differences between patients, which will 
presumably have bearing on how they recover after surgery.  For example, in the 
post-operative period, some patients may sit at home and eat only when they feel like 
it whereas others will be motivated to exercise and pay attention to their nutritional 
intake regardless of their symptomatology.  These confounders were not addressed in 
the current study but an attempt to do so would require larger numbers of patients 
and would be extremely difficult due to the wide heterogeneity in behaviour amongst 
individuals.  
 
Global QoL was poorer and fatigue levels higher in cachectic patients compared with 
non-cachectic patients at baseline.  These differences diminished after removal of the 
tumour with a significant improvement in global QoL in cachectic patients.  Changes 
in QoL after tumour resection have previously been reported.  A positive impact on 
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QoL in patients undergoing surgery for pancreatic cancer has been shown (Kostro 
and Sledzinski, 2008).  A more detailed look at QoL in patients undergoing 
pancreaticoduodenectomy at 1, 3, 6 and 12 months post surgery demonstrated an 
initial decline in QoL at 1 month compared with baseline before it improved 
significantly at 6 and 12 months (Chan et al., 2012).  Patients undergoing 
oesophageal or gastric resection show a similar pattern of deterioration in QoL 
before values started to recover (Barbour et al., 2008, Viklund et al., 2006, Reynolds 
et al., 2006) with a further negative impact in patients undergoing neoadjuvant 
chemotherapy (van Meerten et al., 2008).  Assessment of patients undergoing 
gastrectomy showed a fall in most QoL variables at 3 months which had improved at 
12 month follow up.  However, not all measures returned to normal with poorer 
fatigue, digestive symptoms, eating restrictions and body image disturbance 
persisting at 12 months (Kim et al., 2012).  Indeed, in patients who survive fewer 
than 2 years after oesophageal surgery, QoL scores never return to baseline reported 
figures (Blazeby et al., 2000).  Baseline QoL score has also been shown to relate to 
prognosis (Blazeby et al., 2005a). 
 
Whereas some other investigators have reported persistent long-term deterioration in 
physical function scores after resectional surgery (van Meerten et al., 2008, Djarv et 
al., 2008, Lagergren et al., 2007), the current study did not demonstrate any 
differences in either cachectic or non-cachectic individuals.  This is consistent with 
the lack of difference in most of the direct measures of muscle function.  The reason 
for these differences compared with other studies is not clear, but may represent 
heterogeneity between patient groups, or some bias in patient selection. In non-
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cachectic patients, despite a fall in weight and muscle CSA, QoL measures were 
similar pre and post surgery.  This suggests that in these patients, any negative 
impact of surgery on QoL has diminished by this time, but also emphasises that the 
presence of cachexia is a main determinant of a poorer QoL. 
 
Whilst the current study has yielded some interesting findings, the numbers are 
relatively small which may have given rise to a Type II error and hampered 
interpretation of some results. Chapter 7 highlighted a relationship between gender 
and the impact of cachexia on muscle function, mass and quality.  It is possible that 
the response to surgery in the presence of cachexia is also influenced by gender, but 
this subdivision was not possible due to the small numbers limiting meaningful 
analysis.  The type of tumour and/or operation may also be important.  Previous 
studies have demonstrated post-operative differences in body composition and 
nutritional measures between patients undergoing laparoscopic, distal or total 
gastrectomy (Kiyama et al., 2005, Abdiev et al., 2011).  Similarly, a comparison of 
patients with gastric, oesophageal or pancreatic cancer undergoing resection showed 
reduced weight-loss in those undergoing pancreatic surgery compared to the other 
two groups (Carey et al., 2011).  Variability in QoL measures has also been reported 
according to surgery type (Barbour et al., 2008). Clearly, future longitudinal cachexia 
studies would be better served with larger numbers of both men and women to allow 




In conclusion, this study demonstrates the difficulties of longitudinal follow-up 
studies in patients with advanced disease undergoing palliative surgery.  In the 
present analysis only 10% of palliative patients were available for follow up at 6-8 
months.  In an ideal world, this would be the group that would have likely developed 
progressive cachexia and could have served to validate both molecular and 
physiological skeletal muscle biomarkers of cachexia.  With regard to patients 
undergoing potentially curative surgery, the timescale of the follow-up in the present 
study was too short to allow for recurrence of disease and development of cachexia.  
In fact, those patients who were cachectic pre-operatively, tended to have stabilised 
from their cachexia as a result of tumour resection.  This chapter also emphasises the 
negative impact cachexia can have on the QoL in patients with UGI cancer prior to 









Summary  of  findings  in  Part  II 
 
The studies in Part II outline physiological assessment of skeletal muscle and 
exploration of the phenotype of UGI cancer patients with varying degrees of weight-
loss undergoing surgery.  Chapter 6 described the use of a novel k-means clustering 
technique to allow separation of contractile muscle tissue and non-contractile fatty 
tissue in MR scans from cancer patients.  Female cancer patients appeared to have 
the smallest and highest fat content muscles compared with young and old healthy 
women.  This finding emphasises the need to account for inter/intramuscular changes 
when assessing cross sectional imaging of muscle in cachectic patients, especially if 
comparing with a control group. Chapter 7 combined MR scans with muscle 
functional measures and QoL to assess the influence of cachexia on muscle mass, 
function and mechanical quality.  It was demonstrated that there is variability in the 
impact of cachexia on muscle function, mass and quality according to gender and 
weight-loss.  Furthermore, there appeared to be differences between upper and lower 
limb muscle compartments suggesting that certain muscle groups may be more 
susceptible to wasting than others.  Due to the observation that muscles have 
increased fatty infiltration in cancer patients (Chapter 6) and muscle quality is 
reduced (Chapter 7), the study in Chapter 8 used TEM of skeletal muscle biopsies to 
investigate the relationship between cachexia and intramyocellular lipid droplets.  
Increased numbers of lipid droplets were seen in cancer patients compared with 
controls. Furthermore, the number of lipid droplets rose with progressive weight-loss.  
However, there was a negative correlation between lipid droplet number and CT 
derived measures of intermuscular fat suggesting that fat deposition inside and 
outside of myofibrils needs to be evaluated separately.  The mechanisms responsible 
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for intramyocellular fat accumulation in cachexia remain to be elucidated.  Finally, 
Chapter 9 dealt with a longitudinal study assessing the impact of pre-operative 
cachexia on post-operative functional recovery after major cancer resection.  The 
difficulties of longitudinal follow-up studies in UGI cancer patients were highlighted. 
Around 16% of patients undergoing  ‘curative’  surgery  and  90%  of  those  undergoing  
palliative surgery died before follow-up at 6-8 months. This study also emphasised 
that the presence of cancer cachexia is a key determinant of a poorer QoL.  However, 
a surprising discovery was that pre-operative cachexia appeared to afford a degree of 
protection from deterioration in anthropometric and muscle CSA measures compared 
with non-cachectic patients following tumour resection.   The reasons for this are not 
clear but may relate to a relatively greater benefit in removal of the pro-cachectic 





Chapter  10:  General  discussion 
 
10.1 Overview of results and relevance to cancer cachexia 
For many years there has perhaps been an assumption that the mechanisms 
responsible for cancer cachexia, in general and for skeletal muscle in particular, in 
pre-clinical models are the same mechanisms responsible for muscle wasting in 
humans.  This has been due to the strong evidence from many well conducted animal 
and cell studies.  However, there has been a paucity of clinical data providing 
evidence to back up these assumptions.  Variation in definitions of cachexia, the 
heterogeneity of patient populations and conflicting results between different human 
studies have made it difficult to distil what the true picture is.  Furthermore, studies 
assessing the impact of cachexia on molecular or physiological aspects of skeletal 
muscle in humans have been lacking.  The current thesis has contributed several key 
observations relating to the molecular pathways relevant and the physiological 
phenotype of skeletal muscle in cancer patients with cachexia.   
 
In the first part of the thesis, the hypothesis-testing candidate skeletal muscle 
biomarker study (Chapter 3) demonstrated a lack of parallel with candidate markers, 
such as the atrogenes, relevant in preclinical models.  This was further confirmed in 
the transcriptomic cross-sectional (Chapter 4) and longitudinal (Chapter 5) biomarker 
discovery studies where the atrogenes again failed to appear as prominent markers.  
Instead, the process of human cancer cachexia appears to relate more to relative 
hypo-anabolism with likely suppression of protein turnover.  The results are 
particularly important in considering potential therapies for patients with cancer 
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cachexia.  In the past, emphasis has perhaps been placed on targeting proteolytic 
pathways such as the UPP.  However, the fact that this thesis suggests components of 
the UPP may not play the same role in human cachexia as perhaps assumed, may 
explain the lack of promising trial results.  Perhaps drugs/therapies that are focused 
on overcoming the suppression in protein turnover and improving protein synthesis 
in the future may prove more successful. Other novel discoveries were changes in 
structural elements  of  the  muscle  (β-dystroglycan) or in compensatory pathways 
(CAMK2β) might be better potential biomarkers of cachexia in muscle.  Clearly, 
these findings need confirmation before being proposed for validation studies.  
 
The second part of the thesis centred on physiological assessment and phenotyping 
of skeletal muscle in patients with cancer cachexia.  Although deterioration in muscle 
mass and function are thought to be key features of cancer cachexia, there are very 
few human studies directly assessing these variables.  However, the wider 
availability of cross-sectional imaging has revolutionised body composition studies.  
The use of MR imaging has gained increasing favour due to its image detail and the 
low side-effect profile.  The potential of a novel k-means technique to allow 
differentiation of muscle tissue and non-contractile  ‘fat’  tissue  in MR scans was 
assessed (Chapter 6).  Female cancer patients were shown to have increased fatty 
infiltration of quadriceps muscle compared with young and elderly healthy female 
controls.  This sets precedence for use of such imaging and analysis in future 
cachexia studies.  Given such changes in muscle composition, a key question is 
whether cachexia is not only associated with muscle loss, but whether there is also a 
loss of muscle mechanical quality.  Chapter 7 demonstrated that in men with cancer 
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and women with cachexia there was reduced muscle quality compared with controls.  
Another key finding was the observation that there may be gender differences in the 
impact of cachexia on muscle function, mass and quality in cancer patients.  
Although some previous studies have reported results suggesting differences between 
genders, this has never been explicitly explored and the majority of studies have 
analysed male and female body composition studies together.  This may have 
contributed to misleading results if the distribution of genders differed between 
groups. Likewise, the suggestion that different muscle compartments respond 
differently to the same pro-cachectic stimuli is novel.  Both strength (HGD vs. quads 
strength) and mass (anthropometry upper vs. MR imaging quadriceps) showed 
differences in impact of cachexia and also in recovery from major surgery.  These 
factors need to be considered when deciding on the best endpoints for trials and also 
deserve further exploration.   
 
Further exploration of altered muscle composition/quality in cachexia led to the 
novel observation that there are increased numbers of intramyocellular lipid droplets 
in skeletal muscle of cancer patients associated with increasing weight-loss (Chapter 
8).  The mechanisms for this remain to be investigated, but support other recently 
published data of cross-talk between adipose and muscle tissue in the cachectic 
patient.  The findings of the longitudinal functional study (Chapter 9) highlighted the 
negative impact of cachexia on QoL pre-operatively and also that curative resection 
of the tumour burden allowed recovery of function/mass/QoL.  One of the 
unexpected hurdles encountered in this thesis was the difficulty in attempting to 
carry out a longitudinal study in patients with cancer cachexia undergoing surgery 
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(Chapters 5 and 9). In  particular,  only  10%  of  patients  who  underwent  ‘palliative’  
surgery  and  75%  of  those  who  had  ‘curative’  surgery  were  available  for  follow-up at 
6-8 months.  The next section includes discussion about some of the reasons and 
potential solutions for this, but highlights that researchers need to be thoughtful in 
design of future studies. 
 
In summary, this thesis has identified several potential skeletal muscle molecular 
biomarkers of cancer cachexia.  However, the markers discovered are not consistent 
with pre-clinical models and therefore require further study before moving on to a 
validation programme.  Physiological assessment of patients with cancer cachexia 
established the negative impact that cachexia can have on muscle mass, function, 
muscle quality and QoL, but demonstrated that the degree of impairment varies with 
sex and between muscle groups.  Furthermore, the challenge of carrying out 
longitudinal studies in this patient group where frailty and clinical deterioration limit 
repeated assessments was highlighted. Such issues emphasise the need for a dual 
approach to the classification of cancer cachexia: if molecular markers prove difficult 
to discover or validate, then more specific and robust physiological indices of 
skeletal muscle mass and function may be the more important route to improve 




10.2 Limitations and challenges 
1. Definition 
Limitation of weight-loss cut-off 
It was highlighted in the main introduction to this thesis (Section 1.2.1) that for many 
years cancer cachexia has been poorly defined. This has been due in part to a lack of 
understanding of the molecular processes and the phenotype of human cancer 
cachexia.  In this regard, the current thesis has attempted to investigate and 
contribute novel insights into these areas.  There have also been several proposals for 
cachexia definitions published in recent years, and validation studies of these are 
currently being undertaken.  For this thesis, a weight-loss of more than 5% (early 
biomarker studies) or 10% (phenotype studies) from pre-illness stable weight was 
used to define cachexia.  However, using a simple cut-off may have confounded 
some of the results.  The use of CT in assessing body composition has been gaining 
increasing popularity, and using this methodology it was demonstrated that for a 
given reported % weight-loss, patients could be losing fat and not muscle, losing 
muscle but not fat, or indeed gaining in one tissue compartment but with 
proportionally greater loss in the other (verbal communication Mr Alisdair 
MacDonald, University of Edinburgh).  With the focus of this thesis being on muscle 
biomarkers and muscle phenotype, the impact of cachexia may have been 
underestimated by including patients with reasonable weight-loss, but with minimal 
or no loss of muscle.  Assessment of cohorts with radiological evidence of muscle 
loss (i.e. by CT or MR imaging) may be more useful in future studies.  However, as 
stated in the main introduction to this thesis, there will be few patients  with  ‘healthy’  
measures of body composition pre-illness which would make the calculation of a % 
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loss of muscle mass difficult. An alternative proposal (Fearon et al., 2011) would be 
to combine an absolute measure of muscularity with % weight-loss in order to define 
a cachectic population.  Additionally, a categorical weight-loss cut-off will mean 
those patients who are pre-cachectic (i.e. on the verge of muscle loss) will be 
classified as not cachectic.  This may not have much bearing on the results of 
phenotypic studies when early changes in muscle protein pathways may not 
immediately impact on gross muscle function or mass.  However, it would be highly 
relevant to investigations of intramuscular biomarkers of muscle loss where the 
sensitivity and specificity of early molecular changes will be compromised by 
inaccurate classification of cachectic and non-cachectic patients.  
 
Anorexia, systemic inflammation and muscle function 
Anorexia is common in cancer cachexia and is likely to exacerbate muscle wasting 
due to low intake of protein and amino acids. Although none of the patients included 
in the thesis had supplementary enteral or parenteral feeding, there will likely have 
been a proportion who had a reduced nutritional intake.  It is not clear whether this 
may have influenced any of the results because an assessment of anorexia was not 
performed. Accurate  measurement  of  a  patient’s  food or energy intake can be 
difficult due to the added burden on individuals to write down or weigh foods.  
Likewise, recall and questionnaires are reliant on memory and are open to 
misreporting (Wrieden, 2003).  However, it would be useful to include some form of 
assessment in future studies particularly as, for example, the autophagy pathway can 
be activated by starvation. 
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Similarly, systemic inflammation is a common finding in cachectic patients and CRP 
(as a measure of systemic inflammation) was included in the analysis of both the 
molecular and phenotypic studies.  CRP in combination with weight-loss and 
reduced energy intake has been shown to relate more closely to poorer functional 
status and prognosis than weight-loss alone (Fearon et al., 2006). However, although 
it would be interesting to re-examine results using such a definition, the aim of the 
molecular studies in the current thesis was to look for markers relating to early 
cachexia.  Thus, a definition that classifies a population within the more severe end 
of the cachexia spectrum would not be informative of early molecular changes that 
could be used as biomarkers.   
 
The relevance of weight-loss or indeed muscle loss in the definition of cachexia 
could also be questioned. Whilst many cachectic patients present with weight-loss, if 
a patient centred approach is used, the key symptoms may be weakness and fatigue. 
It could then be argued that how much muscle a patient has is not as important as 
how well the muscle is actually functioning.  The disassociation between muscle 
mass and strength/function was evident in Chapter 7 where a deterioration in muscle 
quality (strength per unit muscle) was seen in patients with increasing weight-loss.  It 
would therefore be useful to explore definitions of cachexia related to muscle quality 
or muscle function as a more meaningful patient-centred definition.   
 
2. Study population 
Patients with UGI cancer undergoing potentially curative surgery were chosen as the 
experimental model for this thesis.  This was because the incidence of cachexia is 
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higher in UGI cancer than other tumour types (Dewys et al., 1980) and also to allow 
access to tissue biopsies at the time of surgery.  Using this approach, a unique set of 
challenges in patient recruitment and investigation were faced. 
 
Challenges with recruitment 
Surgery is the only treatment offering potential cure to patients with UGI cancer.  
Therefore, once a patient has been diagnosed with UGI cancer, they will undergo a 
barrage of investigations and appointments to assess whether they will be suitable for 
surgery. For some patients, such as those with obvious metastases, surgery is not an 
option from the outset.  However, for many others several hospital visits are required 
to assess their cardiovascular fitness, discuss with an oncologist about suitability for 
neoadjuvant chemotherapy, attend appointments with cancer nurse specialists, along 
with meeting the surgical team.  In parallel with this, patients are coming to terms 
with their diagnosis of cancer and facing potential mortality.  Understandably, it can 
be a very emotive time for both patients and their families with the added burden of 
trying to understand their disease and make decisions about treatments.  The 
additional demand of taking part in a research study can therefore appear 
overwhelming to some patients.  Likewise, at a time where hospitals are becoming 
associated with negative emotions and anxieties, asking patients to attend another 
appointment for research purposes can be difficult.  Several obstacles were also 
encountered in trying to keep track of where patients were in the treatment pathway 
and when their date for surgery would be.  These factors obviously contributed to 
some patients being missed, not wishing to participate or only wanting to take part in 
some of the study (e.g. willing to give a baseline muscle biopsy, but not wishing to 
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undertake functional assessment).  Another challenge of carrying out this study in a 
tertiary cancer treatment centre was that the hospital received many referrals from 
surrounding distant geographical areas (e.g. Borders, Fife, Lanarkshire).  
Approaching such patients for consent prior to their operation, or arranging for 
functional assessment or MR scans was difficult because they would be admitted the 
evening before surgery.     
 
However, in spite of these hurdles, the willingness and desire of many patients to 
help contribute to scientific knowledge without the guarantee of direct personal 
benefit was striking.  Their altruism and generosity was a real example of human 
goodness that is very much admired.   
 
Challenges with follow up studies 
One of the hypotheses of this thesis was  ‘that  it  would  be  possible  to  undertake  a  
novel longitudinal study of UGI cancer patients undergoing surgery in order to 
identify a subgroup of patients with progressive cachexia’  to allow longitudinal 
assessment of molecular biomarkers and physiological changes in skeletal muscle.  
At the outset, we had anticipated recruiting 50 patients at baseline and using MR 
imaging to measure quadriceps muscle mass, which could then be tracked 
longitudinally as a direct measure of muscle loss.  The intention was to carry out 
assessments at 6 monthly intervals for 18 months post-operatively and to tie these in 
with their normal hospital clinic review appointments in order to avoid extra hospital 
trips and also because there was no travel budget in the supporting grant.  It was 
difficult to stick rigidly to these 6 monthly intervals owing to the fact that patients 
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not infrequently postponed them to suit holidays or other life events.  The time of 
day in which their appointment was also altered their willingness to stay for a 
research assessment (i.e. if they lived far away with a long drive ahead, potential to 
get caught in rush hour, adding cost to their car parking fee at the hospital). 
 
There was also the challenge of selective attrition.  At the time of contacting patients 
for the first follow up appointment at around 6 months, it became evident that several 
patients had died within this time frame.  These patients were presumably the 
frailer/cachectic patients whereas the fitter patients who did not have progressive 
disease or cachexia were alive and able to return for follow up assessments.  There 
were also some patients with severe cachexia who were crippled with adverse 
symptoms (e.g. weakness, fatigue, nausea) along with the sequelae of having been 
through neoadjuvant chemotherapy and surgery. As such they did not feel able to 
attend for assessments. Thus, the follow up results were probably less informative 
about progression of cachexia due to the fallout of potentially the most informative 
patients.  Table 10.1 outlines the numbers of patients aimed to be recruited at each 
time-interval in comparison with the actual numbers managed for the muscle 
functional assessments and MR scans. 
 
In order to try and counteract these problems, an additional non-surgical cohort was 
recruited who had non-resectable malignancy or metastases with the intention that 
they may be informative by inclusion in the palliative/progressive cachexia cohort.  
However, this similarly proved a difficult cohort to monitor longitudinally.  Patients 
had reduced life expectancy and thus were unlikely to make it to 6 months.    
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Table  10.1:  Anticipated  recruitment  and  actual  number  of  
patients  undergoing  muscle  function  and  mass  assessment 
 
 Baseline FU1 FU2 FU3 
Anticipated 50 35 20 15 
Actual function 54 27 18 9 
Actual MR imaging 33 21 11 6 
 
 
The aim was to recruit 50 patients at baseline and follow them up at ~6 
month intervals for 18 months.  However, patients declined more rapidly 
than anticipated resulting in smaller numbers at follow-up appointments.  
Likewise, numbers of patients undergoing muscle mass assessment 
using MR imaging were less than planned.  Abbreviations: FU, follow-up 




Furthermore, there was variability in an individual’s response to palliative 
chemo/radiotherapy.  For example, one patient with oesophageal cancer undergoing 
palliative chemo/radiotherapy survived a further 2 years with an initial gain in weight 
of 20% following recruitment into the palliative group.  This made interpretation of 
the data very difficult due to small numbers and large inter-individual heterogeneity 
and inclusion of this cohort in the longitudinal study was not felt to be informative. 
 
Heterogeneity of tumour type and operation 
In the current thesis, oesophageal, gastric and pancreatic cancer patients were 
combined for analysis.  Whilst all of these tumours are associated with a high 
incidence of cachexia, it is possible that there are tumour specific differences in the 
mediators and molecular pathways relevant in muscle wasting, or indeed in the 
phenotype.  For example, patients with oesophageal tumours are more likely to have 
dysphagia and pancreatic tumours may be more associated with more rapid weight-
loss (Dewys et al., 1980) and increased systemic inflammation (Fearon et al., 1999) 
than other tumour types.  Likewise, there may be differences in the impact on 
patients undergoing oesophageal resection compared with a gastrectomy or Whipples 
pancreaticoduodenetomy.  Such differences in post-operative nutritional status have 
been reported recently (Carey et al., 2011) and were discussed in Chapter 9.  
However, the numbers involved are small and further multicentre studies will be 
required in order to explore the nuances of tumour specific features of cachexia in a 




Late recurrence of tumour 
At the start of this thesis, the initial supposition was that some of the cancer patients 
would have recurrent disease post-resection (based on previous projects by members 
of the research group) within the time frame of the study.  Thus a repeat assessment 
and biopsy would allow longitudinal assessment of a subpopulation with progressive 
cachexia.  However, the patients that did recur either did so early and died before 
follow up assessment, or remained clinically disease free during the study period and 
then recurred late after the final 18 month follow-up appointment.  Some of this may 
be due to implementation of better pre-operative staging (e.g. the increasing use of 
endoscopic USS, PET scan, and higher resolution CT scans) and thus patients 
undergoing resection were more likely to benefit from the potential of cure. 
Regardless of the reason, it was not possible to test the initial hypothesis.  Rather an 
alternative model was used to investigate the impact of pre-operative cachexia on 
recovery post tumour resection as discussed in Chapter 9. 
 
Impact of co-morbidities 
The main theme of this thesis was to characterise molecular markers and 
physiological changes in skeletal muscle in patients with cancer cachexia.  However, 
cachexia can occur in many other chronic diseases such as COPD, cardiac failure, 
HIV and renal failure.  The interaction of various medications with muscle has also 
been reported (i.e. statins, ACE inhibitors (Parker et al., 2013, Sanders et al., 2005)).  
Although patients were recruited on the basis of the underlying diagnosis of UGI 
cancer, many of these patients also had co-morbidities with a reported incidence of 
cachexia or were on treatments that could potentially affect muscle anabolic or 
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catabolic pathways.  Whilst patients were excluded if they had, for example, 
uncontrolled diabetes or were taking anabolic stimulants, it was not possible to 
control for all potential confounders.  There is thus a challenge in interpreting such 
studies to decipher the mechanisms and phenotype specifically related to cancer 
cachexia.  On the other hand, this is the reality of investigating human disease rather 
than using pre-clinical models where tighter control of confounders can be achieved.  
Whilst it would be interesting to control for medications and other comorbidities, the 
heterogeneity amongst patients would make such studies difficult to design and carry 
out due to the large numbers of patients that would be needed to allow adequate 
stratification of patients into relevant groups for analysis.  Similarly, exclusion of 
patients taking certain medications or with concomitant diseases would likely result 
in small numbers and a study that does not relate to everyday clinical practice. 
 
Impact of gender 
Many previous studies in cancer cachexia have not taken into account any potential 
impact of gender.  The current thesis has suggested there is sexual dimorphism in the 
impact of cachexia on muscle function, mass and quality (Chapter 7).  However, it 
was not possible to divide all of the studies in the thesis by gender due to limitations 
in numbers.   
 
Impact of obesity 
The mean pre-illness BMI of all the cancer patients in this thesis was 28.0 (5.2) 
kg/m2 (range 18.7-53.2 kg/m2) and even at the time of cancer diagnosis was 25.7 (4.5) 
kg/m2 (range 16.7-42.5 kg/m2).   This reflects both the increasing levels of obesity in 
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the West, along with obesity itself being a risk factor for cancer.  Intuition may 
suggest that 10% weight-loss in an individual with a starting BMI of 20 kg/m2 would 
have a more profound effect than the same weight-loss in an individual with a 
starting BMI of 35 kg/m2.  However, there is a lack of evidence to either support or 
refute this.  Recent CT studies have added a further layer of complexity with the 
finding that sarcopenic obesity is an indicator of poor prognosis (Tan et al., 2009).  
Whether there are differences in tumour biology in obese compared with normal 
weight individuals is not known and it is equally possible that the drivers of cachexia 
are distinct in these two groups.  It would appear that, at least in patients who are 
obese, using weight-loss alone as a cut off for cachexia (as in the current thesis) is 
not going to be sufficient to identify those with pre-existing sarcopenia.  In the future, 
utilisation of CT-based body composition analysis, or indeed varying the definition 
of cachexia according to pre-illness BMI may be required in studies that recruit 
obese patients (Martin et al., 2013). 
 
Impact of age 
The mean (SD) age of the cancer patients was 65 (10) years, but spanned from 39-88 
years. Undoubtedly a proportion of those in the upper age range will have lost 
muscle as a result of the sarcopenia of ageing.  How this might influence the progress 
of patients with cancer cachexia is not known; i.e. are the effects simply additive, or 
synergistic.  There is a body of opinion that cancer affecting younger individuals has 
a different pathophysiology with a much stronger genetic component than cancer in 
older people, which is likely to be more influenced by accumulating environmental 
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factors.  It could therefore be supposed that cancer cachexia has similar age-
dependent features but there are, to date, no studies investigating this.    
 
Another challenge faced in this thesis was the recruitment of healthy controls that 
were age-matched to the cancer patients.  Two main sources of control were used.  
Firstly, volunteers from the community were recruited for the phenotypic studies 
using adverts on buses and in bowling clubs.  These individuals tended to be the 
healthy elderly.  The second cohort, for the biomarker discovery studies, included 
‘healthy’  patients  undergoing  surgery  for  benign,  non-inflammatory conditions.  This 
population tended to be younger due to the epidemiology of the underlying diseases 
and also the exclusion of those with co-morbidities, which had increasing incidence 
with age.   These limitations have been discussed in the relevant chapters.  The 
establishment of a collaborative central healthy control database and tissue biobank 
may be useful in the future to try and overcome such difficulties in recruiting 
appropriate controls for individual studies that are limited by time. 
 
3. Molecular biomarker studies 
The molecular studies (Chapters 3-5) will have many of the same limitations that 
have been described in previous paragraphs.  However, there are also unique 
challenges in both collecting the muscle biopsies and in the experiments, which will 





Collection of muscle biopsies 
The first muscle biopsy was collected at the time of surgery after induction of 
general anaesthesia.  All patients had been fasted overnight, but some were admitted 
to hospital the evening before whilst others attended the hospital on the morning of 
surgery.  In the latter group, it is conceivable that a period of morning activity (or 
‘exercise’)  in  getting  to  the  hospital  would  have  activated  some  anabolic  pathways  in  
muscles whereas the bedbound, hospitalised patient would not have this stimulus.   
Some patients would also have high anxiety and stress levels with the thought of 
impending major surgery.  Whether this would result in any meaningful molecular 
changes at muscle level is unknown, but there is a potential link with increased 
cortisol levels (classic stress hormone) and muscle catabolism (Ralliere et al., 1997). 
The specific molecular effects of anaesthesia on human muscle have not been well 
studied. However, descriptions and investigations of malignant hyperthermia (a 
pharmocogenetic condition characterised by disorder of skeletal muscle calcium 
regulation (Hopkins, 2011)) indicate the potential for interaction.   
 
At the follow-up quadriceps biopsy, patients also underwent an overnight fast, but 
these biopsies were carried out under local anaesthetic and there was no additional 
stress of forthcoming major surgery.  It would be hard to control for these influences, 
and whether they are relevant requires further investigation, probably in healthy 






One of the characteristics of cachexia is muscle atrophy.  In animals, this is 
predominantly thought to target Type II muscle fibres (Acharyya and Guttridge, 
2007).  The situation in human cachexia is unclear as there are no studies explicitly 
investigating muscle histology/fibre type.  If the same is true in humans, this raises 
an intriguing conundrum.  In order to extract protein and RNA from muscle biopsies, 
approximately 20mg of tissue was homogenised for all samples in this thesis.  If 
muscle is atrophying, cutting the same amount from the biopsy will result in a larger 
number of muscle fibres being included in the cachectic samples compared to those 
without muscle wasting.  Similarly, if the proteins of cachectic muscles that are being 
degraded relate to myofibrillar rather than sarcoplasmic elements then, in the 
Western blot experiments, loading the same quantity of protein from these muscles 
as non-cachectic muscles will result in a potential bias if the biomarker is derived 
from the sarcoplasmic compartment.  Likewise, using a 20mg piece of tissue does 
not take into account any variability in ratio of Type I:II fibres between individuals.  
Moreover, cells other than myocytes (e.g. adipocytes, endothelium, fibrocytes, 
inflammatory cells) are necessarily included in any biopsy.  This in turn may 
confound assessments of individual biomarkers.  Perhaps the use of techniques such 
as laser capture microdissection to ensure equal numbers of fibres of pure myocytes 
from cachectic and non-cachectic patients may elucidate any potential confounding 





4. Phenotype studies 
Functional assessments 
Functional measurements were carried out at one point in time.  This introduces the 
potential for results to be influenced by how the patients felt on the day.  The 
measures were also voluntary, and although instruction was given to try as hard as 
they could, there will undoubtedly be inter-individual variation according to personal 
motivation.  Other research groups have used forced muscle contraction using 
electric stimulation to overcome this potential problem.  However, in the current 
thesis, it was felt that although it may give a measure of maximal involuntary muscle 
function, it did not reflect real life and may also have been poorly tolerated in the 
frailer cancer patients.  The longitudinal biomarker study in Chapter 4 utilised the 
ActivPAL™ monitor.  This measures daily activity over several days and thus may be 
more  reflective  of  patients’  true  functional  levels. 
 
Challenges with MR scanning 
The project was based in a busy teaching hospital where the radiology department is 
pushed to cope with the demands of inpatient and outpatient clinical requests.  This 
meant that on occasion there was not space to accommodate research scans, or that 
only specific times were available that did not coincide with patient availability. In 
particular, current cancer treatment target times leave very little scope for flexibility 
due to impending operation dates and thus a significant proportion of patients were 
unable to have a pre-operative MR scan.  There are also specific contra-indications to 
MR imaging (i.e. pacemaker, potential metal fragments in orbits, shrapnel), which 
excluded some patients.  In clinical practice, a plain X-ray of the orbits would be 
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performed to exclude a foreign metal body, but the current research project did not 
have funding for additional X-rays or the ethics to support exposure to a dose of 
radiation.  Follow-up appointments were more successful as there could be pre-
planning and request to the radiology department for MR imaging slots.  Although 
the radiographers were very willing to accommodate as much as possible, there were 
periods during the study where the MR scanner was being replaced, serviced or had 
broken down.  All these factors meant the numbers who had MR scans were far 
lower than anticipated and thus the plan to use them to track muscle loss over time 
had to be re-thought.  Part of the solution to this was retrieving CT scans for L3 
analysis of muscularity.  This resulted in being able to assess muscularity in more 
patients at baseline, but again longitudinal measures were limited both by lower 
numbers and by the timing of scans not coinciding with functional assessments.   
 
10.3 Future areas of investigation 
Although this thesis has contributed to an improved understanding of the molecular 
events in skeletal muscle relevant to human cancer cachexia, along with 
characterisation of the physiological phenotype of skeletal muscle in the cachectic 
UGI cancer patient, it has also raised many questions and potential avenues for 
further study.  The discovery of a unique gene signature in skeletal muscle along 
with discovery of β-dystroglycan and CAMK2β  as potential biomarkers of cancer 
cachexia is novel and exciting. However, differences in fold change/protein levels 
between non-cachectic and cachectic patients were reasonably small and the findings 
require further validation in larger cohorts before contemplating their clinical 
application.  Furthermore, it would be interesting to investigate potential geographic 
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differences in the gene profile of cancer cachexia in order to assess the wider 
applicability of the biomarkers.  The studies in this thesis were all in a Caucasian 
European population and it would be useful to investigate whether the same gene 
signature of cancer cachexia is relevant in other ethnicities.  Likewise, the suggestion 
that there may be sex differences in response to cancer cachexia in the phenotype 
studies raises the question of whether there are gender specific molecular pathways 
in human cancer cachexia.  The finding in mice with cancer that cardiac autophagy 
occurs in a sex specific manner (Cosper and Leinwand, 2011) might suggest that the 
same may occur in humans, but this will require further exploration in large datasets.  
There may also be changes that are unique to particular tumour sites. Although all 
the patients had UGI cancer and the majority were adenocarcinoma, it is possible that 
there are subtle differences in the phenotype or molecular mechanisms of cancer 
cachexia according to the underlying diagnosis of gastric, oesophageal or pancreatic 
cancer.   
 
One of the aims of the thesis was to carry out a novel longitudinal study, but as 
discussed throughout the thesis, this was not achievable as first thought.  In the future, 
longitudinal studies will undoubtedly be informative given the fact that cachexia is a 
journey rather than an event.  However, careful study design will be required in order 
to achieve this.  It is also apparent that larger numbers of patients will need to be 
recruited at baseline in order to accommodate the potential fall out in the longitudinal 
studies. The model used in this thesis was patients with UGI cancer undergoing 
surgery which would allow more ready access to tissue biopsies with minimal 
patients discomfort.  The percutaneous quadriceps biopsy technique used in this 
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thesis was tolerated well by the cancer patients undergoing surgery and also at follow 
up under local anaesthesia.  Recruitment of patents who are not undergoing 
resectional surgery may allow larger numbers to take part in cachexia studies.  For 
example, in an audit of gastro-oesophageal cancer referrals to the regional MDT only 
28% of patients were suitable to be assessed for potentially curative surgery.  This 
meant that 72% of patients with UGI malignancies were not approached for 
recruitment into the studies.  It may also be useful to perform follow up assessments 
at more frequent intervals, and perhaps to utilise more portable equipment which 
could allow assessments in the patients home environment rather than being confined 
to the hospital environment.  This may improve the recruitment of patients with 
progressive cachexia and thus the ability to relate the baseline molecular signature to 
those who go on to develop cachexia rather than differentiating those who are 
currently cachectic.   
 
The theme of the thesis was intentionally centred around skeletal muscle as this is the 
key tissue compartment affected by cachexia.  However, access to tissue can be 
associated with complications due to the need for an invasive biopsy.  Exploring 
correlates of the biomarkers that were found to be relevant in muscle (i.e. CAMK2β) 
in other tissue compartments (i.e. blood/urine) may provide biomarkers that are more 
easily accessible and applicable to routine clinical practice.  Likewise, the 
observation of increased numbers of lipid droplets in the skeletal muscle of patients 
with cancer cachexia deserves further investigation into the underlying mechanisms 
and cross-talk between adipose and muscle compartments in patients with cachexia. 
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The suggestion that upper and lower limb muscle compartments respond differently 
to cachexia requires further exploration.  A comprehensive assessment of changes 
and functional measures of all muscle compartments may prove very interesting.  For 
example, if some muscles are more resistant to wasting than others, the reasons for 
this could be explored and potentially shed light on methods of treating the muscles 
that are most sensitive.  Likewise, further exploration of molecular changes in 
different muscle compartments could be equally informative. 
 
Although cachexia is characterised by muscle loss, there are no human studies 
specifically assessing histology/fibre typing of muscles.  Likewise, if RNA/protein is 
degraded in cachexia, it may have implications on molecular studies assessing 
protein and RNA biomarkers.  For example taking a muscle biopsy of the same 
weight from healthy normal sized fibres compared with atrophying fibres may result 
in overloading cachectic muscle samples, which will mask potential differences.  
There is therefore a need to explore this area in more detailed studies. 
 
Another intriguing avenue of investigation would be to focus studies on the non-
cachectic patients. Are there reasons why some patients appear to be resistant to 
muscle wasting despite having the same stage/site of tumour as others who do have 
profound wasting?  Knowledge about muscle molecular pathways and phenotype in 
these resistant patients could provide very informative in searching for potential 
treatment targets for cachectic patients.  Likewise, with this cohort being less frail, 
they are more likely to attend follow up assessments and withstand functional 
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measures rather than the progressive cachexia cohort where many patients become 
too frail to allow longitudinal assessment. 
 
Potential contribution of thesis to future clinical trial design 
The finding that muscle function/mass/quality deteriorates with progressive weight-
loss with subsequent impact on QoL begs the question of how to improve or reverse 
these phenomena.  Treatment trials have tended to focus on single pharmacological 
interventions. However if muscle mass is regulated by diet and exercise, assessment 
of multimodal treatments focussed on diet/exercise/drug interventions may prove 
more useful.  The present thesis has suggested that a focus on promoting anabolism 
via protein synthesis would be important in such a multimodal approach.  Muscle 
biomarker research remains at an early stage but could be studied further within the 
context of such an intervention trial.  For palliative patients, the present thesis 
suggests that the interval over which an intervention should be tested is probably best 
targeted at 2-3 months rather than 6 months.  A post-surgical resection clinical trial 
model seems too heterogeneous and challenging to recommend at present.  From a 
practical viewpoint, serial assessment of muscle mass is probably best achieved by 
using diagnostic CT scans rather than specific MR scans.  The disadvantage of using 
such CT images is that lower limb muscles are likely to be more sensitive to change 
and important differences may be missed.  Functional assessment is important and 
differences between upper and lower limbs suggest that HGD may be less sensitive 
than lower limb extensor strength and power measures.  Furthermore, differences 
between men and women observed in the present thesis suggest that future 
intervention trials may have to at least stratify for gender, if not analyse results 
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separately.  Many of the findings of the present thesis have contributed to the design 
of  an  international  multicentre  trial  entitled  ‘Multimodal  Exercise, Nutrition and 
Anti-inflammatory  Cachexia  Intervention  Trial  (MENAC)’  (Trial  No. NCT01419145, 
(NIH)).  The randomised feasibility pilot of this trial has completed and the results of 
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APPENDIX  I:  Information,  screening,  consent  and  
questionnaires. 
 





THE IDENTIFICATION OF EARLY BIOCHEMICAL AND CLINICAL MARKERS OF CANCER-
ASSOCIATED WASTING 
 
You are being invited to take part in a research study. Before you decide, it is important for 
you to understand why the research is being done and what it will involve. Please take time 
to read the following information carefully. Talk to others about the study if you wish. 
 Part 1 tells you the purpose of this study and what will happen to you if you take part. 
 Part 2 gives you more detailed information about the conduct of the study. 
Ask us if there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
 
Part 1 
What is the purpose of the study? 
The purpose of this research study is to find out what causes people who have cancer to 
become wasted, lose weight and feel tired. This wasting is a significant problem for patients 
as it causes a reduction in both quality and quantity of life. In order to find out what causes 
this problem and if there is any way to predict its development, we are asking patients about 
to undergo surgery for cancer if they would undergo a variety of tests before, during, and 6 
months, 12 months and 18 months after their operation. These tests are mainly to measure 
changes in muscle size, muscle strength and power. We would like to see if any of these 
changes  are  related  to  the  activity  of  certain   ‘markers’  of  wasting  which  we  will  measure   in  
samples of muscle, tumour, blood and urine. These tests are designed to cause the 
minimum of discomfort or inconvenience for anyone involved. 
 
Why have I been chosen? 
You have been chosen because you will soon be having surgery for cancer. We aim to 
recruit 50 participants in total. 
 412 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do, you will be given this 
information sheet to keep and be asked to sign a consent form. You will still be free to 
withdraw at any time in the future and without giving a reason. A decision to withdraw at any 
time, or a decision not to take part, will not affect the standard of care that you receive. 
 
What will happen to me if I take part? 
If you take part, you will be asked to undergo certain tests before your operation, during your 
operation, and at appointments 6 months, 12 months and 18 months after the operation. The 
appointments before and after your operation will be timed to coincide with the normal clinic 
appointments with your surgeon. Therefore, no extra visits to hospital are required if you 
choose to take part in this study. However, if for any reason we are unable to coincide your 
study appointments with your normal clinic appointments, we will provide taxi transport to 
and  from  the  Royal  Infirmary  of  Edinburgh’s  Clinical  Research  Facility.  The  tests  will  include: 
 
 A blood test: The amount of blood taken will be 20ml (providing your blood count is 
normal) and it will be taken from your arm in the usual fashion.  
 
 A urine test: This will be performed in the usual fashion. The amount of urine taken is 20-
30ml. 
 
 Tests of muscle strength and power: These tests will involve you sitting in specialised 
chairs and extending your leg as fast and as hard as you can. These tests will take about 
20 minutes. 
 
 Test of functional ability (timed up-and-go): This test will measure your ability to get up 
out of a chair and walk a few metres then turn around and go back to your chair. It will only 
take a few minutes. 
 
 MRI scans of your legs and arms: These will be carried out in the Department of 
Radiology and will take approximately 20 minutes to perform. Each scan will involve you 
lying flat within the scanner although your whole body does not enter the scanner. There are 
no X-rays or injections involved.  
 
 A questionnaire: This will take approximately 15 minutes to complete but can be taken 




We would initially plan to carry out all of the above tests at one appointment prior to the date 
of your operation. If, after carrying them out, you found that these tests were acceptable to 
perform (as we would hope), we would ask you to repeat the same tests at appointments 
dated 6 months, 12 months and 18 months after your operation. 
 
Apart from the above-described tests, the only other tests will be performed during your 
operation whilst you are asleep (under general anaesthetic): 
 
 A muscle biopsy: Whilst you are asleep (under general anaesthetic) during your 
operation, small muscle samples will be removed from both your abdominal wall and your 
thigh. The abdominal muscle sample will be pea-sized and will be taken from the incision 
through which your operation is being performed. The amount of muscle removed from the 
front of your thigh is even smaller and is taken via a tiny incision (a few millimeters long) 
through which a needle is introduced. This incision will be closed by paper stitches and will 
leave a small mark which will fade.   If you have a thigh muscle biopsy in the outpatient clinic, 
this will be done using a technique known as fine needle aspiration.  A small needle will be 
used under suction to aspirate some muscle from the thigh.  No stitches will be required after 
this and it will not be painful as the needle used is very thin.   
 
  A fat biopsy: When you are asleep under general anaesthetic, a small piece of fat (again, 
about the size of a pea) will be taken from just under the skin and also from the fat layer 
inside of your abdomen. 
 
 A tumour biopsy: After your tumour has been removed it is normally taken to the 
Department of Pathology for microscopic examination by a Consultant Pathologist. One of 
our research team will accompany the tumour specimen to the Department of Pathology, 
where the Consultant Pathologist will remove small biopsies (a few millimeters) of both the 
tumour and the surrounding healthy tissue from the specimen and give it to the researcher 
for analysis.  
 
At one of the appointments dated 6 months, 12 months and 18 months after your operation, 
we would ask that you give us permission for a further thigh muscle biopsy at that time. This 
will be performed under a local anaesthetic injection but will otherwise be the same as the 
one that you have had previously. Obviously we will re-confirm your permission to perform 
this test at that time. 
 
What do I have to do? 
Apart from attendance at the appointments before your operation, and at 6, 12 and 18 




What are the possible disadvantages and risks of taking part? 
We have taken every step in the design of this study to minimise any possible disadvantages 
and risks. 
Regarding the thigh muscle biopsy, you may experience some mild discomfort and stiffness 
in the leg following the procedure, but this should wear off after a few hours. Also, 
approximately 1 in 200 people suffer with bruising following the procedure.  
If you have are having a repeat thigh muscle biopsy because you have lost weight following 
your operation, you may be feeling tired at the time of the procedure. This biopsy will be 
performed under a local anaesthetic injection. The anesthetic agent may sting for a few 
seconds as it is being administered.  
Regarding the MRI scans, some people may occasionally feel claustrophobic within the scan 
machine. However, the machine is smaller than other scan machines you may have been in 
(e.g. CT) and the radiographer remains present with you throughout the scan. The MRI scan 
does not involve X-rays. 
 
What are the possible benefits of taking part? 
We cannot promise that the study will help you, but the information we receive might help 
improve the treatment of patients with cancer and cancer-associated weight-loss. 
 
What happens when the research study stops? 
Following your appointment 18 months after your operation, no further appointments are 
required. However, if any of your blood, muscle, tumour or urine samples remain, we would 
ask your permission to store these samples (in anonymised form) in the University of 
Edinburgh so that we can consider them for use in future research studies that we may carry 




What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. The detailed information on this, including contact details, 
is given in Part 2.   
 
Will my taking part in the study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential.  The details 




What if relevant new information becomes available? 
If any new treatment for cancer or cancer-associated wasting becomes available during the 
time of the study, it will not be withheld from you because of your participation in this study. 
Furthermore, if you require any other treatment for cancer during the course of the study (e.g. 
chemotherapy or radiotherapy), it will not be withheld from you because of your participation 
in this study.   
 
What  will  happen  if  I  don’t  want  to  carry  on  with  the  study? 
You can withdraw from the study at any time. However, we would ask your permission to 
keep in contact with you to monitor your progress. In this way, any information that was 
collected during the time of your participation in the study may still be used for research 
purposes. Any stored blood or tissue samples that can still be identified as yours will be 
destroyed if you wish. 
 
What if there is a problem? 
 Complaints: If you have a concern about any aspect of this study, you should ask to 
speak with the researchers who will do their best to answer your questions. If you remain 
unhappy and wish to complain formally, you can do this through the NHS Complaints 
Procedure. Details can be obtained from the hospital. 
 Harm: In the event that something does go wrong and you are harmed during the 
research study, there are no special compensation arrangements. If you are harmed and this 
is   due   to   someone’s   negligence,   then   you   may   have   grounds for a legal action for 
compensation against the University of Edinburgh but you may have to pay for your legal 
costs. The normal National Health Service complaints mechanism will still be available to 
you. 
 
Will my taking part in this study be kept confidential? 
Yes. All information which is collected about you during the course of the research will be 
kept strictly confidential. However, we would like to inform your GP of your involvement in 
this study but we will require your permission to do this. All other information about you 
which leaves the Royal Infirmary of Edinburgh will have your name and address removed so 
that you cannot be recognised from it. 
Muscle, blood and tumour samples collected during the study may be transferred for the 
purpose of analysis to associated researchers within and outside the European Economic 




What will happen to any samples I give? 
A portion of the blood samples will be immediately analysed by the Department of 
Biochemistry at the Royal Infirmary of Edinburgh. The remainder of the blood samples, along 
with the muscle, tumour and urine samples, will be transferred to the University of Edinburgh 
for analysis. The only individuals who will have direct access to these samples will be the 
members of the research team behind this study. The samples will be analysed in the 
University of Edinburgh by various biochemical techniques in order to measure the levels of 
certain ‘markers’  of  wasting  within   the  various   tissues.  Also,  small  portions  of   the  samples  
may be sent from the University of Edinburgh to our collaborators at the University of Ohio, 
USA,   for   other   biochemical   analyses   which   examine   different   ‘markers’   of   wasting. The 
samples that are sent to the USA will already be anonymised so that you will not be 
identifiable  from  them.  Furthermore,  all  of   these  samples  will  be   ‘used  up’   in  the  USA,  and  
therefore, there will be none left over which will require storage overseas. 
Following all of these different analyses, if any of the samples remain, we would ask your 
permission to store these samples (in anonymised form) in the University of Edinburgh so 
that we can consider them for future research studies (if a local Ethics Committee deems the 
studies appropriate). Professor Kenneth Fearon, Professor of Surgical Oncology, will act as 
custodian for any stored samples. The only other individuals who will have direct access to 
the stored samples will be the members of the research team behind the current study. 
 
Will any genetic tests be done on the samples that I give? 
We have no plans to perform genetic analysis within the remit of this current study. However, 
following this current study, we would ask your permission to store any remaining samples 
so that we may consider them for use in future research studies that we may carry out (if a 
local Ethics Committee deems the study appropriate). Future studies could potentially 
involve genetic analysis, but such studies are at a very early stage of planning and not yet in 
progress. Any results from future genetic studies will not have any healthcare implications for 
you and hence we would not normally feed these results back to you. 
 
What will happen to the results of the current research study?  
The results of this study will be published in medical journals, reports and textbooks. Results 
will be made available to study participants through the Cancer Research UK website. You 
will not be identifiable in any report/publication or report unless you have specifically 
consented to release such information. 
 
Who is organising and funding the research? 
The research is being organised and sponsored by the University of Edinburgh. The 
research is being funded by Cancer Research UK. 
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Who has reviewed the study? 
This study was given a favourable ethical opinion for conduct in the NHS by Lothian 
Research Ethics Committee. This study has also been reviewed by members of the scientific 
committee of Cancer Research UK. 
 
Contact details 
You may contact me (the main researcher) directly by telephoning 0131 242 6520 for further 
information at any time. Alternatively, you may contact Mr Rowan Parks, Senior Lecturer and 
Consultant Surgeon in the Department of Surgery, who is acting as an independent advisor 
– contact 0131 242 3615.  
 
Many thanks for your time. 
 
Mr. Nathan Stephens 
Clinical Research Fellow 
Department of Surgery 











THE IDENTIFICATION OF EARLY BIOCHEMICAL AND CLINICAL MARKERS OF CANCER-
ASSOCIATED WASTING 
 
1. I agree to take part in the above-titled study.  
 
 
2. I confirm that I have read and understand the information sheet dated Feb 2008 
(version 4.1) for the above study. I have had the opportunity to consider the information and ask 
questions, and I have had these answered satisfactorily. 
 
 
3. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
 
4. I understand that relevant sections of any of my medical notes and data collected during 
the study may be looked at by responsible individuals from regulatory authorities or from Lothian 
NHS Trust University Hospitals Division, where it is relevant to my taking part in this research. I 
give permission for these individuals to have access to my records. 
 
 
5. I agree to my GP being informed of my participation in the study.  
 
 
6. I agree to the storage of samples taken during the course of this study so that they may 
be considered for use in future research studies (pending a favourable ethical opinion by Lothian 
Local Research Ethics Committee). 
 
 
7. I agree to the use of samples taken during the course of this study in possible future 





________________________ ________________           ____________________ 





_________________________ ________________           ____________________ 





1. Karnofsky Performance Score 
 
Which of the nine statements below best describes your present physical activity? 
Please circle the relevant number. 
 
 
Your number lies from 80 to 100 only if you are able to carry on normal activity and 
to work. You require no special care. 
 
100   My activity is normal. I have no complaints and show no evidence of my 
condition. 
 
90     I am able to carry on normal activity. I have only minor symptoms of my 
condition. 
 
80     I am able to carry on normal activity but only with effort. I have some minor 





Your number lies from 50 to 70 only if you are able to live at home and care for most 
of your personal needs. You require varying amount of assistance and you are 
unable to work.  
 
70  I am able to fully care for myself. However, I am unable to carry on normal 
activity or to do active work. 
 
60  I require occasional assistance, but I am able to care for most of my personal 
needs. 
 





Your number lies between 20 and 40 if you are unable to care for yourself.  You 
require the equivalent of institutional or hospital care.  
 
40  I am disabled and require special care and assistance. 
 
30  I am severely disabled. I should be admitted to hospital. 
 
20  I am very sick. I am in hospital. Active supportive treatment is necessary. 
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2. EORTC QLQ-C30 
           
Please go on to the next page 
EORTC QLQ-C30  (version 3) 
We are interested in some things about you and your health. Please answer all of the questions 
yourself by circling the number that best applies to you. There are no "right" or "wrong" 
answers. The information that you provide will remain strictly confidential. 
Please fill in your initials:  
Your birthdate (Day, Month, Year):  
Today's date (Day, Month, Year):   
Not at A Quite Very 
all little a bit much 
1.   Do you have any trouble doing strenuous activities, 
like carrying a heavy sho pping bag or a suitcase? 1 2 3 4 
2.   Do you have any trouble taking a  long  walk? 1 2 3 4 
3.   Do you have any trouble taking a  short  walk outside 
of the house? 1 2 3 4 
4.   Do you need to stay in bed or a chair during the day? 1 2 3 4 
5.   Do you need help with eating, dressing,  washing 
yourself or using the toilet? 1 2 3 4 
During the past week: Not at A Quite Very 
All little a bit much 
6.   Were you limited in doing either your work or other 
daily activities? 1 2 3 4 
7.   Were you limited in pursuing your hobbies or other 
leisure time activities? 1 2 3 4 
8.   Were you short of breath? 1 2 3 4 
9.   Have you had pain? 1 2 3 4 
10.   Did you need to rest? 1 2 3 4 
11.   Have you had trouble sleeping? 1 2 3 4 
12.   Have you felt weak? 1 2 3 4 
13.   Have you lacked appetite? 1 2 3 4 
14.   Have you felt nauseated? 1 2 3 4 
15.   Have you vomited? 1 2 3 4 




© Copyright 1995 EORTC Quality of Life Study Group.  All rights reserved.  Version 3.0 
During the past 
week: 
Not at A Quite Ver
y all littl
e 
a bit much 
17.   Have you had diarrhea? 1 2 3 4 
18.   Were you tired? 1 2 3 4 
19.   Did pain interfere with your daily activities? 1 2 3 4 
20.   Have you had difficulty in concentrating on things, 
like reading a newspaper or watching television? 1 2 3 4 
21.   Did you feel tense? 1 2 3 4 
22.   Did you worry? 1 2 3 4 
23.   Did you feel irritable? 1 2 3 4 
24.   Did you feel depressed? 1 2 3 4 
25.   Have you had difficulty remembering things? 1 2 3 4 
26.   Has your physical condition or medical treatment 
interfered with your  family  life? 1 2 3 4 
27.   Has your physical condition or medical treatment 
interfered with your  social activities? 1 2 3 4 
28.   Has your physical condition or medical treatment 
caused you financial difficulties? 1 2 3 4 
For the following questions please circle the number between 1 and 7 
that bes  applies to you 
29. How would you rate your overall  health  during the past week? 
1 2 3 4 5 6 7 
 Very 
poor 
         Excellent 
30. How would you rate your overall  quality of life  during the past week? 
1 2 3 4 5 6 7 
 Very 
poor 
         Excellent 
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Healthy elderly screening questionnaire 
 
Exclusion  criteria  to  define  “medically  stable”  elderly  subjects 
 
 History of myocardial infarction within the previous 2 years 
 Cardiac illness: symptoms of aortic stenosis, acute pericarditis, acute 
myocariditis, aneurysm, severe angina, clinically significant valvular disease, 
uncontrolled dysrrhythmia, claudication, within the last 10 years.  
 Thrombophlebitis or pulmonary embolus within the previous 2 years 
 History of cerebrovascular disease 
 Acute febrile illness within the previous 3 months 
 Severe airflow obstruction 
 Uncontrolled metabolic disease (e.g. thyroid disease) 
 Major systemic disease active within the previous 2 years ( e.g. cancer, 
rheumatoid arthritis) 
 Significant emotional distress, psychotic illness or depression within the 
previous 2 years 
 Lower limb arthritis, classified by inability to perform maximal contraction of 
lower limbs without pain 
 Lower limb fracture sustained within the previous 2 years; upper limb 
fracture sustained within the previous 6 months; non-arthroscopic lower limb 
joint surgery within the previous 2 years 
 Any reason for loss of mobility for greater than 1 week within the previous 2 
months or greater than 2 weeks within the previous 6 months 
 Resting systolic blood pressure.200mmmHg or resting diastolic blood 
pressure >100mmHg  
 Taking beta-blockers or digoxin, or not in sinus rhythm (excluded form 
ergometry because of difficulty interpreting heart rate) 















If  the  answer  is  YES  to  any  of  the  following  questions,  please  give  some  details  
including  dates  where  possible. 
 
 
Have you any history of heart trouble? 




Have you any history of problems with blood vessels? 





Have you any history of chest problems? 




Have you ever smoked? 





Do you suffer from diabetes? 
(if YES please state if insulin dependent) 
 
 
Have you any history of major illness now or in the last 20 years? 









Do you suffer from osteoarthritis? 
(if YES please state joints affected and indicate mild, moderate or severe and any 








Do you have any problems with your bones? 




Have you any history of back problems? If so, when did they start and do they still 














Have you had any acute illness in the last six months? 




Please state any medication, prescribed or over the counter, regularly taken for any 
condition 
 










Do you have any physical disabilities? 




Is there any other illness or condition that affects your general health or interferes 




Approximately how tall are you? 
 
Approximately how much do you weigh? 
 
 
Your  Doctor’s  Name: 
 
Your  Doctor’s  Address: 
 
 
Thank you for completing this questionnaire 
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APPENDIX  II:  Patient  demographics  for  the  tissue  
biobank  and  physiological  assessments 
Tissue biobank and phenotypic measures 
One of the aims of the thesis was to establish a novel biobank of UGI cancer patients.  This 
appendix details all the samples and measurements obtained and the basic demographics of 
the different cohorts. 
 
Patients undergoing surgery for histologically or clinically suspected UGI cancers were 
approached for recruitment. 122 participants were recruited to the tissue biobank.  This 
comprised 19 control patients and 103 cancer patients.  One control patient did not have 
tissue biopsies and was thus excluded and a further couple of controls were excluded as 
detailed below. Post-operatively, 10 cancer patients were excluded due to the pathological 
examination of the resection specimen not showing a carcinoma.  Reasons for exclusion are 
outlined in Table A1. 
 




Table  A1:  Patients  excluded  from  the  tissue  biobank. 
 
Initial patient group Reason for exclusion 
Control 1 No tissue biopsies obtained 
Control 2 Low BMI, myopathy on pathology 
Control 3 Unexplained weight-loss 
  
Cancer Patient 1 Pancreatic neuroendocrine neoplasm 
Cancer Patient 2 Oesophageal  high  grade  dysplasia/Barrett’s 
Cancer Patient 3 Pancreatic neuroendocrine neoplasm 
Cancer Patient 4 Pancreatic tubulovillous adenoma 
Cancer Patient 5 Pancreatic benign tumour 
Cancer Patient 6 Chronic pancreatitis 
Cancer Patient 7 Pancreatic serous microcystic adenoma 
Cancer Patient 8 Duodenal flat tubular adenoma 
Cancer Patient 9 Oesophageal  high  grade  dysplasia/Barrett’s 
Cancer Patient 10 Pancreatic mucinous tumour 
 
 
Abbreviations: BMI, body mass index. 
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Description of cancer patients in the biobank 
Tumour site 
27 patients had oesophageal cancer, 12 patients had gastro-oesophageal junctional cancer, 15 
patients had gastric cancer, 36 patients had pancreatic cancer, 1 patient had duodenal cancer, 
1 patient had common bile duct cancer (cholangiocarcinoma) and 1 patient had a small 
bowel cancer.  Within the pancreatic cancer group, there were some patients who had a 
duodenal or common bile duct cancer invading the pancreas along with one who had a 
synchronous gallbladder carcinoma. 
 
Histology 
The majority of patients had adenocarcinoma (n=81) with 4 of these patients having ACC 
with other histology also (e.g. IPMN).  5 patients had unspecified carcinoma and 7 patients 
had squamous cell carcinoma (oesophageal). 
 
Cancer stage 
Tumours were reported according to the TNM system and then they were classified into 
gross cancer stage group according to the UICC criteria.  1 patient had stage 0 cancer, 13 
stage 1, 23 stage 2, 37 stage 3 and 19 stage 4 cancer. 
 
Cachexia 
When cachexia was defined as pre-operative unintentional weight-loss  ≥5%, 50 patients 
were cachectic and 43 were not cachectic. 
 
Surgery 
The majority of patients underwent surgery (n=87).  67 of these patients had what was 
thought to be a ‘curative’ resection, and 20 patients had a ‘palliative’ operation.  The latter 
group were patients who were found to have metastases on opening the abdominal cavity or 
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where it was not possible to resect the primary tumour (i.e. if invading vessels or extensive 
adhesions from previous surgery).  The types of surgery that were performed were: 
 
Pancreatic cancer: 15 Double bypass (palliative gastrojejunostomy and 
hepaticojejunostomy), 18 Whipples pancreaticoduodenectomy, 1 Distal pancreatectomy 
Gastric cancer: 6 Subtotal gastrectomy, 8 Total gastrectomy, 1 Distal gastrectomy, 
1 Proximal gastrectomy 
Oesophageal cancer: 29 Ivor Lewis oesophagectomy, 2 Transhiatial oesophagectomy,  
2 Thoracoscopic assisted oesophagectomy 
Other: 1 Small bowel resection, 3 Laparotomy only (resection abandoned due to distant 
metastases), 6 patients did not have surgery, but still underwent a muscle biopsy and a blood 
and urine sample were taken.  These patients were thus included in the palliative group. 
 
Basic demographics 
Table A2 shows basic demographics for the cancer patients in the biobank. 
 
Tissue samples in the biobank 
It was not possible to get all tissue biopsies from every patient.  Biopsy samples also varied 
in size with the result that there was insufficient tissue to divide for protein, RNA and TEM.  
The biobank was and is an evolving resource.  As time passed, more potential uses were 
thought of and then ethics approval obtained to collect tissue.  This resulted in, for example, 
the patients first entered into the biobank not having fat biopsies. 
 
Tissue biopsy type, preparation and the number of samples for cancer patients are outlined in 




Table  A2:  Cancer  patient  demographics  in  tissue  biobank 
 
 
Age (years) 65 (10), 39-88 
M:F 65:28 
BMI baseline (kg/m2) 25.7 (4.5), 16.7-42.5 
Weight-loss (%) 7.7 (9.3), -10.4-46.3 
KPS 88.2 (13.2), 50.0-100.0 
 
 
Results are presented as mean (SD), range, or categorically.  
Abbreviations: BMI, body mass index; M, male; F, female; KPS, 
Karnosfky performance score; kg, kilograms; m, metres. 
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Table  A3:  Types  of  tissue  in  the  biobank  (cancer  patients) 
 
Tissue Preparation Number patients 
Muscle Rectus abdominis 87 
Cryo-section 32 
Paraffin for H&E 22 
For Electon Microscopy 23 
Quadriceps 46 
Fat Subcutaneous 68 
Paraffin for H&E 15 
Omentum 51 
Paraffin for H&E 15 
Tumour Tumour 13 
Peri-tumoural normal 6 
Urine 81 
Blood Whole blood 67 




Abbreviations: H&E, haematoxylin and eosin stain. 
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Table  A4:  Numbers  of  cancer  patients  undergoing  
longitudinal  muscle  biopsy  and  blood  measures 
 
Tissue type Baseline Follow-up Matched paired samples 
Quads biopsy 44 23 21 






Description of cancer patients undergoing physiological assessment 
This group was the main focus of the physiological studies (Part II) and comprised a 
subpopulation of the entire cohort.  There were 54 cancer patients in total – 35 males and 19 
females.  Tumour site was: 1 bile duct (cholangiocarcinoma), 9 gastric, 17 oesophageal, 5 
OGJ, 21 pancreas and 1 rectum. Tumour gross stage was: 5 stage 1 cancer, 7 stage 2, 28 
stage 3, 14 stage 4. 23 patients were cachectic (5% weight-loss cut-off) and 31 patients were 
not cachectic. Table A5 illustrates the demographics for this cohort. 
 
Longitudinal cohort 
Table A6 outlines the numbers of patients undergoing follow up measures.  The patients who 
were not contacted for further follow-up were a small group who subsequently entered a trial 
involving a potential anabolic agent and thus were not felt appropriate to include in follow 
up assessment of muscle function and mass.  There were also a few patients who had not yet 
undergone the follow-up appointments at the time of data analysis. 
 
This made the longitudinal analysis difficult as not all had every assessment at each time 
point.  The initial intention of the study was to monitor loss of muscle mass by MR scan.  
However, of the 33 patients where it was possible to obtain a baseline MR scan, only 12 
patients had at least one follow up MR scan to compare to calculate muscle loss.  See 
Chapter 10 for more discussion on these challenges and solutions. 
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Table  A5:  Demographics  for  cohort  of  cancer  patients  
undergoing  muscle  function  measurements. 
 
Age (years) 65 (11), 39-88 
M:F 35:19 
BMI baseline 25.2 (4.3), 20.0-40.0 
Weight-loss (%) 8.4 (9.4), -10.4-43.8 




Results are presented as mean (SD), range, or categorically.   
Abbreviations: BMI, body mass index; M, male; F, female; KPS, 
Karnosfky performance score; kg, kilograms; m, metres. 
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Table  A6:  Numbers  of  cancer  patients  undergoing  each  
physiological  assessment 
 
 Baseline FU 1 FU 2 FU 3 
Total number 54 27 18 9 
MR scan 33 21 11 6 
IKES 50 27 18 9 
LLEP 52 27 18 9 
HGD 51 26 17 9 
STS 43 25 18 9 
TUG 43 25 18 9 
QoL 48 25 17 8 
ActivPAL™ 20 15 10 4 
     
Died 0 14 20 21 
Declined FU 0 7 7 9 
Not for FU 0 6 6 6 
Awaited 0 0 3 9 
 
 
Abbreviations: FU, follow-up assessment; MR, magnetic resonance; 
IKES, isometric knee extensor strength; LLEP, lower limb explosive 
power; HGD, handgrip dynamometry; STS, sit-to-stand time; TUG, 3m 




Description of control patients in the biobank 
18 healthy controls were recruited into the tissue biobank cohort.  Table A7 shows some 
basic demographics for these control patients in the biobank. 
 
All controls underwent surgery.  The types of operations were: 7 Incisional hernia repair, 5 
Other hernia repair (i.e. inguinal, umbilical), 1 Excision rectal stump, 1 Transduodenal 
sphincterotomy, 1 Gastrectomy, 2 Cholecystectomy and 1 Open fundoplication 
 
Tissue biopsy type, preparation and the number of samples for control patients are outlined 
in Table A8. 
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Table  A7:  Demographics  for  control  patients  undergoing  
muscle  biopsy 
 
Age (year) 58 (16), 28-86 
M:F 9:9 
BMI baseline (kg/m2) 27.6 (5.1), 17.9-35.9 
Weight-loss (%) 0.0 (0.0), 0.0-0.0 
KPS 100.0 (0.0), 100.0-100.0 
 
 
Results are presented as mean (SD), range or categorically.  
Abbreviations: BMI, body mass index. M, male; F, female; KPS, 
Karnosfky performance score; kg, kilograms; m, metres. 
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Table  A8:  Types  of  tissue  in  the  biobank  (control  patients) 
 
Tissue Preparation Number patients 
Muscle Rectus abdominis 16 
Cryo-section 6 
Paraffin for H&E 3 
For Electron Microscopy 7 
Quadriceps 5 
Fat Subcutaneous 9 
Paraffin for H&E 4 
Omentum 7 
Paraffin for H&E 3 
Urine  10 
Blood Whole blood 8 










Description of control patients undergoing physiological assessment 
18 healthy older individuals were recruited from the community as controls.  Table A9 
outlines demographics for this cohort. No patients were knowingly taking anabolic/catabolic 
agents or hormone replacement therapy at the time of participation in the study.  All patients 
underwent  a  stringent  screening  questionnaire  to  ensure  that  they  were  truly  ‘healthy’.    An  
example of the questionnaire is outlined earlier in the Appendix. 
 
Additional cohorts used 
There were supplemental groups added, mainly to increase the numbers in the molecular 
analysis and reduce the chance of type 2 errors.  In the Western blot/qRT-PCR analysis for 
FOXO, CAMk2, MuRF1, MAFBx, BNIP3, GABARAPL1, n=9 additional cancer patients 
and 2 additional control patients were included with Rectus abdominis biopsies.  In the cross-
sectional microarray analysis, n=5 additional cancer patients and 1 additional control patients 
were added.  In the TEM analysis, n=1 extra cancer patient was included.  These extra 
biopsies had been collected by a previous research fellow (Mr Richard JE Skipworth) and 
were used with his permission. The specific demographics of the entire group are outlined 
and discussed in the relevant Chapters. 
 
Table A10 outlines normal reference ranges for the plasma markers analysed in the thesis. 
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Table  A9:  Demographics  for  control  patients  undergoing  
physiological  assessments 
 
Age 79 (3), 75-85 
M:F 9:9 
BMI baseline (kg/m2) 25.8 (4.0), 18.5-33.9 
Weight-loss (%) 0.0 (0.0), 0.0-0.0 
KPS 100.0 (0.0), 100.0-100.0 
 
 
Results are presented as mean (SD), range, or categorically.  
Abbreviations: BMI, body mass index; M, male; F, female; KPS, 
Karnosfky performance score; kg, kilograms; m, metres. 
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Table  A10:  Normal  reference  ranges  for  blood  measures 
 
Measure Units Range   
  All Men Women 
CRP mg/l 0-5   
Albumin g/l 35-50   
Haemoglobin g/l  130-180 115-165 
Testosterone nmol/l  10-30 0.4-3.0 
Oestradiol pmol/l  0-160 75-140 
LH U/l  1-9 2-9 
FSH U/l  1-10 3-10 
SHBG nmol/l  6-45 30-120 
Insulin mU/l n/a   
Cortisol nmol/l n/a   
 
 
The reference ranges are based upon the values from the hospital 
laboratories in the Royal Infirmary of Edinburgh.  Abbreviations: CRP, C-
reactive protein; LH, luteinising hormone; FSH, follicular stimulating 




APPENDIX  III:  Presentations  and  publications  arising  
from  thesis 
Presentation of data from this thesis 
Oral presentations 
 
Physical functions and sexual dimorphism 
NA Stephens 
Cancer Cachexia Conference, Boston, USA, September 2012 
INVITED LECTURE 
 
Machiavelli and cancer cachexia 
NA Stephens 
Hospital Grand Rounds 
Wishaw General Hospital, February 2012 
 
Surgical resection relinquishes suppression of skeletal muscle turnover in cancer 
patients 
NA Stephens, IJ Gallagher, AJ MacDonald, RJE Skipworth, H Husi, CA Greig, JA 
Ross, JA Timmons, KCH Fearon 
Society of Academic and Research Surgery meeting, Nottingham, Jan 2012 
 
Skeletal muscle Akt in upper gastrointestinal cancer patients and its potential as a 
biomarker of cachexia 
NA Stephens, IJ Gallagher, JA Ross, KCH Fearon 
Society of Academic and Research Surgery meeting, Nottingham, Jan 2012 
 
Short-term follow up in patients with upper gastrointestinal cancer undergoing 
potentially curative resection 
NA Stephens, BH Tan, RJE Skipworth, AJ MacDonald, JA Ross, CA Greig, KCH 
Fearon 
School of Surgery Day, University of Edinburgh, 
The Royal College of Surgeons of Edinburgh, December 2010 




Hospital Grand Rounds 
Monklands hospital, Airdrie, September 2010 
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Reduced muscle quality is observed with progressive weight-loss in patients with 
cancer 
NA Stephens, C Gray, C White, BH Tan, KCH Fearon, CA Greig 
School of Surgery Day, University of Edinburgh, 
The Royal College of Surgeons of Edinburgh, December 2009 
 
Cancer cachexia – pathway activation in human skeletal muscle 
NA Stephens, IJ Gallagher, BH Tan, O Rooyackers, RJE Skipworth, L Lundell, JA 
Ross, DC Guttridge, JA Timmons, KCH Fearon 
School of Surgery Day, University of Edinburgh, 
The Royal College of Surgeons of Edinburgh, December 2009 
 
Human cancer cachexia – pathway analysis and identification of novel 
biomarkers in skeletal muscle 
NA Stephens, IJ Gallagher, BH Tan, O Rooyackers, RJE Skipworth, L Lundell, JA 
Ross, DC Guttridge, JA Timmons, KCH Fearon 
Society of Academic and Research Surgery meeting, London, Jan 2010 
Presented in PATEY PRIZE session 
Presentation can be viewed on YouTube (http://youtu.be/F8L_X7uY4k4) 
 
Muscle strength, volume and quality in patients with upper gastrointestinal 
cancer 
NA Stephens, C Gray, C Eeley, BH Tan, KCH Fearon, CA Greig 
School of Surgery Day, University of Edinburgh, 
The Royal College of Surgeons of Edinburgh, December 2008 
 
An investigation into the role of Forkhead box class O (FOXO) transcription 
factors in pancreatic and gastro-oesophageal cancer cachexia 
R.I. McMurray, N.A. Stephens, K.C.H. Fearon, J.A. Ross 
School of Surgery Day, University of Edinburgh, 




Suppression of skeletal muscle turnover in cancer cachexia: evidence from the 
transcriptome in sequential human muscle biopsies 
NA Stephens, IJ Gallagher, AJ MacDonald, RJE Skipworth, H Husi, CA Greig, JA 
Ross, JA Timmons, KCH Fearon 
6th Cachexia Conference, Milan, Italy, Dec 2011 
 
Association of lower limb power output and functional ability in cancer cachexia 
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NA Stephens, KCH Fearon, CA Greig 
6th Cachexia Conference, Milan, Italy, Dec 2011 
 
An investigation of potential skeletal muscle protein biomarkers of cancer 
cachexia 
NA Stephens, RJE Skipworth, CA Greig, JA Ross, KCH Fearon 
6th Cachexia Conference, Milan, Italy, Dec 2011 
 
Impact of cancer-associated weight-loss on lower limb muscle mass and function 
NA Stephens, C Gray, AJ MacDonald, BH Tan, IJ Gallagher, RJ Skipworth, JA 
Ross, KC Fearon, CA Greig 
33rd ESPEN Congress, Gothenburg, Sweden, September 2011 
Also presented at RCPSG 2nd Triennial Conference, Glasgow, November 2011 
 
Intramyocellular lipid droplets increase with progression of cachexia in cancer 
patients 
NA Stephens, RJ Skipworth, AJ MacDonald, CA Greig, JA Ross, KC Fearon 
33rd ESPEN Congress, Gothenburg, Sweden, September 2011 
 
Pre-operative weight-loss influences recovery following potentially curative 
resection in patients with upper gastrointestinal cancer 
NA Stephens, AJ MacDonald, RJ Skipworth, CA Greig, KC Fearon 
33rd ESPEN Congress, Gothenburg, Sweden, September 2011 
Also presented at RCPSG 2nd Triennial Conference, Glasgow, November 2011 
 
Upper and lower limb muscle mass in patients undergoing surgery for upper GI 
cancer 
AJ MacDonald, M Esposito, C Gray, NA Stephens, C Greig, KC Fearon 
33rd ESPEN Congress, Gothenburg, Sweden, September 2011 
 
Loss of fat free mass occurs during neoadjuvant chemotherapy for upper GI 
cancer 
AJ MacDonald, N Stephens, M Esposito, J Ross, L Wall, C Greig, V Baracos, KC 
Fearon 
33rd ESPEN Congress, Gothenburg, Sweden, September 2011 
 
Intramyocellular lipid content in human cancer cachexia – an ultrastructural 
analysis 
NA Stephens, RJE Skipworth, CA Greig, JA Ross, KCH Fearon 
5th Cachexia Conference, Barcelona, Spain, December 2009 
 
 445 
Reduced muscle quality is observed with progressive weight-loss in patients with 
cancer 
NA Stephens, C Gray, C White, BH Tan, KCH Fearon, CA Greig 
5th Cachexia Conference, Barcelona, Spain, December 2009 
 
Elucidating the role of the ubiquitin E3 ligases and autophagy pathway in human 
cancer cachexia 
NA Stephens, IJ Gallagher, RJE Skipworth, JA Ross, DC Guttridge, KCH Fearon 
5th Cachexia Conference, Barcelona, Spain, December 2009 
Also presented at RCPSG 2nd Triennial Conference, Glasgow, November 2011 
 
Muscle function in cancer cachexia: Influence of systemic inflammation 
NA Stephens, CD Gray, KC Fearon, CA Greig 
Physiology  Society  meeting  (Human  and  Exercise  Physiology),  King’s  College  
London, April 2009 
 
CAM Kinase 2 β is a valid biomarker of human cancer cachexia 
Stephens N, Gallagher IJ, Rooyackers O, Tan BH, Skipworth RJE, Ross JA, 
Guttridge DC, Timmons JA, Fearon KCH 
14th International Biochemistry of Exercise Conference, University of Guelph, 
Ontario, Canada, June 2009 
 
Quantification and optimisation of muscle volume MR images 
CD Gray, TJ MacGillivray, N Stephens, KCH Fearon, CA Greig 
NHS Lothian Research Symposium, Spring 2009 
 
Myosin heavy chain in human muscle wasting – an early biomarker of cancer 
cachexia? 
NA Stephens, W He, K Guttridge, BH Tan, RJE Skipworth, CA Greig, JA Ross, 
KCH Fearon, DC Guttridge 
30th Congress of ESPEN, Florence, Italy, September 2008 
 
Muscle volume and quality in weight-losing upper gastrointestinal cancer 
patients 
NA Stephens, C Gray, C Eeley, BH Tan, KCH Fearon, CA Greig 
30th Congress of ESPEN, Florence, Italy, September 2008 
 
Systemic inflammation and muscle quality in cancer cachexia 
Stephens NA, Greig CA, Skipworth RJE, Gray CD, Ross JA, Fearon KCH 








Publication of data from this thesis 
Published manuscripts 
 
Suppression of muscle turnover in cancer cachexia: evidence from the 
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Clin Cancer Res, 2012 May 15;18(10):2817-27  
PMID 22452944 
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Sexual dimorphism modulates the impact of cancer cachexia on lower limb 
muscle mass and function 
Stephens NA, Gray C, MacDonald A, Tan BH, Gallagher IJ, Skipworth RJE, Ross 
JA, Fearon KCH, Greig CA 
Clin Nutr, 2012 Jan 20 [Epub ahead of print] 
PMID 22296872 
 
Intramyocellular lipid droplets increase with progression of cachexia in cancer 
patients 
Stephens NA, Skipworth RJ, Macdonald AJ, Greig CA, Ross JA, Fearon KC 
J Cachex Sarcopenia Muscle, 2011 Jun 2(2):111-117 
PMID 21766057 
 
Magnetic resonance imaging with k-means clustering objectively measures whole 
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